0001628280-25-021524.txt : 20250501 0001628280-25-021524.hdr.sgml : 20250501 20250501160824 ACCESSION NUMBER: 0001628280-25-021524 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 97 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250501 DATE AS OF CHANGE: 20250501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CareTrust REIT, Inc. CENTRAL INDEX KEY: 0001590717 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] ORGANIZATION NAME: 05 Real Estate & Construction EIN: 463999490 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36181 FILM NUMBER: 25903131 BUSINESS ADDRESS: STREET 1: 905 CALLE AMANECER, SUITE 300 CITY: SAN CLEMENTE STATE: CA ZIP: 92673 BUSINESS PHONE: (949) 542-3140 MAIL ADDRESS: STREET 1: 905 CALLE AMANECER, SUITE 300 CITY: SAN CLEMENTE STATE: CA ZIP: 92673 10-Q 1 ctre-20250331.htm 10-Q ctre-20250331
0001590717--12-312025Q1falsexbrli:sharesiso4217:USDiso4217:USDxbrli:sharesctre:facilityctre:bedctre:statectre:investmentctre:loaniso4217:GBPxbrli:sharesctre:propertyctre:numberOfFacilityctre:optionctre:option_to_renewctre:leasectre:renewal_optionxbrli:purectre:paymentInstallmentctre:extension_optionctre:unit_bed00015907172025-01-012025-03-3100015907172025-04-3000015907172025-03-3100015907172024-12-3100015907172024-01-012024-03-310001590717us-gaap:CommonStockMember2024-12-310001590717us-gaap:AdditionalPaidInCapitalMember2024-12-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2024-12-310001590717us-gaap:ParentMember2024-12-310001590717us-gaap:NoncontrollingInterestMember2024-12-310001590717us-gaap:CommonStockMember2025-01-012025-03-310001590717us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001590717us-gaap:ParentMember2025-01-012025-03-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2025-01-012025-03-310001590717us-gaap:NoncontrollingInterestMember2025-01-012025-03-310001590717us-gaap:CommonStockMember2025-03-310001590717us-gaap:AdditionalPaidInCapitalMember2025-03-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2025-03-310001590717us-gaap:ParentMember2025-03-310001590717us-gaap:NoncontrollingInterestMember2025-03-310001590717us-gaap:CommonStockMember2023-12-310001590717us-gaap:AdditionalPaidInCapitalMember2023-12-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2023-12-310001590717us-gaap:ParentMember2023-12-310001590717us-gaap:NoncontrollingInterestMember2023-12-3100015907172023-12-310001590717us-gaap:CommonStockMember2024-01-012024-03-310001590717us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001590717us-gaap:ParentMember2024-01-012024-03-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2024-01-012024-03-310001590717us-gaap:NoncontrollingInterestMember2024-01-012024-03-310001590717us-gaap:CommonStockMember2024-03-310001590717us-gaap:AdditionalPaidInCapitalMember2024-03-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2024-03-310001590717us-gaap:ParentMember2024-03-310001590717us-gaap:NoncontrollingInterestMember2024-03-3100015907172024-03-310001590717ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember2025-03-310001590717ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember2025-01-012025-03-310001590717ctre:MortgageSecuredLoanReceivableMember2025-01-012025-03-310001590717ctre:MezzanineLoanReceivableMember2025-01-012025-03-310001590717us-gaap:FinanceReceivablesMember2025-01-012025-03-310001590717us-gaap:FinanceReceivablesMember2025-03-310001590717ctre:CareREITPlcMember2025-03-110001590717ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2025-03-310001590717ctre:SkilledNursingFacilityMemberctre:PropertiesWithPurchaseOptionLeaseExpirationMarch2029NextOption2022Member2025-03-310001590717ctre:SkilledNursingFacilityMemberctre:PropertiesWithPurchaseOptionLeaseExpirationJanuary2030NextOption2026Member2025-03-310001590717ctre:SkilledNursingAndCampusFacilitiesMemberctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2032NextOption2027Member2025-03-310001590717ctre:SkilledNursingAndCampusFacilitiesMemberctre:PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2026Member2025-03-310001590717ctre:SkilledNursingFacilityMemberctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2034NextOption2027Member2025-03-310001590717ctre:SkilledNursingFacilityMemberctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2039NextOption2027Member2025-03-310001590717ctre:SkilledNursingAndCampusFacilitiesMemberctre:PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2026Member2025-01-012025-03-310001590717ctre:SkilledNursingFacilityMemberctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2039NextOption2027Membersrt:MinimumMember2025-01-012025-03-310001590717ctre:SkilledNursingFacilityMemberctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2039NextOption2027Membersrt:MaximumMember2025-01-012025-03-310001590717ctre:SkilledNursingFacilityMemberctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2039NextOption2027Member2025-01-012025-03-310001590717ctre:SkilledNursingFacilityMember2025-03-310001590717ctre:SkilledNursingAndCampusFacilitiesMemberctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2032NextOption2027Member2025-01-012025-03-310001590717ctre:SkilledNursingAndCampusFacilitiesMembersrt:MinimumMember2025-03-310001590717ctre:SkilledNursingAndCampusFacilitiesMembersrt:MaximumMember2025-03-310001590717ctre:FirstOptionMemberctre:SkilledNursingAndCampusFacilitiesMemberctre:PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2027Member2025-03-310001590717ctre:FirstOptionMemberctre:SkilledNursingAndCampusFacilitiesMemberctre:PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2027Member2025-01-012025-03-310001590717ctre:SecondOptionMemberctre:SkilledNursingAndCampusFacilitiesMemberctre:PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2027Member2025-03-310001590717ctre:SecondOptionMemberctre:SkilledNursingAndCampusFacilitiesMemberctre:PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2027Member2025-01-012025-03-310001590717ctre:PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2027Membersrt:MinimumMember2025-03-310001590717ctre:PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2027Membersrt:MaximumMember2025-03-310001590717ctre:SkilledNursingPropertiesMember2025-01-012025-03-310001590717ctre:AssistedLivingFacilityMember2025-01-012025-03-310001590717ctre:SkilledNursingPropertiesMemberctre:JointVentureMember2025-01-012025-03-310001590717ctre:AmendedKalestaLeaseMember2025-03-310001590717ctre:AmendedKalestaLeaseMember2025-02-280001590717ctre:AssistedLivingFacilityMemberctre:JaybirdSeniorLivingInc.Member2024-08-012024-08-010001590717ctre:JaybirdLeaseMember2025-03-310001590717ctre:JaybirdLeaseMember2025-01-010001590717ctre:JaybirdLeaseMember2025-01-012025-03-310001590717ctre:JaybirdLeaseMember2024-08-012024-08-010001590717ctre:MasterLeaseTerminationMember2025-01-010001590717ctre:SkilledNursingPropertiesMember2024-03-012024-03-010001590717ctre:EnsignAmendedTripleNetMasterLeaseMember2024-03-010001590717ctre:SkilledNursingFacilityMemberctre:EnsignMember2024-03-010001590717ctre:EduroAmendedTripleNetMasterLeaseMember2024-03-010001590717ctre:SkilledNursingFacilityMemberctre:NewEmbassyLeaseAgreementMember2024-01-010001590717ctre:MultiServiceCampusPropertiesMemberctre:NewEmbassyLeaseAgreementMember2024-01-010001590717ctre:NewEmbassyLeaseAgreementMember2024-01-010001590717ctre:FacilitiesHeldForSaleMember2025-03-310001590717us-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2024-03-310001590717us-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2024-03-310001590717us-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2024-03-310001590717us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2025-01-012025-03-310001590717us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2024-01-012024-03-310001590717ctre:AssistedLivingFacilitiesMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2025-01-012025-03-310001590717ctre:AssistedLivingFacilitiesMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2024-01-310001590717us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2024-12-310001590717us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2025-01-012025-03-310001590717us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2025-03-310001590717us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2023-12-310001590717us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2024-01-012024-03-310001590717us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2024-03-310001590717us-gaap:LoansReceivableMemberctre:SkilledNursingFacilityMemberctre:MortgageSecuredLoanReceivableMember2025-03-310001590717us-gaap:LoansReceivableMemberctre:CampusMemberctre:MortgageSecuredLoanReceivableMember2025-03-310001590717us-gaap:LoansReceivableMemberctre:AssistedLivingFacilitiesMemberctre:MortgageSecuredLoanReceivableMember2025-03-310001590717us-gaap:LoansReceivableMemberctre:IndependentLivingFacilityMemberctre:MortgageSecuredLoanReceivableMember2025-03-310001590717us-gaap:LoansReceivableMemberctre:MortgageSecuredLoanReceivableMember2025-03-310001590717us-gaap:LoansReceivableMemberctre:MortgageSecuredLoanReceivableMember2024-12-310001590717us-gaap:LoansReceivableMemberctre:SkilledNursingFacilityMemberctre:MezzanineLoanReceivableMember2025-03-310001590717us-gaap:LoansReceivableMemberctre:CampusMemberctre:MezzanineLoanReceivableMember2025-03-310001590717us-gaap:LoansReceivableMemberctre:AssistedLivingFacilitiesMemberctre:MezzanineLoanReceivableMember2025-03-310001590717us-gaap:LoansReceivableMemberctre:IndependentLivingFacilityMemberctre:MezzanineLoanReceivableMember2025-03-310001590717us-gaap:LoansReceivableMemberctre:MezzanineLoanReceivableMember2025-03-310001590717us-gaap:LoansReceivableMemberctre:MezzanineLoanReceivableMember2024-12-310001590717us-gaap:LoansReceivableMember2025-03-310001590717us-gaap:LoansReceivableMember2024-12-310001590717us-gaap:OtherInvestmentsMemberctre:PreferredEquityMember2025-03-310001590717us-gaap:OtherInvestmentsMemberctre:PreferredEquityMember2024-12-310001590717us-gaap:OtherInvestmentsMember2025-03-310001590717us-gaap:OtherInvestmentsMember2024-12-310001590717us-gaap:OtherInvestmentsMemberctre:SkilledNursingFacilityMemberctre:OtherFinancingReceivablesMember2025-03-310001590717us-gaap:OtherInvestmentsMemberctre:CampusMemberctre:OtherFinancingReceivablesMember2025-03-310001590717us-gaap:OtherInvestmentsMemberctre:AssistedLivingFacilitiesMemberctre:OtherFinancingReceivablesMember2025-03-310001590717us-gaap:OtherInvestmentsMemberctre:IndependentLivingFacilityMemberctre:OtherFinancingReceivablesMember2025-03-310001590717us-gaap:OtherInvestmentsMemberctre:OtherFinancingReceivablesMember2025-03-310001590717us-gaap:OtherInvestmentsMemberctre:OtherFinancingReceivablesMember2024-12-310001590717ctre:MortgageSecuredLoanReceivableMember2025-03-310001590717ctre:MezzanineLoanReceivableMember2025-03-310001590717ctre:MortgageSecuredAndMezzanineLoansReceivableMember2025-01-012025-03-310001590717us-gaap:LoansReceivableMemberctre:OtherFinancingReceivablesMember2025-03-310001590717us-gaap:LoansReceivableMemberctre:OtherFinancingReceivablesMember2024-12-310001590717us-gaap:OtherInvestmentsMemberctre:OtherFinancingReceivablesMember2025-01-012025-03-310001590717ctre:OtherRealEstateRelatedInvestmentsMember2025-03-310001590717ctre:OtherRealEstateRelatedInvestmentsMember2024-03-310001590717ctre:SkilledNursingFacilityMemberctre:MezzanineLoanMember2025-01-100001590717stpr:MDctre:SkilledNursingFacilityMemberctre:MezzanineLoanMember2025-01-100001590717ctre:MultiServiceCampusPropertiesMemberctre:MezzanineLoanReceivableMember2024-12-200001590717ctre:SkilledNursingFacilityMember2025-02-012025-02-2800015907172025-02-012025-02-280001590717ctre:MortgageSecuredLoanReceivableJanuary12027MaturityMember2024-01-010001590717ctre:AssistedLivingFacilitiesMemberctre:MortgageSecuredLoanReceivableJanuary12027MaturityMember2024-01-010001590717ctre:SkilledNursingFacilityMemberctre:MezzanineLoanMember2024-01-250001590717ctre:MezzanineLoanMember2024-01-250001590717ctre:MezzanineLoanMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-01-250001590717ctre:MezzanineLoanMemberctre:SecuredOvernightFinancingRateSOFRFloorMember2024-01-250001590717ctre:SkilledNursingFacilityMemberctre:MezzanineLoanMembersrt:MinimumMember2024-01-250001590717ctre:SkilledNursingFacilityMemberctre:MezzanineLoanMembersrt:MaximumMember2024-01-250001590717ctre:SkilledNursingFacilityMemberctre:MezzanineLoanMember2024-02-010001590717ctre:MezzanineLoanMember2024-02-010001590717ctre:SkilledNursingFacilityMemberctre:MezzanineLoanMember2024-02-020001590717ctre:MezzanineLoanMember2024-02-020001590717ctre:MezzanineLoanMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-02-020001590717ctre:MezzanineLoanMemberctre:SecuredOvernightFinancingRateSOFRFloorMember2024-02-020001590717ctre:SkilledNursingFacilityMemberctre:MezzanineLoanMembersrt:MinimumMember2024-02-020001590717ctre:SkilledNursingFacilityMemberctre:MezzanineLoanMembersrt:MaximumMember2024-02-020001590717us-gaap:OtherInvestmentsMemberctre:OtherFinancingReceivablesMember2024-12-050001590717ctre:NewCascadeLeaseMember2024-12-052024-12-050001590717ctre:NewCascadeLeaseMember2024-12-012024-12-010001590717us-gaap:LoansReceivableMember2025-03-310001590717us-gaap:LoansReceivableMember2024-12-310001590717us-gaap:LoansReceivableMember2024-01-012024-03-310001590717us-gaap:LoansReceivableMember2025-01-012025-03-310001590717ctre:MortgageSecuredLoanReceivableMember2025-01-012025-03-310001590717ctre:MortgageSecuredLoanReceivableMember2024-01-012024-03-310001590717ctre:MezzanineLoanReceivableMember2025-01-012025-03-310001590717ctre:MezzanineLoanReceivableMember2024-01-012024-03-310001590717us-gaap:EquityMethodInvestmentsMember2025-01-012025-03-310001590717us-gaap:EquityMethodInvestmentsMember2024-01-012024-03-310001590717ctre:OtherFinancingReceivablesMember2025-01-012025-03-310001590717ctre:OtherFinancingReceivablesMember2024-01-012024-03-310001590717ctre:OtherMember2025-01-012025-03-310001590717ctre:OtherMember2024-01-012024-03-310001590717us-gaap:FairValueInputsLevel1Memberctre:MortgageSecuredLoanReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001590717us-gaap:FairValueInputsLevel2Memberctre:MortgageSecuredLoanReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001590717us-gaap:FairValueInputsLevel3Memberctre:MortgageSecuredLoanReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001590717us-gaap:FairValueMeasurementsRecurringMemberctre:MortgageSecuredLoanReceivableMember2025-03-310001590717us-gaap:FairValueInputsLevel1Memberctre:MezzanineLoanReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001590717us-gaap:FairValueInputsLevel2Memberctre:MezzanineLoanReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001590717us-gaap:FairValueInputsLevel3Memberctre:MezzanineLoanReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001590717us-gaap:FairValueMeasurementsRecurringMemberctre:MezzanineLoanReceivableMember2025-03-310001590717us-gaap:FairValueInputsLevel1Memberus-gaap:FinanceReceivablesMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001590717us-gaap:FairValueInputsLevel2Memberus-gaap:FinanceReceivablesMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001590717us-gaap:FairValueInputsLevel3Memberus-gaap:FinanceReceivablesMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001590717us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FinanceReceivablesMember2025-03-310001590717us-gaap:FairValueInputsLevel1Memberctre:MortgageSecuredAndMezzanineLoansReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001590717us-gaap:FairValueInputsLevel2Memberctre:MortgageSecuredAndMezzanineLoansReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001590717us-gaap:FairValueInputsLevel3Memberctre:MortgageSecuredAndMezzanineLoansReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001590717ctre:MortgageSecuredAndMezzanineLoansReceivableMember2025-03-310001590717us-gaap:FairValueInputsLevel1Memberctre:MortgageSecuredLoanReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001590717us-gaap:FairValueInputsLevel2Memberctre:MortgageSecuredLoanReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001590717us-gaap:FairValueInputsLevel3Memberctre:MortgageSecuredLoanReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001590717us-gaap:FairValueMeasurementsRecurringMemberctre:MortgageSecuredLoanReceivableMember2024-12-310001590717us-gaap:FairValueInputsLevel1Memberctre:MezzanineLoanReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001590717us-gaap:FairValueInputsLevel2Memberctre:MezzanineLoanReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001590717us-gaap:FairValueInputsLevel3Memberctre:MezzanineLoanReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001590717us-gaap:FairValueMeasurementsRecurringMemberctre:MezzanineLoanReceivableMember2024-12-310001590717us-gaap:FairValueInputsLevel1Memberus-gaap:FinanceReceivablesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001590717us-gaap:FairValueInputsLevel2Memberus-gaap:FinanceReceivablesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001590717us-gaap:FairValueInputsLevel3Memberus-gaap:FinanceReceivablesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001590717us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FinanceReceivablesMember2024-12-310001590717us-gaap:FairValueInputsLevel1Memberctre:MortgageSecuredAndMezzanineLoansReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001590717us-gaap:FairValueInputsLevel2Memberctre:MortgageSecuredAndMezzanineLoansReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001590717us-gaap:FairValueInputsLevel3Memberctre:MortgageSecuredAndMezzanineLoansReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001590717ctre:MortgageSecuredAndMezzanineLoansReceivableMember2024-12-310001590717ctre:InvestmentsInRealEstateSecuredLoanMember2024-12-310001590717ctre:InvestmentsInMezzanineLoansMember2024-12-310001590717ctre:InvestmentsInFinancingReceivableMember2024-12-310001590717ctre:InvestmentsInRealEstateSecuredLoanMember2025-01-012025-03-310001590717ctre:InvestmentsInMezzanineLoansMember2025-01-012025-03-310001590717ctre:InvestmentsInFinancingReceivableMember2025-01-012025-03-310001590717ctre:InvestmentsInRealEstateSecuredLoanMember2025-03-310001590717ctre:InvestmentsInMezzanineLoansMember2025-03-310001590717ctre:InvestmentsInFinancingReceivableMember2025-03-310001590717ctre:SecuredAndMezzanineLoansReceivableMember2025-01-012025-03-310001590717ctre:SecuredAndMezzanineLoansReceivableMember2024-01-012024-03-310001590717us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember2025-03-310001590717us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember2024-12-310001590717us-gaap:FairValueInputsLevel3Memberctre:MortgageSecuredLoanReceivableMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2025-03-310001590717ctre:MortgageSecuredLoanReceivableMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2025-03-310001590717ctre:MortgageSecuredLoanReceivableMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2025-03-310001590717us-gaap:FairValueInputsLevel3Memberctre:MezzanineLoanReceivableMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2025-03-310001590717ctre:MezzanineLoanReceivableMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2025-03-310001590717ctre:MezzanineLoanReceivableMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2025-03-310001590717us-gaap:FairValueInputsLevel3Memberus-gaap:FinanceReceivablesMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2025-03-310001590717us-gaap:FairValueInputsLevel3Memberctre:PreferredEquityInvestmentMember2025-03-310001590717us-gaap:FairValueInputsLevel3Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberctre:PreferredEquityInvestmentMember2025-03-310001590717us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberctre:PreferredEquityInvestmentMember2025-03-310001590717us-gaap:FairValueInputsLevel3Memberctre:PreferredEquityInvestmentMember2024-12-310001590717us-gaap:FairValueInputsLevel3Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberctre:PreferredEquityInvestmentMember2024-12-310001590717us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberctre:PreferredEquityInvestmentMember2024-12-310001590717us-gaap:FairValueInputsLevel2Memberctre:SeniorUnsecuredNotesMember2025-03-310001590717us-gaap:FairValueInputsLevel2Memberctre:SeniorUnsecuredNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2025-03-310001590717us-gaap:FairValueInputsLevel2Memberctre:SeniorUnsecuredNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2025-03-310001590717us-gaap:FairValueInputsLevel2Memberctre:SeniorUnsecuredNotesMember2024-12-310001590717us-gaap:FairValueInputsLevel2Memberctre:SeniorUnsecuredNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-12-310001590717us-gaap:FairValueInputsLevel2Memberctre:SeniorUnsecuredNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-12-310001590717us-gaap:FairValueInputsLevel3Membersrt:MinimumMember2025-03-310001590717us-gaap:FairValueInputsLevel3Membersrt:MaximumMember2025-03-310001590717ctre:SeniorUnsecuredNotesMemberus-gaap:SeniorNotesMember2025-03-310001590717ctre:SeniorUnsecuredNotesMemberus-gaap:SeniorNotesMember2024-12-310001590717us-gaap:RevolvingCreditFacilityMember2025-03-310001590717us-gaap:RevolvingCreditFacilityMember2024-12-310001590717ctre:SeniorUnsecuredNotesMemberus-gaap:SeniorNotesMember2021-06-170001590717ctre:SeniorUnsecuredNotesMemberus-gaap:SeniorNotesMember2021-06-172021-06-170001590717ctre:SeniorUnsecuredNotesMemberus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2021-06-172021-06-170001590717ctre:SeniorUnsecuredNotesMemberus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2021-06-172021-06-170001590717us-gaap:RevolvingCreditFacilityMember2024-12-180001590717us-gaap:LetterOfCreditMember2022-12-160001590717ctre:SwinglineLoanMember2022-12-160001590717us-gaap:RevolvingCreditFacilityMember2019-02-080001590717us-gaap:LetterOfCreditMember2019-02-080001590717ctre:SwinglineLoanMember2019-02-080001590717ctre:SeniorUnsecuredTermLoanMemberus-gaap:LoansPayableMember2019-02-080001590717us-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MinimumMember2019-02-082019-02-080001590717us-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MaximumMember2019-02-082019-02-080001590717us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MinimumMember2019-02-082019-02-080001590717us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MaximumMember2019-02-082019-02-080001590717srt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2019-02-082019-02-080001590717srt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2019-02-082019-02-080001590717us-gaap:RevolvingCreditFacilityMember2019-02-082019-02-080001590717ctre:AtTheMarketOfferingProgramMember2025-01-210001590717ctre:AtTheMarketOfferingProgramMember2024-12-310001590717ctre:AtTheMarketOfferingProgramMember2025-01-012025-03-310001590717ctre:AtTheMarketOfferingProgramMember2024-01-012024-03-310001590717ctre:AtTheMarketOfferingProgramMember2025-03-310001590717us-gaap:RestrictedStockMember2021-01-012021-12-310001590717us-gaap:RestrictedStockMember2025-01-012025-03-310001590717us-gaap:RestrictedStockMembersrt:DirectorMember2020-01-012020-12-310001590717ctre:PerformanceSharesTSRUnitsMember2025-01-012025-03-310001590717ctre:PerformanceSharesTSRUnitsMembersrt:MinimumMember2025-01-012025-03-310001590717ctre:PerformanceSharesTSRUnitsMembersrt:MaximumMember2025-01-012025-03-310001590717ctre:RestrictedStockAndPerformanceSharesMember2025-01-012025-03-310001590717ctre:PerformanceStockAwardsAndTotalShareholderReturnUnitsMember2025-01-012025-03-310001590717ctre:PerformanceStockAwardsAndTotalShareholderReturnUnitsMember2024-01-012024-03-310001590717ctre:ReportableSegmentMember2025-01-012025-03-310001590717ctre:ReportableSegmentMember2024-01-012024-03-310001590717ctre:InvestmentOneMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberctre:SkilledNursingFacilityMember2025-03-310001590717ctre:CTREMemberctre:InvestmentOneMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberctre:SkilledNursingFacilityMember2025-03-310001590717ctre:NoncontrollingInterestOwnersMemberctre:InvestmentOneMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberctre:SkilledNursingFacilityMember2025-03-310001590717ctre:InvestmentTwoMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberctre:SkilledNursingFacilityMember2025-03-310001590717ctre:CTREMemberctre:InvestmentTwoMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberctre:SkilledNursingFacilityMember2025-03-310001590717ctre:NoncontrollingInterestOwnersMemberctre:InvestmentTwoMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberctre:SkilledNursingFacilityMember2025-03-310001590717ctre:InvestmentThreeMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberctre:AssistedLivingFacilitiesMember2025-03-310001590717ctre:CTREMemberctre:InvestmentThreeMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberctre:AssistedLivingFacilitiesMember2025-03-310001590717ctre:NoncontrollingInterestOwnersMemberctre:InvestmentThreeMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberctre:AssistedLivingFacilitiesMember2025-03-310001590717ctre:InvestmentFourMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberctre:MultiServiceCampusPropertiesMember2025-03-310001590717ctre:CTREMemberctre:InvestmentFourMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberctre:MultiServiceCampusPropertiesMember2025-03-310001590717ctre:NoncontrollingInterestOwnersMemberctre:InvestmentFourMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberctre:MultiServiceCampusPropertiesMember2025-03-310001590717ctre:InvestmentFiveMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberctre:SkilledNursingFacilityMember2025-03-310001590717ctre:CTREMemberctre:InvestmentFiveMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberctre:SkilledNursingFacilityMember2025-03-310001590717ctre:NoncontrollingInterestOwnersMemberctre:InvestmentFiveMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberctre:SkilledNursingFacilityMember2025-03-310001590717ctre:InvestmentSixMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberctre:SkilledNursingFacilityMember2025-03-310001590717ctre:CTREMemberctre:InvestmentSixMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberctre:SkilledNursingFacilityMember2025-03-310001590717ctre:NoncontrollingInterestOwnersMemberctre:InvestmentSixMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMemberctre:SkilledNursingFacilityMember2025-03-310001590717ctre:InvestmentSevenMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-03-310001590717ctre:CTREMemberctre:InvestmentSevenMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-03-310001590717ctre:NoncontrollingInterestOwnersMemberctre:InvestmentSevenMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-03-310001590717us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-03-310001590717ctre:CTREMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-03-310001590717ctre:NoncontrollingInterestOwnersMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-03-310001590717ctre:JVPartner97.5Member2025-03-310001590717ctre:JVPartnerMember2025-03-310001590717us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-12-310001590717ctre:EnsignAndPennantMember2025-03-310001590717ctre:TenantESGProgramMember2025-03-310001590717ctre:RemainingCommitmentMemberctre:CapitalExpendituresMember2025-03-310001590717ctre:RemainingCommitmentMemberus-gaap:MortgageReceivablesMember2025-03-310001590717ctre:RemainingCommitmentMemberctre:OtherLoansReceivableMember2025-03-310001590717ctre:RemainingCommitmentMemberctre:EarnOutObligationMember2025-03-310001590717ctre:RemainingCommitmentMember2025-03-310001590717ctre:CapitalImprovementsAtTripleNetLeasedFacilitiesMember2025-03-310001590717us-gaap:MortgageReceivablesMemberctre:SkilledNursingFacilityMember2025-01-012025-03-310001590717stpr:VActre:SkilledNursingFacilityMember2025-01-012025-03-310001590717stpr:VActre:SkilledNursingFacilityMember2025-03-310001590717ctre:EnsignMemberctre:SkilledNursingFacilityMember2025-03-310001590717ctre:EnsignMemberctre:MultiServiceCampusPropertiesMember2025-03-310001590717ctre:EnsignMemberctre:AssistedAndIndependentLivingPropertiesMember2025-03-310001590717ctre:EnsignMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310001590717ctre:PriorityManagementGroupLLCMemberctre:SkilledNursingFacilityMember2025-03-310001590717ctre:PriorityManagementGroupLLCMemberctre:MultiServiceCampusPropertiesMember2025-03-310001590717ctre:PriorityManagementGroupLLCMemberctre:AssistedAndIndependentLivingPropertiesMember2025-03-310001590717ctre:PriorityManagementGroupLLCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310001590717ctre:EnsignMemberctre:SkilledNursingFacilityMember2024-03-310001590717ctre:EnsignMemberctre:MultiServiceCampusPropertiesMember2024-03-310001590717ctre:EnsignMemberctre:AssistedAndIndependentLivingPropertiesMember2024-03-310001590717ctre:EnsignMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310001590717ctre:PriorityManagementGroupLLCMemberctre:SkilledNursingFacilityMember2024-03-310001590717ctre:PriorityManagementGroupLLCMemberctre:MultiServiceCampusPropertiesMember2024-03-310001590717ctre:PriorityManagementGroupLLCMemberctre:AssistedAndIndependentLivingPropertiesMember2024-03-310001590717ctre:PriorityManagementGroupLLCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310001590717stpr:CActre:SkilledNursingFacilityMember2025-03-310001590717stpr:CActre:MultiServiceCampusPropertiesMember2025-03-310001590717stpr:CActre:AssistedAndIndependentLivingPropertiesMember2025-03-310001590717stpr:CAus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310001590717stpr:TXctre:SkilledNursingFacilityMember2025-03-310001590717stpr:TXctre:MultiServiceCampusPropertiesMember2025-03-310001590717stpr:TXctre:AssistedAndIndependentLivingPropertiesMember2025-03-310001590717stpr:TXus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310001590717stpr:TNctre:SkilledNursingFacilityMember2025-03-310001590717stpr:TNctre:MultiServiceCampusPropertiesMember2025-03-310001590717stpr:TNctre:AssistedAndIndependentLivingPropertiesMember2025-03-310001590717stpr:TNus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310001590717stpr:CActre:SkilledNursingFacilityMember2024-03-310001590717stpr:CActre:MultiServiceCampusPropertiesMember2024-03-310001590717stpr:CActre:AssistedAndIndependentLivingPropertiesMember2024-03-310001590717stpr:CAus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310001590717stpr:TXctre:SkilledNursingFacilityMember2024-03-310001590717stpr:TXctre:MultiServiceCampusPropertiesMember2024-03-310001590717stpr:TXctre:AssistedAndIndependentLivingPropertiesMember2024-03-310001590717stpr:TXus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310001590717ctre:SkilledNursingFacilityMemberctre:SkilledNursingFacilityCaliforniaJointVentureMemberus-gaap:SubsequentEventMember2025-04-010001590717ctre:SkilledNursingFacilityCaliforniaJointVentureMemberus-gaap:SubsequentEventMember2025-04-012025-04-010001590717ctre:SkilledNursingFacilityMemberctre:SkilledNursingFacilityCaliforniaJointVentureMemberus-gaap:SubsequentEventMember2025-04-012025-04-010001590717ctre:SkilledNursingFacilityMemberctre:SkilledNursingFacilityCaliforniaJointVentureMemberus-gaap:SubsequentEventMember2025-04-010001590717ctre:SkilledNursingFacilityMemberctre:JVPartnerMemberus-gaap:SubsequentEventMember2025-04-012025-04-010001590717ctre:SkilledNursingFacilityMemberus-gaap:SubsequentEventMember2025-04-010001590717ctre:MortgageLoanMemberus-gaap:SubsequentEventMember2025-04-012025-04-300001590717us-gaap:SubsequentEventMemberctre:AtTheMarketOfferingProgramMember2025-04-012025-04-300001590717us-gaap:SubsequentEventMemberctre:AtTheMarketOfferingProgramMember2025-04-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2025
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     

Commission File Number: 001-36181
CareTrust REIT, Inc.
(Exact name of registrant as specified in its charter)
Maryland46-3999490
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
905 Calle Amanecer, Suite 300, San Clemente, CA
92673
(Address of principal executive offices)(Zip Code)
(949) 542-3130
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareCTRENew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.      Yes      No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).      Yes      No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).      Yes      No
As of April 30, 2025, there were 191,688,997 shares of common stock outstanding.





INDEX






PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
(Unaudited)
 
March 31, 2025December 31, 2024
Assets:
Real estate investments, net$2,252,279 $2,226,740 
Financing receivable, at fair value (including accrued interest of $905 as of March 31, 2025 and $281 as of December 31, 2024)
96,628 96,004
Other real estate related investments (including accrued interest of $6,005 as of March 31, 2025 and $4,725 as of December 31, 2024)
799,799 795,203 
Assets held for sale, net16,736 57,261 
Cash and cash equivalents26,510 213,822 
Restricted cash606,000  
Accounts and other receivables1,954 1,174 
Prepaid expenses and other assets, net73,890 35,608 
Deferred financing costs, net10,652 11,204 
Total assets$3,884,448 $3,437,016 
Liabilities and Equity:
Senior unsecured notes payable, net$397,149 $396,927 
Unsecured revolving credit facility425,000  
Accounts payable, accrued liabilities and deferred rent liabilities51,069 56,318 
Dividends payable63,053 54,388 
Total liabilities936,271 507,633 
Commitments and contingencies (Note 13)
Redeemable noncontrolling interest17,396 18,243 
Equity:
Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued and outstanding as of March 31, 2025 and December 31, 2024
  
Common stock, $0.01 par value; 500,000,000 shares authorized, 187,669,948 and 186,993,010 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively
1,877 1,870 
Additional paid-in capital3,455,256 3,439,117 
Cumulative distributions in excess of earnings(529,821)(532,570)
Total stockholders’ equity2,927,312 2,908,417 
Noncontrolling interests3,469 2,723 
Total equity2,930,781 2,911,140 
Total liabilities and equity$3,884,448 $3,437,016 



See accompanying notes to condensed consolidated financial statements.

1

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED INCOME STATEMENTS
(in thousands, except per share amounts)
(Unaudited)
 
 For the Three Months Ended March 31,
 20252024
Revenues:
Rental income$71,646 $53,502 
Interest income from financing receivable2,807  
Interest income from other real estate related investments and other income22,168 9,568 
Total revenues96,621 63,070 
Expenses:
Depreciation and amortization17,841 13,448 
Interest expense6,669 8,228 
Property taxes2,065 1,801 
Impairment of real estate investments 2,744 
Transaction costs888  
Property operating expenses105 660 
General and administrative9,023 6,838 
Total expenses36,591 33,719 
Other income (loss):
Gain on sale of real estate, net3,876 11 
Unrealized gain (loss) on other real estate related investments, net1,287 (612)
Total other income (loss)5,163 (601)
Net income65,193 28,750 
Net (loss) income attributable to noncontrolling interests(609)4 
Net income attributable to CareTrust REIT, Inc.$65,802 $28,746 
Earnings per common share attributable to CareTrust REIT, Inc:
Basic$0.35 $0.22 
Diluted$0.35 $0.22 
Weighted-average number of common shares:
Basic187,152 132,836 
Diluted187,416 133,202 









See accompanying notes to condensed consolidated financial statements.

2

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTEREST
(in thousands, except share and per share amounts)
(Unaudited)
Common StockAdditional
Paid-in
Capital
Cumulative
Distributions in Excess of Earnings
Total Stockholders’ EquityNoncontrolling InterestsTotal
Equity
Redeemable Noncontrolling Interest
SharesAmount
Balance at December 31, 2024186,993,010 $1,870 $3,439,117 $(532,570)$2,908,417 $2,723 $2,911,140 $18,243 
Issuance of common stock, net553,023 6 15,556 — 15,562 — 15,562 — 
Vesting of stock-based compensation awards, net of shares withheld for employee taxes123,915 1 (3,326)— (3,325)— (3,325)— 
Amortization of stock-based compensation— — 3,909 — 3,909 — 3,909 — 
Common dividends ($0.335 per share)
— — — (63,053)(63,053)— (63,053)— 
Distributions to noncontrolling interests— — — — — (2)(2)(900)
Contributions from noncontrolling interests— — — — — 642 642 768 
Net income (loss)— — — 65,802 65,802 106 65,908 (715)
Balance at March 31, 2025187,669,948 $1,877 $3,455,256 $(529,821)$2,927,312 $3,469 $2,930,781 $17,396 

































See accompanying notes to condensed consolidated financial statements.


3

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTEREST
(in thousands, except share and per share amounts)
(Unaudited)
 Common StockAdditional
Paid-in
Capital
Cumulative
Distributions in Excess of Earnings
Total Stockholders’ EquityNoncontrolling InterestsTotal
Equity
Redeemable Noncontrolling Interest
SharesAmount
Balance at December 31, 2023129,992,796 $1,300 $1,883,147 $(467,628)$1,416,819 $1,898 $1,418,717 $ 
Issuance of common stock, net11,600,000 116 269,671 — 269,787 — 269,787 — 
Vesting of stock-based compensation awards, net of shares withheld for employee taxes119,369 1 (2,484)— (2,483)— (2,483)— 
Amortization of stock-based compensation— — 2,120 — 2,120 — 2,120 — 
Common dividends ($0.29 per share)
— — — (41,192)(41,192)— (41,192)— 
Distributions to noncontrolling interests— — — — — (47)(47)— 
Contributions from noncontrolling interests— — — — — 444 444 — 
Net income— — — 28,746 28,746 4 28,750 — 
Balance at March 31, 2024141,712,165 $1,417 $2,152,454 $(480,074)$1,673,797 $2,299 $1,676,096 $ 
















See accompanying notes to condensed consolidated financial statements.

4

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)
 For the Three Months Ended March 31,
 20252024
Cash flows from operating activities:
Net income $65,193 $28,750 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization (including below-market ground leases)17,865 13,462 
Amortization of deferred financing costs914 614 
Unrealized (gain) loss on other real estate related investments, net(1,287)612 
Amortization of stock-based compensation3,909 2,120 
Straight-line rental income7 7 
Amortization of lease incentives49  
Amortization of below market leases(926)(575)
Noncash interest income(1,904)(425)
Gain on sale of real estate, net(3,876)(11)
Impairment of real estate investments 2,744 
Change in operating assets and liabilities:
Accounts and other receivables(788)(15)
Prepaid expenses and other assets, net(3,451)(322)
Accounts payable, accrued liabilities and deferred rent liabilities(4,323)1,859 
Net cash provided by operating activities71,382 48,820 
Cash flows from investing activities:
Acquisitions of real estate, net of deposits applied(40,162)(66,619)
Purchases of equipment, furniture and fixtures and improvements to real estate(2,276)(398)
Investment in real estate related investments(6,389)(52,165)
Principal payments received on real estate related investments and other loans receivable 4,582  
Escrow deposits for potential acquisitions of real estate(36,066)(4,105)
Net proceeds from sales of real estate44,401 46 
Net cash used in investing activities(35,910)(123,241)
Cash flows from financing activities:
Proceeds from the issuance of common stock, net15,562 269,787 
Borrowings under unsecured revolving credit facility425,000  
Payments of deferred financing costs(141)(24)
Net-settle adjustment on restricted stock(3,325)(2,483)
Dividends paid on common stock(54,388)(36,531)
Contributions from noncontrolling interests1,410 444 
Distributions to noncontrolling interests(902)(47)
Net cash provided by financing activities383,216 231,146 
Net increase in cash, cash equivalents and restricted cash418,688 156,725 
Cash, cash equivalents and restricted cash as of the beginning of period213,822 294,448 
Cash, cash equivalents and restricted cash as of the end of period$632,510 $451,173 
Supplemental disclosures of cash flow information:
Interest paid$450 $3,771 
Supplemental schedule of noncash investing and financing activities:
Increase in dividends payable$8,665 $4,661 
Transfer of pre-acquisition costs to acquired assets$ $5 
Sale of real estate settled with note receivable$ $1,000 








See accompanying notes to condensed consolidated financial statements.

5

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)



1. ORGANIZATION
Description of Business—CareTrust REIT, Inc.’s (“CareTrust REIT” or the “Company”) primary business consists of acquiring, financing, developing and owning real property to be leased to third-party tenants in the healthcare sector. As of March 31, 2025, the Company owned, directly or through joint ventures, and leased to independent operators 255 skilled nursing facilities (“SNFs”), multi-service campuses, assisted living facilities (“ALFs”) and independent living facilities (“ILFs”) consisting of 27,672 operational beds and units located in 32 states with the highest concentration of properties by rental income located in California, Texas and Tennessee. As of March 31, 2025, the Company also had other real estate related investments consisting of three preferred equity investments, 15 real estate secured loans receivable, and five mezzanine loans receivable with a carrying value of $799.8 million and one financing receivable with a carrying value of $96.6 million.
Planned Acquisition—On March 11, 2025, the Company announced (the “Rule 2.7 Announcement”) pursuant to Rule 2.7 of the United Kingdom City Code on Takeovers and Mergers (the “Code”) a firm intention to make a cash offer (the “Offer”) to acquire (the “Acquisition”), through its wholly-owned direct subsidiary, CR United Bidco Limited (“Bidco”), the entire issued and to be issued ordinary share capital (other than Scheme Restricted Shares (as defined in the Rule 2.7 Announcement)) of Care REIT plc (“Target”) for 108 pence in cash per ordinary share of Target. Target is a UK-based real estate investment trust listed on the Main Market of the London Stock Exchange focused on investing in care homes throughout the United Kingdom. The Acquisition is intended to be effected by means of a scheme of arrangement (the “Scheme”) under Part 26 of the United Kingdom Companies Act 2006, meaning it is subject to court approval and the satisfaction or waiver of other ordinary conditions to closing, following approval by Target’s shareholders.
 
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. The accompanying consolidated financial statements of the Company include the accounts of CareTrust REIT, its wholly-owned subsidiaries, and variable interest entities (“VIEs”) over which the Company exercises control. All intercompany transactions and account balances within the Company have been eliminated, and net earnings are reduced by the portion of net earnings attributable to noncontrolling interests.
Restricted cash—The Company presents cash and cash equivalents separately from restricted cash within the Company’s condensed consolidated balance sheets. The Company includes restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the condensed consolidated statements of cash flows. The Company provides a reconciliation between the balance sheets and statements of cash flows, as required when the balance includes more than one line item for cash, cash equivalents and restricted cash. The Company also provides a disclosure of the nature of the restrictions related to material restricted cash balances.
As of March 31, 2025, the Company had $606.0 million in restricted cash related to the cash deposited with the trustee for the planned acquisition of Care REIT plc.
Cash, cash equivalents and restricted cash consisted of the following as of March 31, 2025 and December 31, 2024 (dollars in thousands):
March 31, 2025December 31, 2024
Cash and cash equivalents$26,510 $213,822 
Restricted cash606,000  
Cash, cash equivalents and restricted cash$632,510 $213,822 

6

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


3. REAL ESTATE INVESTMENTS, NET
The following table summarizes the Company’s investment in owned properties, and properties held in consolidated joint ventures, held for use as of March 31, 2025 and December 31, 2024 (dollars in thousands):
March 31, 2025December 31, 2024
Land$377,669 $367,044 
Buildings and improvements2,253,424 2,220,287 
Integral equipment, furniture and fixtures113,402 113,803 
Identified intangible assets4,083 4,388 
Real estate investments2,748,578 2,705,522 
Accumulated depreciation and amortization(496,299)(478,782)
Real estate investments, net$2,252,279 $2,226,740 
As of March 31, 2025, all of the Company’s owned facilities held for investment were leased to various operators under triple-net leases. All of the triple-net leases contain annual escalators based on the percentage change in the Consumer Price Index (“CPI”) (but not less than zero), some of which are subject to a cap, or fixed rent escalators. As of March 31, 2025, six facilities were held for sale. See Note 4, Impairment of Real Estate Investments, Assets Held for Sale and Asset Sales, for additional information.
As of March 31, 2025, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements and assets held for sale, was as follows (dollars in thousands):
YearAmount
2025 (nine months)$210,437 
2026283,552 
2027281,850 
2028280,536 
2029276,512 
2030271,031 
Thereafter1,367,365 
Total$2,971,283 

7

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


Tenant Purchase Options
Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):
Asset TypePropertiesLease Expiration
Option Period Open Date(1)
Option Type(2)
Current Cash Rent(3)
SNF1March 202904/01/2022
(4)
A / B
(8)
$858 
SNF1January 203002/01/2026
(4)
A1,200 
(9)
SNF / Campus2October 203203/05/2027
(5)
B3,367 
(10)
SNF / Campus2May 203406/01/2026
(6)
B2,714 
(11)
SNF1November 203412/01/2027
(4)
A1,100 
SNF6November 203912/01/2027
(7)
B10,160 
(1) The Company has not received notice of exercise for the option periods that are currently open.
(2) Option type includes:
A - Fixed base price.
B - Fixed capitalization rate on lease revenue.
(3) Based on annualized cash revenue for contracts in place as of March 31, 2025.
(4) Option window is open until the expiration of the lease term.
(5) Option window is open for six months from the option period open date.
(6) Option window is open for nine months from the option period open date.
(7) Lease agreement provides for the purchase of one to two facilities in each window over four option windows, for a total of six facilities. Each option window opens at the beginning of each of lease years four, five, six, and seven beginning December 1, 2027 and is open for one year.
(8) Option reflects two option types.
(9)     Lease provides for abatement in the first three months. Annual rent beginning in month four is $1.2 million.
(10) Option provides for purchase of any two of the three facilities. The current cash rent shown is an average of the range of $3.2 million to $3.5 million.
(11)     Option provides for purchase of any one of five facilities in the first option window and another one of five facilities in the second option window beginning June 1, 2027. The current cash rent shown is an average of the range of $2.4 million to $3.1 million. Provided the operator exercises its option to extend the term of the master lease, beginning on June 1, 2035 and ending nine months thereafter, the operator will have an option for all facilities then remaining in the master lease.
Rental Income
The following table summarizes components of the Company’s rental income (dollars in thousands):
For the Three Months Ended March 31,
Rental Income20252024
Contractual rent due(1)
$70,776 $52,934 
Straight-line rent(7)(7)
Amortization of lease incentives(49) 
Amortization of below-market lease intangibles926 575 
Total$71,646 $53,502 
(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received. Tenant operating expense reimbursements for the three months ended March 31, 2025 and 2024 were $2.3 million and $1.5 million, respectively.

8

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


Recent Real Estate Acquisitions
The following table summarizes the Company’s acquisitions for the three months ended March 31, 2025 (dollars in thousands):
Type of Property
Purchase Price(1)
Initial Annual Cash Rent(2)
Number of Properties
Number of Beds/Units(3)
Skilled nursing(4)
$20,448 $2,000 1 124 
Assisted living20,637 1,896 1 160 
Total$41,085 $3,896 2 284 
(1) Purchase price includes capitalized acquisition costs.
(2) Initial annual cash rent represents initial cash rent for the first twelve months.
(3) The number of beds/units includes operating beds at the acquisition date.
(4) Includes one SNF held through a joint venture. See Note 12, Variable Interest Entities, for additional information.
Lease Amendments and Terminations
Amended Kalesta Lease. Effective February 28, 2025, the Company acquired one ALF. In connection with the acquisition, the Company amended its existing triple-net master lease with affiliates of Kalesta Healthcare, LLC (“Kalesta”) to include the one ALF and extended the initial lease term. The Kalesta master lease, as amended, had a remaining term at the date of amendment of approximately 15 years. Annual cash rent under the amended Kalesta master lease increased by approximately $1.9 million.
Ridgeline Lease Termination and NC Jaybird Lease. Effective December 31, 2024, the Company terminated its master lease with affiliates of Ridgeline Properties, LLC (“Ridgeline”). The Company entered into a new master lease (the “NC Jaybird Lease”) with affiliates of Jaybird Senior Living, Inc. (“Jaybird”) with respect to two ALFs in North Carolina previously leased to Ridgeline. The NC Jaybird Lease commenced on January 1, 2025 with an initial term of approximately 12 years, featuring two five-year renewal options and CPI-based rent escalators. Under the NC Jaybird Lease, Jaybird will receive three months of abated rent, followed by 15 months of rent calculated as a percentage of the tenants’ gross revenue. Subsequently, the next twelve months will have a fixed annual cash rent amount of $0.8 million increasing annually based on CPI. Annual cash rent under the terminated master lease for the two ALFs in North Carolina was $0.8 million. Four facilities which were under the Ridgeline master lease are currently held for sale and two facilities are in the process of transferring operations.
Amended Eduro Lease and Amended Ensign Lease. On March 1, 2024, operations of two SNFs in Colorado operated by affiliates of Eduro Healthcare, LLC (“Eduro”) were transferred to subsidiaries of The Ensign Group, Inc. (“Ensign”). In connection with the transfer, the Company partially terminated the Eduro master lease and amended one existing triple-net master lease with Ensign to include the two SNFs and extended the initial lease term by 15 years. The applicable Ensign master lease, as amended, had a remaining term at the date of amendment of approximately 20 years with two five-year renewal options and CPI-based rent escalators. Annual cash rent under the applicable Ensign master lease, as amended, increased by approximately $2.1 million and annual cash rent under the Eduro master lease, as amended, decreased by the same amount.
New Embassy Lease and Hillstone Lease Termination. On December 31, 2023, the Company terminated its master lease with affiliates of Hillstone Healthcare, Inc. (“Hillstone”). Effective January 1, 2024, in connection with the December 31, 2023 lease termination, one SNF was removed from the Hillstone master lease, was classified as held for sale as of March 31, 2024 and was sold during the three months ended June 30, 2024. See Note 4, Impairment of Real Estate Investments, Assets Held for Sale and Asset Sales, for additional information. In connection with the lease termination, the Company entered into a new triple-net master lease with a subsidiary of Embassy Healthcare Holdings, Inc. (“Embassy”) with respect to one multi-service campus. The Embassy lease has an initial term of approximately 10 years with two five-year renewal options and CPI-based rent escalators. Initial annual cash rent under the lease is approximately $0.6 million and the master lease provides Embassy with a partial rent abatement until required authorizations with respect to the ALF portion of the facility are obtained and occupancy levels reach a certain percentage.

9

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


4. IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES
Impairment of Real Estate Investments Held for Sale
The Company did not recognize any impairment during the three months ended March 31, 2025. During the three months ended March 31, 2024, the Company recognized aggregate impairment charges of $2.7 million related to properties held for sale, which is reported in impairment of real estate investments in the condensed consolidated income statements.
As of March 31, 2025, there were six facilities classified as held for sale, all of which have been recorded at the lesser of their carrying value or fair value less estimated costs to sell.
The fair values of the assets held for sale were based on estimated sales prices, which are considered to be Level 3 (as defined below) measurements within the fair value hierarchy. Estimated sales prices were determined using a market approach (comparable sales model), which relies on certain assumptions by management, including: (i) comparable market transactions, (ii) estimated prices per unit, and (iii) binding agreements for sales and non-binding offers to purchase from unrelated third-parties. There are inherent uncertainties in making these assumptions. For the Company’s impairment calculations during the three months ended March 31, 2024, the Company’s fair value estimates primarily relied on a market approach and utilized prices per unit ranging from $12,000 to $36,000, with a weighted average price per unit of $16,000.
Asset Sales and Held for Sale Reclassifications
The following table summarizes the Company’s dispositions for the three months ended March 31, 2025 and 2024 (dollars in thousands):
Three Months Ended March 31,
20252024
Number of facilities(1)
5 2 
Net sales proceeds(2)
$44,401 $1,046 
Net carrying value40,525 1,035 
Net gain on sale$3,876 $11 
(1) One non-operational previously impaired facility sold during the three months ended March 31, 2025 was not classified as held for sale as of December 31, 2024.
(2) Net sales proceeds for the three months ended March 31, 2024 includes $1.0 million of seller financing in connection with the sale of one ALF in January 2024.
The following table summarizes the Company’s assets held for sale activity for the periods presented (dollars in thousands):
Net Carrying ValueNumber of Facilities
December 31, 2024$57,261 10
Assets sold(40,525)(4)
March 31, 2025
$16,736 6 
December 31, 2023$15,011 14 
Additions to assets held for sale1,251 1 
Assets sold(1,035)(2)
Impairment of real estate held for sale(2,744) 
March 31, 2024
$12,483 13 

10

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


5. OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS
As of March 31, 2025 and December 31, 2024, the Company’s other real estate related investments, inclusive of accrued interest, consisted of the following (dollars in thousands):
Facility Count and Type
As of March 31, 2025
Loans Receivable, at Fair Value:SNFCampusALFILF
Principal Balance as of March 31, 2025
Fair Value as of March 31, 2025(1)
Fair Value as of December 31, 2024(1)
Weighted Average Contractual Interest Rate(2), (3)
Maturity Date
Mortgage secured loans receivable(4)
614192$654,040 $658,427 $660,392 8.8 %5/31/2025 - 9/30/2039
Mezzanine loans receivable(4)
4142 88,676 87,173 80,612 12.8 %7/25/2027 - 12/31/2034
Total$742,716 $745,600 $741,004 
As of March 31, 2025
Principal Balance as of March 31, 2025
Book Value as of March 31, 2025
Book Value as of December 31, 2024
Weighted Average Contractual Interest RateMaturity Date
Preferred equity$53,782 $54,199 $54,199 11.1 %N/A
Total$53,782 $54,199 $54,199 
Facility Count and Type
As of March 31, 2025
Financing Receivable, at Fair Value:SNFCampusALFILF
Principal Balance as of March 31, 2025
Fair Value as of March 31, 2025(5)
Fair Value as of December 31, 2024(5)
Weighted Average Effective Interest Rate(6)
Maturity Date
Financing Receivable39 52$95,723 $96,628 $96,004 12.0 %11/30/2039
Total$95,723 $96,628 $96,004 
(1)Fair value of mortgage secured loans receivable includes $4.6 million and $3.4 million of accrued interest as of March 31, 2025 and December 31, 2024, respectively. Fair value of mezzanine loans receivable includes $1.0 million and $0.9 million of accrued interest as of March 31, 2025 and December 31, 2024, respectively.
(2)Rates are net of subservicing fee, if applicable.
(3)Three mortgage secured loans receivable and two mezzanine loans receivable use term secured overnight financing rate (“SOFR”), which are subject to a floor for certain of the loans. Term SOFR used as of March 31, 2025 was 4.32%.
(4)If the Company also has extended mezzanine financing to an affiliate of the borrower under a mortgage loan receivable, the applicable facility counts are included in both respective totals.
(5)Fair value of financing receivable includes $0.9 million and $0.3 million of accrued interest as of March 31, 2025 and December 31, 2024, respectively.
(6)The Company leased these facilities back to the seller under a 15-year contract, with two five-year renewal options. The agreement provides for an initial contractual cash yield of 11.0% for the first three years, with annual CPI-based escalators beginning in year four, subject to a 3% cap. The agreement provides for deferred payments equal to 2.0% of the contractual cash yield in the first year and 0.5% of the contractual cash yield in the second year. The agreement also provides for purchase options. At the time the seller-lessee exercises its purchase options, option proceeds will be used to repay any outstanding deferred payments as well as additional payments such that the Company receives a contractual cash yield of 12.5% on its gross investment in the applicable properties through the option exercise date. If any deferred amounts remain unpaid, beginning in year eight, the deferred amounts are to be repaid in 24 equal monthly payments. The Company has not received notice of exercise for the purchase option period currently open.

11

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


The following table summarizes the Company’s other real estate related investments activity for the three months ended March 31, 2025 and 2024 (dollars in thousands):
Three Months Ended March 31,
2025
2024
Origination of other real estate related investments$6,389 $53,165 
Accrued interest, net1,280 425 
Unrealized gain (loss) on other real estate related investments, net1,287 (612)
Prepayments of other real estate related investments(4,360) 
Net change in other real estate related investments$4,596 $52,978 
2025 Other Real Estate Related Investment Transactions
On January 10, 2025, the Company advanced the second installment of a mezzanine loan for one SNF secured by a pledge of membership interests in an up-tier holding company of the borrower group for $6.4 million. The loan bears interest at a rate of 13%, with annual CPI-based escalators. The mezzanine loan is set to mature on December 31, 2034. The mezzanine loan may not be prepaid in whole or in part prior to maturity. The Company elected the fair value option for the mezzanine loan.
In February 2025, the Company received a partial prepayment on one mortgage loan in the amount of $4.4 million in connection with the borrower’s election to release one skilled nursing facility from the loan. The remaining outstanding balance of $2.9 million was subsequently paid off, see Note 15, Subsequent Events, for additional information.
2024 Other Real Estate Related Investment Transactions
On January 1, 2024, the Company closed on the sale of one ALF. In connection with the sale, the Company provided affiliates of the purchaser of the property with a $1.0 million mortgage loan which bears interest at a rate of 9.0%. The mortgage loan is secured by the ALF and is set to mature on January 1, 2027. The mortgage loan may be prepaid in whole before the maturity date. The Company elected the fair value option for the mortgage loan.
On January 25, 2024, the Company extended a $9.8 million mezzanine loan for a portfolio of ten SNFs located in Missouri secured by a pledge of membership interests in an up-tier holding company of the borrower group. The Company participated in the loan alongside a co-lender pursuant to a participation agreement entered into between the Company and the co-lender. Pursuant to such agreement, the Company provided $9.8 million in mezzanine loan proceeds and the co-lender provided the remaining $10.2 million of loan proceeds. As a participant in the loan, and subject to limited exceptions, the Company is entitled to receive its proportionate share of loan payments made by the borrower with each co-lender’s proportionate share being given equal weight. The loan bears interest at term SOFR plus 8.75%, with a term SOFR floor of 6%, payable monthly and net of a 0.75% subservicing fee. Commencing on February 1, 2026, monthly principal payments shall be due. The mezzanine loan is set to mature on July 25, 2027, with two six-month extension options and may (subject to certain restrictions) be prepaid in whole before the maturity date for an exit fee ranging from 1% to 2% of the loan plus unpaid interest payments equal to 24 months (less the amount of monthly interest payments made by the borrower through the date of prepayment). The Company elected the fair value option for the mezzanine loan.
On February 1, 2024, the Company extended a $7.4 million mezzanine loan for one SNF located in California secured by a pledge of membership interests in an up-tier holding company of the borrower group. The loan bears interest at 11.5%, payable monthly. The mezzanine loan is set to mature on January 31, 2029, and may not (subject to certain limited exceptions) be prepaid prior to the date that is 18 months following the loan closing. The Company elected the fair value option for the mezzanine loan.

12

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


On February 2, 2024, the Company extended a $35.0 million mezzanine loan for a portfolio of 15 SNFs located in Virginia secured by a pledge of membership interests in an up-tier holding company of the borrower group. The Company participated in the loan alongside a co-lender pursuant to a participation agreement entered into between the Company and the co-lender. Pursuant to such agreement, the Company provided $35.0 million in mezzanine loan proceeds and the co-lender provided the remaining $50.0 million of loan proceeds. As a participant in the loan, and subject to limited exceptions, the Company is entitled to receive its proportionate share of loan payments made by the borrower with each co-lender’s proportionate share being given equal weight. The loan bears interest at term SOFR plus 8.75%, with a term SOFR floor of 6%, payable monthly and net of a 0.75% subservicing fee. Commencing on February 2, 2026, monthly principal payments shall be due. The mezzanine loan is set to mature on August 1, 2027, with two six-month extension options and may (subject to certain restrictions) be prepaid in whole before the maturity date for an exit fee ranging from 1% to 2% of the loan plus unpaid interest payments equal to 18 months (less the amount of monthly interest payments made by the borrower through the date of prepayment). The Company elected the fair value option for the mezzanine loan.
Financing Receivable
On December 5, 2024, the Company invested $95.7 million, exclusive of transaction costs, to acquire a portfolio of 46 properties in Illinois in a sale and leaseback transaction with affiliates of Cascade Capital Partners, LLC (“Cascade”). In connection with the transaction, the Company entered into a new triple-net master lease with Cascade and provided Cascade with options to repurchase the properties, structured over multiple tranches, with various option window start dates, beginning December 1, 2024, and open through the remainder of the 15-year term. As such, the Company determined that the sale and leaseback transaction met the accounting criteria to be presented as a financing receivable on its consolidated balance sheets and recorded interest income from financing receivable on its consolidated statements of operations. Interest income is based on an imputed interest rate over the term of the applicable financing arrangement and as a result the interest recognized in any particular period will not equal the cash payments from the agreement in that period. Cash received from the financing receivable was $2.2 million during the three months ended March 31, 2025. The Company elected the fair value option for the financing receivable.
Other Loans Receivables
As of March 31, 2025 and December 31, 2024, the Company’s other loans receivable, included in prepaid expenses and other assets, net on the Company’s condensed consolidated balance sheets, consisted of the following (dollars in thousands):
As of March 31, 2025
Investment
Principal Balance as of March 31, 2025
Book Value as of March 31, 2025
Book Value as of December 31, 2024
Weighted Average Contractual Interest RateMaturity Date
Other loans receivable$21,757 $21,820 $22,010 9.0 %9/30/2025 - 12/31/2027
Expected credit loss— (6,994)(6,994)
Total$21,757 $14,826 $15,016 
The following table summarizes the Company’s other loans receivable activity for the three months ended March 31, 2025 and 2024 (dollars in thousands):
Three Months Ended March 31,
2025
2024
Principal payments$(222)$ 
Accrued interest, net32  
Net change in other loans receivable$(190)$ 
Expected credit losses and recoveries are recorded in provision for loan losses, net in the condensed consolidated income statements. During both the three months ended March 31, 2025 and 2024, the Company had no additional expected credit loss and did not consider any loan receivable investments to be impaired.

13

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


The following table summarizes the interest and other income recognized from the Company’s loans receivable and other investments during the three months ended March 31, 2025 and 2024 (dollars in thousands):
For the Three Months Ended March 31,
Investment20252024
Mortgage secured loans receivable$14,388 $3,772 
Mezzanine loans receivable2,821 1,895 
Preferred equity investment1,497 68 
Other loans receivable334 331 
Financing receivable2,807  
Other(1)
3,128 3,502 
Total$24,975 $9,568 
(1) Other income is comprised of interest income on money market funds and escrow deposits.
6. FAIR VALUE MEASUREMENTS
The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.

Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.

The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.

14

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


Items Measured at Fair Value on a Recurring Basis
The following table presents information about the Company’s assets measured at fair value on a recurring basis as of March 31, 2025 and December 31, 2024, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):
Level 1Level 2Level 3
Balance as of March 31, 2025
Assets:
Mortgage secured loans receivable$ $ $658,427 $658,427 
Mezzanine loans receivable  87,173 87,173 
Financing receivable  96,628 96,628 
Total$ $ $842,228 $842,228 
Level 1Level 2Level 3
Balance as of December 31, 2024
Assets:
Mortgage secured loans receivable$ $ $660,392 $660,392 
Mezzanine loans receivable  80,612 80,612 
Financing receivable  96,004 96,004 
Total$ $ $837,008 $837,008 

The following table details the Company’s assets measured at fair value on a recurring basis using Level 3 inputs (dollars in thousands):
Investments in Real Estate Secured LoansInvestments in Mezzanine LoansInvestment in Financing Receivable
Balance at December 31, 2024
$660,392 $80,612 $96,004 
Originations 6,389  
Accrued interest, net1,173 107 624 
Unrealized gain, net1,222 65  
Payments(4,360)  
Balance as of March 31, 2025
$658,427 $87,173 $96,628 
Real estate secured and mezzanine loans receivable: The fair value of the secured and mezzanine loans receivables were estimated using an internal valuation model that considered the expected future cash flows of the investment, the underlying collateral value, market interest rates and other credit enhancements. As such, the Company classifies each instrument as Level 3 due to the significant unobservable inputs used in determining market interest rates for investments with similar terms. During the three months ended March 31, 2025, the Company recorded a net unrealized gain of $1.3 million on its secured and mezzanine loans receivable, to bring the interest rates in line with market rates. During the three months ended March 31, 2024, the Company recorded an unrealized loss of $0.8 million on the Company’s secured and mezzanine loans receivable due to rising interest rates, partially offset by unrealized gains of $0.2 million due to increases in expected cash flows on floating rate loans. Future changes in market interest rates or collateral value could materially impact the estimated discounted cash flows that are used to determine the fair value of the secured and mezzanine loans receivable. As of March 31, 2025 and December 31, 2024, the Company did not have any loans that were 90 days or more past due.
The following table shows the quantitative information about unobservable inputs related to the Level 3 fair value measurements comprising the investments in secured and mezzanine loans receivables as of March 31, 2025:
Type
Book Value as of March 31, 2025
Valuation TechniqueUnobservable InputsRange
Mortgage secured loans receivable$658,427 Discounted cash flowDiscount Rate
8% - 14%
Mezzanine loans receivable87,173 Discounted cash flowDiscount Rate
12% - 14%

15

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


Financing receivable: The fair value was determined using a widely accepted valuation technique, discounted cash flow analysis, on the expected cash flows. The discount rate used to value the future cash inflows of the financing receivable at March 31, 2025 was 12%.
For the three months ended March 31, 2025, there were no classification changes in assets and liabilities with Level 3 inputs in the fair value hierarchy.

Items Disclosed at Fair Value
Considerable judgment is necessary to estimate the fair value disclosure of financial instruments. The estimates of fair value presented herein are not necessarily indicative of the amounts that could be realized upon disposition of the financial instruments. A summary of the face value, carrying amount and fair value of the Company’s preferred equity investments and the Notes (as defined in Note 7, Debt, below) as of March 31, 2025 and December 31, 2024 is as follows (dollars in thousands):  
 March 31, 2025December 31, 2024
 LevelFace
Value
Carrying
Amount
Fair
Value
Face
Value
Carrying
Amount
Fair
Value
Financial assets:
Preferred equity investments3$53,782 $54,199 $54,199 $53,782 $54,199 $54,199 
Financial liabilities:
Senior unsecured notes payable2$400,000 $397,149 $374,880 $400,000 $396,927 $381,812 

Cash and cash equivalents, restricted cash, accounts and other receivables, accounts payable, and accrued liabilities: The carrying values for these instruments approximate their fair values due to the short-term nature of these instruments.

Preferred equity investments: The fair value of the preferred equity investments was estimated using an internal valuation model that considered the expected future cash flows of the investment, the underlying collateral value, market interest rates and other credit enhancements. The Company utilized discount rates of 11% to 15% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

Senior unsecured notes payable: The fair value of the Notes was determined using third-party quotes derived from orderly trades.

Unsecured revolving credit facility: The fair value approximates the carrying value as the interest rates are variable and approximate prevailing market interest rates and spreads for similar debt arrangements.

7. DEBT
The following table summarizes the balance of the Company’s indebtedness as of March 31, 2025 and December 31, 2024 (dollars in thousands):
March 31, 2025December 31, 2024
Principal AmountDeferred Loan FeesCarrying AmountPrincipal AmountDeferred Loan FeesCarrying Amount
Senior unsecured notes payable$400,000 $(2,851)$397,149 $400,000 $(3,073)$396,927 
Unsecured revolving credit facility(1)
425,000  425,000    
$825,000 $(2,851)$822,149 $400,000 $(3,073)$396,927 
(1) Deferred financing fees are included in deferred financing costs, net on the balance sheet, and not reflected as a reduction to the unsecured revolving credit facility.

Senior Unsecured Notes Payable
2028 Senior Notes. On June 17, 2021, the Company’s wholly owned subsidiary, CTR Partnership, L.P. (the “Operating Partnership”), and its wholly owned subsidiary, CareTrust Capital Corp. (together with the Operating Partnership, the “Issuers”), completed a private offering of $400.0 million aggregate principal amount of 3.875% Senior Notes due 2028 (the “Notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A and to non-U.S. persons

16

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended. The Notes were issued at par, resulting in gross proceeds of $400.0 million and net proceeds of approximately $393.8 million after deducting underwriting fees and other offering expenses. The Notes mature on June 30, 2028. The Notes accrue interest at a rate of 3.875% per annum payable semiannually in arrears on June 30 and December 30 of each year, commencing on December 30, 2021.
The Issuers may redeem some or all of the Notes at any time prior to March 30, 2028 at a price equal to 100% of the principal amount of the Notes redeemed plus accrued and unpaid interest on the Notes, if any, to, but not including, the redemption date, plus a “make-whole” premium. At any time on or after March 30, 2028, the Issuers may redeem some or all of the Notes at a redemption price equal to 100% of the principal amount of the Notes redeemed plus accrued interest on the Notes, if any, to, but not including, the redemption date. If certain changes of control of the Company occur, the Issuers will be required to make an offer to holders of the Notes to repurchase their Notes at a price of 101% of their principal amount plus accrued and unpaid interest, if any, to, but not including, the repurchase date.
The obligations under the Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by the Company and all of CareTrust’s existing and future subsidiaries (other than the Issuers) that guarantee obligations under the Amended Credit Facility (as defined below); provided, however, that such guarantees are subject to automatic release under certain customary circumstances.
The indenture governing the Notes contains customary covenants such as limiting the ability of the Company and its restricted subsidiaries to: incur or guarantee additional indebtedness; incur or guarantee secured indebtedness; pay dividends or distributions on, or redeem or repurchase, capital stock; make certain investments or other restricted payments; sell assets; enter into transactions with affiliates; merge or consolidate or sell all or substantially all of their assets; and create restrictions on the ability of the Issuers and their restricted subsidiaries to pay dividends or other amounts to the Issuers. The indenture governing the Notes also requires the Company and its restricted subsidiaries to maintain a specified ratio of unencumbered assets to unsecured indebtedness. These covenants are subject to a number of important and significant limitations, qualifications and exceptions. The indenture governing the Notes also contains customary events of default.
As of March 31, 2025, the Company was in compliance with all applicable financial covenants under the indenture governing the Notes.

Unsecured Revolving Credit Facility
On December 18, 2024, the Operating Partnership, as the borrower, the Company, as guarantor, CareTrust GP, LLC, and certain of the Operating Partnership’s wholly owned subsidiaries, entered into a third amended and restated credit and guaranty agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender (as amended from time to time, the “Third Amended Credit Agreement”). The Third Amended Credit Agreement, which amends and restates the Second Amended Credit Agreement (as defined below) provides for an upsized unsecured revolving credit facility (the “Third Amended Revolving Facility”) with revolving commitments in an aggregate principal amount of $1.2 billion, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments. Future borrowings under the Third Amended Revolving Facility will be used for working capital purposes, for capital expenditures, to fund acquisitions and for general corporate purposes.
On December 16, 2022, the Operating Partnership, as the borrower, the Company, as guarantor, CareTrust GP, LLC, and certain of the Operating Partnership’s wholly owned subsidiaries, entered into a second amended and restated credit and guaranty agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender (as amended from time to time, the “Second Amended Credit Agreement”). The Second Amended Credit Agreement, which amends and restates the Company’s amended and restated credit and guaranty agreement, dated as of February 8, 2019 (as amended, the “Prior Credit Agreement”) provided for: (i) an unsecured revolving credit facility (the “Revolving Facility”) with revolving commitments in an aggregate principal amount of $600.0 million, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments and (ii) the continuation of the unsecured term loan credit facility which was previously extended under the Prior Credit Agreement (the “Term Loan” and together with the Revolving Facility, the “Second Amended Credit Facility”) in an aggregate principal amount of $200.0 million.

17

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


On October 10, 2023, the Operating Partnership, the Company, CareTrust GP, LLC, certain of the Operating Partnership’s wholly owned subsidiaries and KeyBank National Association entered into the First Amendment to the Second Amended Credit Agreement (the “First Amendment”). The First Amendment restates the definition of Consolidated Total Asset Value to include net proceeds from at-the-market forward commitments executed but not yet closed as of the relevant date as if such proceeds had actually been received.
The interest rates applicable to loans under the Third Amended Revolving Facility are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.05% to 0.55% per annum or Adjusted Term SOFR or Adjusted Daily Simple SOFR (each as defined in the Third Amended Credit Agreement) plus a margin ranging from 1.05% to 1.55% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). In addition, the Operating Partnership will pay a facility fee on the revolving commitments under the Third Amended Revolving Facility ranging from 0.15% to 0.35% per annum, based on the debt to asset value ratio of the Company and its consolidated subsidiaries (unless the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt and the Operating Partnership elects to decrease the applicable margin as described above, in which case the Operating Partnership will pay a facility fee on the revolving commitments ranging from 0.125% to 0.30% per annum based on the credit ratings of the Company’s senior long-term unsecured debt).
As of March 31, 2025, the Operating Partnership had borrowings outstanding of $425.0 million under the Third Amended Revolving Facility.
The Third Amended Revolving Facility has a maturity date of February 9, 2029, and includes, at the sole discretion of the Operating Partnership, two six-month extension options.
The Third Amended Credit Facility is guaranteed, jointly and severally, by the Company and its wholly owned subsidiaries that are party to the Third Amended Credit Agreement (other than the Operating Partnership). The Third Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend organizational documents and pay certain dividends and other restricted payments. The Third Amended Credit Agreement requires the Company to comply with financial maintenance covenants to be tested quarterly, consisting of a maximum debt to asset value ratio, a minimum fixed charge coverage ratio, a minimum tangible net worth, a maximum secured debt to asset value ratio, a maximum unsecured debt to unencumbered properties asset value ratio and a minimum unsecured interest coverage ratio. The Third Amended Credit Agreement also contains certain customary events of default, including the failure to make timely payments under the Third Amended Credit Facility or other material indebtedness, the failure to satisfy certain covenants (including the financial maintenance covenants), the occurrence of change of control and specified events of bankruptcy and insolvency.
As of March 31, 2025, the Company was in compliance with all applicable financial covenants under the Third Amended Credit Agreement.
8. EQUITY AND REDEEMABLE NONCONTROLLING INTEREST
Common Stock
At-The-Market Offering—On January 21, 2025, the Company entered into a new equity distribution agreement to issue and sell, from time to time, up to $750.0 million in aggregate offering price of its common stock through an “at-the-market” equity offering program (the “New ATM Program”) and terminated its previous $750.0 million “at-the-market” equity offering program (together, with all previous at-the-market equity offering programs, the “Previous ATM Programs” and together with the New ATM Program, the “ATM Program”). In addition to the issuance and sale of shares of its common stock, the ATM Program also provides for the ability to enter into one or more forward sales agreements (each, an “ATM forward contract”) with sales agents for the sale of the Company’s shares of common stock under the ATM Program.

18

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


In the event the Company enters into an ATM forward contract to sell shares of common stock pursuant to the ATM Program, the Company would expect to fully physically settle forward equity sales by delivery of shares of common stock to the forward purchaser and receive cash proceeds upon one or more settlement dates, which are typically a one-year term, at the Company’s discretion, prior to the final settlement date, at which time the Company would expect to receive aggregate net cash proceeds at settlement equal to the number of shares sold on a forward basis multiplied by the relevant forward price per share. The weighted average forward sale price that the Company would expect to receive upon physical settlement would be subject to adjustment for (i) a floating interest rate factor equal to a specified daily rate less a spread, (ii) the forward purchaser’s stock borrowing costs and (iii) scheduled dividends through the settlement.
The following table summarizes the ATM Program activity (or activity under any predecessor at-the-market equity offering programs) for the three months ended March 31, 2025 and 2024 (in thousands, except per share amounts):
For the Three Months Ended
March 31, 2025
March 31, 2024
Number of shares553 11,600 
Average sales price per share$28.87 $23.55 
Gross proceeds(1)
$15,964 $273,233 
(1) Total gross proceeds is before $0.2 million and $3.4 million of commissions paid to the sales agents during the three months ended March 31, 2025 and 2024, respectively, under the ATM Program.
As of March 31, 2025, the Company had $734.0 million available for future issuances under the New ATM Program.
Dividends on Common StockThe following table summarizes the cash dividends per share of common stock declared by the Company’s board of directors for the first three months of 2025 (dollars in thousands, except per share amounts):
For the Three Months Ended
March 31, 2025
Dividends declared per share$0.335 
Dividends payment dateApril 15, 2025
Dividends payable as of record date$63,053 
Dividends record dateMarch 31, 2025
Redeemable Noncontrolling Interest
Arrangements with noncontrolling interest holders are assessed for appropriate balance sheet classification based on the redemption and other rights held by the noncontrolling interest holder. One of the Company’s noncontrolling interest holders has the ability to put its equity interest to the Company during specified option exercise periods, subject to certain conditions. The put option is payable in cash and subject to changes in redemption value. Accordingly, the Company records the redeemable noncontrolling interest outside of permanent equity. The redeemable noncontrolling interest is adjusted for additional contributions and distributions and the proportionate share of the net earnings or losses. When the redemption of the noncontrolling interest becomes probable, the Company will record the redeemable noncontrolling interest at the greater of its carrying amount or redemption value at the end of each reporting period by making an election either to accrete changes in the redemption value of the redeemable noncontrolling interest over the period from the date it is probable of exercise to the earliest redemption date or to recognize the entire adjustment on the date redemption becomes probable. In addition to the rights of the redeemable noncontrolling interest holder, the Company has the ability to call the interest of the noncontrolling interest holder during specified option exercise periods.
As of March 31, 2025, the redeemable noncontrolling interest did not meet the conditions for redemption.


19

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


9. STOCK-BASED COMPENSATION
All stock-based awards are subject to the terms of the CareTrust REIT, Inc. and CTR Partnership, L.P. Incentive Award Plan (the “Plan”). The Plan provides for the granting of stock-based compensation, including stock options, restricted stock, performance awards, restricted stock units, relative total stockholder return based stock awards and other incentive awards to officers, employees and directors in connection with their employment with or services provided to the Company. Under the Plan, 5,000,000 shares have been authorized for awards.
Under the Plan, restricted stock awards (“RSAs”) typically vest in equal annual installments over a three year period. The board of directors granted certain RSAs in 2025 (“2025 RSAs”) which vest in one installment over one year. RSAs granted to non-employee members of the board of directors (“Board Awards”) vest in full on the earlier to occur of the Company’s next Annual Meeting of Stockholders or one year. Relative total shareholder return units (“TSR Units”) granted since 2021 are subject to both time and market based conditions and cliff vest after a three-year period. The amount of such market awards that will ultimately vest is dependent on the Company’s total shareholder return (“TSR”) performance relative to a custom TSR peer group consisting of other publicly traded healthcare REITs and will range from 0% to 200% of the TSR Units initially granted. The RSAs and Board Awards are valued on the date of grant based on the closing price of the Company’s common stock, while the TSR Units are valued on the date of grant using a Monte Carlo valuation model. The vesting of certain awards may accelerate, as defined in the grant agreement, upon retirement, a change in control or other events.
The following table summarizes the status of the restricted stock award activity for the three months ended March 31, 2025:
SharesWeighted Average Share Price
Unvested balance at December 31, 2024552,999 $23.86 
Granted:
RSAs137,920 27.17 
Vested(145,951)21.16 
Unvested balance at March 31, 2025544,968 $25.42 
As of March 31, 2025, the weighted-average remaining vesting period of such awards was 2.0 years.
The following table summarizes the stock-based compensation expense recognized for the periods presented (dollars in thousands):
 
For the Three Months Ended March 31,
 20252024
Stock-based compensation expense$3,909 $2,120 
As of March 31, 2025, there was $15.8 million of unamortized stock-based compensation expense related to the unvested RSAs and TSR Units.

20

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


10. EARNINGS PER COMMON SHARE
The following table presents the calculation of basic and diluted earnings per common share attributable to CareTrust REIT, Inc. (“EPS”) for the Company’s common stock for the three months ended March 31, 2025 and 2024, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (dollars and shares in thousands, except per share amounts):
 
 For the Three Months Ended March 31,
 20252024
Numerator:
Net income attributable to CareTrust REIT, Inc.$65,802 $28,746 
Less: Net income allocated to participating securities(183)(96)
Numerator for basic and diluted earnings available to common stockholders$65,619 $28,650 
Denominator:
Weighted-average basic common shares outstanding187,152 132,836 
Dilutive potential common shares - TSR Units264 366 
Weighted-average diluted common shares outstanding187,416 133,202 
Earnings per common share attributable to CareTrust REIT, Inc., basic$0.35 $0.22 
Earnings per common share attributable to CareTrust REIT, Inc., diluted$0.35 $0.22 
Antidilutive unvested RSAs excluded from the computation(1)
545 330 
(1)For the three months ended March 31, 2025 and 2024, RSAs are antidilutive.

21

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


11. SEGMENT REPORTING
The Company represents a single reportable segment, based on how its chief operating decision maker (“CODM”) evaluates the businesses and allocates resources. The CODM assesses performance for the Company and decides how to allocate resources based on consolidated net income that is also reported on the condensed consolidated income statements. The CODM does not review segment assets at a different asset level or category than the amounts disclosed in the condensed consolidated balance sheets. The CODM uses net income to evaluate the performance of the Company in deciding whether to reinvest profits into the Company.
The CODM evaluates performance based on net income, as follows (in thousands):
For the Three Months Ended March 31,
20252024
Revenues:
Rental income$71,646 $53,502 
Interest income from financing receivable2,807  
Interest income from other real estate related investments and other income22,168 9,568 
Total revenues96,621 63,070 
Expenses:
Depreciation and amortization17,841 13,448 
Interest expense6,669 8,228 
Property taxes2,065 1,801 
Impairment of real estate investments 2,744 
Transaction costs888  
Property operating expenses105 660 
General and administrative
Cash compensation2,090 1,765 
Incentive compensation1,225 1,500 
Share-based compensation3,909 2,120 
Professional services876 738 
Taxes and insurance218 205 
Other expenses(1)
705 510 
Total general and administrative9,023 6,838 
Total expenses36,591 33,719 
Other income (loss):
Gain on sale of real estate, net3,876 11 
Unrealized gain (loss) on other real estate related investments, net1,287 (612)
Total other income (loss)5,163 (601)
Net income65,193 28,750 
Net (loss) income attributable to noncontrolling interests(609)4 
Net income attributable to CareTrust REIT, Inc.$65,802 $28,746 
(1)Other expenses include certain overhead expenses.

22

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


12. VARIABLE INTEREST ENTITIES
Noncontrolling Interests—The Company has entered into ventures with unrelated third parties to own real estate and has concluded that such ventures are VIEs. As the Company exercises power over and receives economic benefits from the VIEs, the Company is considered the primary beneficiary and consolidates the VIEs.
The following table summarizes the contributions to joint ventures that are consolidated variable interest entities through March 31, 2025 (dollars in thousands):
Gross Investment
Investment YearStateFacility TypeNumber of FacilitiesCTRENoncontrolling InterestsTotal
2023CASNF1$25,459 $653 $26,112 
2023CASNF234,269 879 35,148 
2024CAALF110,760 276 11,036 
2024CAMulti-service campuses228,076 720 28,796 
2024CASNF124,503 628 25,131 
2024 / 2025
(1)
TN, ALSNF28442,327 19,156 461,483 
2024 / 2025
(2)
- --33,663 86734,530 
Total35$599,057 $23,179 $622,236 
(1) The noncontrolling interest is classified as a redeemable noncontrolling interest on the consolidated balance sheets.
(2) The Company entered into a joint venture to acquire real estate. The gross investment amounts represent a deposit. See Note 15, Subsequent Events, for additional information.
Pursuant to the Company’s joint ventures (“JVs”), the Company typically contributes at least 90% of the JV’s total investment amount and receives 100% of the preferred equity interest in the JV and a 50% common equity interest in the JV. The Company’s JV partner contributes the remaining total investment amount in exchange for a 50% common equity interest in the JV.
Total assets and total liabilities include VIE assets and liabilities as follows (dollars in thousands):
March 31, 2025
December 31, 2024
Assets:
Real estate investments, net$581,959 $565,959 
Cash and cash equivalents6,762 6,506 
Accounts and other receivables32  
Prepaid and other assets41,078 8,317 
Total assets629,831 580,782 
Liabilities:
Accounts payable, accrued liabilities and deferred rent liabilities7,847 10,332 
Total liabilities$7,847 $10,332 
13. COMMITMENTS AND CONTINGENCIES
The Company and its subsidiaries are and may become from time to time a party to various claims and lawsuits arising in the ordinary course of business, which are not individually or in the aggregate anticipated to have a material adverse effect on the Company’s results of operations, financial condition or cash flows. Claims and lawsuits may include matters involving general or professional liability asserted against the Company’s tenants, which are the responsibility of the Company’s tenants and for which the Company is entitled to be indemnified by its tenants under the insurance and indemnification provisions in the applicable leases.

23

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


In the normal course of business, the Company enters into various commitments, typically consisting of funding of capital expenditures and short-term working capital loans to existing tenants while they await licensure and certification or are conducting turnaround work in one or more of the Company’s properties.
Capital expenditures for each property leased under the Company’s triple-net leases are generally the responsibility of the tenant, except for the facilities leased under certain master lease agreements, with certain subsidiaries of Ensign and Pennant, under which the tenant will have an option to require the Company to finance certain capital expenditures up to an aggregate of 20% of the Company’s initial investment in such property, subject to a corresponding rent increase at the time of funding. For the Company’s other triple-net master leases, the tenants also have the option to request capital expenditure funding that would generally be subject to a corresponding rent increase at the time of funding, which are subject to tenant compliance with the conditions to the Company’s approval and funding of their requests. The Company has also provided select tenants with strategic capital for facility upkeep and modernization. The Company’s Tenant Code of Conduct and Corporate Responsibility policy (the “Tenant ESG Program”) provides eligible triple-net tenants of the Company with monetary inducements to make sustainable improvements to the Company’s properties. Incentive options include a wide variety of opportunities for tenants to upgrade everything from energy and environmental systems to water-saving landscaping and more. The Company’s board of directors has authorized annual allocations of up to $500,000 to fund the Tenant ESG Program.
The table below summarizes the Company’s existing, known commitments and contingencies as of March 31, 2025 (in thousands):
Remaining Commitment
Capital expenditures(1)
$7,163 
Mortgage loans(2)
9,066 
Other loans receivable(3)
12,166 
Earn-out obligation(4)
10,000 
$38,395 
(1)As of March 31, 2025, the Company had committed to fund expansions, construction, capital improvements and ESG incentives at certain triple-net leased facilities totaling $7.2 million, of which $6.3 million is subject to rent increase at the time of funding.
(2)Includes an earn-out advance of $9.0 million related to one mortgage loan, upon satisfaction of certain conditions.
(3)Represents non-real estate secured loan commitments.
(4)Includes an earn-out obligation of up to $10.0 million under a purchase and sale agreement for one SNF in Virginia, which was acquired during 2024. The earn-out is available, contingent on the operator achieving certain thresholds per the agreement, beginning in October 2025 through October 2026.

14. CONCENTRATION OF RISK
Concentrations of credit risk arise when one or more tenants, operators, or obligors related to the Company’s investments are engaged in similar business activities or activities in the same geographic region, or have similar economic features that would cause their ability to meet contractual obligations, including those to the Company, to be similarly affected by changes in economic conditions.

24

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


Major operator concentration The Company has operators from which it derived 10% or more of its revenue for the three months ended March 31, 2025 and 2024. The following table sets forth information regarding the Company’s major operators as of March 31, 2025 and 2024:
 Number of FacilitiesNumber of Beds/UnitsPercentage of Total Revenue
Operator/BorrowerSNFCampusALF/ILFSNFCampusALF/ILFThree Months Ended
March 31, 2025(1)
Ensign(2)
89 77 9,288 843661 21 %
PACS(2)
23 3 2,809 322 11 %
March 31, 2024(1)
Ensign(2)
85 87 9,024 997 661 30 %
Priority Management Group13 2 1,742 402  13 %
(1) The Company’s rental income and interest income on other real estate related investments, exclusive of operating expense reimbursements.
(2) Ensign and the PACS Group, Inc. (“PACS”) are subject to the registration and reporting requirements of the SEC and are required to file with the SEC annual reports containing audited financial information and quarterly reports containing unaudited financial information. Ensign and PACS’s financial statements, as filed with the SEC, can be found at http://www.sec.gov. The Company has not verified this information through an independent investigation or otherwise.
Major geographic concentration – The following table provides information regarding the Company’s concentrations with respect to certain states, from which the Company derived 10% or more of its revenue for the three months ended March 31, 2025 and 2024:
 Number of FacilitiesNumber of Beds/UnitsPercentage of Total Revenue
StateSNFCampusALF/ILFSNFCampusALF/ILFThree Months Ended
March 31, 2025(1)
CA42 1211 4,979 2,004 1,032 23 %
TX38 32 4,772 476 212 12 %
TN29   3,098   12 %
March 31, 2024(1)
CA4299 5,000 1,527 723 31 %
TX4142 5,193 630 212 20 %
(1) Based on the Company’s rental income and interest income on other real estate related investments, exclusive of operating expense reimbursements.
15. SUBSEQUENT EVENTS
The Company evaluates subsequent events in accordance with ASC 855, Subsequent Events. The Company evaluates subsequent events up until the date the condensed consolidated financial statements are issued.
Recent Acquisitions
On April 1, 2025, the Company purchased one multi-service campus in California for $34.7 million, inclusive of transaction costs, through a JV. The Company contributed $33.8 million to the JV. In exchange, the Company holds 100% of the preferred equity interests in the JV and 50% of the common equity interest in the JV. The JV partner contributed the remaining $0.9 million of the total investment in exchange for 50% of the common equity interest in the JV. In connection with the acquisition of the facility, subsidiaries of the JV entered into a new master lease with affiliates of Ensign. The master lease has an initial term of approximately 15 years, with two five-year renewal options. Annual cash rent under the lease is $3.5 million, with annual CPI-based escalators. See Note 12, Variable Interest Entities, for additional information.

25

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


Mortgage Loan Prepayment
In April 2025, one mortgage loan with a principal balance of $2.9 million was fully prepaid, including all unpaid accrued interest.
At-The-Market Offering of Common Stock
In April 2025, the Company sold 3.4 million shares under the ATM Program for gross proceeds of $99.5 million at an average sales price per share of $28.90.


26

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Forward-Looking Statements
Certain statements in this report may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Those forward-looking statements include all statements that are not historical statements of fact and those regarding our intent, belief or expectations, including, but not limited to, statements regarding: future financing plans, business strategies, growth prospects and operating and financial performance; expectations regarding the making of distributions and the payment of dividends; and compliance with and changes in governmental regulations.
Words such as “anticipate(s),” “expect(s),” “intend(s),” “plan(s),” “believe(s),” “may,” “will,” “would,” “could,” “should,” “seek(s)” and similar expressions, or the negative of these terms, are intended to identify such forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks and uncertainties that could lead to actual results differing materially from those projected, forecasted or expected. Although we believe that the assumptions underlying the forward-looking statements are reasonable, we can give no assurance that our expectations will be attained. Factors which could have a material adverse effect on our operations and future prospects or which could cause actual results to differ materially from our expectations include, but are not limited to: (i) the possibility of an offer or firm intention to make an offer for Care REIT plc by any third party; (ii) our ability to complete the acquisition of Care REIT, integrate its operations and achieve the benefits expected to result from the acquisition; (iii) the ability and willingness of our tenants and borrowers to meet and/or perform their obligations under the agreements we have entered into with them, including without limitation, their respective obligations to indemnify, defend and hold us harmless from and against various claims, litigation and liabilities; (iv) the risk that we may have to incur additional impairment charges related to our assets held for sale if we are unable to sell such assets at the prices we expect; (v) the impact of healthcare reform legislation, including minimum staffing level requirements, on the operating results and financial conditions of our tenants and borrowers; (vi) the ability of our tenants and borrowers to comply with applicable laws, rules and regulations in the operation of the properties we lease to them or finance; (vii) the ability and willingness of our tenants to renew their leases with us upon their expiration, and the ability to reposition our properties on the same or better terms in the event of nonrenewal or in the event we replace an existing tenant, as well as any obligations, including indemnification obligations, we may incur in connection with the replacement of an existing tenant; (viii) the availability of and the ability to identify (a) tenants who meet our credit and operating standards, and (b) suitable acquisition opportunities and the ability to acquire and lease the respective properties to such tenants on favorable terms; (ix) the ability to generate sufficient cash flows to service our outstanding indebtedness; (x) access to debt and equity capital markets; (xi) fluctuating interest rates; (xii) the impact of public health crises, including significant COVID-19 outbreaks as well as other pandemics or epidemics; (xiii) the ability to retain our key management personnel; (xiv) the ability to maintain our status as a real estate investment trust (“REIT”); (xv) changes in the U.S. tax law and other state, federal or local laws, whether or not specific to REITs; (xvi) other risks inherent in the real estate business, including potential liability relating to environmental matters and illiquidity of real estate investments; and (xvii) any additional factors included under Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, as such risk factors may be amended, supplemented or superseded from time to time by other reports we file with the Securities and Exchange Commission (the “SEC”).
Forward-looking statements speak only as of the date of this report. Except in the normal course of our public disclosure obligations, we expressly disclaim any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any statement is based.
Overview
CareTrust REIT is a self-administered, publicly-traded REIT engaged in the ownership, acquisition, financing, development and leasing of skilled nursing, seniors housing and other healthcare-related properties. As of March 31, 2025, we owned, directly or indirectly in consolidated joint ventures, and leased to independent operators 255 skilled nursing facilities (“SNFs”), multi-service campuses, assisted living facilities (“ALFs”) and independent living facilities (“ILFs”) consisting of 27,672 operational beds and units located in 32 states with the highest concentration of properties by rental income located in California, Texas and Tennessee. As of March 31, 2025, we also had other real estate related investments consisting of three preferred equity investments, 15 real estate secured loans receivable and five mezzanine loans receivable with a carrying value of $799.8 million and one financing receivable with a carrying value of $96.6 million.

27

Recent Developments
Planned Acquisition
On March 11, 2025, the Company announced (the “Rule 2.7 Announcement”) pursuant to Rule 2.7 of the United Kingdom City Code on Takeovers and Mergers (the “Code”) a firm intention to make a cash offer (the “Offer”) to acquire (the “Acquisition”), through its wholly-owned direct subsidiary, CR United Bidco Limited (“Bidco”), the entire issued and to be issued ordinary share capital (other than Scheme Restricted Shares (as defined in the Rule 2.7 Announcement)) of Care REIT plc (“Target”). Target is a UK-based real estate investment trust listed on the Main Market of the London Stock Exchange focused on investment in care homes throughout the United Kingdom. The Acquisition is intended to be effected by means of a scheme of arrangement (the “Scheme”) under Part 26 of the United Kingdom Companies Act 2006.
Under the terms of the Scheme, Target shareholders, other than any Sanctions Disqualified Shareholders (as defined in the Rule 2.7 Announcement) will be entitled to receive 108 pence in cash for each Target share they hold, which values the Target’s existing issued and to be issued ordinary share capital at approximately $597 million, and, together with the assumption of Target’s net debt of approximately $259 million, represents a total purchase price of approximately $856 million. Payments will be in Great British Pounds but are expressed in US dollars based on the exchange rate of 0.7501 GBP to 1.00 USD on April 30, 2025.
The transaction has been unanimously approved by the boards of directors of both the Company and Target and has also been approved by the requisite majorities of Target shareholders at the Target shareholder meetings convened to approve it. Completion of the acquisition is further conditioned on (i) sanction of the Scheme by the High Court of Justice of England and Wales and (ii) other customary conditions (the “Conditions”). The Offer is subject to termination if not completed by 11:59 pm (London time) on July 9, 2025 (or such later date (if any) as the Company and Target may agree with the consent of the United Kingdom Panel on Takeovers and Mergers and as the Court may approve (if such approval(s) is/are required)).
Subject to the satisfaction or waiver of the Conditions, it is expected that the Acquisition will be completed in May 2025.

Market Trends and Uncertainties
Recent macroeconomic conditions, particularly market uncertainty, declining consumer sentiment, inflation (including higher supply costs and shortages), elevated interest rates and related changes to consumer spending, has adversely impacted and could continue to adversely impact our tenants’ ability to meet some of their financial obligations to us. Higher interest rates and market volatility have also increased our costs of capital to finance acquisitions and increased our borrowing costs. We continue to monitor changes in the interest rate environment and the effect of changing rates on our business. In addition, current macroeconomic conditions and the resulting market volatility may adversely impact our ability to sell properties on acceptable terms, if at all, which could result in additional impairment charges.
As a result of impacts experienced by our operators due to recent market trends and uncertainties, the ability of some of our tenants and borrowers to meet their financial obligations to us in full has been negatively impacted. From time to time in the past, we have taken actions to reposition one or more properties with a replacement tenant or sell the property and, in certain cases, we have also restructured tenants’ long-term obligations. See “Impairment of Real Estate Assets, Assets Held for Sale and Asset Sales” below. During the three months ended March 31, 2025, we collected 99.2% of contractual rents and interest due from our operators and borrowers excluding cash deposits. In the event our tenants or borrowers are unable to satisfy their obligations to us and we are unable to effect these actions on terms that are as favorable to us as those currently in place, our rental and interest income would be adversely impacted and we may incur additional expenses or obligations and be required to recognize additional impairment charges or fair value adjustments.

Regulatory Updates
In April 2025, the Centers for Medicare and Medicaid Services (“CMS”) proposed a payment rate update to SNF reimbursements for fiscal 2026, which includes a net increase of 2.8% in Medicare Part A payments to SNFs. In July 2024, CMS approved its payment rate update to SNF reimbursements for fiscal year 2025, which includes a net increase of 4.2%, or approximately $1.4 billion, in Medicare Part A payments to SNFs. These increases are expected to partially offset some of our tenants’ higher operating costs.
In April 2025, a U.S. District Court vacated a CMS final rule regarding minimum staffing requirements, which was previously issued on April 22, 2024 and consisted of three core staffing requirements: (1) overall minimum standard of 3.48 total nurse staff hours per resident day; (2) minimum nurse staffing standards of 0.55 hours per resident day for registered nurses and 2.45 hours of care from a certified nurse’s aid per resident per day; and (3) a requirement to have a registered nurse onsite 24 hours a day, seven days a week. The rule included a staggered implementation approach for which CMS was required

28

to publish additional details on compliance as the implementation dates approached. The rule also included possible waivers and temporary hardship exemptions for select facilities; however, no funding for the additional staff would be provided.
On October 13, 2023, California Senate Bill No. 525 (“SB 525”) was signed into law, requiring a substantial increase in the minimum wage for workers operating in certain health care facilities. As a result of SB 525, certain health care facilities (including licensed skilled nursing facilities) operating in California are required to increase the wages of their covered health care employees to at least $21 per hour, which was initially required to be effective from June 1, 2024 to May 31, 2026, $22 or $23 per hour (depending on facility type) from June 1, 2026 to May 31, 2028, and $25 per hour after June 1, 2028. After the initial implementation was delayed by the Governor of California in June 2024, SB 525 went into effect on October 16, 2024.
Recent Investments
The following table summarizes our acquisitions from January 1, 2025 through May 1, 2025 (dollars in thousands):
Type of Property
Purchase Price(1)
Initial Annual Cash Rent(2)
Number of Properties
Number of Beds/Units(3)
Skilled nursing(4)
$20,448 $2,000 124 
Multi-service campuses(5)
34,662 3,479 223 
Assisted living20,637 1,896 160 
Total$75,747 $7,375 507 
(1)Purchase price includes capitalized acquisition costs.
(2)Initial annual cash rent represents initial cash rent for the first twelve months.
(3)The number of beds/units includes operating beds at acquisition date.
(4)Includes one SNF held through a joint venture. See Note 3, Real Estate Investments, Net, and Note 12, Variable Interest Entities, for additional information.
(5)Includes one multi-service campus held through a joint venture.
The following table summarizes our other real estate related investments from January 1, 2025 through May 1, 2025 (dollars in thousands):
Investment TypeInvestment
Annual Initial Interest Income(1)
Number of Properties
Number of Beds/Units(2)
Mezzanine loans receivable$6,389 $842 148 
Total$6,389 $842 148 
(1)Represents annualized acquisition-date interest income, less subservicing fees, if applicable. For floating rate loans, interest income has been calculated using the benchmark rate at loan origination.
(2)The number of beds/units includes operating beds at the investment date.
At-The-Market Offering of Common Stock
On January 21, 2025, we entered into a new equity distribution agreement to issue and sell, from time to time, up to $750.0 million in aggregate offering price of our common stock through an “at-the-market” equity offering program (the “New ATM Program”) and terminated our previous $750.0 million “at-the-market” equity offering program (together, with all previous at-the-market equity offering programs, the “Previous ATM Programs” and together with the New ATM Program, the “ATM Program”). In addition to the issuance and sale of shares of our common stock, we may also enter into one or more forward sales agreements (each, an “ATM forward contract”) with sales agents for the sale of shares of our common stock under the ATM Program. There were no outstanding ATM forward contracts that had not settled as of March 31, 2025.
In the event we enter into an ATM forward contract to sell shares of common stock pursuant to the ATM Program, we would expect to fully physically settle forward equity sales by delivery of shares of common stock to the forward purchaser and receive cash proceeds upon one or more settlement dates, which are typically a one-year term, at our discretion, prior to the final settlement date, at which time we would expect to receive aggregate net cash proceeds at settlement equal to the number of shares sold on a forward basis multiplied by the relevant forward price per share. The weighted average forward sale price that we would expect to receive upon physical settlement would be subject to adjustment for (i) a floating interest rate factor equal to a specified daily rate less a spread, (ii) the forward purchaser’s stock borrowing costs and (iii) scheduled dividends through the settlement.

29

The following tables summarize the ATM Program activity for the three months ended March 31, 2025 and 2024 (in thousands, except per share amounts).
For the Three Months Ended
March 31, 2025March 31, 2024
Number of shares553 11,600 
Average sales price per share$28.87 $23.55 
Gross proceeds(1)
$15,964 $273,233 
(1) Total gross proceeds is before $0.2 million and $3.4 million of commissions paid to the sales agents during the three months ended March 31, 2025 and 2024, respectively, under the ATM Program.
As of March 31, 2025, we had $734.0 million available for future issuances under the New ATM Program. In April 2025, we sold 3.4 million shares for gross proceeds of $99.5 million at an average sales price per share of $28.90. As of May 1, 2025, we had $634.5 million available for future issuances under the New ATM Program.
Impairment of Real Estate Assets, Assets Held for Sale, and Asset Sales
We did not recognize any impairment charges during the three months ended March 31, 2025. During the three months ended March 31, 2024, we recognized an impairment charge of $2.7 million related to properties held for sale, which is reported in impairment of real estate investments in the condensed consolidated income statements.
Asset Sales and Held for Sale Reclassifications
We periodically reassess our investments and tenant relationships, and from time to time we have selectively disposed of certain facilities or investments, or terminated tenant relationships, and we expect to continue making such reassessments and, where appropriate, taking such actions. We classify our real estate investments as held for sale when the applicable criteria have been met, which includes a formal plan to sell the properties that is expected to be completed within one year, among other criteria. Upon designation as held for sale, we cease depreciation and record the investment at the lower of carrying value or estimated fair value less costs to sell, which could result in an impairment of the real estate investments held for sale, if necessary.
The following table summarizes our dispositions for the three months ended March 31, 2025 (dollars in thousands):
For the Three Months Ended March 31,
2025
Number of facilities(1)
Net sales proceeds$44,401 
Net carrying value40,525 
Net gain on sale$3,876 
(1) One non-operational previously impaired facility sold during the three months ended March 31, 2025 was not classified as held for sale as of December 31, 2024.
The following table summarizes our assets held for sale activity for the period presented (dollars in thousands):
Net Carrying ValueNumber of Facilities
December 31, 2024$57,261 10
Assets sold(40,525)(4)
March 31, 2025$16,736 


30

Results of Operations
Three Months Ended March 31, 2025 Compared to Three Months Ended December 31, 2024:
 Three Months EndedIncrease
(Decrease)
Percentage
Difference
 March 31, 2025December 31, 2024
 (dollars in thousands)
Revenues:
Rental income$71,646 $62,199 $9,447 15 %
Interest income from financing receivable2,807 1,009 1,798 178 %
Interest income from other real estate related investments and other income22,168 23,736 (1,568)(7)%
Expenses:
Depreciation and amortization17,841 15,514 2,327 15 %
Interest expense6,669 5,122 1,547 30 %
Property taxes2,065 1,946 119 %
Impairment of real estate investments— 5,353 (5,353)(100)%
Transaction costs888 1,326 (438)(33)%
Provision for loan losses, net— 4,900 (4,900)(100)%
Property operating expenses105 1,322 (1,217)(92)%
General and administrative9,023 9,286 (263)(3)%
Other income:
Gain on sale of real estate, net3,876 46 3,830 *
Unrealized gain on other real estate related investments, net1,287 9,734 (8,447)(87)%
Net income
Net loss attributable to noncontrolling interests(609)(180)(429)238 %
Not meaningful     
Rental income. Rental income increased by approximately $9.4 million as detailed below:
Three Months EndedIncrease (Decrease)
(in thousands)March 31, 2025December 31, 2024
Contractual cash rent$68,500 $59,690 $8,810 
Tenant reimbursements2,276 1,603 673 
Total contractual rent70,776 61,293 9,483 
Straight-line rent(7)(7)— 
Amortization of lease incentives(49)(13)(36)
Amortization of below market leases926 926 — 
Total amount in rental income$71,646 $62,199 $9,447 
Total contractual rent includes initial contractual cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received. Total contractual rent increased by $9.5 million due to a $9.1 million increase in rental income from real estate investments made after September 30, 2024, an increase of $0.7 million in tenant reimbursements, a $0.5 million increase in rental rates for our existing tenants, and an increase of $0.1 million related to the transfer of one facility to a new operator, partially offset by a $0.7 million decrease due to assets sold during the first quarter of 2025 and a $0.2 million decrease in rental income recognized related to certain tenants on a cash basis method of accounting.
Interest income from financing receivable. The $1.8 million increase in interest income from financing receivable was due to an investment classified as a financing receivable in December 2024.
Interest and other income. The $1.6 million, or 7%, decrease in interest and other income was primarily due to a decrease of $1.8 million of interest earned on money market funds and escrow deposits and a decrease of $0.4 million of

31

interest income due to a lower number of days during the three months ended March 31, 2025 compared to the three months ended December 31, 2024, partially offset by an increase of $0.6 million of interest income on new loan investments made after September 30, 2024.
Depreciation and amortization. The $2.3 million, or 15%, increase in depreciation and amortization was primarily due to an increase of $2.9 million due to acquisitions and capital improvements made after September 30, 2024, partially offset by a decrease of $0.5 million due to classifying assets as held for sale after September 30, 2024 and a decrease of $0.1 million due to assets becoming fully depreciated after September 30, 2024.
Interest expense. Interest expense increased by approximately $1.5 million as detailed below:
Change in interest expense for the three months ended March 31, 2025 compared to the three months ended December 31, 2024
(in thousands)
Increases to interest expense due to:
Increase in outstanding borrowing amount for the Revolving Facility$1,421 
Other changes in interest expense126 
Total change to interest expense$1,547 
Property taxes. The $0.1 million, or 6%, increase in property taxes was primarily due to an increase of $0.2 million due to reassessments and increased effective tax rates, partially offset by a decrease of $0.1 million related to properties that were sold subsequent to September 30, 2024.
Impairment of real estate investments. During the three months ended December 31, 2024, we recognized impairment charges of $5.4 million related to properties we plan to sell or repurpose or have sold. No impairment charges were recognized during the three months ended March 31, 2025.
Transaction costs. During the three months ended March 31, 2025, we recognized $0.9 million of unsuccessful acquisition pursuit costs that we classify as transaction costs. During the three months ended December 31, 2024, we recognized $1.3 million of transaction costs related to the investment in a financing receivable for which we elected the fair value option.
Provision for loan losses, net. During the three months ended December 31, 2024, we recorded a $4.9 million expected credit loss related to one other loan receivable with a principal balance of $4.9 million that has been placed on non-accrual status. No provision for loan losses was recognized during the three months ended March 31, 2025.
Property operating expenses. During the three months ended March 31, 2025, we recognized $0.5 million of property operating expenses related to assets we plan to sell or repurpose, re-tenant, or have sold, partially offset by $0.4 million in recoveries. During the three months ended December 31, 2024, we recognized $1.3 million of property operating expenses related to assets we plan to sell or repurpose, re-tenant, or have sold.
General and administrative expense. General and administrative expense decreased by $0.3 million as detailed below:
Three Months EndedIncrease (Decrease)
(in thousands)March 31, 2025December 31, 2024
Share-based compensation$3,909 $1,461 $2,448 
Cash compensation2,090 1,597 493 
Incentive compensation1,225 4,199 (2,974)
Professional services876 848 28 
Taxes and insurance218 258 (40)
Other expenses705 923 (218)
General and administrative expense$9,023 $9,286 $(263)

32

Gain on sale of real estate, net. During the three months ended March 31, 2025, we recorded a $3.9 million gain on sale of real estate related to the sale of three SNFs and one multi-service campus. During the three months ended December 31, 2024, we recorded a $46,000 gain on sale of real estate related to the sale of three ALFs.
Unrealized gain on other real estate related investments, net. During the three months ended March 31, 2025, we recorded $1.8 million of unrealized gains on our secured and mezzanine loans receivable, partially offset by unrealized losses of $0.5 million, to bring the interest rates in line with market rates. During the three months ended December 31, 2024, we recorded $11.1 million of unrealized gains on our secured and mezzanine loans receivable, partially offset by unrealized losses of $1.4 million, primarily due to a decrease in interest rates.
Net loss attributable to noncontrolling interests. The $0.4 million increase in net loss attributable to noncontrolling interests was due to an investment entered into subsequent to September 30, 2024.
Three Months Ended March 31, 2025 Compared to Three Months Ended March 31, 2024:
 Three Months EndedIncrease
(Decrease)
Percentage
Difference
 March 31, 2025March 31, 2024
 (dollars in thousands)
Revenues:
Rental income$71,646 $53,502 $18,144 34 %
Interest income from financing receivable2,807 — 2,807 *
Interest income from other real estate related investments and other income22,168 9,568 12,600 132 %
Expenses:
Depreciation and amortization17,841 13,448 4,393 33 %
Interest expense6,669 8,228 (1,559)(19)%
Property taxes2,065 1,801 264 15 %
Impairment of real estate investments— 2,744 (2,744)(100)%
Transaction costs888 — 888 *
Property operating expenses105 660 (555)(84)%
General and administrative9,023 6,838 2,185 32 %
Other income (loss):
Gain on sale of real estate, net3,876 11 3,865 *
Unrealized gain (loss) on other real estate related investments, net1,287 (612)1,899 (310)%
Net income
Net (loss) income attributable to noncontrolling interests(609)(613)*
Not meaningful     
Rental income. Rental income increased by $18.1 million as detailed below:
Three Months Ended
Increase (Decrease)
(in thousands)March 31, 2025
March 31, 2024
Contractual cash rent$68,500 $51,430 $17,070 
Tenant reimbursements2,276 1,504 772 
Total contractual rent70,776 52,934 17,842 
Straight-line rent(7)(7)— 
Amortization of lease incentives(49)— (49)
Amortization of below market leases926 575 351 
Total amount in rental income$71,646 $53,502 $18,144 
Total contractual rent includes initial contractual cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a

33

cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received. Total contractual rent increased by $17.8 million due to an $18.4 million increase in rental income from real estate investments made after December 31, 2023, a $1.6 million increase in rental rates for our existing tenants and a $0.8 million increase in tenant reimbursements, partially offset by a $2.3 million decrease in rental income recognized related to certain tenants on a cash basis method of accounting and a $0.7 million decrease in rental income related to dispositions made after December 31, 2023.
Interest income from financing receivable. During the three months ended March 31, 2025, we recorded $2.8 million of interest income related to an investment classified as a financing receivable in December 2024.
Interest income from other real estate related investments and other income. The $12.6 million increase in interest and other income was primarily due to an increase of $13.2 million due to the origination of loans receivable after December 31, 2023 and an increase of $0.1 million due to originations of other loans, partially offset by a decrease of $0.4 million of interest income on money market funds and escrow deposits, a decrease of $0.2 million related to a partial prepayment and a $0.1 million decrease of interest income due to placing one other loan on non-accrual status.
Depreciation and amortization. The $4.4 million, or 33%, increase in depreciation and amortization was primarily due to an increase of $5.9 million related to acquisitions and capital improvements made after December 31, 2023, partially offset by a decrease of $0.9 million due to classifying assets as held for sale after December 31, 2023 and a decrease of $0.6 million due to assets becoming fully depreciated after December 31, 2023.
Interest expense. Interest expense decreased by $1.6 million as detailed below:
Change in interest expense for the three months ended March 31, 2025 compared to the three months ended March 31, 2024
(in thousands)
Decreases to interest expense due to:
Decrease due to prepayment of Term Loan$(3,558)
Total decreases to interest expense(3,558)
Increases to interest expense due to:
Increase in outstanding borrowing amount for the Revolving Facility1,421 
Other changes in interest expense578 
Total increases to interest expense1,999 
Total change in interest expense$(1,559)
Property taxes. The $0.3 million, or 15%, increase in property taxes was due to a $0.5 million increase related to acquisitions made after December 31, 2023, partially offset by a decrease of $0.1 million due to reassessments and a decrease of $0.1 million related to properties that were sold subsequent to December 31, 2023.
Impairment of real estate investments. During the three months ended March 31, 2024, we recognized impairment charges of $2.7 million related to properties classified as held for sale. We did not recognize any impairment charges during the three months ended March 31, 2025.
Transaction costs. During the three months ended March 31, 2025, we recognized $0.9 million of unsuccessful acquisition pursuit costs that we classify as transaction costs. We did not recognize any transaction costs during the three months ended March 31, 2024.
Property operating expenses. During the three months ended March 31, 2025, we recognized $0.5 million of property operating expenses related to assets we plan to sell or repurpose, re-tenant, or have sold, partially offset by $0.4 million in recoveries. During the three months ended March 31, 2024, we recognized $0.7 million of property operating expenses related to assets we plan to sell or repurpose, re-tenant or have sold.

34

General and administrative expense. General and administrative expense increased by $2.2 million as detailed below:
Three Months Ended
Increase/(Decrease)
(in thousands)March 31, 2025
March 31, 2024
Share-based compensation$3,909 $2,120 $1,789 
Cash compensation2,090 1,765 325 
Incentive compensation1,225 1,500 (275)
Professional services876 738 138 
Taxes and insurance218 205 13 
Other expenses705 510 195 
General and administrative expense$9,023 $6,838 $2,185 
Gain on sale of real estate, net. During the three months ended March 31, 2025, we recorded a $3.9 million gain on sale of real estate related to the sale of three SNFs and one multi-service campus. During the three months ended March 31, 2024, we recorded an $11,000 gain on sale of real estate, net related to the sale of one SNF and one ALF.
Unrealized gain (loss) on other real estate related investments, net. During the three months ended March 31, 2025, we recorded $1.8 million of unrealized gains on our secured and mezzanine loans receivable, partially offset by unrealized losses of $0.5 million, to bring the interest rates in line with market rates. During the three months ended March 31, 2024, we recorded a $0.8 million unrealized loss on our secured and mezzanine loans receivable due to an increase in interest rates, partially offset by unrealized gains of $0.2 million due to an increase in expected cash flows on floating rate loans.
Net loss (income) attributable to noncontrolling interests. The $0.6 million increase in net loss attributable to noncontrolling interests was due to an investment entered into subsequent to December 31, 2023.
Liquidity and Capital Resources
To qualify as a REIT for federal income tax purposes, we are required to distribute at least 90% of our REIT taxable income, determined without regard to the dividends paid deduction and excluding any net capital gains, to our stockholders on an annual basis. Accordingly, we intend to make, but are not contractually bound to make, regular quarterly dividends to common stockholders from cash flow from operating activities. All such dividends are at the discretion of our board of directors.
Our short-term liquidity requirements consist primarily of operating and interest expenses directly associated with our properties, including:
interest expense and scheduled debt maturities on outstanding indebtedness;
general and administrative expenses;
dividend plans;
operating lease obligations; and
capital expenditures for improvements to our properties.
In addition, in connection with our planned acquisition of Care REIT plc, we expect to pay an aggregate of approximately $597 million in cash to the Target shareholders, other than any Sanctions Disqualified Shareholders (as defined in the Rule 2.7 Announcement). We have deposited $606.0 million in an escrow account to be used to satisfy the purchase consideration in connection with planned acquisition, which is classified as restricted cash on our condensed consolidated balance sheet as of March 31, 2025. In connection with the planned acquisition, we would also assume Target’s net debt of approximately $259 million.
Our long-term liquidity needs consist primarily of funds necessary to pay for acquisitions and other investments (including mortgage and mezzanine loan originations), capital expenditures, and scheduled debt maturities. We intend to invest in and/or develop additional healthcare and seniors housing properties as suitable opportunities arise and so long as adequate sources of financing are available. We expect that future investments in and/or development of properties, including any improvements or renovations of current or newly-acquired properties, will depend on and will be financed by, in whole or in part, our existing cash, borrowings available to us under the Third Amended Credit Facility (as defined below), future borrowings or the proceeds from sales of shares of our common stock pursuant to our ATM Program or additional issuances of common stock or other securities. In addition, we may seek financing from U.S. government agencies, including through Fannie Mae and the U.S. Department of Housing and Urban Development, in appropriate circumstances in connection with acquisitions and refinancing of existing mortgage loans.

35

We believe that our expected operating cash flow from rent collections and interest payments on our other real estate related investments, together with our cash balance, available borrowing capacity under the Third Amended Revolving Facility (as defined below) and availability under the ATM Program will be sufficient to meet ongoing debt service requirements, dividend plans, operating lease obligations, capital expenditures, working capital requirements, the financing of our planned acquisition of Care REIT plc and other needs for at least the next 12 months. We expect to meet our long-term liquidity needs with cash flows from operations and financing arrangements. While we may from time to time sell properties as part of our hold / investment strategy on an investment-by-investment basis, we currently do not expect to sell any of our properties to meet liquidity needs. Our quarterly cash dividend and any failure of our operators to pay rent or of our borrowers to make interest or principal payments may impact our available capital resources.
We have filed an automatic shelf registration statement with the U.S. Securities and Exchange Commission that expires in February 2026 and at or prior to such time we expect to file a new shelf registration statement. The shelf registration statement allows us or certain of our subsidiaries, as applicable, to offer and sell shares of common stock, preferred stock, warrants, rights, units and debt securities through underwriters, dealers or agents or directly to purchasers, in one or more offerings on a continuous or delayed basis, in amounts, at prices and on terms we determine at the time of the offering. On January 21, 2025, we entered into the New ATM Program. In addition to the issuance and sale of shares of our common stock, we may also enter into one or more ATM forward contracts with sales agents for the sale of shares of our common stock under the ATM Program. See “At-The-Market Offering of Common Stock” for information regarding activity under the ATM Program.
Although we are subject to restrictions on our ability to incur indebtedness, we expect that we will be able to refinance existing indebtedness or incur additional indebtedness for acquisitions or other purposes, if needed. However, there can be no assurance that we will be able to refinance our indebtedness, incur additional indebtedness or access additional sources of capital, such as by issuing common stock or other debt or equity securities, on terms that are acceptable to us or at all.
As of March 31, 2025, we are in compliance with all debt covenants on our outstanding indebtedness.
Cash Flows
The following table presents selected data from our condensed consolidated statements of cash flows for the periods presented (dollars in thousands):
 For the Three Months Ended March 31,
 20252024
 
Net cash provided by operating activities$71,382 $48,820 
Net cash used in investing activities(35,910)(123,241)
Net cash provided by financing activities383,216 231,146 
Net increase in cash, cash equivalents and restricted cash418,688 156,725 
Cash, cash equivalents and restricted cash as of the beginning of period213,822 294,448 
Cash, cash equivalents and restricted cash as of the end of period$632,510 $451,173 
Net cash provided by operating activities increased for the three months ended March 31, 2025 compared to the three months ended March 31, 2024. Operating cash inflows are derived primarily from the rental payments received under our lease agreements and interest income received on our other real estate related investments, including as a result of new investments. Operating cash outflows consist primarily of interest expense on our borrowings and general and administrative expenses. The net increase of $22.6 million in cash provided by operating activities for the three months ended March 31, 2025 compared to the three months ended March 31, 2024 is primarily due to an increase in rental income received, an increase in interest income received on our other real estate related investments, and a decrease in cash paid for interest expense, partially offset by an increase in cash paid for general and administrative expense.
Cash used in investing activities for the three months ended March 31, 2025 was primarily comprised of $82.6 million in acquisitions of real estate, investment in real estate related investments and escrow deposits for potential acquisitions of real estate and $2.3 million of purchases of equipment, furniture and fixtures and improvements to real estate, partially offset by $44.4 million in net proceeds from the sale of real estate and $4.6 million in principal payments received from our other real estate related investments and other loans receivable. Cash used in investing activities for the three months ended March 31, 2024 was primarily comprised of $122.9 million in acquisitions of real estate, investment in real estate related investments and other loans receivable and escrow deposits for potential acquisitions of real estate and $0.4 million of purchases of equipment, furniture and fixtures and improvements to real estate.

36

Our cash flows provided by financing activities for the three months ended March 31, 2025 were primarily comprised of $425.0 million in borrowings under our Third Amended Revolving Facility (as defined below), $15.5 million in net proceeds from the issuance of common stock and $1.4 million in contributions from noncontrolling interests, partially offset by $54.4 million in dividends paid, a $3.3 million net settlement adjustment on restricted stock, $0.9 million in distributions to noncontrolling interests, and a $0.1 million payment of deferred financing costs. Our cash flows provided by financing activities for the three months ended March 31, 2024 were primarily comprised of $269.8 million in net proceeds from the issuance of common stock and $0.4 million in contributions from noncontrolling interests, partially offset by $36.5 million in dividends paid and a $2.5 million net settlement adjustment on restricted stock.
Material Cash Requirements
Our material cash requirements from known contractual and other obligations include:
3.875% Senior Unsecured Notes due 2028
On June 17, 2021, our wholly owned subsidiary, CTR Partnership, L.P. (the “Operating Partnership”), and its wholly owned subsidiary, CareTrust Capital Corp. (together with the Operating Partnership, the “Issuers”), completed a private offering of $400.0 million aggregate principal amount of 3.875% Senior Notes due 2028 (the “Notes”). The Notes mature on June 30, 2028. The Notes accrue interest at a rate of 3.875% per annum payable semiannually in arrears on June 30 and December 30 of each year, commencing on December 30, 2021. The obligations under the Notes are guaranteed, jointly and severally, on an unsecured basis, by us and all of our subsidiaries (other than the Issuers) that guarantee obligations under the Amended Credit Facility (as defined below). As of March 31, 2025, we were in compliance with all applicable financial covenants under the indenture governing the Notes. See Note 7, Debt, to our condensed consolidated financial statements included in this report for further information about the Notes.
Unsecured Revolving Credit Facility and Term Loan
On December 16, 2022, we, together with certain of our subsidiaries, entered into a second amended and restated credit and guaranty agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender (as amended from time to time, the “Second Amended Credit Agreement”). The Operating Partnership is the borrower under the Second Amended Credit Agreement, and the obligations thereunder are guaranteed, jointly and severally, on an unsecured basis, by us and substantially all of our subsidiaries. The Second Amended Credit Agreement, which amends and restates our amended and restated credit and guaranty agreement, dated as of February 8, 2019 (as amended, the “Prior Credit Agreement”) provided for: (i) an unsecured revolving credit facility (the “Revolving Facility”) with revolving commitments in an aggregate principal amount of $600.0 million, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments and (ii) the continuation of the unsecured term loan credit facility which was previously extended under the Prior Credit Agreement (the “Term Loan” and together with the Revolving Facility, the “Second Amended Credit Facility”) in an aggregate principal amount of $200.0 million. Future borrowings under the Second Amended Credit Facility will be used for working capital purposes, for capital expenditures, to fund acquisitions and for general corporate purposes.
On October 10, 2023, we entered into the First Amendment to the Second Amended Credit Agreement with KeyBank National Association (the “First Amendment”). The First Amendment restates the definition of Consolidated Total Asset Value to include net proceeds from at-the-market forward commitments executed but not yet closed as of the relevant date as if such proceeds had actually been received.
On December 18, 2024, we, together with certain of our subsidiaries, entered into a third amended and restated credit and guaranty agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender, and the lenders party thereto (as amended from time to time, the “Third Amended Credit Agreement”). The Third Amended Credit Agreement, which amends and restates our Second Amended Credit Agreement provides for an unsecured revolving credit facility (the “Third Amended Revolving Facility”) with revolving commitments in an aggregate principal amount of $1.2 billion, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments. Future borrowings under the Third Amended Revolving Facility will be used for working capital purposes, for capital expenditures, to fund acquisitions and for general corporate purposes.
The Third Amended Credit Agreement also provides that, subject to customary conditions, including obtaining lender commitments and pro forma compliance with financial maintenance covenants under the Third Amended Credit Agreement, the Operating Partnership may seek to increase the aggregate principal amount of the revolving commitments and/or establish one or more new tranches of term loans under the Third Amended Credit Facility in an aggregate amount not to exceed $800.0 million.

37

As of March 31, 2025, we had borrowings outstanding of $425.0 million under the Third Amended Revolving Facility. The Revolving Facility has a maturity date of February 9, 2029, and includes, at our sole discretion, two six-month extension options.
The interest rates applicable to loans under the Third Amended Revolving Facility are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.05% to 0.55% per annum or Adjusted Term SOFR or Adjusted Daily Simple SOFR (each as defined in the Third Amended Credit Agreement) plus a margin ranging from 1.05% to 1.55% per annum based on the debt to asset value ratio of the Company and our consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if we obtain certain specified investment grade ratings on our senior long-term unsecured debt). In addition, the Operating Partnership will pay a facility fee on the revolving commitments under the Third Amended Revolving Facility ranging from 0.15% to 0.35% per annum, based on the debt to asset value ratio of the Company and our consolidated subsidiaries (unless we obtain certain specified investment grade ratings on our senior long-term unsecured debt and the Operating Partnership elects to decrease the applicable margin as described above, in which case the Operating Partnership will pay a facility fee on the revolving commitments ranging from 0.125% to 0.30% per annum based off the credit ratings of the Company’s senior long-term unsecured debt).
As of March 31, 2025, we were in compliance with all applicable financial covenants under the Third Amended Credit Agreement. See Note 7, Debt, to our condensed consolidated financial statements included in this report for further information about the Third Amended Credit Agreement.
Commitments and Contingencies
As of March 31, 2025, we had committed to fund expansions, construction, capital improvements and ESG incentives, which provides eligible triple-net tenants with monetary inducements to make sustainable improvements to our properties, at certain triple-net leased facilities totaling $7.2 million, of which $6.3 million is subject to rent increase at the time of funding. We expect to fund the capital expenditures in the next one to two years. As of March 31, 2025, we have non-real estate secured loan commitments of $12.2 million. We are also party to a purchase and sale agreement which provides for an earn-out obligation of up to $10.0 million for one SNF in Virginia which was acquired during 2024. The earn-out is available, contingent on the operator achieving certain thresholds per the agreement, beginning in October 2025 through October 2026. In addition, one mortgage loan includes an earn-out advance of $9.0 million upon satisfaction of certain conditions. See Note 13, Commitments and Contingencies, to our condensed consolidated financial statements included in this report for further information.
Dividend Plans
We are required to pay dividends in order to maintain our REIT status and we expect to make quarterly dividend payments in cash with the annual dividend amount no less than 90% of our annual REIT taxable income, determined without regard to the dividends paid deduction and excluding any net capital gains. See Note 8, Equity, to our condensed consolidated financial statements included in this report for a summary of the cash dividends per share of our common stock declared by our board of directors for the three months ended March 31, 2025.
Critical Accounting Policies and Estimates
Our condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information set forth in the Accounting Standards Codification, as published by the Financial Accounting Standards Board. GAAP requires us to make estimates and assumptions regarding future events that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. We base these estimates on our experience and assumptions we believe to be reasonable under the circumstances. However, if our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, we may have applied a different accounting treatment, resulting in a different presentation of our financial statements. We periodically reevaluate our estimates and assumptions, and in the event they prove to be different from actual results, we make adjustments in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Please refer to “Critical Accounting Policies and Estimates” in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 12, 2025, for further information regarding the critical accounting policies that affect our more significant estimates and judgments used in the preparation of our condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. There have been no material changes in such critical accounting policies during the three months ended March 31, 2025.

38

 
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Our primary market risk exposure is interest rate risk with respect to our variable rate indebtedness.
Our Third Amended Credit Agreement provides for revolving commitments in an aggregate principal amount of $1.2 billion from a syndicate of banks and other financial institutions.
The interest rates applicable to loans under the Revolving Facility are, at the Company’s option, equal to either a base rate plus a margin ranging from 0.05% to 0.55% per annum or Adjusted Term SOFR or Adjusted Daily Simple SOFR (each as defined in the Third Amended Credit Agreement) plus a margin ranging from 1.05% to 1.55% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). As of March 31, 2025, we had borrowings outstanding of $425.0 million under the Third Amended Revolving Facility.
An increase in interest rates could make the financing of any acquisition by us more costly as well as increase the costs of our variable rate debt obligations. Rising interest rates could also limit our ability to refinance our debt when it matures or cause us to pay higher interest rates upon refinancing and increase interest expense on refinanced indebtedness. Increased inflation may also have a pronounced negative impact on the interest expense we pay in connection with our outstanding indebtedness, as these costs could increase at a rate higher than our rents.
Based on our outstanding debt balance as of March 31, 2025 described above and the interest rates applicable to our outstanding debt at March 31, 2025, assuming a 100 basis point increase in the interest rates related to our variable rate debt, interest expense would have increased approximately $1.1 million for the three months ended March 31, 2025.
We may, in the future, manage, or hedge, interest rate risks related to our borrowings by means of interest rate swap agreements. However, the REIT provisions of the Internal Revenue Code of 1986, as amended, substantially limit our ability to hedge our assets and liabilities. See “Risk Factors — Risks Related to Our Status as a REIT — Complying with REIT requirements may limit our ability to hedge effectively and may cause us to incur tax liabilities,” which is included in our Annual Report on Form 10-K for the year ended December 31, 2024. As of March 31, 2025, we had no swap agreements to hedge our interest rate risks. We also expect to manage our exposure to interest rate risk by maintaining a mix of fixed and variable rates for our indebtedness.

Item 4. Controls and Procedures.
Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is processed, recorded, summarized and reported within the time periods specified in the SEC’s rules and regulations and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
As of March 31, 2025, we carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, regarding the effectiveness of our disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, as of March 31, 2025.
Changes in Internal Control over Financial Reporting
There has been no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended March 31, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

39

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.
The Company and its subsidiaries are and may become from time to time a party to various claims and lawsuits arising in the ordinary course of business, but none of the Company or any of its subsidiaries is, and none of their respective properties are, the subject of any material legal proceedings. Claims and lawsuits may include matters involving general or professional liability asserted against its tenants, which are the responsibility of its tenants and for which the Company is entitled to be indemnified by its tenants under the insurance and indemnification provisions in the applicable leases.

Item 1A. Risk Factors.
We have disclosed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 risk factors which materially affect our business, financial condition, or results of operations. There have been no material changes from the risk factors previously disclosed, except as noted below.
The intended benefits of the Care REIT acquisition may not be realized.
On March 11, 2025, we announced a firm intention to make a cash offer to acquire Care REIT plc (“Care REIT”), which owns 137 care homes across England, Scotland and Northern Ireland. The acquisition is intended to be implemented by means of a court-sanctioned scheme of arrangement (the “Scheme”) under Part 26 of the United Kingdom Companies Act 2006. The transaction has been unanimously approved by the boards of directors of both the Company and Target and has been approved by the requisite majorities of Target shareholders at the Target shareholder meetings convened to approve the transaction. The closing is conditioned on (i) sanction of the Scheme by the High Court of Justice of England and Wales and (ii) other customary conditions. If these conditions are not satisfied, the Care REIT acquisition will not be completed and the market price of our common stock may be adversely affected.
Even if the Care REIT acquisition is successfully completed, the intended benefits may not be realized. The acquisition poses risks for our ongoing operations, including, among others; that senior management's attention may be diverted from the management of daily operations in our U.S. operations to the integration of the Care REIT properties; costs and expenses associated with any undisclosed or potential liabilities; that the Care REIT properties may not perform as well as anticipated; and unforeseen difficulties may arise in integrating operations in the United Kingdom into our company.
As a result of the foregoing, we cannot assure you that the Care REIT acquisition will be accretive to us in the near term or at all. Furthermore, if we fail to complete the acquisition or realize the intended benefits of the Care REIT properties, the market price of our common stock may be adversely affected.
We will be subject to additional risks from our investment in Care REIT and any other international investments.
Care REIT will be our first major investment in the United Kingdom. We may also pursue other significant acquisition opportunities outside the United States, including in the United Kingdom and elsewhere in Europe. International investment may expose us to a variety of risks that are different from and in addition to those commonly found in our current markets. Our acquisition of Care REIT and any other investments we may make internationally will subject us to additional risks, including:
complying with a wide variety of foreign laws;
fluctuations in exchange rates between foreign currencies and the U.S. dollar and exchange controls;
limited experience with local business and cultural factors that differ from our usual standards and practices;
challenges in establishing effective controls and procedures to regulate operations in different regions;
the impact of regional or country-specific business cycles and economic instability;
the impact of extreme weather or weather-related conditions and other natural disasters that may affect specific locations in which our properties are located, including hurricanes, flash floods, sea-level rise and coastal erosion, that may affect Care REIT' properties or other properties we may acquire outside the United States; and
political instability or civil unrest.
If we are unable to adequately address these risks, they could adversely affect our business, financial position or results of operations.

40


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
During the three months ended March 31, 2025, we acquired shares of our common stock held by employees who tendered shares to satisfy tax withholding obligations upon the vesting of previously issued restricted stock awards. Specifically, the number of shares of common stock acquired from employees and the average prices paid per share for each month in the three months ended March 31, 2025 are shown in the table below.
PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced Repurchase ProgramMaximum Dollar Value of Shares that May Yet be Purchased Under the Repurchase Program
January 1 - January 31, 202568,789 $26.50 — $— 
February 1 - February 28, 2025— — — — 
March 1 - March 31, 2025— — — — 
Total68,789 $26.50 — 


41


Item 5. Other Information.
None.

Item 6. Exhibits.
Exhibit
Number
 Description of the Document
 
 
Equity Distribution Agreement, dated January 21, 2025, by and among CareTrust REIT, Inc., CTR Partnership, L.P. and (i) BMO Capital Markets Corp., BofA Securities, Inc., Huntington Securities, Inc., Jefferies LLC, J.P. Morgan Securities LLC, KeyBanc Capital Markets Inc., M&T Securities, Inc., Raymond James & Associates, Inc., RBC Capital Markets, LLC, Robert W. Baird & Co. Incorporated and Wells Fargo Securities, LLC and (ii) Bank of Montreal, Bank of America, N.A., Huntington Securities, Inc., Jefferies LLC, JPMorgan Chase Bank, National Association, KeyBanc Capital Markets Inc., Raymond James & Associates, Inc., Royal Bank of Canada, Robert W. Baird & Co. Incorporated and Wells Fargo Bank, National Association, including the form of master forward sale agreement included as Annex A thereto (Exhibit 1.1 to the Company's Current Report on Form 8-K, filed on January 21, 2025, is incorporated herein by reference).
 
 
 
*101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
*101.SCH Inline XBRL Taxonomy Extension Schema Document
*101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
*101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
*101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
*101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
*104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
* Filed herewith
** Furnished herewith


42

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
CareTrust REIT, Inc.
May 1, 2025By:/s/ William M. Wagner
William M. Wagner
Chief Financial Officer and Treasurer
(duly authorized officer and principal financial officer)


43
EX-31.1 2 ctre20250331q1ex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION
I, David M. Sedgwick, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of CareTrust REIT, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
By:/s/ David M. Sedgwick
David M. Sedgwick
President and Chief Executive Officer
Date: May 1, 2025

EX-31.2 3 ctre20250331q1ex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION
I, William M. Wagner, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of CareTrust REIT, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
By:/s/ William M. Wagner
William M. Wagner
Chief Financial Officer and Treasurer
Date: May 1, 2025

EX-32.1 4 ctre20250331q1ex321.htm EX-32.1 Document

Exhibit 32.1
Certification of Chief Executive Officer and
Chief Financial Officer Pursuant to
18 U.S.C. Section 1350, As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report on Form 10-Q of CareTrust REIT, Inc. (the “Company”) for the quarterly period ended March 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), David M. Sedgwick, as President and Chief Executive Officer of the Company, and William M. Wagner, as Chief Financial Officer and Treasurer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/ David M. Sedgwick
Name:
David M. Sedgwick
Title:President and Chief Executive Officer
Date:May 1, 2025
/s/ William M. Wagner
Name:William M. Wagner
Title:Chief Financial Officer and Treasurer
Date:May 1, 2025


EX-101.SCH 5 ctre-20250331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED INCOME STATEMENTS link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTEREST link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - ORGANIZATION link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - REAL ESTATE INVESTMENTS, NET link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - EQUITY AND REDEEMABLE NONCONTROLLING INTEREST link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - EARNINGS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - SEGMENT REPORTING link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - VARIABLE INTEREST ENTITIES link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - CONCENTRATION OF RISK link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9955513 - Disclosure - REAL ESTATE INVESTMENTS, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 9955514 - Disclosure - IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - (Tables) link:presentationLink link:calculationLink link:definitionLink 9955515 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955516 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955517 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 9955518 - Disclosure - EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Tables) link:presentationLink link:calculationLink link:definitionLink 9955519 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9955520 - Disclosure - EARNINGS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9955521 - Disclosure - SEGMENT REPORTING (Tables) link:presentationLink link:calculationLink link:definitionLink 9955522 - Disclosure - VARIABLE INTEREST ENTITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9955523 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9955524 - Disclosure - CONCENTRATION OF RISK (Tables) link:presentationLink link:calculationLink link:definitionLink 9955525 - Disclosure - ORGANIZATION (Details) link:presentationLink link:calculationLink link:definitionLink 9955526 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955527 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 9955528 - Disclosure - REAL ESTATE INVESTMENTS, NET - Schedule of Investment in Owned Properties (Details) link:presentationLink link:calculationLink link:definitionLink 9955529 - Disclosure - REAL ESTATE INVESTMENTS, NET - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955530 - Disclosure - REAL ESTATE INVESTMENTS, NET - Schedule of Total Future Contractual Minimum Rental Income (Details) link:presentationLink link:calculationLink link:definitionLink 9955531 - Disclosure - REAL ESTATE INVESTMENTS, NET - Schedule of Tenant Purchase Options (Details) link:presentationLink link:calculationLink link:definitionLink 9955532 - Disclosure - REAL ESTATE INVESTMENTS, NET - Schedule of Rental Income (Details) link:presentationLink link:calculationLink link:definitionLink 9955533 - Disclosure - REAL ESTATE INVESTMENTS, NET - Schedule of Real Estate Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 9955534 - Disclosure - REAL ESTATE INVESTMENTS, NET - Lease Amendments and Terminations Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955535 - Disclosure - IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955536 - Disclosure - IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - Schedule of Company's Dispositions (Details) link:presentationLink link:calculationLink link:definitionLink 9955537 - Disclosure - IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - Schedule of Company's Assets Held for Sale Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955538 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Other Real Estate Related Investments, At Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9955539 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Real Estate Related Investment Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955540 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Other Real Estate Related Investment Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955542 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Loan Receivable Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955543 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Interest and Other Income (Details) link:presentationLink link:calculationLink link:definitionLink 9955544 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Items Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9955545 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Assets Measured at Fair Value on a Recurring Basis Using Level 3 Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 9955546 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955547 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Quantitative Information About Unobservable Inputs Related to Level 3 Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9955548 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Face Value, Carrying Amount and Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955549 - Disclosure - DEBT - Schedule of Debt Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955550 - Disclosure - DEBT - Senior Unsecured Notes Payable Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955551 - Disclosure - DEBT - Unsecured Revolving Credit Facility Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955552 - Disclosure - EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955553 - Disclosure - EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - Schedule of At-The-Market Offering Program (Details) link:presentationLink link:calculationLink link:definitionLink 9955554 - Disclosure - EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - Schedule of Dividends on Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9955555 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955556 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Award and Performance Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955557 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9955558 - Disclosure - EARNINGS PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 9955559 - Disclosure - SEGMENT REPORTING (Details) link:presentationLink link:calculationLink link:definitionLink 9955560 - Disclosure - VARIABLE INTEREST ENTITIES - Schedule of Variable Interest Entities Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9955561 - Disclosure - VARIABLE INTEREST ENTITIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955562 - Disclosure - VARIABLE INTEREST ENTITIES - Schedule of Variable Interest Entities (Details) link:presentationLink link:calculationLink link:definitionLink 9955563 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955564 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9955565 - Disclosure - CONCENTRATION OF RISK (Details) link:presentationLink link:calculationLink link:definitionLink 9955566 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 ctre-20250331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 ctre-20250331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 ctre-20250331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT TN TENNESSEE Borrowings under unsecured revolving credit facility Proceeds from Long-Term Lines of Credit New Cascade Lease New Cascade Lease [Member] New Cascade Lease Lease Expiration October 2032, Next option 2027 Properties With Purchase Option, Lease Expiration October 2032, Next Option 2027 [Member] Properties With Purchase Option, Lease Expiration October 2032, Next Option 2027 Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Weighted-average remaining vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities Skilled Nursing, Multi-Service Campuses, Assisted living and Independent Living Facilities Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities [Member] Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities Cover [Abstract] Cover [Abstract] Principal Balance Principal Amount after Allowance for Credit Loss Principal Amount after Allowance for Credit Loss Performance Shares T S R Units Performance Shares T S R Units [Member] Performance Shares T S R Units Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Board of Directors Director [Member] Discount Rate Measurement Input, Discount Rate [Member] Unrealized (gain) loss on other real estate related investments, net Unrealized Gain (Loss) On Other Real Estate Related Investments, Operating Cash Flows Unrealized Gain (Loss) On Other Real Estate Related Investments, Operating Cash Flows Schedule of Recent Real Estate Acquisitions Schedule Of Assets Acquisitions [Table Text Block] Schedule Of Assets Acquisitions Trading Symbol Trading Symbol Equity ownership percentage (as percent) Equity Method Investment, Ownership Percentage Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] ALF Assisted Living Facilities [Member] Assisted Living Facilities Amortization of lease incentives Amortization of lease incentives Lease Incentive Amortization Lease Incentive Amortization All Trading Arrangements All Trading Arrangements [Member] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of Reconciliation of Weighted-Average Common Shares Outstanding Used in Calculation of Basic EPS to Diluted EPS Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Common dividends (in usd per share) Dividends declared per share (in usd per share) Common Stock, Dividends, Per Share, Declared Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] ILF Independent Living Facility [Member] Independent Living Facility Schedule of Interest and Other Income Interest and Other Income [Table Text Block] Other Commitments [Line Items] Other Commitments [Line Items] Number of facilities Number of Facilities Number Of Facilities Number Of Facilities Distributions to noncontrolling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Pay vs Performance Disclosure [Line Items] Redeemable noncontrolling interest Beginning balance Ending balance Redeemable Noncontrolling Interest, Equity, Carrying Amount Line of Credit Facility [Table] Line of Credit Facility [Table] 2027 Lessor, Operating Lease, Payment to be Received, Year Two Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Number of purchase option window Number Of Purchase Option Window Number Of Purchase Option Window 2030 Lessor, Operating Lease, Payment to be Received, Year Five Lease Arrangements [Domain] Lease Arrangements [Domain] Lease Arrangements Accounts and other receivables Increase (Decrease) in Accounts Receivable ORGANIZATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] TX TEXAS Deferred rent as percentage of contractual cash yield Deferred Rent As Percentage Of Contractual Cash Yield, Year One Deferred Rent As Percentage Of Contractual Cash Yield, Year One FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Award Timing Disclosures [Line Items] Financial Asset, Aging [Axis] Financial Asset, Aging [Axis] Investment, Name [Domain] Investment, Name [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Financing Receivable, Past Due [Table] Financing Receivable, Past Due [Table] Lessor, operating lease, rent calculated as a percentage of subtenant's gross revenue, period Lessor, Operating Lease, Rent Calculated As A Percentage Of Subtenant's Gross Revenue, Period Lessor, Operating Lease, Rent Calculated As A Percentage Of Subtenant's Gross Revenue, Period Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Common stock, outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Property taxes Property taxes Real Estate Tax Expense Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Lease Expiration May 2034, Next option 2026 Properties With Purchase Option, Lease Expiration May 2034, Next Option 2026 [Member] Properties With Purchase Option, Lease Expiration May 2034, Next Option 2026 Investments, All Other Investments [Abstract] Investment Five Investment Five [Member] Investment Five Lease Expiration January 2030, Next Option 2026 Properties With Purchase Option, Lease Expiration January 2030, Next Option 2026 [Member] Properties With Purchase Option, Lease Expiration January 2030, Next Option 2026 Share price (in usd per share) Sale of Stock, Price Per Share Term Loan Loans Payable [Member] Operating lease lessor cash yield term Operating Lease Lessor Cash Yield Term Operating Lease Lessor Cash Yield Term Proceeds from issuance or sale of equity Proceeds from Issuance or Sale of Equity Entity Tax Identification Number Entity Tax Identification Number Authorized aggregate offering price of common stock Securities Offering, Authorized Amount Securities Offering, Authorized Amount Identified intangible assets Finite-Lived Intangible Assets, Gross Schedule of Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] VARIABLE INTEREST ENTITIES Variable Interest Entity Disclosure [Text Block] Real estate investments Net carrying value at beginning Net carrying value at ending Real Estate Investment Property, at Cost Increase Decrease in Assets Held for Sale [Roll Forward] Increase Decrease in Assets Held for Sale [Roll Forward] Increase Decrease in Assets Held for Sale Class of Financing Receivable [Domain] Class of Financing Receivable [Domain] Amended Kalesta Lease Amended Kalesta Lease [Member] Amended Kalesta Lease Period prior to March 30 2028 Debt Instrument, Redemption, Period Two [Member] Receivable Type [Axis] Receivable Type [Axis] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Mortgage loans Mortgage Receivable [Member] Average sales price per share (in usd per share) Shares Issued During Period, Average Price Per Share Shares Issued During Period, Average Price Per Share Earnings per common share attributable to CareTrust REIT, Inc: Earnings Per Share Reconciliation [Abstract] Initial Annual Cash Rent Operating Leases, Anticipated Initial Annual Lease Revenues Operating Leases, Anticipated Initial Annual Lease Revenues Senior unsecured notes payable 2028 Senior Notes Senior Unsecured Notes [Member] Senior Unsecured Notes [Member] Equity Components [Axis] Equity Components [Axis] Straight-line rental income Straight-line rent Straight Line Rent Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Balance at beginning of period Balance at ending of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Taxes and insurance Taxes And Insurance Expenses Taxes And Insurance Expenses Principal amount Origination of other real estate related investments Financing Receivable, Principal Amount Financing Receivable, Principal Amount Total expenses Costs and Expenses Investment in Financing Receivable Investments in Financing Receivable [Member] Investments in Financing Receivable Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Impairment of real estate investments Impairment of real estate investments Impairment Losses Related to Real Estate Partnerships Receivable [Domain] Receivable [Domain] Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional paid-in capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Accrued interest, net Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Accrued Interest Net Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Accrued Interest Net Escrow deposits for potential acquisitions of real estate Payments for Deposits on Real Estate Acquisitions Number of Properties Number Of Properties Acquired Number Of Properties Acquired Disposal Group Classification [Axis] Disposal Group Classification [Axis] Number of states with properties Number of States in which Entity Operates Supplemental schedule of noncash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Amortization of below market leases Amortization of Below Market Lease Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Interest income from financing receivable Interest income from financing receivable Interest Income, Financing Receivable, before Allowance for Credit Loss Entity Small Business Entity Small Business Transaction costs Transaction Costs Transaction Costs Company Selected Measure Amount Company Selected Measure Amount Commitment Category [Axis] Commitment Category [Axis] Commitment Category Geographical [Axis] Geographical [Axis] Tenant ESG Program Tenant ESG Program [Member] Tenant ESG Program Tabular List, Table Tabular List [Table Text Block] Financing receivable Financing Receivable [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Weighted Average Weighted Average [Member] 2025 (nine months) Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Antidilutive unvested RSAs and TSR Units excluded from the computation (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Weighted Average Contractual Interest Rate Weighted average interest rate Financing Receivable, Weighted Average Interest Rate Financing Receivable, Weighted Average Interest Rate Capital expenditures Capital Expenditures [Member] Capital Expenditures Schedule of Rental Income Operating Lease, Lease Income [Table Text Block] Credit Facility [Domain] Credit Facility [Domain] Number of loans Number Of Loans Number Of Loans Cash, cash equivalents and restricted cash as of the beginning of period Cash, cash equivalents and restricted cash as of the end of period Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Basis spread on variable rate (percent) Financing Receivable, Variable Basis Interest Rate Financing Receivable, Variable Basis Interest Rate Increase in dividends payable Increase Decrease In Dividends Payable Increase Decrease In Dividends Payable Annual cash rent increase under amended lease Annual Cash Rent Increase Under Amended Lease Annual Cash Rent Increase Under Amended Lease Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Unamortized stock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Impairment of real estate investments Impairment of Real Estate Net-settle adjustment on restricted stock Payment, Tax Withholding, Share-Based Payment Arrangement Mortgage secured loan receivable Mortgage Secured Loan Receivable January 1, 2027 Maturity [Member] Mortgage Secured Loan Receivable January 1, 2027 Maturity Commitment Category [Domain] Commitment Category [Domain] Commitment Category Other loans receivable Loans Receivable [Member] Eduro Amended Triple-Net Master Lease Eduro Amended Triple-Net Master Lease [Member] Eduro Amended Triple-Net Master Lease Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Employee Stock Option Share-Based Payment Arrangement, Option [Member] Number of Beds/Units Number Of Beds Or Units In Properties Acquired Number Of Beds Or Units In Properties Acquired Jv Partner JV Partner [Member] JV Partner Vested (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Purchase option, window open period Purchase Option, Window Open Period Purchase Option, Window Open Period Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Net carrying value Real Estate Investment Property, Net Carrying Value Real Estate Investment Property, Net Carrying Value Jaybird Lease Jaybird Lease [Member] Jaybird Lease Accumulated depreciation and amortization Real Estate Investment Property, Accumulated Depreciation PSAs and TSR Units Performance Stock Awards And Total Shareholder Return Units [Member] Performance Stock Awards And Total Shareholder Return Units Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Basis spread on variable rate (as percent) Debt Instrument, Basis Spread on Variable Rate Ensign Amended Triple-Net Master Lease Ensign Amended Triple-Net Master Lease [Member] Ensign Amended Triple-Net Master Lease Second Option Second Option [Member] Second Option Award Type [Axis] Award Type [Axis] Lessor, operating lease, payment to be received, next rolling 12 months Lessor, Operating Lease, Payment to be Received, Next Rolling 12 Months Lease Expiration November 2034, Next Option 2027 Properties With Purchase Option, Lease Expiration November 2034, Next Option 2027 [Member] Properties With Purchase Option, Lease Expiration November 2034, Next Option 2027 VIRGINIA VIRGINIA Restricted cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Lease Contractual Term [Domain] Lease Contractual Term [Domain] Repayments of Debt Repayments of Debt Total liabilities Liabilities Noncontrolling interests Equity, Attributable to Noncontrolling Interest Schedule of Cash, Cash Equivalents and Restricted Cash Schedule of Cash and Cash Equivalents [Table Text Block] Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Funding commitment Other Commitment Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Unsecured revolving credit facility Revolving Credit Facility [Member] Number of facilities, impairment of real estate held for sale Number Of Real Estate Properties, Impairment Of Real Estate Held For Sale Number Of Real Estate Properties, Impairment Of Real Estate Held For Sale Expiration Date Trading Arrangement Expiration Date CTRE CTRE [Member] CTRE Number of monthly installment payments Number Of Monthly Installment Payments Number Of Monthly Installment Payments Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Current cash rent Lessor, Annualized Cash Revenue For Contracts In Place Lessor, Annualized Cash Revenue For Contracts In Place Lessor, operating lease, renewal options terms Lessor, Operating Lease, Renewal Options Terms Lessor, Operating Lease, Renewal Options Terms Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Repayment Of Loan Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Repayment Of Loan Preferred equity investments, fair value disclosure Equity Method Investments, Fair Value Disclosure Property operating expenses Property operating expenses Cost of Other Property Operating Expense Total Shareholder Return Amount Total Shareholder Return Amount Common stock, issued (in shares) Common Stock, Shares, Issued Less: Net income allocated to participating securities Undistributed Earnings (Loss) Allocated to Participating Securities, Basic Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Percentage of Total Revenue Concentration Risk, Percentage Credit facility borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Financial Asset, Aging [Domain] Financial Asset, Aging [Domain] Mortgage loan receivable Financing Receivable, before Allowance for Credit Loss Master Lease Termination Master Lease Termination [Member] Master Lease Termination Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Subsequent Event [Line Items] Subsequent Event [Line Items] Proceeds from sale of finance receivables Proceeds from Sale of Finance Receivables Accounts and other receivables Accounts Receivable, after Allowance for Credit Loss Jaybird Senior Living, Inc. Jaybird Senior Living, Inc. [Member] Jaybird Senior Living, Inc. Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Unrealized gain (loss) on increases in projected forward interest rates Unrealized Gain (Loss) On Decrease In Projected Forward Interest Rates Unrealized Gain (Loss) On Decrease In Projected Forward Interest Rates Joint Venture Joint Venture [Member] Joint Venture Common stock, authorized (in shares) Common Stock, Shares Authorized Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Diluted (in shares) Weighted-average diluted common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Financing receivable, at fair value (including accrued interest of $905000 as of March 31, 2025 and $281000 as of December 31, 2024) Net change in other real estate related investments Net change in other real estate related investments Financing Receivable, after Allowance for Credit Loss Originations Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Loan Originations Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Loan Originations MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total stockholders’ equity Equity, Attributable to Parent Real estate investments, net Real estate investments, net Real Estate Investment Property, Net Net income (loss) Temporary Equity, Net Income Amortization of below-market lease intangibles Operating Lease, Lease Income, Amortization Of Below-Market Lease Intangible Operating Lease, Lease Income, Amortization Of Below-Market Lease Intangible Principal payments Financing Receivable, Principal Payments Received Financing Receivable, Principal Payments Received Lease extended period Lease Extended Period Of Lease Lease Extended Period Of Lease Schedule of Investment in Owned Properties Schedule of Real Estate Properties [Table Text Block] Gain on sale of real estate, net Gain on sale of real estate, net Net gain on sale Gains (Losses) on Sales of Investment Real Estate Concentration Risk Type [Domain] Concentration Risk Type [Domain] Recurring Fair Value, Recurring [Member] Number of facilities, additions to assets held for sale Number Of Real Estate Properties, Held-for-Sale Number Of Real Estate Properties, Held-for-Sale Ownership percentage held by noncontrolling interest (as percent) Subsidiary, Ownership Percentage, Parent Loans receivable, book value Loans Receivable, Fair Value Loans Receivable, Fair Value Number of shares authorized for awards (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Sale of Stock [Domain] Sale of Stock [Domain] Carrying Amount Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus Sale leaseback transaction, lease term Sale Leaseback Transaction, Lease Term All Executive Categories All Executive Categories [Member] Dilutive potential common shares (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Ensign and Pennant Ensign And Pennant [Member] Ensign And Pennant Finance receivable, number of extension options Finance Receivable, Number Of Extension Options Finance Receivable, Number Of Extension Options Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Assets: Assets [Abstract] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Document Type Document Type Facility fee on revolving commitment fees (as percent) Line of Credit Facility, Commitment Fee Percentage Investment in real estate related investments Payments to Acquire Loans Receivable Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Period after March 30 2028 Debt Instrument, Redemption, Period Three [Member] Ensign Ensign [Member] Ensign [Member] CODM Evaluation of Performance Based on Net Income Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Mezzanine Loan Mezzanine Loan [Member] Mezzanine Loan Aggregate required financing of capital expenditures as percentage of initial investment in property (as percent) Aggregate Required Financing Of Capital Expenditures As Percentage Of Initial Investment In Property Aggregate Required Financing Of Capital Expenditures As Percentage Of Initial Investment In Property Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Annual cash rent Annual Cash Rent Annual Cash Rent Total Stockholders’ Equity Parent [Member] Subsequent Event [Table] Subsequent Event [Table] Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Payments of deferred financing costs Payments of Financing Costs Liabilities: Liabilities [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Revenues: Revenues: Revenues [Abstract] SNF SNF Skilled Nursing Facility [Member] Skilled Nursing Facility [Member] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Reportable Segment Reportable Segment [Member] Reportable Segment Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Lessor, Lease, Description [Line Items] Lessor, Lease, Description [Line Items] Distributions to noncontrolling interests Payments to Noncontrolling Interests Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] 2026 Lessor, Operating Lease, Payment to be Received, Year One Number of facilities in process of transferring operations Number Of Facilities In Process Of Transferring Operations Number Of Facilities In Process Of Transferring Operations Name Outstanding Recovery, Individual Name Preferred equity Preferred Equity [Member] Preferred Equity Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Authorized annual fund Authorized Annual Fund Authorized Annual Fund Title of Individual [Axis] Title and Position [Axis] Additional Paid-in Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Number of property secured by pledge Number Of Property Secured By A Pledge Number Of Property Secured By A Pledge Future Contractual Minimum Rental Income Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Dividends paid on common stock Payments of Ordinary Dividends, Common Stock Preferred equity investments, face value Equity Method Investment, Aggregate Cost Facilities Held For Sale Facilities Held For Sale [Member] Facilities Held For Sale Class of Stock [Line Items] Class of Stock [Line Items] CONCENTRATION OF RISK Concentration Risk Disclosure [Text Block] Investment, Name [Axis] Investment, Name [Axis] Redemption price of notes (as percent) Debt Instrument, Redemption Price, Percentage Other expenses Other General and Administrative Expense Class of Stock [Axis] Class of Stock [Axis] Diluted (in usd per share) Earnings per common share attributable to CareTrust REIT, Inc., diluted (in usd per share) Earnings Per Share, Diluted Title of Individual [Domain] Title and Position [Domain] Dividends on common stock Dividends, Common Stock [Abstract] Counterparty Name [Domain] Counterparty Name [Domain] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Ownership [Axis] Ownership [Axis] Preferred stock, issued (in shares) Preferred Stock, Shares Issued Customer [Axis] Customer [Axis] 2028 Lessor, Operating Lease, Payment to be Received, Year Three Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Share-based compensation Share-Based Payment Arrangement, Noncash Expense Schedule of Restricted Stock Award and Performance Award Activity Share-Based Payment Arrangement, Activity [Table Text Block] Net income Net income (loss) Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Schedule of Loan Receivable Activity Schedule of Loan Receivable Activity [Table Text Block] Schedule of Loan Receivable Activity Preferred equity investment Equity Method Investments [Member] Other income (loss): Other income (loss): Nonoperating Income (Expense) [Abstract] Certain Capital Improvements at Triple-Net Leased Facilities Capital Improvements At Triple Net Leased Facilities [Member] Capital Improvements At Triple Net Leased Facilities Interest rate (as percent) Debt Instrument, Interest Rate, Stated Percentage Distributions to noncontrolling interests Distributions to noncontrolling interests Distributions to noncontrolling interests Initial lease term (in years) Lessor, Operating Lease, Term of Contract Lease Expiration March 2029, Next option 2022 Properties With Purchase Option, Lease Expiration March 2029, Next Option 2022 [Member] Properties With Purchase Option, Lease Expiration March 2029, Next Option 2022 Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Unrealized gain (loss) on other real estate related investments, net Unrealized gain, net Unrealized (gain) loss on other real estate related investments, net Unrealized gain (loss) on other real estate related investments, net Unrealized Gain (Loss) On Other Real Estate Related Investments Unrealized Gain (Loss) On Other Real Estate Related Investments Facility Count and Type Facility Count by Type Facility Count by Type Numerator for diluted earnings available to common stockholders Net Income (Loss) Available to Common Stockholders, Diluted Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Measurement input Preferred Equity Investments, Measurement Input Preferred Equity Investments, Measurement Input Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Interest expense Interest expense Interest Expense, Operating and Nonoperating Net change in other loans receivable Loan Receivable, Net Change Fair Value Loan Receivable, Net Change Fair Value IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES Impairment of Real Estate Investments, Assets Held for Sale And Asset Sales [Text Block] Impairment of Real Estate Investments, Assets Held for Sale And Asset Sales Variable Rate [Domain] Variable Rate [Domain] Fair Value Financing Receivable, Fair Value Disclosure Financing Receivable, Fair Value Disclosure Business Acquisition [Line Items] Business Acquisition [Line Items] Total liabilities and equity Liabilities and Equity SUBSEQUENT EVENTS Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Prepaid expenses and other assets, net Increase (Decrease) in Prepaid Expense and Other Assets Incentive compensation Incentive Compensation Incentive Compensation Investment Three Investment Three [Member] Investment Three Noncontrolling Interest [Table] Noncontrolling Interest [Table] Sale of real estate settled with note receivable Noncash or Part Noncash Divestiture, Amount of Consideration Received Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Number of facilities acquired Number Of Facilities Acquired Number Of Facilities Acquired Disposed of by Sale Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Buildings and improvements Investment Building and Building Improvements Number of facilities Number Of Facilities Disposed Number Of Facilities Disposed Underlying Security Market Price Change Underlying Security Market Price Change, Percent Measurement Input Type [Axis] Measurement Input Type [Axis] Rental income Total Rental income Operating Lease, Lease Income Individual: Individual [Axis] Name of Property [Domain] Name of Property [Domain] Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Total Lessor, Operating Lease, Payment to be Received Restricted cash Restricted cash Restricted Cash Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Measurement Input Type [Domain] Measurement Input Type [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Expenses: Expenses: Operating Expenses [Abstract] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Net carrying value, assets sold Real Estate Investment Property, Assets Held For Sale, Dispositions Real Estate Investment Property, Assets Held For Sale, Dispositions Unvested, beginning balance (in usd per share) Unvested, ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and Equity: Liabilities and Equity [Abstract] Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Fair Value Estimate of Fair Value Measurement [Member] Expected credit loss Financing Receivable, Allowance for Credit Loss Senior unsecured notes payable, fair value disclosure Notes Payable, Fair Value Disclosure First Option First Option [Member] First Option Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Preferred ownership (as percent) Preferred Ownership Percentage Preferred Ownership Percentage Concentration Risk [Table] Concentration Risk [Table] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Other real estate related investments, accrued interest Real Estate Investments, Accrued Interest Real Estate Investments, Accrued Interest Principal Amount Long-Term Debt, Gross Exercise Price Award Exercise Price Dividends payable as of record date Dividends Payable, Current Lease Contractual Term [Axis] Lease Contractual Term [Axis] CA CALIFORNIA Real Estate Properties [Line Items] Real Estate Properties [Line Items] Financing receivable, mortgage prepaid loan amount Financing Receivable, Mortgage Prepaid Loan Amount Financing Receivable, Mortgage Prepaid Loan Amount EARNINGS PER COMMON SHARE Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Subsequent Event Subsequent Event [Member] Investment Six Investment Six [Member] Investment Six ATM Program At-The-Market Offering Program [Member] At-The-Market Offering Program [Member] Investments in Mezzanine Loans Investments in Mezzanine Loans [Member] Investments in Mezzanine Loans Equity: Equity, Attributable to Parent [Abstract] Granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Name of Property [Axis] Name of Property [Axis] Gross Investment Investments Business combination, share price, expected (in usd per share) Business Combination, Share Price, Expected Business Combination, Share Price, Expected Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table] Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table] JV Partner 97.5% JV Partner 97.5% [Member] JV Partner 97.5% Segments [Domain] Segments [Domain] Lease renewal term (in years) Lessor, Operating Lease, Renewal Term Interest income from other real estate related investments and other income Interest income from other real estate related investments and other income Interest and Other Income Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Number of facilities, assets sold Number Of Real Estate Properties Sold Number Of Real Estate Properties Sold All Individuals All Individuals [Member] Number of renewal options Lessor, Operating Lease, Number Of Renewal Options Lessor, Operating Lease, Number Of Renewal Options SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Care REIT plc Care REIT plc [Member] Care REIT plc New Embassy Lease Agreement New Embassy Lease Agreement [Member] New Embassy Lease Agreement Earn-out obligation Earn-Out Obligation [Member] Earn-Out Obligation PEO PEO [Member] Investment Four Investment Four [Member] Investment Four Real Estate [Line Items] Real Estate [Line Items] Schedule of Asset Sales and Held for Sale Reclassifications Schedule Of Asset Sales And Held For Sale Reclassifications [Table Text Block] Schedule Of Asset Sales And Held For Sale Reclassifications Variable Rate [Axis] Variable Rate [Axis] Name Trading Arrangement, Individual Name Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Other Other [Member] Other Portion of funding commitment subject to rent increase at time of funding Portion Of Commitment Subject To Rent Increase At Time Of Funding Portion Of Commitment Subject To Rent Increase At Time Of Funding Schedule of Commitments and Contingencies Commitments And Contingencies [Table Text Block] Commitments And Contingencies Assisted living Assisted Living Facility [Member] Assisted Living Facility [Member] 2029 Lessor, Operating Lease, Payment to be Received, Year Four Senior unsecured notes payable, net Unsecured Long-Term Debt, Noncurrent Schedules of Concentration of Risk Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Other Commitments [Domain] Other Commitments [Domain] Dividends payable Dividends Payable Assets: Assets, Fair Value Disclosure [Abstract] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Depreciation and amortization (including below-market ground leases) Depreciation and Amortization (Including Below-Market Ground Leases, Excluding Amortization of Deferred Financing Costs) Depreciation and Amortization (Including Below-Market Ground Leases, Excluding Amortization of Deferred Financing Costs) SNF / Campus Skilled Nursing And Campus Facilities [Member] Skilled Nursing And Campus Facilities Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Contractual cash yield Contractual Cash Yield Contractual Cash Yield Local Phone Number Local Phone Number Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Investment interest rate (as percent) Investment Interest Rate Schedule of Other Real Estate Related Investment Activity Schedule of Other Real Estate Investment Activity [Table Text Block] Schedule of Other Real Estate Investment Activity Prices per unit input Price Per Unit, Value, Measurement Input Price Per Unit, Value, Measurement Input Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Change in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Transfer of pre-acquisition costs to acquired assets Transfer Of Preacquisition Costs To Acquired Assets Transfer Of Preacquisition Costs To Acquired Assets Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] PEO Total Compensation Amount PEO Total Compensation Amount Campus Campus [Member] Campus Real Estate [Domain] Real Estate [Domain] Percentage cap Percentage Cap Percentage Cap Lessor, Lease, Description [Table] Lessor, Lease, Description [Table] PACS Priority Management Group LLC [Member] Priority Management Group LLC Redemption price, percentage upon change of control (as percent) Debt Instrument Redemption Price Upon Change Of Control As Percentage Of Principal Amount Debt instrument redemption price upon change of control as percentage of principal amount. Commissions paid on stock issuance Payments of Stock Issuance Costs COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Vesting of stock-based compensation awards, net of shares withheld for employee taxes Restricted Stock, Value, Shares Issued Net of Tax Withholdings Common Stock Common Stock [Member] Measure: Measure [Axis] Asset Class [Domain] Asset Class [Domain] Long-Lived Assets Held-for-Sale by Asset Type [Axis] Long-Lived Asset, Held-for-Sale, Type [Axis] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Assets Measured at Fair Value on a Recurring Basis Using Level 3 Inputs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Issuance of common stock, net (in shares) Number of shares (in shares) Stock Issued During Period, Shares, New Issues Entity Emerging Growth Company Entity Emerging Growth Company Number of extension options Line Of Credit Facility, Number Of Extension Options Line Of Credit Facility, Number Of Extension Options Principal payments received on real estate related investments and other loans receivable Proceeds from Collection of Loans Receivable Segment Reporting [Abstract] Cash compensation Cash Compensation Cash Compensation Other Investments Other Investments [Member] Entity Central Index Key Entity Central Index Key Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Investment Two Investment Two [Member] Investment Two Swingline Loan Swingline Loan [Member] Swingline Loan [Member] Schedule of Tenant Purchase Options Schedule of Tenant Purchase Options [Table Text Block] Schedule of Tenant Purchase Options Discontinued Operations and Disposal Groups [Abstract] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Early termination fee Early Termination Fee, Percentage Early Termination Fee, Percentage Lease Expiration May 2034, Next option 2027 Properties With Purchase Option, Lease Expiration May 2034, Next Option 2027 [Member] Properties With Purchase Option, Lease Expiration May 2034, Next Option 2027 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST Equity [Text Block] Accounts payable, accrued liabilities and deferred rent liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Initial contractual cash yield Operating Lease Lessor Cash Yield Percentage Operating Lease Lessor Cash Yield Percentage Mortgage Secured and Mezzanine Loans Receivable Mortgage Secured And Mezzanine Loans Receivable [Member] Mortgage Secured And Mezzanine Loans Receivable Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Financial Instrument [Axis] Financial Instrument [Axis] SEGMENT REPORTING Segment Reporting Disclosure [Text Block] Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Number of purchase option types Number of Purchase Option Types Number of Purchase Option Types Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Amortization of stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Professional services Professional Fees RSAs Restricted Stock [Member] Remaining offering amount available Securities Offering, Remaining Authorized Amount Securities Offering, Remaining Authorized Amount Net carrying value, additions to assets held for sale Real Estate Investment Property, Assets Held For Sale, Additions Real Estate Investment Property, Assets Held For Sale, Additions Entity Shell Company Entity Shell Company Measurement Basis [Axis] Measurement Basis [Axis] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Loan receivable Loans Receivable, Fair Value Disclosure Schedule of Dividends on Common Stock Dividends Declared [Table Text Block] Facility fee on revolving commitment fee based on investment grade ratings (as percent) Line Of Credit, Commitment Fee Based On Investment Grade Rating, Percentage Line Of Credit, Commitment Fee Based On Investment Grade Rating, Percentage Title Trading Arrangement, Individual Title Share-based payment award, percentage of original awards granted Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Based On Total Shareholder Return Metric, Percentage Of Original Awards Granted Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Based On Total Shareholder Return Metric, Percentage Of Original Awards Granted Accrued interest, net Loan Receivable, Accrued Interest Loan Receivable, Accrued Interest Consolidated Entities [Axis] Consolidated Entities [Axis] Statement [Table] Statement [Table] Measurement Frequency [Domain] Measurement Frequency [Domain] Counterparty Name [Axis] Counterparty Name [Axis] Other real estate related investments (including accrued interest of $6,005 as of March 31, 2025 and $4,725 as of December 31, 2024) Aggregate carrying value Real Estate Investments, Joint Ventures Geographic Concentration Risk Geographic Concentration Risk [Member] Schedule of Variable Interest Entities Schedule of Variable Interest Entities [Table Text Block] City Area Code City Area Code Financing Receivable, Past Due [Line Items] Financing Receivable, Past Due [Line Items] Number of facilities currently held for sale Number Of Facilities Currently Held For Sale Number Of Facilities Currently Held For Sale Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Number of leases amended Number Of Leases Amended Number Of Leases Amended Disposal Group Classification [Domain] Disposal Group Classification [Domain] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Level 1 Fair Value, Inputs, Level 1 [Member] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Notes payable Notes Payable Senior Notes [Member] Expected term Stock Issued, Term Stock Issued, Term Thereafter Lessor, Operating Lease, Payment to be Received, after Year Five Purchase option, number of properties Purchase Option, Number Of Properties Purchase Option, Number Of Properties Lease Arrangements [Axis] Lease Arrangements [Axis] Lease Arrangements Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Financial assets: Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Quantitative Information About Unobservable Inputs Related to Level 3 Fair Value Measurements Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Weighted Average Share Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Other Commitments [Axis] Other Commitments [Axis] Preferred equity investments Preferred Equity Investment [Member] Preferred Equity Investment Subsequent Event Type [Axis] Subsequent Event Type [Axis] Gross proceeds from issuance Proceeds from Issuance of Unsecured Debt Purchases of equipment, furniture and fixtures and improvements to real estate Payments To Acquire Equipment, Furniture And Fixtures And Develop Real Estate Assets Payments To Acquire Equipment, Furniture And Fixtures And Develop Real Estate Assets Earnings Per Share [Abstract] Earnings Per Share [Abstract] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Equity [Abstract] Equity [Abstract] Class of Stock [Domain] Class of Stock [Domain] Discounted cash flow Valuation Technique, Discounted Cash Flow [Member] Other Income, Excluding Interest Other Income, Excluding Interest Other Income, Excluding Interest Net income (loss) Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest Deferred Loan Fees Debt Issuance Costs, Gross General and administrative Total general and administrative General and Administrative Expense Contributed to JV Payments to Acquire Interest in Joint Venture Subservicing fee percentage Subservicing Fee Percentage Subservicing Fee Percentage Tenant operating expense reimbursement Operating Leases, Tenant Operating Expense Reimbursement Operating Leases, Tenant Operating Expense Reimbursement Number of operational beds and units in facilities Number Of Operational Beds And Units In Facilities Number Of Operational Beds And Units In Facilities Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Mortgage Loan Mortgage Loan [Member] Mortgage Loan Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount ALF/ILF Assisted and Independent Living Properties [Member] Assisted and Independent Living Properties [Member] Credit Facility [Axis] Credit Facility [Axis] Amendment Flag Amendment Flag Carrying Amount Reported Value Measurement [Member] Entity Registrant Name Entity Registrant Name Accounts payable, accrued liabilities and deferred rent liabilities Accounts Payable and Other Accrued Liabilities Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Fair Value as of Grant Date Award Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Subsequent Events [Abstract] Subsequent Events [Abstract] Sale of stock, number of shares issued in transaction Sale of Stock, Number of Shares Issued in Transaction Level 2 Fair Value, Inputs, Level 2 [Member] MARYLAND MARYLAND DEBT Debt Disclosure [Text Block] Deferred financing costs, net Debt Issuance Costs, Net Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Accrued interest, net Financing Receivable, Accrued Interest, before Allowance for Credit Loss Geographical [Domain] Geographical [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Investment Seven Investment Seven [Member] Investment Seven Senior unsecured notes payable, face value Debt instrument, face amount Debt Instrument, Face Amount Issuance of common stock, net Stock Issued During Period, Value, New Issues Prepaid expenses and other assets, net Prepaid and other assets Prepaid Expense and Other Assets Net change in other loans receivable Loan Receivable, Net Change Loan Receivable, Net Change Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Remaining Commitment Remaining Commitment [Member] Remaining Commitment Skilled nursing Skilled Nursing Properties [Member] Skilled Nursing Properties [Member] Common stock, $0.01 par value; 500,000,000 shares authorized, 187,669,948 and 186,993,010 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively Common Stock, Value, Issued Land Land Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Integral equipment, furniture and fixtures Fixtures and Equipment, Gross Mezzanine loans receivable Mezzanine Loan Receivable [Member] Mezzanine Loan Receivable [Member] Mezzanine Loan Receivable Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Senior unsecured term loan Senior Unsecured Term Loan [Member] Senior Unsecured Term Loan [Member] Contingent earnout liability Contingent Earnout Liability Contingent Earnout Liability Extension option term (in months) Line Of Credit Facility Extension Option Term Line of credit facility extension option term. Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Provision for loan losses, net Financing Receivable, Credit Loss, Expense (Reversal) Schedule of Other Real Estate Related Investments, at Fair Value Investment [Table Text Block] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Other real estate related investments, fair value adjustments, unrealized gain Other Real Estate Related Investments, Fair Value Adjustments, Unrealized Gain Other Real Estate Related Investments, Fair Value Adjustments, Unrealized Gain OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS Other Real Estate Related And Other Investments [Text Block] Other Real Estate Related And Other Investments Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued and outstanding as of March 31, 2025 and December 31, 2024 Preferred Stock, Value, Issued Other loans receivable Other Loans Receivable [Member] Other Loans Receivable Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction RSAs and PSAs Restricted Stock And Performance Shares [Member] Restricted Stock And Performance Shares [Member] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Basic (in usd per share) Earnings per common share attributable to CareTrust REIT, Inc., basic (in usd per share) Earnings Per Share, Basic Cumulative distributions in excess of earnings Accumulated Distributions in Excess of Net Income Period of option window Period Of Option Window Period Of Option Window REAL ESTATE INVESTMENTS, NET Real Estate Disclosure [Text Block] Proceeds from the issuance of common stock, net Gross proceeds Proceeds from Issuance of Common Stock Net proceeds from sales of real estate Net sales proceeds Proceeds from Sale, Real Estate, Held-for-Investment Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Class of Financing Receivable [Axis] Class of Financing Receivable [Axis] Prepayments of other real estate related investments Prepayments Of Other Real Estate Related Investments Prepayments Of Other Real Estate Related Investments Ownership [Domain] Ownership [Domain] Contributions from noncontrolling interests Temporary Equity, Contributions From Noncontrolling Interests Temporary Equity, Contributions From Noncontrolling Interests Number of Beds/Units Number Of Units And Beds In Facilities Number Of Units And Beds In Facilities Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Numerator for basic earnings available to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Net proceeds from issuance Proceeds from Debt, Net of Issuance Costs Lease Expiration November 2039, Next Option 2027 Properties With Purchase Option, Lease Expiration November 2039, Next Option 2027 [Member] Properties With Purchase Option, Lease Expiration November 2039, Next Option 2027 Disposal Group, Held-for-sale, Not Discontinued Operations Disposal Group, Held-for-Sale, Not Discontinued Operations [Member] Valuation, Market Approach Valuation, Market Approach [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Number of properties with right to operate Number Of Properties With Right To Operate Number Of Properties With Right To Operate Weighted-average number of common shares: Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Total assets Assets Other Real Estate Related Investments Other Real Estate Related Investments [Member] Other Real Estate Related Investments Unsecured revolving credit facility Long-Term Line of Credit Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Long-Lived Assets Held-for-Sale, Name [Domain] Long-Lived Assets Held-for-Sale, Name [Domain] Contributions from noncontrolling interests Noncontrolling Interest, Increase from Subsidiary Equity Issuance Schedule of Items Measured at Fair Value on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Investment One Investment One [Member] Investment One Accrued interest, net Change In Financing Receivable, Accrued Interest, After Allowance For Credit Loss Change In Financing Receivable, Accrued Interest, After Allowance For Credit Loss Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 13) Commitments and contingencies Commitments and Contingencies Number of properties Number of properties Number of facilities at beginning Number of facilities at ending Number of Real Estate Properties Financing receivable Other Financing Receivables [Member] Other Financing Receivables Financing Receivable, Allowance for Credit Loss [Line Items] Financing Receivable, Allowance for Credit Loss [Line Items] Termination Date Trading Arrangement Termination Date Contractual rent due Operating Lease, Lease Income, Lease Payments Net carrying value, impairment of real estate held for sale Real Estate Investment Property, Impairment Of Real Estate Held For Sale Real Estate Investment Property, Impairment Of Real Estate Held For Sale Skilled Nursing Facility, California, Joint Venture Skilled Nursing Facility, California, Joint Venture [Member] Skilled Nursing Facility, California, Joint Venture Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Total revenues Revenues STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Purchase Price Asset Acquisition, Consideration Transferred Entity Address, City or Town Entity Address, City or Town Period of unpaid interest payments due upon prepayment Loan Receivable, Period Of Unpaid Interest Payments Due Upon Prepayment Loan Receivable, Period Of Unpaid Interest Payments Due Upon Prepayment Loans receivable, measurement input Loans Receivable, Measurement Input Loans Receivable, Measurement Input Debt Instrument [Axis] Debt Instrument [Axis] Noncontrolling Interest [Abstract] Amortization of stock-based compensation Stock-based compensation expense Share-Based Payment Arrangement, Expense Net income attributable to CareTrust REIT, Inc. Net income attributable to CareTrust REIT, Inc. Net Income (Loss) Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Schedule of Face Value, Carrying Amount and Fair Value of Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Secured and Mezzanine Loans Receivable Secured And Mezzanine Loans Receivable [Member] Secured And Mezzanine Loans Receivable Other Commitments [Table] Other Commitments [Table] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Total other income (loss) Nonoperating Gains (Losses) Financing Receivable, Allowance for Credit Loss [Table] Financing Receivable, Allowance for Credit Loss [Table] Properties Number Of Properties With Tenant Purchase Option Number Of Properties With Tenant Purchase Option Consolidated Entities [Domain] Consolidated Entities [Domain] Vesting of stock-based compensation awards, net of shares withheld for employee taxes (in shares) Restricted Stock, Shares Issued Net of Shares for Tax Withholdings Document Fiscal Year Focus Document Fiscal Year Focus Held for Sale Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member] Noncontrolling Interests Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Schedule of Real Estate Properties [Table] Real Estate Property, Ownership [Table] Entity Address, Address Line Two Entity Address, Address Line Two Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Common dividends Dividends, Common Stock Term of contract Lessee, Operating Lease, Term of Contract Name Forgone Recovery, Individual Name Mortgage secured loans receivable Mortgage secured loans receivable Mortgage Secured Loan Receivable [Member] Mortgage Secured Loan Receivable Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Contributions from noncontrolling interests Proceeds from Noncontrolling Interests Noncash interest income Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Base Rate Base Rate [Member] Secured Overnight Financing Rate (SOFR) Floor Secured Overnight Financing Rate (SOFR) Floor [Member] Secured Overnight Financing Rate (SOFR) Floor Unvested, beginning balance (in shares) Unvested, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Asset Class [Axis] Asset Class [Axis] Insider Trading Arrangements [Line Items] Deferred rent as percentage of contractual cash yield, year two Deferred Rent As Percentage Of Contractual Cash Yield, Year Two Deferred Rent As Percentage Of Contractual Cash Yield, Year Two Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Schedule of At-The-Market Offering Program Schedule of Stock by Class [Table Text Block] Real Estate [Abstract] Real Estate [Abstract] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Financing receivable, mortgage prepaid loan, outstanding Financing Receivable, Mortgage Prepaid Loan, Outstanding Financing Receivable, Mortgage Prepaid Loan, Outstanding PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Cumulative Distributions in Excess of Earnings Accumulated Distributions in Excess of Net Income [Member] Adjustment to Compensation: Adjustment to Compensation [Axis] Acquisitions of real estate, net of deposits applied Payments to Acquire Commercial Real Estate Net (loss) income attributable to noncontrolling interests Net (loss) income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Document Transition Report Document Transition Report Assets held for sale, net Asset, Held-for-Sale, Not Part of Disposal Group Document Quarterly Report Document Quarterly Report Financial liabilities: Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract] Finance receivable, extension option, term Finance Receivable, Extension Option, Term Finance Receivable, Extension Option, Term Customer [Domain] Customer [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Entity Current Reporting Status Entity Current Reporting Status Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Number of preferred equity investments Number Of Preferred Equity Investment Number Of Preferred Equity Investment Basic (in shares) Weighted-average basic common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Greater than 90 Days Past Due Financial Asset, Equal to or Greater than 90 Days Past Due [Member] Multi-service campuses Campus Multi-Service Campus Properties [Member] Multi-Service Campus Properties [Member] Noncontrolling Interests Noncontrolling Interest Owners [Member] Noncontrolling Interest Owners Investments in Real Estate Secured Loans Investments in Real Estate Secured Loan [Member] Investments in Real Estate Secured Loan Real Estate, Type of Property [Axis] Real Estate, Type of Property [Axis] Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Amortization of deferred financing costs Amortization of Debt Issuance Costs and Discounts Real Estate [Table] Real Estate [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Unrealized gain (loss) on other real estate related investments, net Unrealized Loss on Other Real Estate Related Investments Unrealized Loss on Other Real Estate Related Investments Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Payables for purchase of property plant and equipment Payables for Purchase of Property Plant and Equipment Payables for Purchase of Property Plant and Equipment Rental Revenue Revenue Benchmark [Member] Subfacility capacity as percentage of available revolving commitments (as percent) Line Of Credit, Subfacility, Capacity As Percentage Of Available Revolving Commitments Line Of Credit, Subfacility, Capacity As Percentage Of Available Revolving Commitments Entity Filer Category Entity Filer Category Schedule of Total Future Contractual Minimum Rental Income Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block] Letter of Credit Letter of Credit [Member] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 9 ctre-20250331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover - shares
3 Months Ended
Mar. 31, 2025
Apr. 30, 2025
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2025  
Document Transition Report false  
Entity File Number 001-36181  
Entity Registrant Name CareTrust REIT, Inc.  
Entity Incorporation, State or Country Code MD  
Entity Tax Identification Number 46-3999490  
Entity Address, Address Line One 905 Calle Amanecer  
Entity Address, Address Line Two Suite 300  
Entity Address, City or Town San Clemente  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92673  
City Area Code 949  
Local Phone Number 542-3130  
Title of 12(b) Security Common Stock, par value $0.01 per share  
Trading Symbol CTRE  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   191,688,997
Entity Central Index Key 0001590717  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Assets:    
Real estate investments, net $ 2,252,279 $ 2,226,740
Financing receivable, at fair value (including accrued interest of $905000 as of March 31, 2025 and $281000 as of December 31, 2024) 96,628 96,004
Other real estate related investments (including accrued interest of $6,005 as of March 31, 2025 and $4,725 as of December 31, 2024) 799,799 795,203
Assets held for sale, net 16,736 57,261
Cash and cash equivalents 26,510 213,822
Restricted cash 606,000 0
Accounts and other receivables 1,954 1,174
Prepaid expenses and other assets, net 73,890 35,608
Deferred financing costs, net 10,652 11,204
Total assets 3,884,448 3,437,016
Liabilities and Equity:    
Senior unsecured notes payable, net 397,149 396,927
Unsecured revolving credit facility 425,000 0
Accounts payable, accrued liabilities and deferred rent liabilities 51,069 56,318
Dividends payable 63,053 54,388
Total liabilities 936,271 507,633
Commitments and contingencies (Note 13)
Redeemable noncontrolling interest 17,396 18,243
Equity:    
Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued and outstanding as of March 31, 2025 and December 31, 2024 0 0
Common stock, $0.01 par value; 500,000,000 shares authorized, 187,669,948 and 186,993,010 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively 1,877 1,870
Additional paid-in capital 3,455,256 3,439,117
Cumulative distributions in excess of earnings (529,821) (532,570)
Total stockholders’ equity 2,927,312 2,908,417
Noncontrolling interests 3,469 2,723
Total equity 2,930,781 2,911,140
Total liabilities and equity $ 3,884,448 $ 3,437,016
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Statement of Financial Position [Abstract]    
Accrued interest, net $ 905 $ 281
Other real estate related investments, accrued interest $ 6,005 $ 4,725
Preferred stock, par value (in usd per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 100,000,000 100,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in usd per share) $ 0.01 $ 0.01
Common stock, authorized (in shares) 500,000,000 500,000,000
Common stock, issued (in shares) 187,669,948 186,993,010
Common stock, outstanding (in shares) 187,669,948 186,993,010
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED INCOME STATEMENTS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenues:    
Rental income $ 71,646 $ 53,502
Interest income from financing receivable 2,807 0
Interest income from other real estate related investments and other income 22,168 9,568
Total revenues 96,621 63,070
Expenses:    
Depreciation and amortization 17,841 13,448
Interest expense 6,669 8,228
Property taxes 2,065 1,801
Impairment of real estate investments 0 2,744
Property operating expenses 105 660
General and administrative 9,023 6,838
Total expenses 36,591 33,719
Other income (loss):    
Gain on sale of real estate, net 3,876 11
Unrealized gain (loss) on other real estate related investments, net 1,287 (612)
Total other income (loss) 5,163 (601)
Net income 65,193 28,750
Net (loss) income attributable to noncontrolling interests (609) 4
Net income attributable to CareTrust REIT, Inc. $ 65,802 $ 28,746
Earnings per common share attributable to CareTrust REIT, Inc:    
Basic (in usd per share) $ 0.35 $ 0.22
Diluted (in usd per share) $ 0.35 $ 0.22
Weighted-average number of common shares:    
Basic (in shares) 187,152 132,836
Diluted (in shares) 187,416 133,202
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - USD ($)
$ in Thousands
Total
Total Stockholders’ Equity
Common Stock
Additional Paid-in Capital
Cumulative Distributions in Excess of Earnings
Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2023     129,992,796      
Beginning balance at Dec. 31, 2023 $ 1,418,717 $ 1,416,819 $ 1,300 $ 1,883,147 $ (467,628) $ 1,898
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock, net (in shares)     11,600,000      
Issuance of common stock, net 269,787 269,787 $ 116 269,671    
Vesting of stock-based compensation awards, net of shares withheld for employee taxes (in shares)     119,369      
Vesting of stock-based compensation awards, net of shares withheld for employee taxes (2,483) (2,483) $ 1 (2,484)    
Amortization of stock-based compensation 2,120 2,120   2,120    
Common dividends (41,192) (41,192)     (41,192)  
Distributions to noncontrolling interests (47)         (47)
Contributions from noncontrolling interests 444         444
Net income (loss) 28,750 28,746     28,746 4
Ending balance (in shares) at Mar. 31, 2024     141,712,165      
Ending balance at Mar. 31, 2024 1,676,096 1,673,797 $ 1,417 2,152,454 (480,074) 2,299
Beginning balance at Dec. 31, 2023 0          
Ending balance at Mar. 31, 2024 $ 0          
Beginning balance (in shares) at Dec. 31, 2024 186,993,010   186,993,010      
Beginning balance at Dec. 31, 2024 $ 2,911,140 2,908,417 $ 1,870 3,439,117 (532,570) 2,723
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock, net (in shares)     553,023      
Issuance of common stock, net 15,562 15,562 $ 6 15,556    
Vesting of stock-based compensation awards, net of shares withheld for employee taxes (in shares)     123,915      
Vesting of stock-based compensation awards, net of shares withheld for employee taxes (3,325) (3,325) $ 1 (3,326)    
Amortization of stock-based compensation 3,909 3,909   3,909    
Common dividends (63,053) (63,053)     (63,053)  
Distributions to noncontrolling interests (2)         (2)
Contributions from noncontrolling interests 642         642
Net income (loss) 65,908 65,802     65,802 106
Net income (loss) $ 65,193          
Ending balance (in shares) at Mar. 31, 2025 187,669,948   187,669,948      
Ending balance at Mar. 31, 2025 $ 2,930,781 $ 2,927,312 $ 1,877 $ 3,455,256 $ (529,821) $ 3,469
Beginning balance at Dec. 31, 2024 18,243          
Increase (Decrease) in Temporary Equity [Roll Forward]            
Distributions to noncontrolling interests (900)          
Contributions from noncontrolling interests 768          
Net income (loss) (715)          
Ending balance at Mar. 31, 2025 $ 17,396          
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Parenthetical) - $ / shares
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Statement of Stockholders' Equity [Abstract]    
Common dividends (in usd per share) $ 0.335 $ 0.29
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash flows from operating activities:    
Net income $ 65,193 $ 28,750
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization (including below-market ground leases) 17,865 13,462
Amortization of deferred financing costs 914 614
Unrealized (gain) loss on other real estate related investments, net (1,287) 612
Amortization of stock-based compensation 3,909 2,120
Straight-line rental income 7 7
Amortization of lease incentives 49 0
Amortization of below market leases (926) (575)
Noncash interest income (1,904) (425)
Gain on sale of real estate, net (3,876) (11)
Impairment of real estate investments 0 2,744
Change in operating assets and liabilities:    
Accounts and other receivables (788) (15)
Prepaid expenses and other assets, net (3,451) (322)
Accounts payable, accrued liabilities and deferred rent liabilities (4,323) 1,859
Net cash provided by operating activities 71,382 48,820
Cash flows from investing activities:    
Acquisitions of real estate, net of deposits applied (40,162) (66,619)
Purchases of equipment, furniture and fixtures and improvements to real estate (2,276) (398)
Investment in real estate related investments (6,389) (52,165)
Principal payments received on real estate related investments and other loans receivable 4,582 0
Escrow deposits for potential acquisitions of real estate (36,066) (4,105)
Net proceeds from sales of real estate 44,401 46
Net cash used in investing activities (35,910) (123,241)
Cash flows from financing activities:    
Proceeds from the issuance of common stock, net 15,562 269,787
Borrowings under unsecured revolving credit facility 425,000 0
Payments of deferred financing costs (141) (24)
Net-settle adjustment on restricted stock (3,325) (2,483)
Dividends paid on common stock (54,388) (36,531)
Contributions from noncontrolling interests 1,410 444
Distributions to noncontrolling interests (902) (47)
Net cash provided by financing activities 383,216 231,146
Net increase in cash, cash equivalents and restricted cash 418,688 156,725
Cash, cash equivalents and restricted cash as of the beginning of period 213,822 294,448
Cash, cash equivalents and restricted cash as of the end of period 632,510 451,173
Supplemental disclosures of cash flow information:    
Interest paid 450 3,771
Supplemental schedule of noncash investing and financing activities:    
Increase in dividends payable 8,665 4,661
Transfer of pre-acquisition costs to acquired assets 0 5
Sale of real estate settled with note receivable $ 0 $ 1,000
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.25.1
ORGANIZATION
3 Months Ended
Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION ORGANIZATION
Description of Business—CareTrust REIT, Inc.’s (“CareTrust REIT” or the “Company”) primary business consists of acquiring, financing, developing and owning real property to be leased to third-party tenants in the healthcare sector. As of March 31, 2025, the Company owned, directly or through joint ventures, and leased to independent operators 255 skilled nursing facilities (“SNFs”), multi-service campuses, assisted living facilities (“ALFs”) and independent living facilities (“ILFs”) consisting of 27,672 operational beds and units located in 32 states with the highest concentration of properties by rental income located in California, Texas and Tennessee. As of March 31, 2025, the Company also had other real estate related investments consisting of three preferred equity investments, 15 real estate secured loans receivable, and five mezzanine loans receivable with a carrying value of $799.8 million and one financing receivable with a carrying value of $96.6 million.
Planned Acquisition—On March 11, 2025, the Company announced (the “Rule 2.7 Announcement”) pursuant to Rule 2.7 of the United Kingdom City Code on Takeovers and Mergers (the “Code”) a firm intention to make a cash offer (the “Offer”) to acquire (the “Acquisition”), through its wholly-owned direct subsidiary, CR United Bidco Limited (“Bidco”), the entire issued and to be issued ordinary share capital (other than Scheme Restricted Shares (as defined in the Rule 2.7 Announcement)) of Care REIT plc (“Target”) for 108 pence in cash per ordinary share of Target. Target is a UK-based real estate investment trust listed on the Main Market of the London Stock Exchange focused on investing in care homes throughout the United Kingdom. The Acquisition is intended to be effected by means of a scheme of arrangement (the “Scheme”) under Part 26 of the United Kingdom Companies Act 2006, meaning it is subject to court approval and the satisfaction or waiver of other ordinary conditions to closing, following approval by Target’s shareholders.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. The accompanying consolidated financial statements of the Company include the accounts of CareTrust REIT, its wholly-owned subsidiaries, and variable interest entities (“VIEs”) over which the Company exercises control. All intercompany transactions and account balances within the Company have been eliminated, and net earnings are reduced by the portion of net earnings attributable to noncontrolling interests.
Restricted cash—The Company presents cash and cash equivalents separately from restricted cash within the Company’s condensed consolidated balance sheets. The Company includes restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the condensed consolidated statements of cash flows. The Company provides a reconciliation between the balance sheets and statements of cash flows, as required when the balance includes more than one line item for cash, cash equivalents and restricted cash. The Company also provides a disclosure of the nature of the restrictions related to material restricted cash balances.
As of March 31, 2025, the Company had $606.0 million in restricted cash related to the cash deposited with the trustee for the planned acquisition of Care REIT plc.
Cash, cash equivalents and restricted cash consisted of the following as of March 31, 2025 and December 31, 2024 (dollars in thousands):
March 31, 2025December 31, 2024
Cash and cash equivalents$26,510 $213,822 
Restricted cash606,000 — 
Cash, cash equivalents and restricted cash$632,510 $213,822 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.25.1
REAL ESTATE INVESTMENTS, NET
3 Months Ended
Mar. 31, 2025
Real Estate [Abstract]  
REAL ESTATE INVESTMENTS, NET REAL ESTATE INVESTMENTS, NET
The following table summarizes the Company’s investment in owned properties, and properties held in consolidated joint ventures, held for use as of March 31, 2025 and December 31, 2024 (dollars in thousands):
March 31, 2025December 31, 2024
Land$377,669 $367,044 
Buildings and improvements2,253,424 2,220,287 
Integral equipment, furniture and fixtures113,402 113,803 
Identified intangible assets4,083 4,388 
Real estate investments2,748,578 2,705,522 
Accumulated depreciation and amortization(496,299)(478,782)
Real estate investments, net$2,252,279 $2,226,740 
As of March 31, 2025, all of the Company’s owned facilities held for investment were leased to various operators under triple-net leases. All of the triple-net leases contain annual escalators based on the percentage change in the Consumer Price Index (“CPI”) (but not less than zero), some of which are subject to a cap, or fixed rent escalators. As of March 31, 2025, six facilities were held for sale. See Note 4, Impairment of Real Estate Investments, Assets Held for Sale and Asset Sales, for additional information.
As of March 31, 2025, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements and assets held for sale, was as follows (dollars in thousands):
YearAmount
2025 (nine months)$210,437 
2026283,552 
2027281,850 
2028280,536 
2029276,512 
2030271,031 
Thereafter1,367,365 
Total$2,971,283 
Tenant Purchase Options
Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):
Asset TypePropertiesLease Expiration
Option Period Open Date(1)
Option Type(2)
Current Cash Rent(3)
SNF1March 202904/01/2022
(4)
A / B
(8)
$858 
SNF1January 203002/01/2026
(4)
A1,200 
(9)
SNF / Campus2October 203203/05/2027
(5)
B3,367 
(10)
SNF / Campus2May 203406/01/2026
(6)
B2,714 
(11)
SNF1November 203412/01/2027
(4)
A1,100 
SNF6November 203912/01/2027
(7)
B10,160 
(1) The Company has not received notice of exercise for the option periods that are currently open.
(2) Option type includes:
A - Fixed base price.
B - Fixed capitalization rate on lease revenue.
(3) Based on annualized cash revenue for contracts in place as of March 31, 2025.
(4) Option window is open until the expiration of the lease term.
(5) Option window is open for six months from the option period open date.
(6) Option window is open for nine months from the option period open date.
(7) Lease agreement provides for the purchase of one to two facilities in each window over four option windows, for a total of six facilities. Each option window opens at the beginning of each of lease years four, five, six, and seven beginning December 1, 2027 and is open for one year.
(8) Option reflects two option types.
(9)     Lease provides for abatement in the first three months. Annual rent beginning in month four is $1.2 million.
(10) Option provides for purchase of any two of the three facilities. The current cash rent shown is an average of the range of $3.2 million to $3.5 million.
(11)     Option provides for purchase of any one of five facilities in the first option window and another one of five facilities in the second option window beginning June 1, 2027. The current cash rent shown is an average of the range of $2.4 million to $3.1 million. Provided the operator exercises its option to extend the term of the master lease, beginning on June 1, 2035 and ending nine months thereafter, the operator will have an option for all facilities then remaining in the master lease.
Rental Income
The following table summarizes components of the Company’s rental income (dollars in thousands):
For the Three Months Ended March 31,
Rental Income20252024
Contractual rent due(1)
$70,776 $52,934 
Straight-line rent(7)(7)
Amortization of lease incentives(49)— 
Amortization of below-market lease intangibles926 575 
Total$71,646 $53,502 
(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received. Tenant operating expense reimbursements for the three months ended March 31, 2025 and 2024 were $2.3 million and $1.5 million, respectively.
Recent Real Estate Acquisitions
The following table summarizes the Company’s acquisitions for the three months ended March 31, 2025 (dollars in thousands):
Type of Property
Purchase Price(1)
Initial Annual Cash Rent(2)
Number of Properties
Number of Beds/Units(3)
Skilled nursing(4)
$20,448 $2,000 124 
Assisted living20,637 1,896 160 
Total$41,085 $3,896 284 
(1) Purchase price includes capitalized acquisition costs.
(2) Initial annual cash rent represents initial cash rent for the first twelve months.
(3) The number of beds/units includes operating beds at the acquisition date.
(4) Includes one SNF held through a joint venture. See Note 12, Variable Interest Entities, for additional information.
Lease Amendments and Terminations
Amended Kalesta Lease. Effective February 28, 2025, the Company acquired one ALF. In connection with the acquisition, the Company amended its existing triple-net master lease with affiliates of Kalesta Healthcare, LLC (“Kalesta”) to include the one ALF and extended the initial lease term. The Kalesta master lease, as amended, had a remaining term at the date of amendment of approximately 15 years. Annual cash rent under the amended Kalesta master lease increased by approximately $1.9 million.
Ridgeline Lease Termination and NC Jaybird Lease. Effective December 31, 2024, the Company terminated its master lease with affiliates of Ridgeline Properties, LLC (“Ridgeline”). The Company entered into a new master lease (the “NC Jaybird Lease”) with affiliates of Jaybird Senior Living, Inc. (“Jaybird”) with respect to two ALFs in North Carolina previously leased to Ridgeline. The NC Jaybird Lease commenced on January 1, 2025 with an initial term of approximately 12 years, featuring two five-year renewal options and CPI-based rent escalators. Under the NC Jaybird Lease, Jaybird will receive three months of abated rent, followed by 15 months of rent calculated as a percentage of the tenants’ gross revenue. Subsequently, the next twelve months will have a fixed annual cash rent amount of $0.8 million increasing annually based on CPI. Annual cash rent under the terminated master lease for the two ALFs in North Carolina was $0.8 million. Four facilities which were under the Ridgeline master lease are currently held for sale and two facilities are in the process of transferring operations.
Amended Eduro Lease and Amended Ensign Lease. On March 1, 2024, operations of two SNFs in Colorado operated by affiliates of Eduro Healthcare, LLC (“Eduro”) were transferred to subsidiaries of The Ensign Group, Inc. (“Ensign”). In connection with the transfer, the Company partially terminated the Eduro master lease and amended one existing triple-net master lease with Ensign to include the two SNFs and extended the initial lease term by 15 years. The applicable Ensign master lease, as amended, had a remaining term at the date of amendment of approximately 20 years with two five-year renewal options and CPI-based rent escalators. Annual cash rent under the applicable Ensign master lease, as amended, increased by approximately $2.1 million and annual cash rent under the Eduro master lease, as amended, decreased by the same amount.
New Embassy Lease and Hillstone Lease Termination. On December 31, 2023, the Company terminated its master lease with affiliates of Hillstone Healthcare, Inc. (“Hillstone”). Effective January 1, 2024, in connection with the December 31, 2023 lease termination, one SNF was removed from the Hillstone master lease, was classified as held for sale as of March 31, 2024 and was sold during the three months ended June 30, 2024. See Note 4, Impairment of Real Estate Investments, Assets Held for Sale and Asset Sales, for additional information. In connection with the lease termination, the Company entered into a new triple-net master lease with a subsidiary of Embassy Healthcare Holdings, Inc. (“Embassy”) with respect to one multi-service campus. The Embassy lease has an initial term of approximately 10 years with two five-year renewal options and CPI-based rent escalators. Initial annual cash rent under the lease is approximately $0.6 million and the master lease provides Embassy with a partial rent abatement until required authorizations with respect to the ALF portion of the facility are obtained and occupancy levels reach a certain percentage.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.25.1
IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES
3 Months Ended
Mar. 31, 2025
Discontinued Operations and Disposal Groups [Abstract]  
IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES
Impairment of Real Estate Investments Held for Sale
The Company did not recognize any impairment during the three months ended March 31, 2025. During the three months ended March 31, 2024, the Company recognized aggregate impairment charges of $2.7 million related to properties held for sale, which is reported in impairment of real estate investments in the condensed consolidated income statements.
As of March 31, 2025, there were six facilities classified as held for sale, all of which have been recorded at the lesser of their carrying value or fair value less estimated costs to sell.
The fair values of the assets held for sale were based on estimated sales prices, which are considered to be Level 3 (as defined below) measurements within the fair value hierarchy. Estimated sales prices were determined using a market approach (comparable sales model), which relies on certain assumptions by management, including: (i) comparable market transactions, (ii) estimated prices per unit, and (iii) binding agreements for sales and non-binding offers to purchase from unrelated third-parties. There are inherent uncertainties in making these assumptions. For the Company’s impairment calculations during the three months ended March 31, 2024, the Company’s fair value estimates primarily relied on a market approach and utilized prices per unit ranging from $12,000 to $36,000, with a weighted average price per unit of $16,000.
Asset Sales and Held for Sale Reclassifications
The following table summarizes the Company’s dispositions for the three months ended March 31, 2025 and 2024 (dollars in thousands):
Three Months Ended March 31,
20252024
Number of facilities(1)
Net sales proceeds(2)
$44,401 $1,046 
Net carrying value40,525 1,035 
Net gain on sale$3,876 $11 
(1) One non-operational previously impaired facility sold during the three months ended March 31, 2025 was not classified as held for sale as of December 31, 2024.
(2) Net sales proceeds for the three months ended March 31, 2024 includes $1.0 million of seller financing in connection with the sale of one ALF in January 2024.
The following table summarizes the Company’s assets held for sale activity for the periods presented (dollars in thousands):
Net Carrying ValueNumber of Facilities
December 31, 2024$57,261 10
Assets sold(40,525)(4)
March 31, 2025
$16,736 
December 31, 2023$15,011 14 
Additions to assets held for sale1,251 
Assets sold(1,035)(2)
Impairment of real estate held for sale(2,744)— 
March 31, 2024
$12,483 13 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.25.1
OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS
3 Months Ended
Mar. 31, 2025
Investments, All Other Investments [Abstract]  
OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS
As of March 31, 2025 and December 31, 2024, the Company’s other real estate related investments, inclusive of accrued interest, consisted of the following (dollars in thousands):
Facility Count and Type
As of March 31, 2025
Loans Receivable, at Fair Value:SNFCampusALFILF
Principal Balance as of March 31, 2025
Fair Value as of March 31, 2025(1)
Fair Value as of December 31, 2024(1)
Weighted Average Contractual Interest Rate(2), (3)
Maturity Date
Mortgage secured loans receivable(4)
614192$654,040 $658,427 $660,392 8.8 %5/31/2025 - 9/30/2039
Mezzanine loans receivable(4)
4142— 88,676 87,173 80,612 12.8 %7/25/2027 - 12/31/2034
Total$742,716 $745,600 $741,004 
As of March 31, 2025
Principal Balance as of March 31, 2025
Book Value as of March 31, 2025
Book Value as of December 31, 2024
Weighted Average Contractual Interest RateMaturity Date
Preferred equity$53,782 $54,199 $54,199 11.1 %N/A
Total$53,782 $54,199 $54,199 
Facility Count and Type
As of March 31, 2025
Financing Receivable, at Fair Value:SNFCampusALFILF
Principal Balance as of March 31, 2025
Fair Value as of March 31, 2025(5)
Fair Value as of December 31, 2024(5)
Weighted Average Effective Interest Rate(6)
Maturity Date
Financing Receivable39— 52$95,723 $96,628 $96,004 12.0 %11/30/2039
Total$95,723 $96,628 $96,004 
(1)Fair value of mortgage secured loans receivable includes $4.6 million and $3.4 million of accrued interest as of March 31, 2025 and December 31, 2024, respectively. Fair value of mezzanine loans receivable includes $1.0 million and $0.9 million of accrued interest as of March 31, 2025 and December 31, 2024, respectively.
(2)Rates are net of subservicing fee, if applicable.
(3)Three mortgage secured loans receivable and two mezzanine loans receivable use term secured overnight financing rate (“SOFR”), which are subject to a floor for certain of the loans. Term SOFR used as of March 31, 2025 was 4.32%.
(4)If the Company also has extended mezzanine financing to an affiliate of the borrower under a mortgage loan receivable, the applicable facility counts are included in both respective totals.
(5)Fair value of financing receivable includes $0.9 million and $0.3 million of accrued interest as of March 31, 2025 and December 31, 2024, respectively.
(6)The Company leased these facilities back to the seller under a 15-year contract, with two five-year renewal options. The agreement provides for an initial contractual cash yield of 11.0% for the first three years, with annual CPI-based escalators beginning in year four, subject to a 3% cap. The agreement provides for deferred payments equal to 2.0% of the contractual cash yield in the first year and 0.5% of the contractual cash yield in the second year. The agreement also provides for purchase options. At the time the seller-lessee exercises its purchase options, option proceeds will be used to repay any outstanding deferred payments as well as additional payments such that the Company receives a contractual cash yield of 12.5% on its gross investment in the applicable properties through the option exercise date. If any deferred amounts remain unpaid, beginning in year eight, the deferred amounts are to be repaid in 24 equal monthly payments. The Company has not received notice of exercise for the purchase option period currently open.
The following table summarizes the Company’s other real estate related investments activity for the three months ended March 31, 2025 and 2024 (dollars in thousands):
Three Months Ended March 31,
2025
2024
Origination of other real estate related investments$6,389 $53,165 
Accrued interest, net1,280 425 
Unrealized gain (loss) on other real estate related investments, net1,287 (612)
Prepayments of other real estate related investments(4,360)— 
Net change in other real estate related investments$4,596 $52,978 
2025 Other Real Estate Related Investment Transactions
On January 10, 2025, the Company advanced the second installment of a mezzanine loan for one SNF secured by a pledge of membership interests in an up-tier holding company of the borrower group for $6.4 million. The loan bears interest at a rate of 13%, with annual CPI-based escalators. The mezzanine loan is set to mature on December 31, 2034. The mezzanine loan may not be prepaid in whole or in part prior to maturity. The Company elected the fair value option for the mezzanine loan.
In February 2025, the Company received a partial prepayment on one mortgage loan in the amount of $4.4 million in connection with the borrower’s election to release one skilled nursing facility from the loan. The remaining outstanding balance of $2.9 million was subsequently paid off, see Note 15, Subsequent Events, for additional information.
2024 Other Real Estate Related Investment Transactions
On January 1, 2024, the Company closed on the sale of one ALF. In connection with the sale, the Company provided affiliates of the purchaser of the property with a $1.0 million mortgage loan which bears interest at a rate of 9.0%. The mortgage loan is secured by the ALF and is set to mature on January 1, 2027. The mortgage loan may be prepaid in whole before the maturity date. The Company elected the fair value option for the mortgage loan.
On January 25, 2024, the Company extended a $9.8 million mezzanine loan for a portfolio of ten SNFs located in Missouri secured by a pledge of membership interests in an up-tier holding company of the borrower group. The Company participated in the loan alongside a co-lender pursuant to a participation agreement entered into between the Company and the co-lender. Pursuant to such agreement, the Company provided $9.8 million in mezzanine loan proceeds and the co-lender provided the remaining $10.2 million of loan proceeds. As a participant in the loan, and subject to limited exceptions, the Company is entitled to receive its proportionate share of loan payments made by the borrower with each co-lender’s proportionate share being given equal weight. The loan bears interest at term SOFR plus 8.75%, with a term SOFR floor of 6%, payable monthly and net of a 0.75% subservicing fee. Commencing on February 1, 2026, monthly principal payments shall be due. The mezzanine loan is set to mature on July 25, 2027, with two six-month extension options and may (subject to certain restrictions) be prepaid in whole before the maturity date for an exit fee ranging from 1% to 2% of the loan plus unpaid interest payments equal to 24 months (less the amount of monthly interest payments made by the borrower through the date of prepayment). The Company elected the fair value option for the mezzanine loan.
On February 1, 2024, the Company extended a $7.4 million mezzanine loan for one SNF located in California secured by a pledge of membership interests in an up-tier holding company of the borrower group. The loan bears interest at 11.5%, payable monthly. The mezzanine loan is set to mature on January 31, 2029, and may not (subject to certain limited exceptions) be prepaid prior to the date that is 18 months following the loan closing. The Company elected the fair value option for the mezzanine loan.
On February 2, 2024, the Company extended a $35.0 million mezzanine loan for a portfolio of 15 SNFs located in Virginia secured by a pledge of membership interests in an up-tier holding company of the borrower group. The Company participated in the loan alongside a co-lender pursuant to a participation agreement entered into between the Company and the co-lender. Pursuant to such agreement, the Company provided $35.0 million in mezzanine loan proceeds and the co-lender provided the remaining $50.0 million of loan proceeds. As a participant in the loan, and subject to limited exceptions, the Company is entitled to receive its proportionate share of loan payments made by the borrower with each co-lender’s proportionate share being given equal weight. The loan bears interest at term SOFR plus 8.75%, with a term SOFR floor of 6%, payable monthly and net of a 0.75% subservicing fee. Commencing on February 2, 2026, monthly principal payments shall be due. The mezzanine loan is set to mature on August 1, 2027, with two six-month extension options and may (subject to certain restrictions) be prepaid in whole before the maturity date for an exit fee ranging from 1% to 2% of the loan plus unpaid interest payments equal to 18 months (less the amount of monthly interest payments made by the borrower through the date of prepayment). The Company elected the fair value option for the mezzanine loan.
Financing Receivable
On December 5, 2024, the Company invested $95.7 million, exclusive of transaction costs, to acquire a portfolio of 46 properties in Illinois in a sale and leaseback transaction with affiliates of Cascade Capital Partners, LLC (“Cascade”). In connection with the transaction, the Company entered into a new triple-net master lease with Cascade and provided Cascade with options to repurchase the properties, structured over multiple tranches, with various option window start dates, beginning December 1, 2024, and open through the remainder of the 15-year term. As such, the Company determined that the sale and leaseback transaction met the accounting criteria to be presented as a financing receivable on its consolidated balance sheets and recorded interest income from financing receivable on its consolidated statements of operations. Interest income is based on an imputed interest rate over the term of the applicable financing arrangement and as a result the interest recognized in any particular period will not equal the cash payments from the agreement in that period. Cash received from the financing receivable was $2.2 million during the three months ended March 31, 2025. The Company elected the fair value option for the financing receivable.
Other Loans Receivables
As of March 31, 2025 and December 31, 2024, the Company’s other loans receivable, included in prepaid expenses and other assets, net on the Company’s condensed consolidated balance sheets, consisted of the following (dollars in thousands):
As of March 31, 2025
Investment
Principal Balance as of March 31, 2025
Book Value as of March 31, 2025
Book Value as of December 31, 2024
Weighted Average Contractual Interest RateMaturity Date
Other loans receivable$21,757 $21,820 $22,010 9.0 %9/30/2025 - 12/31/2027
Expected credit loss— (6,994)(6,994)
Total$21,757 $14,826 $15,016 
The following table summarizes the Company’s other loans receivable activity for the three months ended March 31, 2025 and 2024 (dollars in thousands):
Three Months Ended March 31,
2025
2024
Principal payments$(222)$— 
Accrued interest, net32 — 
Net change in other loans receivable$(190)$— 
Expected credit losses and recoveries are recorded in provision for loan losses, net in the condensed consolidated income statements. During both the three months ended March 31, 2025 and 2024, the Company had no additional expected credit loss and did not consider any loan receivable investments to be impaired.
The following table summarizes the interest and other income recognized from the Company’s loans receivable and other investments during the three months ended March 31, 2025 and 2024 (dollars in thousands):
For the Three Months Ended March 31,
Investment20252024
Mortgage secured loans receivable$14,388 $3,772 
Mezzanine loans receivable2,821 1,895 
Preferred equity investment1,497 68 
Other loans receivable334 331 
Financing receivable2,807 — 
Other(1)
3,128 3,502 
Total$24,975 $9,568 
(1) Other income is comprised of interest income on money market funds and escrow deposits.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.25.1
FAIR VALUE MEASUREMENTS
3 Months Ended
Mar. 31, 2025
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.

Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.

The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.
Items Measured at Fair Value on a Recurring Basis
The following table presents information about the Company’s assets measured at fair value on a recurring basis as of March 31, 2025 and December 31, 2024, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):
Level 1Level 2Level 3
Balance as of March 31, 2025
Assets:
Mortgage secured loans receivable$— $— $658,427 $658,427 
Mezzanine loans receivable— — 87,173 87,173 
Financing receivable— — 96,628 96,628 
Total$— $— $842,228 $842,228 
Level 1Level 2Level 3
Balance as of December 31, 2024
Assets:
Mortgage secured loans receivable$— $— $660,392 $660,392 
Mezzanine loans receivable— — 80,612 80,612 
Financing receivable— — 96,004 96,004 
Total$— $— $837,008 $837,008 

The following table details the Company’s assets measured at fair value on a recurring basis using Level 3 inputs (dollars in thousands):
Investments in Real Estate Secured LoansInvestments in Mezzanine LoansInvestment in Financing Receivable
Balance at December 31, 2024
$660,392 $80,612 $96,004 
Originations— 6,389 — 
Accrued interest, net1,173 107 624 
Unrealized gain, net1,222 65 — 
Payments(4,360)— — 
Balance as of March 31, 2025
$658,427 $87,173 $96,628 
Real estate secured and mezzanine loans receivable: The fair value of the secured and mezzanine loans receivables were estimated using an internal valuation model that considered the expected future cash flows of the investment, the underlying collateral value, market interest rates and other credit enhancements. As such, the Company classifies each instrument as Level 3 due to the significant unobservable inputs used in determining market interest rates for investments with similar terms. During the three months ended March 31, 2025, the Company recorded a net unrealized gain of $1.3 million on its secured and mezzanine loans receivable, to bring the interest rates in line with market rates. During the three months ended March 31, 2024, the Company recorded an unrealized loss of $0.8 million on the Company’s secured and mezzanine loans receivable due to rising interest rates, partially offset by unrealized gains of $0.2 million due to increases in expected cash flows on floating rate loans. Future changes in market interest rates or collateral value could materially impact the estimated discounted cash flows that are used to determine the fair value of the secured and mezzanine loans receivable. As of March 31, 2025 and December 31, 2024, the Company did not have any loans that were 90 days or more past due.
The following table shows the quantitative information about unobservable inputs related to the Level 3 fair value measurements comprising the investments in secured and mezzanine loans receivables as of March 31, 2025:
Type
Book Value as of March 31, 2025
Valuation TechniqueUnobservable InputsRange
Mortgage secured loans receivable$658,427 Discounted cash flowDiscount Rate
8% - 14%
Mezzanine loans receivable87,173 Discounted cash flowDiscount Rate
12% - 14%
Financing receivable: The fair value was determined using a widely accepted valuation technique, discounted cash flow analysis, on the expected cash flows. The discount rate used to value the future cash inflows of the financing receivable at March 31, 2025 was 12%.
For the three months ended March 31, 2025, there were no classification changes in assets and liabilities with Level 3 inputs in the fair value hierarchy.

Items Disclosed at Fair Value
Considerable judgment is necessary to estimate the fair value disclosure of financial instruments. The estimates of fair value presented herein are not necessarily indicative of the amounts that could be realized upon disposition of the financial instruments. A summary of the face value, carrying amount and fair value of the Company’s preferred equity investments and the Notes (as defined in Note 7, Debt, below) as of March 31, 2025 and December 31, 2024 is as follows (dollars in thousands):  
 March 31, 2025December 31, 2024
 LevelFace
Value
Carrying
Amount
Fair
Value
Face
Value
Carrying
Amount
Fair
Value
Financial assets:
Preferred equity investments3$53,782 $54,199 $54,199 $53,782 $54,199 $54,199 
Financial liabilities:
Senior unsecured notes payable2$400,000 $397,149 $374,880 $400,000 $396,927 $381,812 

Cash and cash equivalents, restricted cash, accounts and other receivables, accounts payable, and accrued liabilities: The carrying values for these instruments approximate their fair values due to the short-term nature of these instruments.

Preferred equity investments: The fair value of the preferred equity investments was estimated using an internal valuation model that considered the expected future cash flows of the investment, the underlying collateral value, market interest rates and other credit enhancements. The Company utilized discount rates of 11% to 15% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

Senior unsecured notes payable: The fair value of the Notes was determined using third-party quotes derived from orderly trades.

Unsecured revolving credit facility: The fair value approximates the carrying value as the interest rates are variable and approximate prevailing market interest rates and spreads for similar debt arrangements.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.25.1
DEBT
3 Months Ended
Mar. 31, 2025
Debt Disclosure [Abstract]  
DEBT DEBT
The following table summarizes the balance of the Company’s indebtedness as of March 31, 2025 and December 31, 2024 (dollars in thousands):
March 31, 2025December 31, 2024
Principal AmountDeferred Loan FeesCarrying AmountPrincipal AmountDeferred Loan FeesCarrying Amount
Senior unsecured notes payable$400,000 $(2,851)$397,149 $400,000 $(3,073)$396,927 
Unsecured revolving credit facility(1)
425,000 — 425,000 — — — 
$825,000 $(2,851)$822,149 $400,000 $(3,073)$396,927 
(1) Deferred financing fees are included in deferred financing costs, net on the balance sheet, and not reflected as a reduction to the unsecured revolving credit facility.

Senior Unsecured Notes Payable
2028 Senior Notes. On June 17, 2021, the Company’s wholly owned subsidiary, CTR Partnership, L.P. (the “Operating Partnership”), and its wholly owned subsidiary, CareTrust Capital Corp. (together with the Operating Partnership, the “Issuers”), completed a private offering of $400.0 million aggregate principal amount of 3.875% Senior Notes due 2028 (the “Notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A and to non-U.S. persons
outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended. The Notes were issued at par, resulting in gross proceeds of $400.0 million and net proceeds of approximately $393.8 million after deducting underwriting fees and other offering expenses. The Notes mature on June 30, 2028. The Notes accrue interest at a rate of 3.875% per annum payable semiannually in arrears on June 30 and December 30 of each year, commencing on December 30, 2021.
The Issuers may redeem some or all of the Notes at any time prior to March 30, 2028 at a price equal to 100% of the principal amount of the Notes redeemed plus accrued and unpaid interest on the Notes, if any, to, but not including, the redemption date, plus a “make-whole” premium. At any time on or after March 30, 2028, the Issuers may redeem some or all of the Notes at a redemption price equal to 100% of the principal amount of the Notes redeemed plus accrued interest on the Notes, if any, to, but not including, the redemption date. If certain changes of control of the Company occur, the Issuers will be required to make an offer to holders of the Notes to repurchase their Notes at a price of 101% of their principal amount plus accrued and unpaid interest, if any, to, but not including, the repurchase date.
The obligations under the Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by the Company and all of CareTrust’s existing and future subsidiaries (other than the Issuers) that guarantee obligations under the Amended Credit Facility (as defined below); provided, however, that such guarantees are subject to automatic release under certain customary circumstances.
The indenture governing the Notes contains customary covenants such as limiting the ability of the Company and its restricted subsidiaries to: incur or guarantee additional indebtedness; incur or guarantee secured indebtedness; pay dividends or distributions on, or redeem or repurchase, capital stock; make certain investments or other restricted payments; sell assets; enter into transactions with affiliates; merge or consolidate or sell all or substantially all of their assets; and create restrictions on the ability of the Issuers and their restricted subsidiaries to pay dividends or other amounts to the Issuers. The indenture governing the Notes also requires the Company and its restricted subsidiaries to maintain a specified ratio of unencumbered assets to unsecured indebtedness. These covenants are subject to a number of important and significant limitations, qualifications and exceptions. The indenture governing the Notes also contains customary events of default.
As of March 31, 2025, the Company was in compliance with all applicable financial covenants under the indenture governing the Notes.

Unsecured Revolving Credit Facility
On December 18, 2024, the Operating Partnership, as the borrower, the Company, as guarantor, CareTrust GP, LLC, and certain of the Operating Partnership’s wholly owned subsidiaries, entered into a third amended and restated credit and guaranty agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender (as amended from time to time, the “Third Amended Credit Agreement”). The Third Amended Credit Agreement, which amends and restates the Second Amended Credit Agreement (as defined below) provides for an upsized unsecured revolving credit facility (the “Third Amended Revolving Facility”) with revolving commitments in an aggregate principal amount of $1.2 billion, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments. Future borrowings under the Third Amended Revolving Facility will be used for working capital purposes, for capital expenditures, to fund acquisitions and for general corporate purposes.
On December 16, 2022, the Operating Partnership, as the borrower, the Company, as guarantor, CareTrust GP, LLC, and certain of the Operating Partnership’s wholly owned subsidiaries, entered into a second amended and restated credit and guaranty agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender (as amended from time to time, the “Second Amended Credit Agreement”). The Second Amended Credit Agreement, which amends and restates the Company’s amended and restated credit and guaranty agreement, dated as of February 8, 2019 (as amended, the “Prior Credit Agreement”) provided for: (i) an unsecured revolving credit facility (the “Revolving Facility”) with revolving commitments in an aggregate principal amount of $600.0 million, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments and (ii) the continuation of the unsecured term loan credit facility which was previously extended under the Prior Credit Agreement (the “Term Loan” and together with the Revolving Facility, the “Second Amended Credit Facility”) in an aggregate principal amount of $200.0 million.
On October 10, 2023, the Operating Partnership, the Company, CareTrust GP, LLC, certain of the Operating Partnership’s wholly owned subsidiaries and KeyBank National Association entered into the First Amendment to the Second Amended Credit Agreement (the “First Amendment”). The First Amendment restates the definition of Consolidated Total Asset Value to include net proceeds from at-the-market forward commitments executed but not yet closed as of the relevant date as if such proceeds had actually been received.
The interest rates applicable to loans under the Third Amended Revolving Facility are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.05% to 0.55% per annum or Adjusted Term SOFR or Adjusted Daily Simple SOFR (each as defined in the Third Amended Credit Agreement) plus a margin ranging from 1.05% to 1.55% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). In addition, the Operating Partnership will pay a facility fee on the revolving commitments under the Third Amended Revolving Facility ranging from 0.15% to 0.35% per annum, based on the debt to asset value ratio of the Company and its consolidated subsidiaries (unless the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt and the Operating Partnership elects to decrease the applicable margin as described above, in which case the Operating Partnership will pay a facility fee on the revolving commitments ranging from 0.125% to 0.30% per annum based on the credit ratings of the Company’s senior long-term unsecured debt).
As of March 31, 2025, the Operating Partnership had borrowings outstanding of $425.0 million under the Third Amended Revolving Facility.
The Third Amended Revolving Facility has a maturity date of February 9, 2029, and includes, at the sole discretion of the Operating Partnership, two six-month extension options.
The Third Amended Credit Facility is guaranteed, jointly and severally, by the Company and its wholly owned subsidiaries that are party to the Third Amended Credit Agreement (other than the Operating Partnership). The Third Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend organizational documents and pay certain dividends and other restricted payments. The Third Amended Credit Agreement requires the Company to comply with financial maintenance covenants to be tested quarterly, consisting of a maximum debt to asset value ratio, a minimum fixed charge coverage ratio, a minimum tangible net worth, a maximum secured debt to asset value ratio, a maximum unsecured debt to unencumbered properties asset value ratio and a minimum unsecured interest coverage ratio. The Third Amended Credit Agreement also contains certain customary events of default, including the failure to make timely payments under the Third Amended Credit Facility or other material indebtedness, the failure to satisfy certain covenants (including the financial maintenance covenants), the occurrence of change of control and specified events of bankruptcy and insolvency.
As of March 31, 2025, the Company was in compliance with all applicable financial covenants under the Third Amended Credit Agreement.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.25.1
EQUITY AND REDEEMABLE NONCONTROLLING INTEREST
3 Months Ended
Mar. 31, 2025
Equity [Abstract]  
EQUITY AND REDEEMABLE NONCONTROLLING INTEREST EQUITY AND REDEEMABLE NONCONTROLLING INTEREST
Common Stock
At-The-Market Offering—On January 21, 2025, the Company entered into a new equity distribution agreement to issue and sell, from time to time, up to $750.0 million in aggregate offering price of its common stock through an “at-the-market” equity offering program (the “New ATM Program”) and terminated its previous $750.0 million “at-the-market” equity offering program (together, with all previous at-the-market equity offering programs, the “Previous ATM Programs” and together with the New ATM Program, the “ATM Program”). In addition to the issuance and sale of shares of its common stock, the ATM Program also provides for the ability to enter into one or more forward sales agreements (each, an “ATM forward contract”) with sales agents for the sale of the Company’s shares of common stock under the ATM Program.
In the event the Company enters into an ATM forward contract to sell shares of common stock pursuant to the ATM Program, the Company would expect to fully physically settle forward equity sales by delivery of shares of common stock to the forward purchaser and receive cash proceeds upon one or more settlement dates, which are typically a one-year term, at the Company’s discretion, prior to the final settlement date, at which time the Company would expect to receive aggregate net cash proceeds at settlement equal to the number of shares sold on a forward basis multiplied by the relevant forward price per share. The weighted average forward sale price that the Company would expect to receive upon physical settlement would be subject to adjustment for (i) a floating interest rate factor equal to a specified daily rate less a spread, (ii) the forward purchaser’s stock borrowing costs and (iii) scheduled dividends through the settlement.
The following table summarizes the ATM Program activity (or activity under any predecessor at-the-market equity offering programs) for the three months ended March 31, 2025 and 2024 (in thousands, except per share amounts):
For the Three Months Ended
March 31, 2025
March 31, 2024
Number of shares553 11,600 
Average sales price per share$28.87 $23.55 
Gross proceeds(1)
$15,964 $273,233 
(1) Total gross proceeds is before $0.2 million and $3.4 million of commissions paid to the sales agents during the three months ended March 31, 2025 and 2024, respectively, under the ATM Program.
As of March 31, 2025, the Company had $734.0 million available for future issuances under the New ATM Program.
Dividends on Common Stock—The following table summarizes the cash dividends per share of common stock declared by the Company’s board of directors for the first three months of 2025 (dollars in thousands, except per share amounts):
For the Three Months Ended
March 31, 2025
Dividends declared per share$0.335 
Dividends payment dateApril 15, 2025
Dividends payable as of record date$63,053 
Dividends record dateMarch 31, 2025
Redeemable Noncontrolling Interest
Arrangements with noncontrolling interest holders are assessed for appropriate balance sheet classification based on the redemption and other rights held by the noncontrolling interest holder. One of the Company’s noncontrolling interest holders has the ability to put its equity interest to the Company during specified option exercise periods, subject to certain conditions. The put option is payable in cash and subject to changes in redemption value. Accordingly, the Company records the redeemable noncontrolling interest outside of permanent equity. The redeemable noncontrolling interest is adjusted for additional contributions and distributions and the proportionate share of the net earnings or losses. When the redemption of the noncontrolling interest becomes probable, the Company will record the redeemable noncontrolling interest at the greater of its carrying amount or redemption value at the end of each reporting period by making an election either to accrete changes in the redemption value of the redeemable noncontrolling interest over the period from the date it is probable of exercise to the earliest redemption date or to recognize the entire adjustment on the date redemption becomes probable. In addition to the rights of the redeemable noncontrolling interest holder, the Company has the ability to call the interest of the noncontrolling interest holder during specified option exercise periods.
As of March 31, 2025, the redeemable noncontrolling interest did not meet the conditions for redemption.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.25.1
STOCK-BASED COMPENSATION
3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
All stock-based awards are subject to the terms of the CareTrust REIT, Inc. and CTR Partnership, L.P. Incentive Award Plan (the “Plan”). The Plan provides for the granting of stock-based compensation, including stock options, restricted stock, performance awards, restricted stock units, relative total stockholder return based stock awards and other incentive awards to officers, employees and directors in connection with their employment with or services provided to the Company. Under the Plan, 5,000,000 shares have been authorized for awards.
Under the Plan, restricted stock awards (“RSAs”) typically vest in equal annual installments over a three year period. The board of directors granted certain RSAs in 2025 (“2025 RSAs”) which vest in one installment over one year. RSAs granted to non-employee members of the board of directors (“Board Awards”) vest in full on the earlier to occur of the Company’s next Annual Meeting of Stockholders or one year. Relative total shareholder return units (“TSR Units”) granted since 2021 are subject to both time and market based conditions and cliff vest after a three-year period. The amount of such market awards that will ultimately vest is dependent on the Company’s total shareholder return (“TSR”) performance relative to a custom TSR peer group consisting of other publicly traded healthcare REITs and will range from 0% to 200% of the TSR Units initially granted. The RSAs and Board Awards are valued on the date of grant based on the closing price of the Company’s common stock, while the TSR Units are valued on the date of grant using a Monte Carlo valuation model. The vesting of certain awards may accelerate, as defined in the grant agreement, upon retirement, a change in control or other events.
The following table summarizes the status of the restricted stock award activity for the three months ended March 31, 2025:
SharesWeighted Average Share Price
Unvested balance at December 31, 2024552,999 $23.86 
Granted:
RSAs137,920 27.17 
Vested(145,951)21.16 
Unvested balance at March 31, 2025544,968 $25.42 
As of March 31, 2025, the weighted-average remaining vesting period of such awards was 2.0 years.
The following table summarizes the stock-based compensation expense recognized for the periods presented (dollars in thousands):
 
For the Three Months Ended March 31,
 20252024
Stock-based compensation expense$3,909 $2,120 
As of March 31, 2025, there was $15.8 million of unamortized stock-based compensation expense related to the unvested RSAs and TSR Units.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.25.1
EARNINGS PER COMMON SHARE
3 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
EARNINGS PER COMMON SHARE EARNINGS PER COMMON SHARE
The following table presents the calculation of basic and diluted earnings per common share attributable to CareTrust REIT, Inc. (“EPS”) for the Company’s common stock for the three months ended March 31, 2025 and 2024, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (dollars and shares in thousands, except per share amounts):
 
 For the Three Months Ended March 31,
 20252024
Numerator:
Net income attributable to CareTrust REIT, Inc.$65,802 $28,746 
Less: Net income allocated to participating securities(183)(96)
Numerator for basic and diluted earnings available to common stockholders$65,619 $28,650 
Denominator:
Weighted-average basic common shares outstanding187,152 132,836 
Dilutive potential common shares - TSR Units264 366 
Weighted-average diluted common shares outstanding187,416 133,202 
Earnings per common share attributable to CareTrust REIT, Inc., basic$0.35 $0.22 
Earnings per common share attributable to CareTrust REIT, Inc., diluted$0.35 $0.22 
Antidilutive unvested RSAs excluded from the computation(1)
545 330 
(1)For the three months ended March 31, 2025 and 2024, RSAs are antidilutive.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT REPORTING
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
SEGMENT REPORTING SEGMENT REPORTING
The Company represents a single reportable segment, based on how its chief operating decision maker (“CODM”) evaluates the businesses and allocates resources. The CODM assesses performance for the Company and decides how to allocate resources based on consolidated net income that is also reported on the condensed consolidated income statements. The CODM does not review segment assets at a different asset level or category than the amounts disclosed in the condensed consolidated balance sheets. The CODM uses net income to evaluate the performance of the Company in deciding whether to reinvest profits into the Company.
The CODM evaluates performance based on net income, as follows (in thousands):
For the Three Months Ended March 31,
20252024
Revenues:
Rental income$71,646 $53,502 
Interest income from financing receivable2,807 — 
Interest income from other real estate related investments and other income22,168 9,568 
Total revenues96,621 63,070 
Expenses:
Depreciation and amortization17,841 13,448 
Interest expense6,669 8,228 
Property taxes2,065 1,801 
Impairment of real estate investments— 2,744 
Transaction costs888 — 
Property operating expenses105 660 
General and administrative
Cash compensation2,090 1,765 
Incentive compensation1,225 1,500 
Share-based compensation3,909 2,120 
Professional services876 738 
Taxes and insurance218 205 
Other expenses(1)
705 510 
Total general and administrative9,023 6,838 
Total expenses36,591 33,719 
Other income (loss):
Gain on sale of real estate, net3,876 11 
Unrealized gain (loss) on other real estate related investments, net1,287 (612)
Total other income (loss)5,163 (601)
Net income65,193 28,750 
Net (loss) income attributable to noncontrolling interests(609)
Net income attributable to CareTrust REIT, Inc.$65,802 $28,746 
(1)Other expenses include certain overhead expenses.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.25.1
VARIABLE INTEREST ENTITIES
3 Months Ended
Mar. 31, 2025
Noncontrolling Interest [Abstract]  
VARIABLE INTEREST ENTITIES VARIABLE INTEREST ENTITIES
Noncontrolling Interests—The Company has entered into ventures with unrelated third parties to own real estate and has concluded that such ventures are VIEs. As the Company exercises power over and receives economic benefits from the VIEs, the Company is considered the primary beneficiary and consolidates the VIEs.
The following table summarizes the contributions to joint ventures that are consolidated variable interest entities through March 31, 2025 (dollars in thousands):
Gross Investment
Investment YearStateFacility TypeNumber of FacilitiesCTRENoncontrolling InterestsTotal
2023CASNF1$25,459 $653 $26,112 
2023CASNF234,269 879 35,148 
2024CAALF110,760 276 11,036 
2024CAMulti-service campuses228,076 720 28,796 
2024CASNF124,503 628 25,131 
2024 / 2025
(1)
TN, ALSNF28442,327 19,156 461,483 
2024 / 2025
(2)
- --33,663 86734,530 
Total35$599,057 $23,179 $622,236 
(1) The noncontrolling interest is classified as a redeemable noncontrolling interest on the consolidated balance sheets.
(2) The Company entered into a joint venture to acquire real estate. The gross investment amounts represent a deposit. See Note 15, Subsequent Events, for additional information.
Pursuant to the Company’s joint ventures (“JVs”), the Company typically contributes at least 90% of the JV’s total investment amount and receives 100% of the preferred equity interest in the JV and a 50% common equity interest in the JV. The Company’s JV partner contributes the remaining total investment amount in exchange for a 50% common equity interest in the JV.
Total assets and total liabilities include VIE assets and liabilities as follows (dollars in thousands):
March 31, 2025
December 31, 2024
Assets:
Real estate investments, net$581,959 $565,959 
Cash and cash equivalents6,762 6,506 
Accounts and other receivables32 — 
Prepaid and other assets41,078 8,317 
Total assets629,831 580,782 
Liabilities:
Accounts payable, accrued liabilities and deferred rent liabilities7,847 10,332 
Total liabilities$7,847 $10,332 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.25.1
COMMITMENTS AND CONTINGENCIES
3 Months Ended
Mar. 31, 2025
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
The Company and its subsidiaries are and may become from time to time a party to various claims and lawsuits arising in the ordinary course of business, which are not individually or in the aggregate anticipated to have a material adverse effect on the Company’s results of operations, financial condition or cash flows. Claims and lawsuits may include matters involving general or professional liability asserted against the Company’s tenants, which are the responsibility of the Company’s tenants and for which the Company is entitled to be indemnified by its tenants under the insurance and indemnification provisions in the applicable leases.
In the normal course of business, the Company enters into various commitments, typically consisting of funding of capital expenditures and short-term working capital loans to existing tenants while they await licensure and certification or are conducting turnaround work in one or more of the Company’s properties.
Capital expenditures for each property leased under the Company’s triple-net leases are generally the responsibility of the tenant, except for the facilities leased under certain master lease agreements, with certain subsidiaries of Ensign and Pennant, under which the tenant will have an option to require the Company to finance certain capital expenditures up to an aggregate of 20% of the Company’s initial investment in such property, subject to a corresponding rent increase at the time of funding. For the Company’s other triple-net master leases, the tenants also have the option to request capital expenditure funding that would generally be subject to a corresponding rent increase at the time of funding, which are subject to tenant compliance with the conditions to the Company’s approval and funding of their requests. The Company has also provided select tenants with strategic capital for facility upkeep and modernization. The Company’s Tenant Code of Conduct and Corporate Responsibility policy (the “Tenant ESG Program”) provides eligible triple-net tenants of the Company with monetary inducements to make sustainable improvements to the Company’s properties. Incentive options include a wide variety of opportunities for tenants to upgrade everything from energy and environmental systems to water-saving landscaping and more. The Company’s board of directors has authorized annual allocations of up to $500,000 to fund the Tenant ESG Program.
The table below summarizes the Company’s existing, known commitments and contingencies as of March 31, 2025 (in thousands):
Remaining Commitment
Capital expenditures(1)
$7,163 
Mortgage loans(2)
9,066 
Other loans receivable(3)
12,166 
Earn-out obligation(4)
10,000 
$38,395 
(1)As of March 31, 2025, the Company had committed to fund expansions, construction, capital improvements and ESG incentives at certain triple-net leased facilities totaling $7.2 million, of which $6.3 million is subject to rent increase at the time of funding.
(2)Includes an earn-out advance of $9.0 million related to one mortgage loan, upon satisfaction of certain conditions.
(3)Represents non-real estate secured loan commitments.
(4)Includes an earn-out obligation of up to $10.0 million under a purchase and sale agreement for one SNF in Virginia, which was acquired during 2024. The earn-out is available, contingent on the operator achieving certain thresholds per the agreement, beginning in October 2025 through October 2026.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.25.1
CONCENTRATION OF RISK
3 Months Ended
Mar. 31, 2025
Risks and Uncertainties [Abstract]  
CONCENTRATION OF RISK CONCENTRATION OF RISK
Concentrations of credit risk arise when one or more tenants, operators, or obligors related to the Company’s investments are engaged in similar business activities or activities in the same geographic region, or have similar economic features that would cause their ability to meet contractual obligations, including those to the Company, to be similarly affected by changes in economic conditions.
Major operator concentration The Company has operators from which it derived 10% or more of its revenue for the three months ended March 31, 2025 and 2024. The following table sets forth information regarding the Company’s major operators as of March 31, 2025 and 2024:
 Number of FacilitiesNumber of Beds/UnitsPercentage of Total Revenue
Operator/BorrowerSNFCampusALF/ILFSNFCampusALF/ILFThree Months Ended
March 31, 2025(1)
Ensign(2)
89 79,288 843661 21 %
PACS(2)
23 3— 2,809 322— 11 %
March 31, 2024(1)
Ensign(2)
85 89,024 997 661 30 %
Priority Management Group13 2— 1,742 402 — 13 %
(1) The Company’s rental income and interest income on other real estate related investments, exclusive of operating expense reimbursements.
(2) Ensign and the PACS Group, Inc. (“PACS”) are subject to the registration and reporting requirements of the SEC and are required to file with the SEC annual reports containing audited financial information and quarterly reports containing unaudited financial information. Ensign and PACS’s financial statements, as filed with the SEC, can be found at http://www.sec.gov. The Company has not verified this information through an independent investigation or otherwise.
Major geographic concentration – The following table provides information regarding the Company’s concentrations with respect to certain states, from which the Company derived 10% or more of its revenue for the three months ended March 31, 2025 and 2024:
 Number of FacilitiesNumber of Beds/UnitsPercentage of Total Revenue
StateSNFCampusALF/ILFSNFCampusALF/ILFThree Months Ended
March 31, 2025(1)
CA42 1211 4,979 2,004 1,032 23 %
TX38 34,772 476 212 12 %
TN29 — — 3,098 — — 12 %
March 31, 2024(1)
CA4295,000 1,527 723 31 %
TX4145,193 630 212 20 %
(1) Based on the Company’s rental income and interest income on other real estate related investments, exclusive of operating expense reimbursements.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.25.1
SUBSEQUENT EVENTS
3 Months Ended
Mar. 31, 2025
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS
The Company evaluates subsequent events in accordance with ASC 855, Subsequent Events. The Company evaluates subsequent events up until the date the condensed consolidated financial statements are issued.
Recent Acquisitions
On April 1, 2025, the Company purchased one multi-service campus in California for $34.7 million, inclusive of transaction costs, through a JV. The Company contributed $33.8 million to the JV. In exchange, the Company holds 100% of the preferred equity interests in the JV and 50% of the common equity interest in the JV. The JV partner contributed the remaining $0.9 million of the total investment in exchange for 50% of the common equity interest in the JV. In connection with the acquisition of the facility, subsidiaries of the JV entered into a new master lease with affiliates of Ensign. The master lease has an initial term of approximately 15 years, with two five-year renewal options. Annual cash rent under the lease is $3.5 million, with annual CPI-based escalators. See Note 12, Variable Interest Entities, for additional information.
Mortgage Loan Prepayment
In April 2025, one mortgage loan with a principal balance of $2.9 million was fully prepaid, including all unpaid accrued interest.
At-The-Market Offering of Common Stock
In April 2025, the Company sold 3.4 million shares under the ATM Program for gross proceeds of $99.5 million at an average sales price per share of $28.90.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Pay vs Performance Disclosure    
Net Income (Loss) $ 65,802 $ 28,746
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Arrangements
3 Months Ended
Mar. 31, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. The accompanying consolidated financial statements of the Company include the accounts of CareTrust REIT, its wholly-owned subsidiaries, and variable interest entities (“VIEs”) over which the Company exercises control. All intercompany transactions and account balances within the Company have been eliminated, and net earnings are reduced by the portion of net earnings attributable to noncontrolling interests.
Restricted cash Restricted cash—The Company presents cash and cash equivalents separately from restricted cash within the Company’s condensed consolidated balance sheets. The Company includes restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the condensed consolidated statements of cash flows. The Company provides a reconciliation between the balance sheets and statements of cash flows, as required when the balance includes more than one line item for cash, cash equivalents and restricted cash. The Company also provides a disclosure of the nature of the restrictions related to material restricted cash balances.
Fair Value Measurements
The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.

Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.

The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
Schedule of Cash, Cash Equivalents and Restricted Cash
Cash, cash equivalents and restricted cash consisted of the following as of March 31, 2025 and December 31, 2024 (dollars in thousands):
March 31, 2025December 31, 2024
Cash and cash equivalents$26,510 $213,822 
Restricted cash606,000 — 
Cash, cash equivalents and restricted cash$632,510 $213,822 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.25.1
REAL ESTATE INVESTMENTS, NET (Tables)
3 Months Ended
Mar. 31, 2025
Real Estate [Abstract]  
Schedule of Investment in Owned Properties
The following table summarizes the Company’s investment in owned properties, and properties held in consolidated joint ventures, held for use as of March 31, 2025 and December 31, 2024 (dollars in thousands):
March 31, 2025December 31, 2024
Land$377,669 $367,044 
Buildings and improvements2,253,424 2,220,287 
Integral equipment, furniture and fixtures113,402 113,803 
Identified intangible assets4,083 4,388 
Real estate investments2,748,578 2,705,522 
Accumulated depreciation and amortization(496,299)(478,782)
Real estate investments, net$2,252,279 $2,226,740 
Schedule of Total Future Contractual Minimum Rental Income
As of March 31, 2025, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements and assets held for sale, was as follows (dollars in thousands):
YearAmount
2025 (nine months)$210,437 
2026283,552 
2027281,850 
2028280,536 
2029276,512 
2030271,031 
Thereafter1,367,365 
Total$2,971,283 
Schedule of Tenant Purchase Options
Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):
Asset TypePropertiesLease Expiration
Option Period Open Date(1)
Option Type(2)
Current Cash Rent(3)
SNF1March 202904/01/2022
(4)
A / B
(8)
$858 
SNF1January 203002/01/2026
(4)
A1,200 
(9)
SNF / Campus2October 203203/05/2027
(5)
B3,367 
(10)
SNF / Campus2May 203406/01/2026
(6)
B2,714 
(11)
SNF1November 203412/01/2027
(4)
A1,100 
SNF6November 203912/01/2027
(7)
B10,160 
(1) The Company has not received notice of exercise for the option periods that are currently open.
(2) Option type includes:
A - Fixed base price.
B - Fixed capitalization rate on lease revenue.
(3) Based on annualized cash revenue for contracts in place as of March 31, 2025.
(4) Option window is open until the expiration of the lease term.
(5) Option window is open for six months from the option period open date.
(6) Option window is open for nine months from the option period open date.
(7) Lease agreement provides for the purchase of one to two facilities in each window over four option windows, for a total of six facilities. Each option window opens at the beginning of each of lease years four, five, six, and seven beginning December 1, 2027 and is open for one year.
(8) Option reflects two option types.
(9)     Lease provides for abatement in the first three months. Annual rent beginning in month four is $1.2 million.
(10) Option provides for purchase of any two of the three facilities. The current cash rent shown is an average of the range of $3.2 million to $3.5 million.
(11)     Option provides for purchase of any one of five facilities in the first option window and another one of five facilities in the second option window beginning June 1, 2027. The current cash rent shown is an average of the range of $2.4 million to $3.1 million. Provided the operator exercises its option to extend the term of the master lease, beginning on June 1, 2035 and ending nine months thereafter, the operator will have an option for all facilities then remaining in the master lease.
Schedule of Rental Income
The following table summarizes components of the Company’s rental income (dollars in thousands):
For the Three Months Ended March 31,
Rental Income20252024
Contractual rent due(1)
$70,776 $52,934 
Straight-line rent(7)(7)
Amortization of lease incentives(49)— 
Amortization of below-market lease intangibles926 575 
Total$71,646 $53,502 
(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received. Tenant operating expense reimbursements for the three months ended March 31, 2025 and 2024 were $2.3 million and $1.5 million, respectively.
Schedule of Recent Real Estate Acquisitions
The following table summarizes the Company’s acquisitions for the three months ended March 31, 2025 (dollars in thousands):
Type of Property
Purchase Price(1)
Initial Annual Cash Rent(2)
Number of Properties
Number of Beds/Units(3)
Skilled nursing(4)
$20,448 $2,000 124 
Assisted living20,637 1,896 160 
Total$41,085 $3,896 284 
(1) Purchase price includes capitalized acquisition costs.
(2) Initial annual cash rent represents initial cash rent for the first twelve months.
(3) The number of beds/units includes operating beds at the acquisition date.
(4) Includes one SNF held through a joint venture. See Note 12, Variable Interest Entities, for additional information.
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.25.1
IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - (Tables)
3 Months Ended
Mar. 31, 2025
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Asset Sales and Held for Sale Reclassifications
The following table summarizes the Company’s dispositions for the three months ended March 31, 2025 and 2024 (dollars in thousands):
Three Months Ended March 31,
20252024
Number of facilities(1)
Net sales proceeds(2)
$44,401 $1,046 
Net carrying value40,525 1,035 
Net gain on sale$3,876 $11 
(1) One non-operational previously impaired facility sold during the three months ended March 31, 2025 was not classified as held for sale as of December 31, 2024.
(2) Net sales proceeds for the three months ended March 31, 2024 includes $1.0 million of seller financing in connection with the sale of one ALF in January 2024.
The following table summarizes the Company’s assets held for sale activity for the periods presented (dollars in thousands):
Net Carrying ValueNumber of Facilities
December 31, 2024$57,261 10
Assets sold(40,525)(4)
March 31, 2025
$16,736 
December 31, 2023$15,011 14 
Additions to assets held for sale1,251 
Assets sold(1,035)(2)
Impairment of real estate held for sale(2,744)— 
March 31, 2024
$12,483 13 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.25.1
OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS (Tables)
3 Months Ended
Mar. 31, 2025
Investments, All Other Investments [Abstract]  
Schedule of Other Real Estate Related Investments, at Fair Value
As of March 31, 2025 and December 31, 2024, the Company’s other real estate related investments, inclusive of accrued interest, consisted of the following (dollars in thousands):
Facility Count and Type
As of March 31, 2025
Loans Receivable, at Fair Value:SNFCampusALFILF
Principal Balance as of March 31, 2025
Fair Value as of March 31, 2025(1)
Fair Value as of December 31, 2024(1)
Weighted Average Contractual Interest Rate(2), (3)
Maturity Date
Mortgage secured loans receivable(4)
614192$654,040 $658,427 $660,392 8.8 %5/31/2025 - 9/30/2039
Mezzanine loans receivable(4)
4142— 88,676 87,173 80,612 12.8 %7/25/2027 - 12/31/2034
Total$742,716 $745,600 $741,004 
As of March 31, 2025
Principal Balance as of March 31, 2025
Book Value as of March 31, 2025
Book Value as of December 31, 2024
Weighted Average Contractual Interest RateMaturity Date
Preferred equity$53,782 $54,199 $54,199 11.1 %N/A
Total$53,782 $54,199 $54,199 
Facility Count and Type
As of March 31, 2025
Financing Receivable, at Fair Value:SNFCampusALFILF
Principal Balance as of March 31, 2025
Fair Value as of March 31, 2025(5)
Fair Value as of December 31, 2024(5)
Weighted Average Effective Interest Rate(6)
Maturity Date
Financing Receivable39— 52$95,723 $96,628 $96,004 12.0 %11/30/2039
Total$95,723 $96,628 $96,004 
(1)Fair value of mortgage secured loans receivable includes $4.6 million and $3.4 million of accrued interest as of March 31, 2025 and December 31, 2024, respectively. Fair value of mezzanine loans receivable includes $1.0 million and $0.9 million of accrued interest as of March 31, 2025 and December 31, 2024, respectively.
(2)Rates are net of subservicing fee, if applicable.
(3)Three mortgage secured loans receivable and two mezzanine loans receivable use term secured overnight financing rate (“SOFR”), which are subject to a floor for certain of the loans. Term SOFR used as of March 31, 2025 was 4.32%.
(4)If the Company also has extended mezzanine financing to an affiliate of the borrower under a mortgage loan receivable, the applicable facility counts are included in both respective totals.
(5)Fair value of financing receivable includes $0.9 million and $0.3 million of accrued interest as of March 31, 2025 and December 31, 2024, respectively.
(6)The Company leased these facilities back to the seller under a 15-year contract, with two five-year renewal options. The agreement provides for an initial contractual cash yield of 11.0% for the first three years, with annual CPI-based escalators beginning in year four, subject to a 3% cap. The agreement provides for deferred payments equal to 2.0% of the contractual cash yield in the first year and 0.5% of the contractual cash yield in the second year. The agreement also provides for purchase options. At the time the seller-lessee exercises its purchase options, option proceeds will be used to repay any outstanding deferred payments as well as additional payments such that the Company receives a contractual cash yield of 12.5% on its gross investment in the applicable properties through the option exercise date. If any deferred amounts remain unpaid, beginning in year eight, the deferred amounts are to be repaid in 24 equal monthly payments. The Company has not received notice of exercise for the purchase option period currently open.
Schedule of Other Real Estate Related Investment Activity
The following table summarizes the Company’s other real estate related investments activity for the three months ended March 31, 2025 and 2024 (dollars in thousands):
Three Months Ended March 31,
2025
2024
Origination of other real estate related investments$6,389 $53,165 
Accrued interest, net1,280 425 
Unrealized gain (loss) on other real estate related investments, net1,287 (612)
Prepayments of other real estate related investments(4,360)— 
Net change in other real estate related investments$4,596 $52,978 
As of March 31, 2025 and December 31, 2024, the Company’s other loans receivable, included in prepaid expenses and other assets, net on the Company’s condensed consolidated balance sheets, consisted of the following (dollars in thousands):
As of March 31, 2025
Investment
Principal Balance as of March 31, 2025
Book Value as of March 31, 2025
Book Value as of December 31, 2024
Weighted Average Contractual Interest RateMaturity Date
Other loans receivable$21,757 $21,820 $22,010 9.0 %9/30/2025 - 12/31/2027
Expected credit loss— (6,994)(6,994)
Total$21,757 $14,826 $15,016 
Schedule of Loan Receivable Activity
The following table summarizes the Company’s other loans receivable activity for the three months ended March 31, 2025 and 2024 (dollars in thousands):
Three Months Ended March 31,
2025
2024
Principal payments$(222)$— 
Accrued interest, net32 — 
Net change in other loans receivable$(190)$— 
Schedule of Interest and Other Income
The following table summarizes the interest and other income recognized from the Company’s loans receivable and other investments during the three months ended March 31, 2025 and 2024 (dollars in thousands):
For the Three Months Ended March 31,
Investment20252024
Mortgage secured loans receivable$14,388 $3,772 
Mezzanine loans receivable2,821 1,895 
Preferred equity investment1,497 68 
Other loans receivable334 331 
Financing receivable2,807 — 
Other(1)
3,128 3,502 
Total$24,975 $9,568 
(1) Other income is comprised of interest income on money market funds and escrow deposits.
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.25.1
FAIR VALUE MEASUREMENTS (Tables)
3 Months Ended
Mar. 31, 2025
Fair Value Disclosures [Abstract]  
Schedule of Items Measured at Fair Value on a Recurring Basis
The following table presents information about the Company’s assets measured at fair value on a recurring basis as of March 31, 2025 and December 31, 2024, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):
Level 1Level 2Level 3
Balance as of March 31, 2025
Assets:
Mortgage secured loans receivable$— $— $658,427 $658,427 
Mezzanine loans receivable— — 87,173 87,173 
Financing receivable— — 96,628 96,628 
Total$— $— $842,228 $842,228 
Level 1Level 2Level 3
Balance as of December 31, 2024
Assets:
Mortgage secured loans receivable$— $— $660,392 $660,392 
Mezzanine loans receivable— — 80,612 80,612 
Financing receivable— — 96,004 96,004 
Total$— $— $837,008 $837,008 
Schedule of Assets Measured at Fair Value on a Recurring Basis Using Level 3 Inputs
The following table details the Company’s assets measured at fair value on a recurring basis using Level 3 inputs (dollars in thousands):
Investments in Real Estate Secured LoansInvestments in Mezzanine LoansInvestment in Financing Receivable
Balance at December 31, 2024
$660,392 $80,612 $96,004 
Originations— 6,389 — 
Accrued interest, net1,173 107 624 
Unrealized gain, net1,222 65 — 
Payments(4,360)— — 
Balance as of March 31, 2025
$658,427 $87,173 $96,628 
Schedule of Quantitative Information About Unobservable Inputs Related to Level 3 Fair Value Measurements
The following table shows the quantitative information about unobservable inputs related to the Level 3 fair value measurements comprising the investments in secured and mezzanine loans receivables as of March 31, 2025:
Type
Book Value as of March 31, 2025
Valuation TechniqueUnobservable InputsRange
Mortgage secured loans receivable$658,427 Discounted cash flowDiscount Rate
8% - 14%
Mezzanine loans receivable87,173 Discounted cash flowDiscount Rate
12% - 14%
Schedule of Face Value, Carrying Amount and Fair Value of Financial Instruments A summary of the face value, carrying amount and fair value of the Company’s preferred equity investments and the Notes (as defined in Note 7, Debt, below) as of March 31, 2025 and December 31, 2024 is as follows (dollars in thousands):  
 March 31, 2025December 31, 2024
 LevelFace
Value
Carrying
Amount
Fair
Value
Face
Value
Carrying
Amount
Fair
Value
Financial assets:
Preferred equity investments3$53,782 $54,199 $54,199 $53,782 $54,199 $54,199 
Financial liabilities:
Senior unsecured notes payable2$400,000 $397,149 $374,880 $400,000 $396,927 $381,812 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.25.1
DEBT (Tables)
3 Months Ended
Mar. 31, 2025
Debt Disclosure [Abstract]  
Schedule of Debt Instruments
The following table summarizes the balance of the Company’s indebtedness as of March 31, 2025 and December 31, 2024 (dollars in thousands):
March 31, 2025December 31, 2024
Principal AmountDeferred Loan FeesCarrying AmountPrincipal AmountDeferred Loan FeesCarrying Amount
Senior unsecured notes payable$400,000 $(2,851)$397,149 $400,000 $(3,073)$396,927 
Unsecured revolving credit facility(1)
425,000 — 425,000 — — — 
$825,000 $(2,851)$822,149 $400,000 $(3,073)$396,927 
(1) Deferred financing fees are included in deferred financing costs, net on the balance sheet, and not reflected as a reduction to the unsecured revolving credit facility.
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.25.1
EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Tables)
3 Months Ended
Mar. 31, 2025
Equity [Abstract]  
Schedule of At-The-Market Offering Program
The following table summarizes the ATM Program activity (or activity under any predecessor at-the-market equity offering programs) for the three months ended March 31, 2025 and 2024 (in thousands, except per share amounts):
For the Three Months Ended
March 31, 2025
March 31, 2024
Number of shares553 11,600 
Average sales price per share$28.87 $23.55 
Gross proceeds(1)
$15,964 $273,233 
(1) Total gross proceeds is before $0.2 million and $3.4 million of commissions paid to the sales agents during the three months ended March 31, 2025 and 2024, respectively, under the ATM Program.
Schedule of Dividends on Common Stock The following table summarizes the cash dividends per share of common stock declared by the Company’s board of directors for the first three months of 2025 (dollars in thousands, except per share amounts):
For the Three Months Ended
March 31, 2025
Dividends declared per share$0.335 
Dividends payment dateApril 15, 2025
Dividends payable as of record date$63,053 
Dividends record dateMarch 31, 2025
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.25.1
STOCK-BASED COMPENSATION (Tables)
3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Restricted Stock Award and Performance Award Activity
The following table summarizes the status of the restricted stock award activity for the three months ended March 31, 2025:
SharesWeighted Average Share Price
Unvested balance at December 31, 2024552,999 $23.86 
Granted:
RSAs137,920 27.17 
Vested(145,951)21.16 
Unvested balance at March 31, 2025544,968 $25.42 
Schedule of Stock-Based Compensation Expense
The following table summarizes the stock-based compensation expense recognized for the periods presented (dollars in thousands):
 
For the Three Months Ended March 31,
 20252024
Stock-based compensation expense$3,909 $2,120 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.25.1
EARNINGS PER COMMON SHARE (Tables)
3 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
Schedule of Reconciliation of Weighted-Average Common Shares Outstanding Used in Calculation of Basic EPS to Diluted EPS
The following table presents the calculation of basic and diluted earnings per common share attributable to CareTrust REIT, Inc. (“EPS”) for the Company’s common stock for the three months ended March 31, 2025 and 2024, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (dollars and shares in thousands, except per share amounts):
 
 For the Three Months Ended March 31,
 20252024
Numerator:
Net income attributable to CareTrust REIT, Inc.$65,802 $28,746 
Less: Net income allocated to participating securities(183)(96)
Numerator for basic and diluted earnings available to common stockholders$65,619 $28,650 
Denominator:
Weighted-average basic common shares outstanding187,152 132,836 
Dilutive potential common shares - TSR Units264 366 
Weighted-average diluted common shares outstanding187,416 133,202 
Earnings per common share attributable to CareTrust REIT, Inc., basic$0.35 $0.22 
Earnings per common share attributable to CareTrust REIT, Inc., diluted$0.35 $0.22 
Antidilutive unvested RSAs excluded from the computation(1)
545 330 
(1)For the three months ended March 31, 2025 and 2024, RSAs are antidilutive.
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT REPORTING (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
CODM Evaluation of Performance Based on Net Income
The CODM evaluates performance based on net income, as follows (in thousands):
For the Three Months Ended March 31,
20252024
Revenues:
Rental income$71,646 $53,502 
Interest income from financing receivable2,807 — 
Interest income from other real estate related investments and other income22,168 9,568 
Total revenues96,621 63,070 
Expenses:
Depreciation and amortization17,841 13,448 
Interest expense6,669 8,228 
Property taxes2,065 1,801 
Impairment of real estate investments— 2,744 
Transaction costs888 — 
Property operating expenses105 660 
General and administrative
Cash compensation2,090 1,765 
Incentive compensation1,225 1,500 
Share-based compensation3,909 2,120 
Professional services876 738 
Taxes and insurance218 205 
Other expenses(1)
705 510 
Total general and administrative9,023 6,838 
Total expenses36,591 33,719 
Other income (loss):
Gain on sale of real estate, net3,876 11 
Unrealized gain (loss) on other real estate related investments, net1,287 (612)
Total other income (loss)5,163 (601)
Net income65,193 28,750 
Net (loss) income attributable to noncontrolling interests(609)
Net income attributable to CareTrust REIT, Inc.$65,802 $28,746 
(1)Other expenses include certain overhead expenses.
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.25.1
VARIABLE INTEREST ENTITIES (Tables)
3 Months Ended
Mar. 31, 2025
Noncontrolling Interest [Abstract]  
Schedule of Variable Interest Entities
The following table summarizes the contributions to joint ventures that are consolidated variable interest entities through March 31, 2025 (dollars in thousands):
Gross Investment
Investment YearStateFacility TypeNumber of FacilitiesCTRENoncontrolling InterestsTotal
2023CASNF1$25,459 $653 $26,112 
2023CASNF234,269 879 35,148 
2024CAALF110,760 276 11,036 
2024CAMulti-service campuses228,076 720 28,796 
2024CASNF124,503 628 25,131 
2024 / 2025
(1)
TN, ALSNF28442,327 19,156 461,483 
2024 / 2025
(2)
- --33,663 86734,530 
Total35$599,057 $23,179 $622,236 
(1) The noncontrolling interest is classified as a redeemable noncontrolling interest on the consolidated balance sheets.
(2) The Company entered into a joint venture to acquire real estate. The gross investment amounts represent a deposit. See Note 15, Subsequent Events, for additional information.
Total assets and total liabilities include VIE assets and liabilities as follows (dollars in thousands):
March 31, 2025
December 31, 2024
Assets:
Real estate investments, net$581,959 $565,959 
Cash and cash equivalents6,762 6,506 
Accounts and other receivables32 — 
Prepaid and other assets41,078 8,317 
Total assets629,831 580,782 
Liabilities:
Accounts payable, accrued liabilities and deferred rent liabilities7,847 10,332 
Total liabilities$7,847 $10,332 
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.25.1
COMMITMENTS AND CONTINGENCIES (Tables)
3 Months Ended
Mar. 31, 2025
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Commitments and Contingencies
The table below summarizes the Company’s existing, known commitments and contingencies as of March 31, 2025 (in thousands):
Remaining Commitment
Capital expenditures(1)
$7,163 
Mortgage loans(2)
9,066 
Other loans receivable(3)
12,166 
Earn-out obligation(4)
10,000 
$38,395 
(1)As of March 31, 2025, the Company had committed to fund expansions, construction, capital improvements and ESG incentives at certain triple-net leased facilities totaling $7.2 million, of which $6.3 million is subject to rent increase at the time of funding.
(2)Includes an earn-out advance of $9.0 million related to one mortgage loan, upon satisfaction of certain conditions.
(3)Represents non-real estate secured loan commitments.
(4)Includes an earn-out obligation of up to $10.0 million under a purchase and sale agreement for one SNF in Virginia, which was acquired during 2024. The earn-out is available, contingent on the operator achieving certain thresholds per the agreement, beginning in October 2025 through October 2026.
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.25.1
CONCENTRATION OF RISK (Tables)
3 Months Ended
Mar. 31, 2025
Risks and Uncertainties [Abstract]  
Schedules of Concentration of Risk
Major operator concentration The Company has operators from which it derived 10% or more of its revenue for the three months ended March 31, 2025 and 2024. The following table sets forth information regarding the Company’s major operators as of March 31, 2025 and 2024:
 Number of FacilitiesNumber of Beds/UnitsPercentage of Total Revenue
Operator/BorrowerSNFCampusALF/ILFSNFCampusALF/ILFThree Months Ended
March 31, 2025(1)
Ensign(2)
89 79,288 843661 21 %
PACS(2)
23 3— 2,809 322— 11 %
March 31, 2024(1)
Ensign(2)
85 89,024 997 661 30 %
Priority Management Group13 2— 1,742 402 — 13 %
(1) The Company’s rental income and interest income on other real estate related investments, exclusive of operating expense reimbursements.
(2) Ensign and the PACS Group, Inc. (“PACS”) are subject to the registration and reporting requirements of the SEC and are required to file with the SEC annual reports containing audited financial information and quarterly reports containing unaudited financial information. Ensign and PACS’s financial statements, as filed with the SEC, can be found at http://www.sec.gov. The Company has not verified this information through an independent investigation or otherwise.
Major geographic concentration – The following table provides information regarding the Company’s concentrations with respect to certain states, from which the Company derived 10% or more of its revenue for the three months ended March 31, 2025 and 2024:
 Number of FacilitiesNumber of Beds/UnitsPercentage of Total Revenue
StateSNFCampusALF/ILFSNFCampusALF/ILFThree Months Ended
March 31, 2025(1)
CA42 1211 4,979 2,004 1,032 23 %
TX38 34,772 476 212 12 %
TN29 — — 3,098 — — 12 %
March 31, 2024(1)
CA4295,000 1,527 723 31 %
TX4145,193 630 212 20 %
(1) Based on the Company’s rental income and interest income on other real estate related investments, exclusive of operating expense reimbursements.
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.25.1
ORGANIZATION (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2025
USD ($)
investment
loan
bed
state
facility
Mar. 11, 2025
£ / shares
Dec. 31, 2024
USD ($)
Real Estate Properties [Line Items]      
Number of states with properties | state 32    
Number of preferred equity investments | investment 3    
Aggregate carrying value | $ $ 799,799   $ 795,203
Care REIT plc      
Real Estate Properties [Line Items]      
Business combination, share price, expected (in usd per share) | £ / shares   £ 108  
Mortgage secured loans receivable      
Real Estate Properties [Line Items]      
Number of loans 15    
Mezzanine loans receivable      
Real Estate Properties [Line Items]      
Number of loans 5    
Financing receivable      
Real Estate Properties [Line Items]      
Number of loans 1    
Aggregate carrying value | $ $ 96,600    
Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities      
Real Estate Properties [Line Items]      
Number of properties | facility 255    
Number of operational beds and units in facilities | bed 27,672    
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Accounting Policies [Abstract]    
Restricted cash $ 606,000 $ 0
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Mar. 31, 2024
Dec. 31, 2023
Cash, Cash Equivalents and Restricted Cash        
Cash and cash equivalents $ 26,510 $ 213,822    
Restricted cash 606,000 0    
Cash, cash equivalents and restricted cash $ 632,510 $ 213,822 $ 451,173 $ 294,448
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.25.1
REAL ESTATE INVESTMENTS, NET - Schedule of Investment in Owned Properties (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Real Estate [Abstract]    
Land $ 377,669 $ 367,044
Buildings and improvements 2,253,424 2,220,287
Integral equipment, furniture and fixtures 113,402 113,803
Identified intangible assets 4,083 4,388
Real estate investments 2,748,578 2,705,522
Accumulated depreciation and amortization (496,299) (478,782)
Real estate investments, net $ 2,252,279 $ 2,226,740
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.25.1
REAL ESTATE INVESTMENTS, NET - Narrative (Details)
3 Months Ended
Mar. 31, 2025
facility
Real Estate [Line Items]  
Number of facilities currently held for sale 4
Jaybird Lease  
Real Estate [Line Items]  
Lessor, operating lease, renewal options terms 5 years
Number of facilities in process of transferring operations 2
Skilled Nursing, Multi-Service Campuses, Assisted living and Independent Living Facilities  
Real Estate [Line Items]  
Number of properties 255
Skilled Nursing, Multi-Service Campuses, Assisted living and Independent Living Facilities | Held for Sale  
Real Estate [Line Items]  
Number of properties 6
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.25.1
REAL ESTATE INVESTMENTS, NET - Schedule of Total Future Contractual Minimum Rental Income (Details)
$ in Thousands
Mar. 31, 2025
USD ($)
Future Contractual Minimum Rental Income  
2025 (nine months) $ 210,437
2026 283,552
2027 281,850
2028 280,536
2029 276,512
2030 271,031
Thereafter 1,367,365
Total $ 2,971,283
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.25.1
REAL ESTATE INVESTMENTS, NET - Schedule of Tenant Purchase Options (Details) - 3 months ended Mar. 31, 2025
property
option
facility
numberOfFacility
USD ($)
numberOfFacility
Lessor, Lease, Description [Line Items]      
Period of option window 6 months    
Number of purchase option window | option 4    
Number of purchase option types | option 2    
Lease Expiration May 2034, Next option 2027 | Minimum      
Lessor, Lease, Description [Line Items]      
Current cash rent   $ 2,400,000  
Lease Expiration May 2034, Next option 2027 | Maximum      
Lessor, Lease, Description [Line Items]      
Current cash rent   3,100,000  
SNF      
Lessor, Lease, Description [Line Items]      
Current cash rent   1,200,000  
SNF | Lease Expiration March 2029, Next option 2022      
Lessor, Lease, Description [Line Items]      
Properties | property 1    
Current cash rent   858,000  
SNF | Lease Expiration January 2030, Next Option 2026      
Lessor, Lease, Description [Line Items]      
Properties | property 1    
Current cash rent   1,200,000  
SNF | Lease Expiration November 2034, Next Option 2027      
Lessor, Lease, Description [Line Items]      
Properties | property 1    
Current cash rent   1,100,000  
SNF | Lease Expiration November 2039, Next Option 2027      
Lessor, Lease, Description [Line Items]      
Properties 6   1
Current cash rent   10,160,000  
Purchase option, window open period 1 year    
SNF | Lease Expiration November 2039, Next Option 2027 | Minimum      
Lessor, Lease, Description [Line Items]      
Purchase option, number of properties | numberOfFacility 2    
SNF | Lease Expiration November 2039, Next Option 2027 | Maximum      
Lessor, Lease, Description [Line Items]      
Purchase option, number of properties | numberOfFacility 6    
SNF / Campus | Minimum      
Lessor, Lease, Description [Line Items]      
Current cash rent   3,200,000  
SNF / Campus | Maximum      
Lessor, Lease, Description [Line Items]      
Current cash rent   3,500,000  
SNF / Campus | Lease Expiration October 2032, Next option 2027      
Lessor, Lease, Description [Line Items]      
Properties 2   2
Current cash rent   3,367,000  
Purchase option, number of properties | numberOfFacility 3    
SNF / Campus | Lease Expiration May 2034, Next option 2026      
Lessor, Lease, Description [Line Items]      
Properties | property 2    
Current cash rent   $ 2,714,000  
Period of option window 9 months    
SNF / Campus | Lease Expiration May 2034, Next option 2027 | First Option      
Lessor, Lease, Description [Line Items]      
Properties | property 1    
Purchase option, number of properties | facility 5    
SNF / Campus | Lease Expiration May 2034, Next option 2027 | Second Option      
Lessor, Lease, Description [Line Items]      
Properties | property 1    
Purchase option, number of properties | facility 5    
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.25.1
REAL ESTATE INVESTMENTS, NET - Schedule of Rental Income (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Real Estate [Abstract]    
Contractual rent due $ 70,776 $ 52,934
Straight-line rent (7) (7)
Amortization of lease incentives (49) 0
Amortization of below-market lease intangibles 926 575
Total 71,646 53,502
Tenant operating expense reimbursement $ 2,300 $ 1,500
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.25.1
REAL ESTATE INVESTMENTS, NET - Schedule of Real Estate Acquisitions (Details)
$ in Thousands
3 Months Ended
Mar. 01, 2024
facility
Mar. 31, 2025
USD ($)
property
facility
bed
Business Acquisition [Line Items]    
Purchase Price   $ 41,085
Initial Annual Cash Rent   $ 3,896
Number of Properties | property   2
Number of Beds/Units | bed   284
Skilled nursing    
Business Acquisition [Line Items]    
Purchase Price   $ 20,448
Initial Annual Cash Rent   $ 2,000
Number of Properties 2 1
Number of Beds/Units | bed   124
Skilled nursing | Joint Venture    
Business Acquisition [Line Items]    
Number of Properties | facility   1
Assisted living    
Business Acquisition [Line Items]    
Purchase Price   $ 20,637
Initial Annual Cash Rent   $ 1,896
Number of Properties | property   1
Number of Beds/Units | bed   160
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.25.1
REAL ESTATE INVESTMENTS, NET - Lease Amendments and Terminations Narrative (Details)
$ in Millions
3 Months Ended
Aug. 01, 2024
facility
Mar. 01, 2024
USD ($)
renewal_option
facility
lease
Mar. 31, 2025
property
facility
Feb. 28, 2025
USD ($)
Jan. 01, 2025
USD ($)
facility
option_to_renew
Jan. 01, 2024
USD ($)
facility
renewal_option
Real Estate [Line Items]            
Number of facilities currently held for sale     4      
Number of Properties | property     2      
Amended Kalesta Lease            
Real Estate [Line Items]            
Initial lease term (in years)     15 years      
Lessor, operating lease, payment to be received, next rolling 12 months | $       $ 1.9    
Jaybird Lease            
Real Estate [Line Items]            
Initial lease term (in years)     12 years      
Lessor, operating lease, payment to be received, next rolling 12 months | $         $ 0.8  
Number of renewal options | option_to_renew         2  
Lessor, operating lease, renewal options terms     5 years      
Lessor, operating lease, rent calculated as a percentage of subtenant's gross revenue, period 15 months          
Number of facilities in process of transferring operations     2      
Master Lease Termination            
Real Estate [Line Items]            
Number of facilities         2  
Annual cash rent | $         $ 0.8  
Ensign Amended Triple-Net Master Lease            
Real Estate [Line Items]            
Initial lease term (in years)   20 years        
Number of renewal options | renewal_option   2        
Number of leases amended | lease   1        
Lease renewal term (in years)   5 years        
Eduro Amended Triple-Net Master Lease            
Real Estate [Line Items]            
Annual cash rent increase under amended lease | $   $ 2.1        
New Embassy Lease Agreement            
Real Estate [Line Items]            
Initial lease term (in years)           10 years
Number of renewal options | renewal_option           2
Annual cash rent | $           $ 0.6
Lease renewal term (in years)           5 years
Assisted living            
Real Estate [Line Items]            
Number of Properties | property     1      
Skilled nursing            
Real Estate [Line Items]            
Number of Properties   2 1      
SNF | New Embassy Lease Agreement            
Real Estate [Line Items]            
Number of facilities           1
Multi-service campuses | New Embassy Lease Agreement            
Real Estate [Line Items]            
Number of facilities           1
Jaybird Senior Living, Inc. | Assisted living            
Real Estate [Line Items]            
Number of facilities acquired 2          
Ensign | SNF            
Real Estate [Line Items]            
Initial lease term (in years)   15 years        
Number of properties with right to operate   2        
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.25.1
IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - Narrative (Details)
3 Months Ended
Mar. 31, 2025
USD ($)
facility
Mar. 31, 2024
USD ($)
Real Estate [Line Items]    
Impairment of real estate investments $ 0 $ 2,700,000
Minimum | Level 3 | Valuation, Market Approach    
Real Estate [Line Items]    
Prices per unit input   12,000
Maximum | Level 3 | Valuation, Market Approach    
Real Estate [Line Items]    
Prices per unit input   36,000
Weighted Average | Level 3 | Valuation, Market Approach    
Real Estate [Line Items]    
Prices per unit input   $ 16,000
Facilities Held For Sale    
Real Estate [Line Items]    
Number of properties | facility 6  
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.25.1
IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - Schedule of Company's Dispositions (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2025
USD ($)
facility
Mar. 31, 2024
USD ($)
facility
Jan. 31, 2024
facility
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Net sales proceeds $ 44,401 $ 46  
Net gain on sale $ 3,876 $ 11  
Disposed of by Sale      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Number of facilities | facility 5 2  
Net sales proceeds $ 44,401 $ 1,046  
Net carrying value 40,525 1,035  
Net gain on sale 3,876 $ 11  
Disposed of by Sale | ALF      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Net sales proceeds $ 1,000    
Number of properties | facility     1
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.25.1
IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - Schedule of Company's Assets Held for Sale Activity (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2025
USD ($)
facility
Mar. 31, 2024
USD ($)
facility
Increase Decrease in Assets Held for Sale [Roll Forward]    
Net carrying value at beginning $ 2,705,522  
Net carrying value at ending 2,748,578  
Disposal Group, Held-for-sale, Not Discontinued Operations    
Increase Decrease in Assets Held for Sale [Roll Forward]    
Net carrying value at beginning 57,261 $ 15,011
Net carrying value, additions to assets held for sale   1,251
Net carrying value, assets sold (40,525) (1,035)
Net carrying value, impairment of real estate held for sale   (2,744)
Net carrying value at ending $ 16,736 $ 12,483
Number of facilities at beginning | facility 10 14
Number of facilities, additions to assets held for sale | facility   1
Number of facilities, assets sold | facility (4) (2)
Number of facilities, impairment of real estate held for sale | facility   0
Number of facilities at ending | facility 6 13
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.25.1
OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Other Real Estate Related Investments, At Fair Value (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2025
USD ($)
facility
option
paymentInstallment
Dec. 31, 2024
USD ($)
Dec. 05, 2024
USD ($)
Real Estate Properties [Line Items]      
Accrued interest, net $ 905 $ 281  
Net change in other real estate related investments $ 96,628 96,004  
Number of monthly installment payments | paymentInstallment 24    
Other loans receivable      
Real Estate Properties [Line Items]      
Principal amount $ 742,716    
Fair Value 745,600 741,004  
Other Investments      
Real Estate Properties [Line Items]      
Principal amount 53,782    
Fair Value $ 54,199 54,199  
Mortgage secured loans receivable      
Real Estate Properties [Line Items]      
Number of properties | facility 3    
Mortgage secured loans receivable | Other loans receivable      
Real Estate Properties [Line Items]      
Principal amount $ 654,040    
Fair Value $ 658,427 660,392  
Weighted Average Contractual Interest Rate 8.80%    
Accrued interest, net $ 4,600 3,400  
Mortgage secured loans receivable | SNF | Other loans receivable      
Real Estate Properties [Line Items]      
Facility Count and Type | facility 61    
Mortgage secured loans receivable | Campus | Other loans receivable      
Real Estate Properties [Line Items]      
Facility Count and Type | facility 4    
Mortgage secured loans receivable | ALF | Other loans receivable      
Real Estate Properties [Line Items]      
Facility Count and Type | facility 19    
Mortgage secured loans receivable | ILF | Other loans receivable      
Real Estate Properties [Line Items]      
Facility Count and Type | facility 2    
Mezzanine loans receivable      
Real Estate Properties [Line Items]      
Number of properties | facility 2    
Mezzanine loans receivable | Other loans receivable      
Real Estate Properties [Line Items]      
Principal amount $ 88,676    
Fair Value $ 87,173 80,612  
Weighted Average Contractual Interest Rate 12.80%    
Accrued interest, net $ 1,000 900  
Mezzanine loans receivable | SNF | Other loans receivable      
Real Estate Properties [Line Items]      
Facility Count and Type | facility 41    
Mezzanine loans receivable | Campus | Other loans receivable      
Real Estate Properties [Line Items]      
Facility Count and Type | facility 4    
Mezzanine loans receivable | ALF | Other loans receivable      
Real Estate Properties [Line Items]      
Facility Count and Type | facility 2    
Mezzanine loans receivable | ILF | Other loans receivable      
Real Estate Properties [Line Items]      
Facility Count and Type | facility 0    
Preferred equity | Other Investments      
Real Estate Properties [Line Items]      
Principal amount $ 53,782    
Fair Value $ 54,199 54,199  
Weighted Average Contractual Interest Rate 11.10%    
Financing receivable | Other loans receivable      
Real Estate Properties [Line Items]      
Accrued interest, net $ 900 300  
Financing receivable | Other Investments      
Real Estate Properties [Line Items]      
Principal amount 95,723   $ 95,700
Fair Value $ 96,628 $ 96,004  
Weighted Average Contractual Interest Rate 12.00%    
Term of contract 15 years    
Number of renewal options | option 2    
Lease extended period 5 years    
Initial contractual cash yield 11.00%    
Deferred rent as percentage of contractual cash yield 2.00%    
Deferred rent as percentage of contractual cash yield, year two 0.50%    
Operating lease lessor cash yield term 3 years    
Percentage cap 3.00%    
Contractual cash yield 12.50%    
Financing receivable | SNF | Other Investments      
Real Estate Properties [Line Items]      
Facility Count and Type | facility 39    
Financing receivable | Campus | Other Investments      
Real Estate Properties [Line Items]      
Facility Count and Type | facility 0    
Financing receivable | ALF | Other Investments      
Real Estate Properties [Line Items]      
Facility Count and Type | facility 5    
Financing receivable | ILF | Other Investments      
Real Estate Properties [Line Items]      
Facility Count and Type | facility 2    
Mortgage Secured and Mezzanine Loans Receivable      
Real Estate Properties [Line Items]      
Basis spread on variable rate (percent) 4.32%    
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.25.1
OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Real Estate Related Investment Activity (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Mar. 31, 2024
Other Real Estate Related Investments    
Financing Receivable, Allowance for Credit Loss [Line Items]    
Origination of other real estate related investments $ 6,389 $ 53,165
Accrued interest, net 1,280 425
Unrealized gain (loss) on other real estate related investments, net 1,287 (612)
Prepayments of other real estate related investments (4,360) 0
Net change in other loans receivable 4,596 $ 52,978
Other loans receivable    
Financing Receivable, Allowance for Credit Loss [Line Items]    
Origination of other real estate related investments $ 21,757  
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.25.1
OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Narrative (Details)
1 Months Ended 3 Months Ended
Dec. 05, 2024
USD ($)
facility
Dec. 01, 2024
Feb. 28, 2025
USD ($)
Mar. 31, 2025
USD ($)
property
Mar. 31, 2024
USD ($)
Jan. 10, 2025
USD ($)
facility
Dec. 20, 2024
Feb. 02, 2024
USD ($)
extension_option
facility
Feb. 01, 2024
USD ($)
facility
Jan. 25, 2024
USD ($)
facility
extension_option
Jan. 01, 2024
USD ($)
facility
Financing Receivable, Allowance for Credit Loss [Line Items]                      
Financing receivable, mortgage prepaid loan, outstanding     $ 2,900,000                
Number of Properties | property       2              
Proceeds from sale of finance receivables       $ 2,200,000              
New Cascade Lease                      
Financing Receivable, Allowance for Credit Loss [Line Items]                      
Number of Properties | facility 46                    
Sale leaseback transaction, lease term   15 years                  
Other Investments                      
Financing Receivable, Allowance for Credit Loss [Line Items]                      
Principal amount       53,782,000              
Mezzanine Loan                      
Financing Receivable, Allowance for Credit Loss [Line Items]                      
Principal amount               $ 50,000,000   $ 10,200,000  
Investment interest rate (as percent)                 11.50%    
Finance receivable, number of extension options | extension_option               2   2  
Finance receivable, extension option, term               6 months   6 months  
Mezzanine Loan | Secured Overnight Financing Rate (SOFR)                      
Financing Receivable, Allowance for Credit Loss [Line Items]                      
Investment interest rate (as percent)               8.75%   8.75%  
Subservicing fee percentage               0.75%   0.75%  
Mezzanine Loan | Secured Overnight Financing Rate (SOFR) Floor                      
Financing Receivable, Allowance for Credit Loss [Line Items]                      
Investment interest rate (as percent)               6.00%   6.00%  
Mezzanine Loan | SNF                      
Financing Receivable, Allowance for Credit Loss [Line Items]                      
Principal amount               $ 35,000,000 $ 7,400,000 $ 9,800,000  
Number of facilities | facility               15 1 10  
Period of unpaid interest payments due upon prepayment               18 months 18 months 24 months  
Mezzanine Loan | SNF | Minimum                      
Financing Receivable, Allowance for Credit Loss [Line Items]                      
Early termination fee               1.00%   1.00%  
Mezzanine Loan | SNF | Maximum                      
Financing Receivable, Allowance for Credit Loss [Line Items]                      
Early termination fee               2.00%   2.00%  
Mezzanine Loan Receivable [Member] | Multi-service campuses                      
Financing Receivable, Allowance for Credit Loss [Line Items]                      
Investment interest rate (as percent)             13.00%        
Mortgage secured loan receivable                      
Financing Receivable, Allowance for Credit Loss [Line Items]                      
Number of facilities | facility                     1
Mortgage secured loan receivable | ALF                      
Financing Receivable, Allowance for Credit Loss [Line Items]                      
Principal amount                     $ 1,000,000
Investment interest rate (as percent)                     9.00%
Financing receivable | Other Investments                      
Financing Receivable, Allowance for Credit Loss [Line Items]                      
Principal amount $ 95,700,000     95,723,000              
Other loans receivable                      
Financing Receivable, Allowance for Credit Loss [Line Items]                      
Principal amount       21,757,000              
Provision for loan losses, net       $ 0 $ 0            
SNF                      
Financing Receivable, Allowance for Credit Loss [Line Items]                      
Financing receivable, mortgage prepaid loan amount     $ 4,400,000                
SNF | Mezzanine Loan                      
Financing Receivable, Allowance for Credit Loss [Line Items]                      
Number of property secured by pledge | facility           1          
SNF | Mezzanine Loan | MARYLAND                      
Financing Receivable, Allowance for Credit Loss [Line Items]                      
Principal amount           $ 6,400,000          
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.25.1
OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Other Real Estate Related Investment Activity (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Real Estate Properties [Line Items]    
Net change in other real estate related investments $ 96,628 $ 96,004
Other loans receivable    
Real Estate Properties [Line Items]    
Principal amount 21,757  
Mortgage loan receivable $ 21,820 22,010
Weighted average interest rate 9.00%  
Expected credit loss $ (6,994) (6,994)
Principal Balance 21,757  
Net change in other real estate related investments $ 14,826 $ 15,016
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.25.1
OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Loan Receivable Activity (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Investments, All Other Investments [Abstract]    
Principal payments $ (222) $ 0
Accrued interest, net 32 0
Net change in other loans receivable $ (190) $ 0
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.25.1
OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Interest and Other Income (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Real Estate Properties [Line Items]    
Interest income from other real estate related investments and other income $ 22,168 $ 9,568
Other Income, Excluding Interest 24,975 9,568
Mortgage secured loans receivable    
Real Estate Properties [Line Items]    
Interest income from other real estate related investments and other income 14,388 3,772
Mezzanine loans receivable    
Real Estate Properties [Line Items]    
Interest income from other real estate related investments and other income 2,821 1,895
Preferred equity investment    
Real Estate Properties [Line Items]    
Interest income from other real estate related investments and other income 1,497 68
Other loans receivable    
Real Estate Properties [Line Items]    
Interest income from other real estate related investments and other income 334 331
Financing receivable    
Real Estate Properties [Line Items]    
Interest income from other real estate related investments and other income 2,807 0
Other    
Real Estate Properties [Line Items]    
Interest income from other real estate related investments and other income $ 3,128 $ 3,502
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.25.1
FAIR VALUE MEASUREMENTS - Schedule of Items Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Mortgage Secured and Mezzanine Loans Receivable    
Assets:    
Loan receivable $ 842,228 $ 837,008
Mortgage Secured and Mezzanine Loans Receivable | Level 1 | Recurring    
Assets:    
Loan receivable 0 0
Mortgage Secured and Mezzanine Loans Receivable | Level 2 | Recurring    
Assets:    
Loan receivable 0 0
Mortgage Secured and Mezzanine Loans Receivable | Level 3 | Recurring    
Assets:    
Loan receivable 842,228 837,008
Mortgage secured loans receivable | Recurring    
Assets:    
Loan receivable 658,427 660,392
Mortgage secured loans receivable | Level 1 | Recurring    
Assets:    
Loan receivable 0 0
Mortgage secured loans receivable | Level 2 | Recurring    
Assets:    
Loan receivable 0 0
Mortgage secured loans receivable | Level 3 | Recurring    
Assets:    
Loan receivable 658,427 660,392
Mezzanine loans receivable | Recurring    
Assets:    
Loan receivable 87,173 80,612
Mezzanine loans receivable | Level 1 | Recurring    
Assets:    
Loan receivable 0 0
Mezzanine loans receivable | Level 2 | Recurring    
Assets:    
Loan receivable 0 0
Mezzanine loans receivable | Level 3 | Recurring    
Assets:    
Loan receivable 87,173 80,612
Financing receivable | Recurring    
Assets:    
Loan receivable 96,628 96,004
Financing receivable | Level 1 | Recurring    
Assets:    
Loan receivable 0 0
Financing receivable | Level 2 | Recurring    
Assets:    
Loan receivable 0 0
Financing receivable | Level 3 | Recurring    
Assets:    
Loan receivable $ 96,628 $ 96,004
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.25.1
FAIR VALUE MEASUREMENTS - Schedule of Assets Measured at Fair Value on a Recurring Basis Using Level 3 Inputs (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Unrealized gain, net $ 1,287 $ (612)
Investments in Real Estate Secured Loans    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance at beginning of period 660,392  
Originations 0  
Accrued interest, net 1,173  
Unrealized gain, net 1,222  
Payments (4,360)  
Balance at ending of period 658,427  
Investments in Mezzanine Loans    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance at beginning of period 80,612  
Originations 6,389  
Accrued interest, net 107  
Unrealized gain, net 65  
Payments 0  
Balance at ending of period 87,173  
Investment in Financing Receivable    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance at beginning of period 96,004  
Originations 0  
Accrued interest, net 624  
Unrealized gain, net 0  
Payments 0  
Balance at ending of period $ 96,628  
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.25.1
FAIR VALUE MEASUREMENTS - Narrative (Details)
3 Months Ended
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Financing Receivable, Past Due [Line Items]      
Unrealized (gain) loss on other real estate related investments, net $ (1,287,000) $ 612,000  
Minimum | Level 3      
Financing Receivable, Past Due [Line Items]      
Measurement input 0.11    
Maximum | Level 3      
Financing Receivable, Past Due [Line Items]      
Measurement input 0.15    
Greater than 90 Days Past Due      
Financing Receivable, Past Due [Line Items]      
Mortgage loan receivable $ 0   $ 0
Secured and Mezzanine Loans Receivable      
Financing Receivable, Past Due [Line Items]      
Other real estate related investments, fair value adjustments, unrealized gain $ 1,300,000    
Unrealized (gain) loss on other real estate related investments, net   800,000  
Unrealized gain (loss) on increases in projected forward interest rates   $ 200,000  
Financing receivable | Level 3 | Discount Rate | Discounted cash flow      
Financing Receivable, Past Due [Line Items]      
Loans receivable, measurement input 0.12    
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.25.1
FAIR VALUE MEASUREMENTS - Schedule of Quantitative Information About Unobservable Inputs Related to Level 3 Fair Value Measurements (Details) - Level 3 - Discount Rate - Discounted cash flow
$ in Thousands
Mar. 31, 2025
USD ($)
Mortgage secured loans receivable  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Loans receivable, book value $ 658,427
Mortgage secured loans receivable | Minimum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Loans receivable, measurement input 0.08
Mortgage secured loans receivable | Maximum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Loans receivable, measurement input 0.14
Mezzanine loans receivable  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Loans receivable, book value $ 87,173
Mezzanine loans receivable | Minimum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Loans receivable, measurement input 0.12
Mezzanine loans receivable | Maximum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Loans receivable, measurement input 0.14
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.25.1
FAIR VALUE MEASUREMENTS - Schedule of Face Value, Carrying Amount and Fair Value of Financial Instruments (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Level 3 | Preferred equity investments    
Financial assets:    
Preferred equity investments, face value $ 53,782 $ 53,782
Level 3 | Preferred equity investments | Carrying Amount    
Financial assets:    
Preferred equity investments, fair value disclosure 54,199 54,199
Level 3 | Preferred equity investments | Fair Value    
Financial assets:    
Preferred equity investments, fair value disclosure 54,199 54,199
Level 2 | Senior unsecured notes payable    
Financial liabilities:    
Senior unsecured notes payable, face value 400,000 400,000
Level 2 | Carrying Amount | Senior unsecured notes payable    
Financial liabilities:    
Senior unsecured notes payable, fair value disclosure 397,149 396,927
Level 2 | Fair Value | Senior unsecured notes payable    
Financial liabilities:    
Senior unsecured notes payable, fair value disclosure $ 374,880 $ 381,812
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.25.1
DEBT - Schedule of Debt Instruments (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Debt Instrument [Line Items]    
Principal Amount $ 825,000 $ 400,000
Deferred Loan Fees (2,851) (3,073)
Carrying Amount 822,149 396,927
Unsecured revolving credit facility    
Debt Instrument [Line Items]    
Principal Amount 425,000 0
Deferred Loan Fees 0 0
Carrying Amount 425,000 0
Senior unsecured notes payable | Notes payable    
Debt Instrument [Line Items]    
Principal Amount 400,000 400,000
Deferred Loan Fees (2,851) (3,073)
Carrying Amount $ 397,149 $ 396,927
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.25.1
DEBT - Senior Unsecured Notes Payable Narrative (Details) - 2028 Senior Notes - Notes Payable
Jun. 17, 2021
USD ($)
Debt Instrument [Line Items]  
Debt instrument, face amount $ 400,000,000
Interest rate (as percent) 3.875%
Gross proceeds from issuance $ 400,000,000
Net proceeds from issuance $ 393,800,000
Redemption price, percentage upon change of control (as percent) 101.00%
Period prior to March 30 2028  
Debt Instrument [Line Items]  
Redemption price of notes (as percent) 100.00%
Period after March 30 2028  
Debt Instrument [Line Items]  
Redemption price of notes (as percent) 100.00%
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.25.1
DEBT - Unsecured Revolving Credit Facility Narrative (Details)
Feb. 08, 2019
USD ($)
extension_option
Mar. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 18, 2024
USD ($)
Dec. 16, 2022
Line of Credit Facility [Line Items]          
Unsecured revolving credit facility   $ 425,000,000 $ 0    
Senior unsecured term loan | Term Loan          
Line of Credit Facility [Line Items]          
Debt instrument, face amount $ 200,000,000.0        
Unsecured revolving credit facility          
Line of Credit Facility [Line Items]          
Credit facility borrowing capacity $ 600,000,000.0     $ 1,200,000,000  
Unsecured revolving credit facility   $ 425,000,000.0      
Number of extension options | extension_option 2        
Extension option term (in months) 6 months        
Unsecured revolving credit facility | Minimum          
Line of Credit Facility [Line Items]          
Facility fee on revolving commitment fees (as percent) 0.15%        
Facility fee on revolving commitment fee based on investment grade ratings (as percent) 0.125%        
Unsecured revolving credit facility | Minimum | Base Rate          
Line of Credit Facility [Line Items]          
Basis spread on variable rate (as percent) 0.05%        
Unsecured revolving credit facility | Minimum | Secured Overnight Financing Rate (SOFR)          
Line of Credit Facility [Line Items]          
Basis spread on variable rate (as percent) 1.05%        
Unsecured revolving credit facility | Maximum          
Line of Credit Facility [Line Items]          
Facility fee on revolving commitment fees (as percent) 0.35%        
Facility fee on revolving commitment fee based on investment grade ratings (as percent) 0.30%        
Unsecured revolving credit facility | Maximum | Base Rate          
Line of Credit Facility [Line Items]          
Basis spread on variable rate (as percent) 0.55%        
Unsecured revolving credit facility | Maximum | Secured Overnight Financing Rate (SOFR)          
Line of Credit Facility [Line Items]          
Basis spread on variable rate (as percent) 1.55%        
Letter of Credit          
Line of Credit Facility [Line Items]          
Subfacility capacity as percentage of available revolving commitments (as percent) 10.00%       10.00%
Swingline Loan          
Line of Credit Facility [Line Items]          
Subfacility capacity as percentage of available revolving commitments (as percent) 10.00%       10.00%
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.25.1
EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - Narrative (Details) - ATM Program - USD ($)
3 Months Ended
Mar. 31, 2025
Jan. 21, 2025
Dec. 31, 2024
Class of Stock [Line Items]      
Authorized aggregate offering price of common stock   $ 750,000,000.0 $ 750,000,000
Expected term 1 year    
Remaining offering amount available $ 734,000,000.0    
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.25.1
EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - Schedule of At-The-Market Offering Program (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Class of Stock [Line Items]    
Gross proceeds $ 15,562 $ 269,787
ATM Program    
Class of Stock [Line Items]    
Number of shares (in shares) 553 11,600
Average sales price per share (in usd per share) $ 28.87 $ 23.55
Gross proceeds $ 15,964 $ 273,233
Commissions paid on stock issuance $ 200 $ 3,400
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.25.1
EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - Schedule of Dividends on Common Stock (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dividends on common stock    
Dividends declared per share (in usd per share) $ 0.335 $ 0.29
Dividends payable as of record date $ 63,053  
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.25.1
STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2025
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares authorized for awards (in shares) 5,000,000    
Unamortized stock-based compensation expense $ 15.8    
RSAs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period (in years) 1 year 3 years  
RSAs | Board of Directors      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period (in years)     1 year
Performance Shares T S R Units      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period (in years) 3 years    
Performance Shares T S R Units | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based payment award, percentage of original awards granted 0.00%    
Performance Shares T S R Units | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based payment award, percentage of original awards granted 200.00%    
RSAs and PSAs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted-average remaining vesting period (in years) 2 years    
XML 80 R70.htm IDEA: XBRL DOCUMENT v3.25.1
STOCK-BASED COMPENSATION - Schedule of Restricted Stock Award and Performance Award Activity (Details)
3 Months Ended
Mar. 31, 2025
$ / shares
shares
Shares  
Unvested, beginning balance (in shares) | shares 552,999
Vested (in shares) | shares (145,951)
Unvested, ending balance (in shares) | shares 544,968
Weighted Average Share Price  
Unvested, beginning balance (in usd per share) | $ / shares $ 23.86
Vested (in usd per share) | $ / shares 21.16
Unvested, ending balance (in usd per share) | $ / shares $ 25.42
RSAs  
Shares  
Granted (in shares) | shares 137,920
Weighted Average Share Price  
Granted (in usd per share) | $ / shares $ 27.17
XML 81 R71.htm IDEA: XBRL DOCUMENT v3.25.1
STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]    
Stock-based compensation expense $ 3,909 $ 2,120
XML 82 R72.htm IDEA: XBRL DOCUMENT v3.25.1
EARNINGS PER COMMON SHARE (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Numerator:    
Net income attributable to CareTrust REIT, Inc. $ 65,802 $ 28,746
Less: Net income allocated to participating securities (183) (96)
Numerator for basic earnings available to common stockholders 65,619 28,650
Numerator for diluted earnings available to common stockholders $ 65,619 $ 28,650
Denominator:    
Weighted-average basic common shares outstanding (in shares) 187,152 132,836
Weighted-average diluted common shares outstanding (in shares) 187,416 133,202
Earnings per common share attributable to CareTrust REIT, Inc., basic (in usd per share) $ 0.35 $ 0.22
Earnings per common share attributable to CareTrust REIT, Inc., diluted (in usd per share) $ 0.35 $ 0.22
Antidilutive unvested RSAs and TSR Units excluded from the computation (in shares) 545 330
PSAs and TSR Units    
Denominator:    
Dilutive potential common shares (in shares) 264 366
XML 83 R73.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT REPORTING (Details) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenues:    
Rental income $ 71,646,000 $ 53,502,000
Interest income from financing receivable 2,807,000 0
Interest income from other real estate related investments and other income 22,168,000 9,568,000
Total revenues 96,621,000 63,070,000
Expenses:    
Depreciation and amortization 17,841,000 13,448,000
Interest expense 6,669,000 8,228,000
Property taxes 2,065,000 1,801,000
Impairment of real estate investments 0 2,700,000
Transaction costs 888,000 0
Property operating expenses 105,000 660,000
Total general and administrative 9,023,000 6,838,000
Total expenses 36,591,000 33,719,000
Other income (loss):    
Gain on sale of real estate, net 3,876,000 11,000
Unrealized gain (loss) on other real estate related investments, net 1,287,000 (612,000)
Total other income (loss) 5,163,000 (601,000)
Net income 65,193,000 28,750,000
Net (loss) income attributable to noncontrolling interests (609,000) 4,000
Net income attributable to CareTrust REIT, Inc. 65,802,000 28,746,000
Reportable Segment    
Revenues:    
Rental income 71,646,000 53,502,000
Interest income from financing receivable 2,807,000 0
Interest income from other real estate related investments and other income 22,168,000 9,568,000
Total revenues 96,621,000 63,070,000
Expenses:    
Depreciation and amortization 17,841,000 13,448,000
Interest expense 6,669,000 8,228,000
Property taxes 2,065,000 1,801,000
Impairment of real estate investments 0 2,744,000
Transaction costs 888,000 0
Property operating expenses 105,000 660,000
Cash compensation 2,090,000 1,765,000
Incentive compensation 1,225,000 1,500,000
Share-based compensation 3,909,000 2,120,000
Professional services 876,000 738,000
Taxes and insurance 218,000 205,000
Other expenses 705,000 510,000
Total general and administrative 9,023,000 6,838,000
Total expenses 36,591,000 33,719,000
Other income (loss):    
Gain on sale of real estate, net 3,876,000 11,000
Unrealized gain (loss) on other real estate related investments, net 1,287,000 (612,000)
Total other income (loss) 5,163,000 (601,000)
Net income 65,193,000 28,750,000
Net (loss) income attributable to noncontrolling interests (609,000) 4,000
Net income attributable to CareTrust REIT, Inc. $ 65,802,000 $ 28,746,000
XML 84 R74.htm IDEA: XBRL DOCUMENT v3.25.1
VARIABLE INTEREST ENTITIES - Schedule of Variable Interest Entities Investments (Details) - Variable Interest Entity, Primary Beneficiary
$ in Thousands
Mar. 31, 2025
USD ($)
facility
Noncontrolling Interest [Line Items]  
Number of Facilities | facility 35
Gross Investment $ 622,236
Investment Seven  
Noncontrolling Interest [Line Items]  
Number of Facilities | facility 0
Gross Investment $ 34,530
CTRE  
Noncontrolling Interest [Line Items]  
Gross Investment 599,057
CTRE | Investment Seven  
Noncontrolling Interest [Line Items]  
Gross Investment 33,663
Noncontrolling Interests  
Noncontrolling Interest [Line Items]  
Gross Investment 23,179
Noncontrolling Interests | Investment Seven  
Noncontrolling Interest [Line Items]  
Gross Investment $ 867
SNF | Investment One  
Noncontrolling Interest [Line Items]  
Number of Facilities | facility 1
Gross Investment $ 26,112
SNF | Investment Two  
Noncontrolling Interest [Line Items]  
Number of Facilities | facility 2
Gross Investment $ 35,148
SNF | Investment Five  
Noncontrolling Interest [Line Items]  
Number of Facilities | facility 1
Gross Investment $ 25,131
SNF | Investment Six  
Noncontrolling Interest [Line Items]  
Number of Facilities | facility 28
Gross Investment $ 461,483
SNF | CTRE | Investment One  
Noncontrolling Interest [Line Items]  
Gross Investment 25,459
SNF | CTRE | Investment Two  
Noncontrolling Interest [Line Items]  
Gross Investment 34,269
SNF | CTRE | Investment Five  
Noncontrolling Interest [Line Items]  
Gross Investment 24,503
SNF | CTRE | Investment Six  
Noncontrolling Interest [Line Items]  
Gross Investment 442,327
SNF | Noncontrolling Interests | Investment One  
Noncontrolling Interest [Line Items]  
Gross Investment 653
SNF | Noncontrolling Interests | Investment Two  
Noncontrolling Interest [Line Items]  
Gross Investment 879
SNF | Noncontrolling Interests | Investment Five  
Noncontrolling Interest [Line Items]  
Gross Investment 628
SNF | Noncontrolling Interests | Investment Six  
Noncontrolling Interest [Line Items]  
Gross Investment $ 19,156
ALF | Investment Three  
Noncontrolling Interest [Line Items]  
Number of Facilities | facility 1
Gross Investment $ 11,036
ALF | CTRE | Investment Three  
Noncontrolling Interest [Line Items]  
Gross Investment 10,760
ALF | Noncontrolling Interests | Investment Three  
Noncontrolling Interest [Line Items]  
Gross Investment $ 276
Multi-service campuses | Investment Four  
Noncontrolling Interest [Line Items]  
Number of Facilities | facility 2
Gross Investment $ 28,796
Multi-service campuses | CTRE | Investment Four  
Noncontrolling Interest [Line Items]  
Gross Investment 28,076
Multi-service campuses | Noncontrolling Interests | Investment Four  
Noncontrolling Interest [Line Items]  
Gross Investment $ 720
XML 85 R75.htm IDEA: XBRL DOCUMENT v3.25.1
VARIABLE INTEREST ENTITIES - Narrative (Details)
Mar. 31, 2025
Jv Partner  
Noncontrolling Interest [Line Items]  
Preferred ownership (as percent) 100.00%
Equity ownership percentage (as percent) 50.00%
JV Partner 97.5%  
Noncontrolling Interest [Line Items]  
Ownership percentage held by noncontrolling interest (as percent) 90.00%
XML 86 R76.htm IDEA: XBRL DOCUMENT v3.25.1
VARIABLE INTEREST ENTITIES - Schedule of Variable Interest Entities (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Assets:    
Real estate investments, net $ 2,252,279 $ 2,226,740
Cash and cash equivalents 26,510 213,822
Accounts and other receivables 1,954 1,174
Prepaid and other assets 73,890 35,608
Total assets 3,884,448 3,437,016
Liabilities:    
Accounts payable, accrued liabilities and deferred rent liabilities 51,069 56,318
Total liabilities 936,271 507,633
Variable Interest Entity, Primary Beneficiary    
Assets:    
Real estate investments, net 581,959 565,959
Cash and cash equivalents 6,762 6,506
Accounts and other receivables 32 0
Prepaid and other assets 41,078 8,317
Total assets 629,831 580,782
Liabilities:    
Accounts payable, accrued liabilities and deferred rent liabilities 7,847 10,332
Total liabilities $ 7,847 $ 10,332
XML 87 R77.htm IDEA: XBRL DOCUMENT v3.25.1
COMMITMENTS AND CONTINGENCIES - Narrative (Details)
$ in Thousands
Mar. 31, 2025
USD ($)
Ensign and Pennant  
Other Commitments [Line Items]  
Aggregate required financing of capital expenditures as percentage of initial investment in property (as percent) 20.00%
Tenant ESG Program  
Other Commitments [Line Items]  
Authorized annual fund $ 500
XML 88 R78.htm IDEA: XBRL DOCUMENT v3.25.1
COMMITMENTS AND CONTINGENCIES - Schedule of Commitments and Contingencies (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2025
USD ($)
facility
Dec. 31, 2024
USD ($)
Other Commitments [Line Items]    
Commitments and contingencies
SNF | VIRGINIA    
Other Commitments [Line Items]    
Contingent earnout liability $ 10,000  
Number of properties | facility 1  
Mortgage loans | SNF    
Other Commitments [Line Items]    
Contingent earnout liability $ 9,000  
Certain Capital Improvements at Triple-Net Leased Facilities    
Other Commitments [Line Items]    
Funding commitment 7,200  
Portion of funding commitment subject to rent increase at time of funding 6,300  
Remaining Commitment    
Other Commitments [Line Items]    
Commitments and contingencies 38,395  
Remaining Commitment | Capital expenditures    
Other Commitments [Line Items]    
Commitments and contingencies 7,163  
Remaining Commitment | Mortgage loans    
Other Commitments [Line Items]    
Commitments and contingencies 9,066  
Remaining Commitment | Other loans receivable    
Other Commitments [Line Items]    
Commitments and contingencies 12,166  
Remaining Commitment | Earn-out obligation    
Other Commitments [Line Items]    
Commitments and contingencies $ 10,000  
XML 89 R79.htm IDEA: XBRL DOCUMENT v3.25.1
CONCENTRATION OF RISK (Details)
3 Months Ended
Mar. 31, 2025
facility
unit_bed
Mar. 31, 2024
unit_bed
facility
Rental Revenue | Geographic Concentration Risk | CA    
Concentration Risk [Line Items]    
Percentage of Total Revenue 23.00% 31.00%
Rental Revenue | Geographic Concentration Risk | TX    
Concentration Risk [Line Items]    
Percentage of Total Revenue 12.00% 20.00%
Rental Revenue | Geographic Concentration Risk | TN    
Concentration Risk [Line Items]    
Percentage of Total Revenue 12.00%  
SNF | CA    
Concentration Risk [Line Items]    
Number of Facilities | facility 42 42
Number of Beds/Units | unit_bed 4,979 5,000
SNF | TX    
Concentration Risk [Line Items]    
Number of Facilities | facility 38 41
Number of Beds/Units | unit_bed 4,772 5,193
SNF | TN    
Concentration Risk [Line Items]    
Number of Facilities | facility 29  
Number of Beds/Units | unit_bed 3,098  
Campus | CA    
Concentration Risk [Line Items]    
Number of Facilities | facility 12 9
Number of Beds/Units | unit_bed 2,004 1,527
Campus | TX    
Concentration Risk [Line Items]    
Number of Facilities | facility 3 4
Number of Beds/Units | unit_bed 476 630
Campus | TN    
Concentration Risk [Line Items]    
Number of Facilities | facility 0  
Number of Beds/Units | unit_bed 0  
ALF/ILF | CA    
Concentration Risk [Line Items]    
Number of Facilities | facility 11 9
Number of Beds/Units | unit_bed 1,032 723
ALF/ILF | TX    
Concentration Risk [Line Items]    
Number of Facilities | facility 2 2
Number of Beds/Units | unit_bed 212 212
ALF/ILF | TN    
Concentration Risk [Line Items]    
Number of Facilities | facility 0  
Number of Beds/Units | unit_bed 0  
Ensign | Rental Revenue | Customer Concentration Risk    
Concentration Risk [Line Items]    
Percentage of Total Revenue 21.00% 30.00%
Ensign | SNF    
Concentration Risk [Line Items]    
Number of Facilities | facility 89 85
Number of Beds/Units | unit_bed 9,288 9,024
Ensign | Campus    
Concentration Risk [Line Items]    
Number of Facilities | facility 7 8
Number of Beds/Units | unit_bed 843 997
Ensign | ALF/ILF    
Concentration Risk [Line Items]    
Number of Facilities | facility 7 7
Number of Beds/Units | unit_bed 661 661
PACS | Rental Revenue | Customer Concentration Risk    
Concentration Risk [Line Items]    
Percentage of Total Revenue 11.00% 13.00%
PACS | SNF    
Concentration Risk [Line Items]    
Number of Facilities | facility 23 13
Number of Beds/Units | unit_bed 2,809 1,742
PACS | Campus    
Concentration Risk [Line Items]    
Number of Facilities | facility 3 2
Number of Beds/Units | unit_bed 322 402
PACS | ALF/ILF    
Concentration Risk [Line Items]    
Number of Facilities | facility 0 0
Number of Beds/Units | unit_bed 0 0
XML 90 R80.htm IDEA: XBRL DOCUMENT v3.25.1
SUBSEQUENT EVENTS (Details) - Subsequent Event
$ / shares in Units, $ in Millions
1 Months Ended
Apr. 01, 2025
USD ($)
facility
option
Apr. 30, 2025
USD ($)
$ / shares
shares
ATM Program    
Subsequent Event [Line Items]    
Sale of stock, number of shares issued in transaction | shares   3,400,000
Proceeds from issuance or sale of equity   $ 99.5
Share price (in usd per share) | $ / shares   $ 28.90
Mortgage Loan    
Subsequent Event [Line Items]    
Repayments of Debt   $ 2.9
Skilled Nursing Facility, California, Joint Venture    
Subsequent Event [Line Items]    
Payables for purchase of property plant and equipment $ 34.7  
SNF    
Subsequent Event [Line Items]    
Initial lease term (in years) 15 years  
Number of renewal options | option 2  
Lease renewal term (in years) 5 years  
Annual cash rent $ 3.5  
SNF | Skilled Nursing Facility, California, Joint Venture    
Subsequent Event [Line Items]    
Equity ownership percentage (as percent) 50.00%  
SNF | Skilled Nursing Facility, California, Joint Venture    
Subsequent Event [Line Items]    
Number of property secured by pledge | facility 1  
Contributed to JV $ 33.8  
Ownership percentage held by noncontrolling interest (as percent) 100.00%  
SNF | Jv Partner    
Subsequent Event [Line Items]    
Contributed to JV $ 0.9  
EXCEL 91 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( J!H5I&QTU(E0 ,T 0 9&]C4')O<',O87!P+GAM M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ) M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$, M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2B4^BQ-+.9,)AP3)^0T$).,,&9B 55R(3#?.*IO04)]. M>&<7?/Q([0QS%K#%@!UE$+4 IJ>)\3BV#5P $XPPA?Q50+<0Y^J?V+D#[)0< MLU]2PS#4PVK.E1T$O#X^/,_K5K[+9#J+Y57VBHX1-^P\^65U>[>]9UIR>5WQ M621A'^_1S80RY8-[9)- MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQ MEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1 M]E6\W*.76!4!EQC?-*HU+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++ M9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D> M/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO> M1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9= M=N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8 MT='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7 M\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I M=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;R MWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z M;I,[2$R<><41 71% B.5' 86%S+D4.Z2D 83 > MLX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[ MM'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ M#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1. M"CS<_N\-L,+$CN'MB[\!4$L#!!0 ( J!H5HJ!@(#Y 4 +@? 8 M>&PO=V]R:W-H965T&ULM9EK;]LV%(;_"N$-PP;$D4CY$G>. M 4=-MF!-Z\;>AF[8!UJB;:&2J%&4G?S['4JVE 04K0G5ET2W\YH/;^[AW>O 8;'=2/;!FTX1N MV9+)WY.%@#NK5/&#B,5IP&,DV.:Z-\?O7,=1 ?D7?P3LD+ZX1@IES?E7=7/O M7_=L52(6,D\J"0K_]LQE8:B4H!S_'D5[Y6^JP)?7)_6['!Y@UC1E+@__#'RY MN^Y=]9#/-C0+Y2,__,J.0$.EY_$PS?^B0_'M8-!#7I9*'AV#H011$!?_Z=.Q M(EX&V#4!Y!A W@3@NE]PC@%YS5E%R7*L]U32V53P Q+J:U!3%WG=Y-% $\2J M&9=2P-L XN3,Y7LF4!^E.RI8.K4D:*HWEG>,ORGB24V\@QYX+'&OBN.4]>/D>HZQ?OZ> MKU,IH,O]HZNA0F&@5U#C\%V:4(]=]V"@I4SL66_VPW=X9/^LP_M&8J]@!R7L MP*0^>\^]#(:H1*OGA.E(S>'8[G_6(1FC6B(-2Z1A,Z3/&162B? 9/;*$"ZG# M,TM)D>DJQ35&M<0;E7BC9G@+)@+NJU&(8![0-IY9J1QWM0//&-^209H+X=S5H;&J;:AC2&M02\*@&OC(6ZC64@G]%=$#+T,8O63.C S!JV MC?O."%]A'9PQM"7#FWH2^?D1R,^LYD,AE,;"VO,;@M+ZEX M21/>N>^#>GIQND ?X#OT*=:WJUER8@^12T,8_O.(QLS35IIK%FG+79DA;+0? M9N[5@6NYS9+++(!QX=CZ9N["#>'*#F&SH7F+ZZH[&,(K?HBUJ&:Y)8V1&S*5 MQ[3YQQS>EK9R2MCL;][2EC/60O!]$'OZ7FW6=.=:T"XL$ZX\$S9;G;>@"YY* M&J*_@J1^4C8K3LAH[&A)NS!-N')-V&QU\@X[A^5]/9A9 .9?+5875@E77@F; MCD[V-'/.UVX)5S9)6SV.:M 0A[@&X3)C^N?T))Y MF8"6U$*><4P\BB ++R7WOEZ@A JTIV'&T/?VI8U1 DO;?.&OK8,N7!2I7!0Q M^QPP^GX0;]'R.5KS4(=^1L!=/=YJ]P^ZL$JDLDK$[&M.C8ENG[P=C;>LU@N? M$?KX9:GGZ\(:D["!Y'*!Y%&/F@9@1M'-UD*KU-]OS7KU.XSF./:\E7V MAS2R/[<1$ULU,'\!!;D#AQ E--8WK5FP'K0+]T,J]T/,YN74D#LG":[E? M9(YKBU>Y(-)HR^AUBE_F^_CH4R;!T\8J@VJ)OY&_.=9#H3;,U=2YT7Z&)WAT M=369C*?67@=962'2:.O(A2E5@.>[CWWVA'YC^G8T2]FVC8<3>XS'6H@N[(Y3 MV1WGC%LYYLN[(%7>]@L#JV;:S#TCU^]CY6ZU!PQ=^!^G\C^.V;:4.[DO2>_@ MH7:*/2-6MU5M#FO+6'D@Q^Q8WC(>-^?K*V."8MGY;'TO/\,-:J/B_.M!^H M2I@I"MD&0NW+,3%:*;4Y MFTQDLF)K*D_%AN7PS5(4:ZK@MGB8R$W!:%HM6F<3XCC!9$UY/IJ>5Y_=%--S M4:J,Y^RF0+)C"[QV8S$>D%E\3=GC_+@&NE0[H7XJ6^^IAG:G4QBD8H94M:9NI6 M/'YA=4"^]I>(3%;_H\?:UAFAI)1*K.O%@&#-\]UO^E0GXF !]@86D'H!^=T% M;KW K0+=(:O"FE-%I^>%>$2%M@9O^J+*3;4:HN&YWL:%*N!;#NO4=/;]>GYU MO;B:([A:?/_V=7YY!S>?+K]=7L^NT.++U=7= GU /Q9S].[D/3I!/$=W*U%* MFJ?R?*( @_8T2>KG?=H]CPP\[R]:G"(7CQ%QB&]8/K,OG[.D6>X=+Y] Y$WX MI F?5/[< 7^74C(ESTQQ[!9ZYH7Z=)W)#4W8Q0B.CV3%EHVF;]_@P/EHBNJ5 MG!W%Z#8QNC;OTUM&,\2DHHK!YFWA"HZADF.4,V4*?.T]@=P?4:N)X5[F>>TSSA^0-TB83Q+;W/V!A1A9:4%VA+LY*A M=SQ/LC+51C1)BI*E$)EBD#N%Q!*=Q([O. ZB4M]!R26KIN80U"TZ(1%N#:"H MV/J>%4UAO3>E98?:/P@W#@(2=9)BLG(."3^'Z7$[P4;QC'\Z^3$9.83QS4G)6B2$EB3LCNZ:,6R M% &=(4EUG0S4=-"#@(/0#3I ^U9^2 )LQADV.$,KSAF5JRK!B;Y@OTHHZ4QO MF EGV$- A\['9P&*^Q&A)B!1@W0Z(4^(57!$UU6&JH)7M1[<.! >7?Q]D+<0(OM>YTDHM0UKO,HZM.P;P[&1,;]#8]]KX/38(3#@;.*G991'2O8FX)M M*$\1>P*M)=DA:%K5[&"5UHZ/3HH;Q=WT&LQ '4@!;@<_9DA4%;/^R M:<&)D#:\N)] )_!)%Z_!#).AIHA;[L96VIS>"04=<9=3(SS2SU,4>9[7;=HF M0\\-'1P,0&RI%[M6??&-TWN><<7K,KB"XZ^>C7H#6UG\3P7':WD[CKOE<&PG M\07+.?3D$NH_*75)Y4)!"C;T>4?G0P75IT\W#K'7912C71"3<&"_6J+%=J;] MT0 NV%9DV^H,P"W7\B/1._ELQ-VG.(_X_<9HL!OHC+BE0?P"#^Y[8Y/)+]^>[ /HY_-88DH$,X7#W=L)@%KAXJ!>UI(GMK#GG6YXR&#'V81DQ]HDP M=((!C"U?8CMA[OK/2WGLDV'L!B3$79!].]\) W= )>&6.K&= M.V=BO>:U1*QDB,@5E#6#!@]U\>X:#B;"KE'?V3V;FP@R=J/_[^AXO&O)F-C) M^):EC*UU 4$+RG7LA<@R?:SWVM@X^_49%H?083I[9C*+B#>P9:0E8H*MK&%A M"6*E\#\>2U_)VW&SJXS(%PN8BA^ZLE?@'GL-$L^'0K8U0#6+" M\WWB]XZ[R="-8688 -S*#F*7';-R7<) #]E$*==3V'VI\4O]LHT])4Q6.\-H MD<,^&6F&])7%!Y_$$>GRC-'0)?Y@UELA0NQ"9$>'5=6N1):R0KY] \\//U9# MKUDXD;Y\("#C7-R=(8R&3N0-YKY5&L2N-*[-M&#."9@,,<9#;^Y(JS6(76OT%%'5/BR0X]X[1/.$9C(T M3FB3@U?A^N\0T,T>.!RDC"UAI7,:0M3%[M7^[D:)3?5V_%XH)=;5Y8I1J%YM M -\O!0BD^D:_<&_^P#+]#U!+ P04 " *@:%:D>8LTFH# "I"P & M 'AL+W=OS")VU@D=F8[+=NGWW$20M*FMVE]:&SGG']^QSZV3W_%Q8L, M"%'H-0J9'!B!4O&E:4HO(!&6%SPF#-[,N8BP@JY8F#(6!/NI4Q2:CF6US0A3 M9KC]=&PJW#Y/5$@9F0HDDRC"XO<5"?EJ8-C&V\ C701*#YAN/\8+,B/J:SP5 MT#,+%9]&A$G*&1)D/C"&]N7(=K1#:O&-DI4LM9$.Y9GS%]VY]0>&I8E(2#RE M)3 \EF1$PE K <>O7-0HOJD=R^TW]>LT> CF&4LRXN%WZJM@8'0-Y),Y3D+U MR%^#6?B)*#W=SBX.0.SJ$. MC=RAD0::D:5AC;'";E_P%1+:&M1T(YV;U!NBH4POXTP)>$O!3[FCA_OQY'XV M&2-HS1[N;L?#)^A<#>^&]Z,)FMU,)D\S=#K%@C 5$$4]')ZA3^CK;(Q.3\[0 M":(,/04\D9CYLF\J8-+*II=__RK[OK/E^U^PN$ -^QPYEM.J<1_M=A\3KW!O M5MU-F(EB.IQB.IQ4K[%%;Z:P(I"E"O$YNJ8,,X_B$$VYI&G6_1@^2R4@]W[6 MA9II-^NU]8:\E#'VR," '2>)6!+#_?C!;EN?ZP+_3V*5:6@4T]#8I>X./4\D MQ(>U5034U3EB1-5%G,FT4QE]8BS=G@7+N"P'LFGC=.W"IL+7+/B:._D>(!4% MG"*P-$ '2P;M$!Z:> DC>@7E.9P1U3#J(FANT+6MC1 VC9H=IU4?0ZN(H;4S MABF<5T0(P(--[KV/(<:("+N@?&-'H*;*L9W%W651P>P5N;R?NB$<1')'_ MF,V]0[)YCU$%V[;>KT#K"/##DSF7+4]A:TLV'V1:Q2_=X/81^(=E >8!+EZ%_*[6C>EF=<7?;66F_.^WTU M7[.JKC61T43CE69\$0=S/:.:9>+ULH=[[QU/Z6JM34=_?+&A*S9C^NOF44*KOX^R2'/&52HX MDFQYV;O"YQ.2&(?"XM^4O:K&.S)47H3X;AJWB\M>8!"QC,VU"4'AL6,3EF4F M$N#XKPK:VW_3.#;?WZ/_59 ',B]4L8G(OJ4+O;[L)3VT8$NZS?23>/V;580B M$V\N,E7\HM?*-NBA^59ID5?.@"!/>?FD;U4B&@X0Q^U *@?2=AAT.(250U@0 M+9$5M&ZHIN,+*5Z1--80S;P4N2F\@4W*S3#.M(1_4_#3X\G#__CG]N;J&1JW]Y.'NRF:/4/K;GK_/$.GZ.OL!GW^] =2:RJ90BE'SVNQ590O MU GZ=-"^Z&O 9K[0GU"T)T;>B5T3;\ [ M*L]0B$\0"4CDP#/YN/O R?NU)2N [>K6^_X3CXT\7K2,$.6 [V+ >^Z,"2:YK!5)B+G+F8ENYQX6XJ MS&X\Q/$@ONCOFA1LJRB, K*W.L 6[;%%7FRW7#-@K"MT:"E%CI8IIWR>\A64 MI#E+=_0E<^(N0T<-1"0)ABW8ME'@AASO(<>_#EGH-9, %_(,?U'-X#V#QP*L M=M #-58K!*NPLNP>C-@F17"Q9FFLAJ3;BP#>VO MQC'!+6RV51P&PXZL)WMPB7>I3M] (U7'4DV.N52/%.R Y6C/;863 '? (S4\ MXL]?OJ&I-*4!B>5!\6@4#2=JXBEJ%63;A P'@P[(M6!BKU+5&34/F)50HZO! M=P,-[<0%5G9MHSCN*!>X%CWL5[TOC /"K%Q%"]BDI4H;Q#OW-!W8I2T@81NI M;14G8=/-HJ%L;1J+W.76;A$(\Z -:*AV-O\7UH:!;ZG FE M_G#68>Q5SE\MQ,>*=DBZ5D/LE\,O<-Q"4(85S5AK?9X@SK0S ;;VA=$:LMU%A*_%MXS[=G4$8<*1GC4QN8P M@U1'';60U#I(_#IHP%7SH)-M6[*)DW1T<5:_]S&_.,MVY3I)V<<<%;O-)LZ_O6/K[/%\ MA$??W[A)[E=E]<;DXFP;W[-;5G[:?LSYJ\F!LDPV+"V2+$4YNSL?7>*W$76K M G7$GPE[+(Z.474JG[/L2_7B:GD^,JH6L35;E!4BYG\>V)2MUQ6)M^/O!CHZ MU%D5/#[^3@_KD^_=6AH_+N.+LSQ[1'D5S6G5 M0:UO79HKDJ15*MZ6.?\TX>7*B^GUS ]FMX&/^-'M]?LK_W+.7]S.^9\/P6Q^ MBZY#%/SQZ6K^3W0Y\]%-X ?!A\MW[P,TNY[Q,O.;Z_?OKV81NIK-@YO@=H[& MZ-.MCU[]_!K]C)(4S5?9KHC397$V*7F#JVHGBZ9Q[_:-(R<:-\_*>*TH-NU1 M#-V6V>++*ELO65[\\I-+L/,;"O[>)>4W!='7$Z?99L/'38U4E [TI2^7RZ0: M=[Q1'^-D.>:=,HVWB?K?-Y5Z*+JZ>#K@A4%RNY0 M$.=IDMZKNCS2\V=9NLC2,L_6_)-[=)66+&=%*9 F/,L.J48.J49JM'D"_8[= M)VG5+#YWK.-TP= KWNAB%?,*7J.X1#Y;O$$4_XJ(0:@J6[3\:M)^6VSC!3L? M\5FY8/D#&UW\\A.VC=]4.00)\_YQ''L\\F#\>I EEM" F+ M@&"=W*"'W* #94N^'5)P4<8[\/ZZ'4U01Q/ MB?]H)D/TKQL^UA%?UQ_C?/EO53>;D,,.$N9#P@)(6 @)BX!@G52R#JED:4?F M55'LZ@')EY7%?ADLJC3Z%:7\0OEH!E=ECA8]-',@8;XE3]@\M/HG#'?(6D-( M6 0$ZV2%?<@*^_E9H0R4! M@G4D<0Z2.%I)_N27:=4"RA6II1A7=VC+2AU^VUK$^QN_:HXO]D.WBJM'+K_C M*%+V&:[SKXQALKX*__LB0&N;=+0 0X)\QW% />H+2SY 62=(20L M H)U4;XK3PJ"V&J.*H_6I,82L,0*"=03$ M1NO.&%H)&^-AF3PD2W;*0S'DM#;Y9$<$M7K&^?HF#54,E!;V/(<(JM:N;$>F M&M;*UK5FR@RE75LE4=LJC9Y8<8[BA9*^ 4,72U!: $H+06G1$YW;U;MUMK#> MVII6VA[TOLNSS3#%9?O(-$U1<5##"I06@-)"4%KT1.=V%6_]*JPWK&;\JB?A M"F\8>K7."O75<N8XG+J#K,M,5Y6=NBP9)!TL)^IQ IPDXIT5I=6&M_ M7 3I4N,I?XCS@X=H*C4"=;= :7Y#Z]S$F-C!!-N6<&D+6G$(2HN@:-T$:0TL MK'>PA 3IE10*>\AV;$-T\Z?J0.IXHF/1! H>M".J*.,(MHAIB?/!FWTJG-#=FJP:WL>-;"4 M(Y!VC=^_X@"TXA"4%D'1N@G0^DY8;SP]N3JH1?>D"8%X&&-3DESA GF&*RVG MOH*(74<24L91D_*:Q1U=1>#8HL02B9&J@0ZAZD67M&80,7[@KBZ!-&:FH#0? ME!: TD)06@1%ZZ94:U01O5'UHMU=/7MP!H$Z6D3V>2R+&D38- A :PU!:1$4 MK9L;1X]KZ4VMP7N\1/$4E&79H@_=+\QOPHXG;^E9*B7)$L)"_7D.5N5_\9P4 M:8TGHC>>_B_;O/HV#1[ID#2?R)X2)GSY%AT2T%I#4%H$1>OF5&NA$;V%]L.V M>XEL:(TIOX(29XA>87X3IMOQ/4&29@A0OPN*UE6S];N(WN]ZR;8OD>TBZAF> MJ$^?*%_?S,$7<7WJ#$'KC*!H72%;DXWH3;8^F[]$MM3&-C4L\1&*GG&^ODF# M10-US'J>0P15:U>VU@LC>B_L19N_1'YN:2Q=0(':8J"T )06@M(B?=]VU6[- M+J(WNUZX]4MDP\DV)<%!/2Y06@!*"T%IT1.=VU6\=;>(WMWJM?5+9 O(MCS# M%955A;F&="\$^A 5*"WL=PJ1(@P;MEH+VEIB5/]\5"\M&D;G3M+"GKA$ZJL: M.LI :0$H+02E15"T;@JT%A;56UC]]_\M97+(1A%V'=OV/%,O1=O!=^&4^Y?4,5/HQ+3&F6!35_0&D! M*"T$I450M&Y.M!81-9^S]S1GFVV6Q_FW_OM.%/2!*U":#TH+0&DA*"V"HG73 MJ?6HJ-ZC>M$],E4\_.2)7]R;ZELP.#- S2Q06@A*BZ!HW6.MWLZ

1QQ,VBJKVEP!H!: M:*"T$)060=&Z&=":;51OMCWG:E_QM4"'2@_RZBL>G!"@%ALH+02E15"T?4), MCG[(J/HE+*XNOQ4IT)K=<;SQQN'#.M__N-3^19EMZ]\V^IR59;:I#U&PO=V]R:W-H965T&ULK51M;YLP$/XK)S9MK;0%"NG+ MN@0I+W2+E) LI)NF:1\<<()5P-1VDO;?[VP(2ZNTVH=]P;[S/8_O.7S7V7%Q M)U-*%3SD62&[5JI4>6W;,DYI3F2+E[3 DQ47.5%HBK4M2T%)8D!Y9KN.^S3CNZYU9NT=<[9.E7;8?J_<9H1RU+(NF 9S]8HM*N=65!0E=DDZDY MWWVEM9YSS1?S3)HO[.I8QX)X(Q7/:S!FD+.B6LE#78<# /(F-H8-*IAA?Z+D1)XRA"G_,$T' 9A% P! M=]%T/!KV%FA$"UPF0;B(8'H#P;?;T>(G],(AS(-A$$QZ_7$ X31$S&(^'8]' MX1<8A8M@'D0+.)D100N54L5BDIW"1W@+-L@4O;)C*TQ:7VW'=8+]*D'WA00] MF' DDQ 4"4V>XFT4VRAV]XK[[JN$$R):X)U] -=QSX_D,_AW>/N5=+SF!WB& MSWN!+U)$46P+!7P%D>+Q7_]]K'H5>_LXNYX! MU[(D,>U:V.22BBVU_'=OSBZD_R>R)X5H-X5HO\;N#WB>8U\G;,L26B02 M3E@!&YE 247U>DZ/Z:](KPRI'EE;WVEY'O[8[:&P*NKR293[J0FJ$K8/VBBG M8FVFBX28;PI5O:_&6PVP/@XPT^C/_#C8>J:?[;\TU53$U[-FA82,KI#2:5WB M6!#5I*D,Q4O3K$NNL/7--L7A3(4.P/,5YVIOZ N:<>__ 5!+ P04 " * M@:%:G?G)O^D( #_)@ & 'AL+W=OS8(NB.L5C+)I/]];=E M@VVL!V$K7Q)LM\3I5JO/:>&+%YG_4"O."_1SG6;J+&6^C@JXS)]':I/S**D&K=,1&8_#T3H2V6!^4=U[R.<7LBQ2D?&''*ER MO8[RUVN>RI?+ 1[L;_PNGE>%OC&:7VRB9[[@Q??-0PY7HV:61*QYIH3,4,Z7 MEX,K?'[#0CV@LOA#\!?5^8RT*T]2_M 7=\GE8*P1\93'A9XB@G];?L/35,\$ M./[:33IHOE,/['[>S_ZE8H4OY'IGR(I5I>#Z0 E?!F5:?&[?/F5[QP* M]'RQ3%7U%[WL;,<#%)>JD.O=8$"P%EG]/_JY"T1G ,QC'T!V TA_ ',,H+L! MM'*T1E:Y=1L5T?PBER\HU]8PF_Y0Q:8:#=Z(3"_CHLCAJ8!QQ?SFV_WMY_O% MYUL$GQ;??KN[O7J$B\4C_/OZ^?YQ@;Y]03=7BU_1E]^^_;E 0_1]<8L^_/(1 M_8)$AAY7LE11EJB+40%H])RC>/?-U_4W$\Q4TNMP*2%#V]OGT9 M@_=:["!:81.MT+N,MQPFC454E]TL0=%:YH7XN[[Q >*5EHD.R),FA2&P MP0\(W',N2[!-.=18]=$6H/I;@\[2XLDT#'H)8+&B+"3V!)@T+DV\+EUU/9!+ M7?=YGL,"+T4602J ,[%4A;6J30Q ,\QZH$V;L&-S 'G:0)YZ(7_/@*53\3> M_/ ,]/P1I5(II/$7*YXC_11Q540%A\\I_$L@E;=\E^=G.IMM[DP-J$,,6ZSG MD&D58L<:S!J'9B>M 5!=_&.H*3F!X*]!IZCJF0WTS(!#9^-9#[-I1#!Q5 X\ M;OER[(4-GR,M#8;Z 40Z*R#N[BJWFZV+HA];K\DAR@ZKXY."6VU##1/P@FRR MTS4V<+!^3"TVKHB2%BLY"6M51M"NC-3UPPJ7F)D[(V$?L,4JF 0.S"VW8R]Q MSN^!,#0SB*S@4'%]/+>;Z7"'S<;]DF$S8\0%M*5@[.?@_T*IT$5"14!O$-Q. MF7"6A-V4!U#H=&*$UF*&L0-P2\W8RV7SN_4F$KFN63VXW6IF11UX4G.'V#0A M$^8HS+CE1QSZE=XJRIXUOJXX4(J#NM!TF8KH2:1NH8"]]'NJ4GBOV0YCT1(K M/L*L<0R\O_-\STPQ%]OH*77L8Y,LAY/IM+]T%BOLVATMIV(_J3[D'+(M0?RG MIAO>15TOH'N/6'B3L@#W8=O,B(,Y<4N=^ AW[J.\B5YU8,] C,9YR0^2K7*F M43::J;I/K4Z9E#EDE/0UN<4,3X.9W2G2,BOQ,^O]6^6V#3JQD"BF4]*#;C%C MTZE+%9"6;PD^J=FK:]4;N@3BY?%3-_][S788A9;)R1$FC_\JA1*:R)6-;&JI MO9%@ MFYV:2BW_CO@F(A;3;&H;&:%KLP#+$K%5MZ)WYZ?RCS>*6%AT;,P:F- MIITSM"SS3!1ESJN]M10_]>=ZHXFU3EO>:2H;WZTN6NB>$(-C;69T-G7XUZH" MXE<%=PV5:M8ZTCI8X5NX/Z33OERTF04$AX["35J50/PJX2$'P24V@!LJ8!WS MFF8 NCSJ4:?,IS+*5(>BK,Z:LH$%9FGQZ8]#-UME0?RM]V<5ZS'-GEG*'&UD MH44\.!BYMYO5#;.5'M)P'!HY9[%C>.Q:LU8:$+\TT/4=]DC,>;*KDEJ4O@FY M2?Z,04'H [>8A0[4K40@?HG0L%*IJB2REG8K:!OU!S/<%Z4V.TPH80XI35J5 M0&8GD5)[N'&,E+SJXV12>J?9#D]A6UE!_;+BX2#E8-,CH50)@:CZ(>C:UKH] MTH3J:.;IZVZH/YN_EKF, 863J$R2Z!JE2!6X[*6 M=5N9;JL#*[@4!5I&L59XKU8_+!T^"<;C?DI:[!REC+;:@/JUP<.^3I]XW$8M M'(]9?^O;K(BCL:.=$_PC73XOAM %%- Z1\V1<)V6CZ;(1A16X2;AT2D'?]:&;=H1B M[")GVI(S/4[.( 3SW>EFY#!]%52'5;/;$GT66Z<6"&] M"VGMJ:CM.!P:9"/-+'8S MV"&.GH.U/,S\//R/G.-:J/O<8B;GAE!DC6UOL6,!QA-'G64M-S-_Y[\HH8^M MVCZ0L(E0<2I5U11J<;$78)";]1L74!ZLBHN]ZS' >\UV&)*6ZIF?ZN_VA^*: M>:S>FFS- F/%3",ZF3A(AK6'^V/G VU-33I"XM75(C-3$TQ#X[=2MKJ!^77#8PX] M/"C*JE+D?-CIBVM=J0FYNJDU9WVP:W7B^"\(%A-'U6>M=F!^[; P?YI!M>I, MT(LH5I"9U3&&[XAB]Q6A#[II@KO2OT8_ZKQ*M.;Y<_6&E4+5<7/]*DYSMWZ+ MZQJ?WU0O._7N7^'SJ^J=IE$[3?UJV-J+0FZJ M%Y:>9%'(=?5QQ2/H>[0!/%]*",CN0G]!\\[;_/]02P,$% @ "H&A6AJ6 M&K7J!0 40T !@ !X;"]W;W)KRB$J5'F:CT>ZPDLKTC@_CWJ4[/K1-T,K0I1.^J2KI[DY(V^51;]Q;;5RI M>1EX8WA\6,LY75/X4E\Z? T[*X6JR'AEC7 T.^I-QN].WK!\%/A#T=)OK 5' M,K7VEC_.BJ/>B &1ICRP!8E_"SHEK=D08'QK;?8ZEZRXN5Y9_Q!C1RQ3Z>G4 MZC]5$YN'YRADK4(6<2='$>6O,LCC0V>7PK$TK/$BAAJU 4X9+LIU<#A5T O'%U>_ M33Z?_36Y.;OX?#@,L,C[P[S5/DG:V2/:V^+*;>^5KF=-2K MV9=;4._XY8OQ[NC@B?#>=.&]>-A[3W+U_L9^/L M0)Q*1S<._2BNWI_=],69R0?Q;._ BU>\RD8']X7BYOA 6"="26(E8ZM:FKOV M\+6HG6(V$-/6H%E00N028UUK*%=&EZ"DC2L M@:YK3! +M$Z#BOTKE)')9U8V/ M#CTG$):T6CQB:/)I;2@"W(3UN-K9IEI;*!9%LK*]_NY>UH:$)D(QIE3X:+PQ M"NG6-I>,"FG?SH3G^?)@NU"F*H ^"9T#JSE N&XDVY(RC.D=JHQIU;"1VXHV M39Y*K7!'&27[XH:^R^3YA@PW%=%S:BJUMZ*4Z"CLNM10%'%BK5M'"^PD6K@? M/ZI/!+ T(^<@2>A<]-J&0E^,=^X91;%UBN:LS#0#=#SC+S='>RN; S$ MI99(9"$F/)!><6U6S'!AVJ2.'TZJ,;9!20OQ:H,%KAHXSP9[8M(>@ M==\C)ZY"B4 (L=O@KH*)F!!?PB-J>4_]@GJ#97W)-)?+6O$4O4J-'DIIQ#4_]TA

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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 93 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 95 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 354 349 1 false 129 0 false 19 false false R1.htm 0000001 - Document - Cover Sheet http://www.caretrustreit.com/role/Cover Cover Cover 1 false false R2.htm 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - CONDENSED CONSOLIDATED INCOME STATEMENTS Sheet http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS CONDENSED CONSOLIDATED INCOME STATEMENTS Statements 4 false false R5.htm 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTEREST Sheet http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST CONDENSED CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTEREST Statements 5 false false R6.htm 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Parenthetical) Sheet http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTERESTParenthetical CONDENSED CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Parenthetical) Statements 6 false false R7.htm 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 9952157 - Disclosure - ORGANIZATION Sheet http://www.caretrustreit.com/role/ORGANIZATION ORGANIZATION Notes 8 false false R9.htm 9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 9952159 - Disclosure - REAL ESTATE INVESTMENTS, NET Sheet http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNET REAL ESTATE INVESTMENTS, NET Notes 10 false false R11.htm 9952160 - Disclosure - IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES Sheet http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALES IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES Notes 11 false false R12.htm 9952161 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS Sheet http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTS OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS Notes 12 false false R13.htm 9952162 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 13 false false R14.htm 9952163 - Disclosure - DEBT Sheet http://www.caretrustreit.com/role/DEBT DEBT Notes 14 false false R15.htm 9952164 - Disclosure - EQUITY AND REDEEMABLE NONCONTROLLING INTEREST Sheet http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTEREST EQUITY AND REDEEMABLE NONCONTROLLING INTEREST Notes 15 false false R16.htm 9952165 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 16 false false R17.htm 9952166 - Disclosure - EARNINGS PER COMMON SHARE Sheet http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHARE EARNINGS PER COMMON SHARE Notes 17 false false R18.htm 9952167 - Disclosure - SEGMENT REPORTING Sheet http://www.caretrustreit.com/role/SEGMENTREPORTING SEGMENT REPORTING Notes 18 false false R19.htm 9952168 - Disclosure - VARIABLE INTEREST ENTITIES Sheet http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIES VARIABLE INTEREST ENTITIES Notes 19 false false R20.htm 9952169 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 20 false false R21.htm 9952170 - Disclosure - CONCENTRATION OF RISK Sheet http://www.caretrustreit.com/role/CONCENTRATIONOFRISK CONCENTRATION OF RISK Notes 21 false false R22.htm 9952171 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.caretrustreit.com/role/SUBSEQUENTEVENTS SUBSEQUENT EVENTS Notes 22 false false R23.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 23 false false R24.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 24 false false R25.htm 9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 25 false false R26.htm 9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 26 false false R27.htm 9955513 - Disclosure - REAL ESTATE INVESTMENTS, NET (Tables) Sheet http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETTables REAL ESTATE INVESTMENTS, NET (Tables) Tables http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNET 27 false false R28.htm 9955514 - Disclosure - IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - (Tables) Sheet http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESTables IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - (Tables) Tables http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALES 28 false false R29.htm 9955515 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS (Tables) Sheet http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSTables OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS (Tables) Tables http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTS 29 false false R30.htm 9955516 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTS 30 false false R31.htm 9955517 - Disclosure - DEBT (Tables) Sheet http://www.caretrustreit.com/role/DEBTTables DEBT (Tables) Tables http://www.caretrustreit.com/role/DEBT 31 false false R32.htm 9955518 - Disclosure - EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Tables) Sheet http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTTables EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Tables) Tables http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTEREST 32 false false R33.htm 9955519 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATION 33 false false R34.htm 9955520 - Disclosure - EARNINGS PER COMMON SHARE (Tables) Sheet http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHARETables EARNINGS PER COMMON SHARE (Tables) Tables http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHARE 34 false false R35.htm 9955521 - Disclosure - SEGMENT REPORTING (Tables) Sheet http://www.caretrustreit.com/role/SEGMENTREPORTINGTables SEGMENT REPORTING (Tables) Tables http://www.caretrustreit.com/role/SEGMENTREPORTING 35 false false R36.htm 9955522 - Disclosure - VARIABLE INTEREST ENTITIES (Tables) Sheet http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESTables VARIABLE INTEREST ENTITIES (Tables) Tables http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIES 36 false false R37.htm 9955523 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIES 37 false false R38.htm 9955524 - Disclosure - CONCENTRATION OF RISK (Tables) Sheet http://www.caretrustreit.com/role/CONCENTRATIONOFRISKTables CONCENTRATION OF RISK (Tables) Tables http://www.caretrustreit.com/role/CONCENTRATIONOFRISK 38 false false R39.htm 9955525 - Disclosure - ORGANIZATION (Details) Sheet http://www.caretrustreit.com/role/ORGANIZATIONDetails ORGANIZATION (Details) Details http://www.caretrustreit.com/role/ORGANIZATION 39 false false R40.htm 9955526 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Sheet http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Details 40 false false R41.htm 9955527 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashCashEquivalentsandRestrictedCashDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) Details 41 false false R42.htm 9955528 - Disclosure - REAL ESTATE INVESTMENTS, NET - Schedule of Investment in Owned Properties (Details) Sheet http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofInvestmentinOwnedPropertiesDetails REAL ESTATE INVESTMENTS, NET - Schedule of Investment in Owned Properties (Details) Details 42 false false R43.htm 9955529 - Disclosure - REAL ESTATE INVESTMENTS, NET - Narrative (Details) Sheet http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETNarrativeDetails REAL ESTATE INVESTMENTS, NET - Narrative (Details) Details 43 false false R44.htm 9955530 - Disclosure - REAL ESTATE INVESTMENTS, NET - Schedule of Total Future Contractual Minimum Rental Income (Details) Sheet http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails REAL ESTATE INVESTMENTS, NET - Schedule of Total Future Contractual Minimum Rental Income (Details) Details 44 false false R45.htm 9955531 - Disclosure - REAL ESTATE INVESTMENTS, NET - Schedule of Tenant Purchase Options (Details) Sheet http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails REAL ESTATE INVESTMENTS, NET - Schedule of Tenant Purchase Options (Details) Details 45 false false R46.htm 9955532 - Disclosure - REAL ESTATE INVESTMENTS, NET - Schedule of Rental Income (Details) Sheet http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRentalIncomeDetails REAL ESTATE INVESTMENTS, NET - Schedule of Rental Income (Details) Details 46 false false R47.htm 9955533 - Disclosure - REAL ESTATE INVESTMENTS, NET - Schedule of Real Estate Acquisitions (Details) Sheet http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRealEstateAcquisitionsDetails REAL ESTATE INVESTMENTS, NET - Schedule of Real Estate Acquisitions (Details) Details 47 false false R48.htm 9955534 - Disclosure - REAL ESTATE INVESTMENTS, NET - Lease Amendments and Terminations Narrative (Details) Sheet http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails REAL ESTATE INVESTMENTS, NET - Lease Amendments and Terminations Narrative (Details) Details 48 false false R49.htm 9955535 - Disclosure - IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - Narrative (Details) Sheet http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - Narrative (Details) Details http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESTables 49 false false R50.htm 9955536 - Disclosure - IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - Schedule of Company's Dispositions (Details) Sheet http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysDispositionsDetails IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - Schedule of Company's Dispositions (Details) Details 50 false false R51.htm 9955537 - Disclosure - IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - Schedule of Company's Assets Held for Sale Activity (Details) Sheet http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysAssetsHeldforSaleActivityDetails IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - Schedule of Company's Assets Held for Sale Activity (Details) Details 51 false false R52.htm 9955538 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Other Real Estate Related Investments, At Fair Value (Details) Sheet http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Other Real Estate Related Investments, At Fair Value (Details) Details 52 false false R53.htm 9955539 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Real Estate Related Investment Activity (Details) Sheet http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofRealEstateRelatedInvestmentActivityDetails OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Real Estate Related Investment Activity (Details) Details 53 false false R54.htm 9955540 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Narrative (Details) Sheet http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Narrative (Details) Details 54 false false R55.htm 9955541 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Other Real Estate Related Investment Activity (Details) Sheet http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentActivityDetails OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Other Real Estate Related Investment Activity (Details) Details 55 false false R56.htm 9955542 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Loan Receivable Activity (Details) Sheet http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofLoanReceivableActivityDetails OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Loan Receivable Activity (Details) Details 56 false false R57.htm 9955543 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Interest and Other Income (Details) Sheet http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofInterestandOtherIncomeDetails OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Interest and Other Income (Details) Details 57 false false R58.htm 9955544 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Items Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails FAIR VALUE MEASUREMENTS - Schedule of Items Measured at Fair Value on a Recurring Basis (Details) Details 58 false false R59.htm 9955545 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Assets Measured at Fair Value on a Recurring Basis Using Level 3 Inputs (Details) Sheet http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails FAIR VALUE MEASUREMENTS - Schedule of Assets Measured at Fair Value on a Recurring Basis Using Level 3 Inputs (Details) Details 59 false false R60.htm 9955546 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details) Sheet http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails FAIR VALUE MEASUREMENTS - Narrative (Details) Details 60 false false R61.htm 9955547 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Quantitative Information About Unobservable Inputs Related to Level 3 Fair Value Measurements (Details) Sheet http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails FAIR VALUE MEASUREMENTS - Schedule of Quantitative Information About Unobservable Inputs Related to Level 3 Fair Value Measurements (Details) Details 61 false false R62.htm 9955548 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Face Value, Carrying Amount and Fair Value of Financial Instruments (Details) Sheet http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails FAIR VALUE MEASUREMENTS - Schedule of Face Value, Carrying Amount and Fair Value of Financial Instruments (Details) Details 62 false false R63.htm 9955549 - Disclosure - DEBT - Schedule of Debt Instruments (Details) Sheet http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails DEBT - Schedule of Debt Instruments (Details) Details 63 false false R64.htm 9955550 - Disclosure - DEBT - Senior Unsecured Notes Payable Narrative (Details) Notes http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails DEBT - Senior Unsecured Notes Payable Narrative (Details) Details 64 false false R65.htm 9955551 - Disclosure - DEBT - Unsecured Revolving Credit Facility Narrative (Details) Sheet http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails DEBT - Unsecured Revolving Credit Facility Narrative (Details) Details 65 false false R66.htm 9955552 - Disclosure - EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - Narrative (Details) Sheet http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - Narrative (Details) Details 66 false false R67.htm 9955553 - Disclosure - EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - Schedule of At-The-Market Offering Program (Details) Sheet http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTScheduleofAtTheMarketOfferingProgramDetails EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - Schedule of At-The-Market Offering Program (Details) Details 67 false false R68.htm 9955554 - Disclosure - EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - Schedule of Dividends on Common Stock (Details) Sheet http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTScheduleofDividendsonCommonStockDetails EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - Schedule of Dividends on Common Stock (Details) Details 68 false false R69.htm 9955555 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 69 false false R70.htm 9955556 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Award and Performance Award Activity (Details) Sheet http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockAwardandPerformanceAwardActivityDetails STOCK-BASED COMPENSATION - Schedule of Restricted Stock Award and Performance Award Activity (Details) Details 70 false false R71.htm 9955557 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details) Sheet http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details) Details 71 false false R72.htm 9955558 - Disclosure - EARNINGS PER COMMON SHARE (Details) Sheet http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails EARNINGS PER COMMON SHARE (Details) Details http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHARETables 72 false false R73.htm 9955559 - Disclosure - SEGMENT REPORTING (Details) Sheet http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails SEGMENT REPORTING (Details) Details http://www.caretrustreit.com/role/SEGMENTREPORTINGTables 73 false false R74.htm 9955560 - Disclosure - VARIABLE INTEREST ENTITIES - Schedule of Variable Interest Entities Investments (Details) Sheet http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails VARIABLE INTEREST ENTITIES - Schedule of Variable Interest Entities Investments (Details) Details 74 false false R75.htm 9955561 - Disclosure - VARIABLE INTEREST ENTITIES - Narrative (Details) Sheet http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESNarrativeDetails VARIABLE INTEREST ENTITIES - Narrative (Details) Details 75 false false R76.htm 9955562 - Disclosure - VARIABLE INTEREST ENTITIES - Schedule of Variable Interest Entities (Details) Sheet http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesDetails VARIABLE INTEREST ENTITIES - Schedule of Variable Interest Entities (Details) Details 76 false false R77.htm 9955563 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) Sheet http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails COMMITMENTS AND CONTINGENCIES - Narrative (Details) Details 77 false false R78.htm 9955564 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Commitments and Contingencies (Details) Sheet http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails COMMITMENTS AND CONTINGENCIES - Schedule of Commitments and Contingencies (Details) Details 78 false false R79.htm 9955565 - Disclosure - CONCENTRATION OF RISK (Details) Sheet http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails CONCENTRATION OF RISK (Details) Details http://www.caretrustreit.com/role/CONCENTRATIONOFRISKTables 79 false false R80.htm 9955566 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails SUBSEQUENT EVENTS (Details) Details http://www.caretrustreit.com/role/SUBSEQUENTEVENTS 80 false false All Reports Book All Reports ctre-20250331.htm ctre-20250331.xsd ctre-20250331_cal.xml ctre-20250331_def.xml ctre-20250331_lab.xml ctre-20250331_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 97 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ctre-20250331.htm": { "nsprefix": "ctre", "nsuri": "http://www.caretrustreit.com/20250331", "dts": { "inline": { "local": [ "ctre-20250331.htm" ] }, "schema": { "local": [ "ctre-20250331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "ctre-20250331_cal.xml" ] }, "definitionLink": { "local": [ "ctre-20250331_def.xml" ] }, "labelLink": { "local": [ "ctre-20250331_lab.xml" ] }, "presentationLink": { "local": [ "ctre-20250331_pre.xml" ] } }, "keyStandard": 236, "keyCustom": 113, "axisStandard": 38, "axisCustom": 2, "memberStandard": 46, "memberCustom": 75, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 354, "entityCount": 1, "segmentCount": 129, "elementCount": 746, "unitCount": 19, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 633, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.caretrustreit.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RealEstateInvestmentPropertyNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R3": { "role": "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FinancingReceivableAccruedInterestBeforeAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ctre:RealEstateInvestmentsAccruedInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R4": { "role": "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "longName": "9952153 - Statement - CONDENSED CONSOLIDATED INCOME STATEMENTS", "shortName": "CONDENSED CONSOLIDATED INCOME STATEMENTS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": null }, "R5": { "role": "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST", "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTEREST", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTEREST", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTERESTParenthetical", "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": null }, "R7": { "role": "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ctre:DepreciationAndAmortizationIncludingBelowMarketGroundLeasesExcludingAmortizationOfDeferredFinancingCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R8": { "role": "http://www.caretrustreit.com/role/ORGANIZATION", "longName": "9952157 - Disclosure - ORGANIZATION", "shortName": "ORGANIZATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNET", "longName": "9952159 - Disclosure - REAL ESTATE INVESTMENTS, NET", "shortName": "REAL ESTATE INVESTMENTS, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RealEstateDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RealEstateDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALES", "longName": "9952160 - Disclosure - IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES", "shortName": "IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "ctre:ImpairmentOfRealEstateInvestmentsAssetsHeldForSaleAndAssetSalesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ctre:ImpairmentOfRealEstateInvestmentsAssetsHeldForSaleAndAssetSalesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTS", "longName": "9952161 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS", "shortName": "OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "ctre:OtherRealEstateRelatedAndOtherInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ctre:OtherRealEstateRelatedAndOtherInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTS", "longName": "9952162 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.caretrustreit.com/role/DEBT", "longName": "9952163 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTEREST", "longName": "9952164 - Disclosure - EQUITY AND REDEEMABLE NONCONTROLLING INTEREST", "shortName": "EQUITY AND REDEEMABLE NONCONTROLLING INTEREST", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATION", "longName": "9952165 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHARE", "longName": "9952166 - Disclosure - EARNINGS PER COMMON SHARE", "shortName": "EARNINGS PER COMMON SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.caretrustreit.com/role/SEGMENTREPORTING", "longName": "9952167 - Disclosure - SEGMENT REPORTING", "shortName": "SEGMENT REPORTING", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIES", "longName": "9952168 - Disclosure - VARIABLE INTEREST ENTITIES", "shortName": "VARIABLE INTEREST ENTITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "9952169 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.caretrustreit.com/role/CONCENTRATIONOFRISK", "longName": "9952170 - Disclosure - CONCENTRATION OF RISK", "shortName": "CONCENTRATION OF RISK", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.caretrustreit.com/role/SUBSEQUENTEVENTS", "longName": "9952171 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "longName": "9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETTables", "longName": "9955513 - Disclosure - REAL ESTATE INVESTMENTS, NET (Tables)", "shortName": "REAL ESTATE INVESTMENTS, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESTables", "longName": "9955514 - Disclosure - IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - (Tables)", "shortName": "IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "ctre:ScheduleOfAssetSalesAndHeldForSaleReclassificationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ctre:ScheduleOfAssetSalesAndHeldForSaleReclassificationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSTables", "longName": "9955515 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS (Tables)", "shortName": "OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSTables", "longName": "9955516 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.caretrustreit.com/role/DEBTTables", "longName": "9955517 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTTables", "longName": "9955518 - Disclosure - EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Tables)", "shortName": "EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONTables", "longName": "9955519 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "shortName": "STOCK-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHARETables", "longName": "9955520 - Disclosure - EARNINGS PER COMMON SHARE (Tables)", "shortName": "EARNINGS PER COMMON SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.caretrustreit.com/role/SEGMENTREPORTINGTables", "longName": "9955521 - Disclosure - SEGMENT REPORTING (Tables)", "shortName": "SEGMENT REPORTING (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESTables", "longName": "9955522 - Disclosure - VARIABLE INTEREST ENTITIES (Tables)", "shortName": "VARIABLE INTEREST ENTITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESTables", "longName": "9955523 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "ctre:CommitmentsAndContingenciesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ctre:CommitmentsAndContingenciesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKTables", "longName": "9955524 - Disclosure - CONCENTRATION OF RISK (Tables)", "shortName": "CONCENTRATION OF RISK (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.caretrustreit.com/role/ORGANIZATIONDetails", "longName": "9955525 - Disclosure - ORGANIZATION (Details)", "shortName": "ORGANIZATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NumberOfStatesInWhichEntityOperates", "unitRef": "state", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:NumberOfStatesInWhichEntityOperates", "unitRef": "state", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "longName": "9955526 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RestrictedCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": null }, "R41": { "role": "http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashCashEquivalentsandRestrictedCashDetails", "longName": "9955527 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofInvestmentinOwnedPropertiesDetails", "longName": "9955528 - Disclosure - REAL ESTATE INVESTMENTS, NET - Schedule of Investment in Owned Properties (Details)", "shortName": "REAL ESTATE INVESTMENTS, NET - Schedule of Investment in Owned Properties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Land", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:Land", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETNarrativeDetails", "longName": "9955529 - Disclosure - REAL ESTATE INVESTMENTS, NET - Narrative (Details)", "shortName": "REAL ESTATE INVESTMENTS, NET - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "ctre:NumberOfFacilitiesCurrentlyHeldForSale", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-45", "name": "us-gaap:NumberOfRealEstateProperties", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R44": { "role": "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails", "longName": "9955530 - Disclosure - REAL ESTATE INVESTMENTS, NET - Schedule of Total Future Contractual Minimum Rental Income (Details)", "shortName": "REAL ESTATE INVESTMENTS, NET - Schedule of Total Future Contractual Minimum Rental Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails", "longName": "9955531 - Disclosure - REAL ESTATE INVESTMENTS, NET - Schedule of Tenant Purchase Options (Details)", "shortName": "REAL ESTATE INVESTMENTS, NET - Schedule of Tenant Purchase Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "ctre:PeriodOfOptionWindow", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ctre:ScheduleOfTenantPurchaseOptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ctre:PeriodOfOptionWindow", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ctre:ScheduleOfTenantPurchaseOptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRentalIncomeDetails", "longName": "9955532 - Disclosure - REAL ESTATE INVESTMENTS, NET - Schedule of Rental Income (Details)", "shortName": "REAL ESTATE INVESTMENTS, NET - Schedule of Rental Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRealEstateAcquisitionsDetails", "longName": "9955533 - Disclosure - REAL ESTATE INVESTMENTS, NET - Schedule of Real Estate Acquisitions (Details)", "shortName": "REAL ESTATE INVESTMENTS, NET - Schedule of Real Estate Acquisitions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfAssetsAcquisitionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfAssetsAcquisitionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "longName": "9955534 - Disclosure - REAL ESTATE INVESTMENTS, NET - Lease Amendments and Terminations Narrative (Details)", "shortName": "REAL ESTATE INVESTMENTS, NET - Lease Amendments and Terminations Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "ctre:NumberOfFacilitiesCurrentlyHeldForSale", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-69", "name": "us-gaap:LessorOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R49": { "role": "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails", "longName": "9955535 - Disclosure - IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - Narrative (Details)", "shortName": "IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ImpairmentOfRealEstate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-85", "name": "ctre:PricePerUnitValueMeasurementInput", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R50": { "role": "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysDispositionsDetails", "longName": "9955536 - Disclosure - IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - Schedule of Company's Dispositions (Details)", "shortName": "IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - Schedule of Company's Dispositions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromSaleOfRealEstateHeldforinvestment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-88", "name": "ctre:NumberOfFacilitiesDisposed", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfAssetSalesAndHeldForSaleReclassificationsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R51": { "role": "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysAssetsHeldforSaleActivityDetails", "longName": "9955537 - Disclosure - IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - Schedule of Company's Assets Held for Sale Activity (Details)", "shortName": "IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES - Schedule of Company's Assets Held for Sale Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:RealEstateInvestmentPropertyAtCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-92", "name": "us-gaap:RealEstateInvestmentPropertyAtCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfAssetSalesAndHeldForSaleReclassificationsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R52": { "role": "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails", "longName": "9955538 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Other Real Estate Related Investments, At Fair Value (Details)", "shortName": "OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Other Real Estate Related Investments, At Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FinancingReceivableAccruedInterestBeforeAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ctre:NumberOfMonthlyInstallmentPayments", "unitRef": "paymentinstallment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R53": { "role": "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofRealEstateRelatedInvestmentActivityDetails", "longName": "9955539 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Real Estate Related Investment Activity (Details)", "shortName": "OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Real Estate Related Investment Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-128", "name": "ctre:FinancingReceivablePrincipalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfOtherRealEstateInvestmentActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-128", "name": "ctre:FinancingReceivablePrincipalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfOtherRealEstateInvestmentActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "longName": "9955540 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Narrative (Details)", "shortName": "OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-134", "name": "ctre:FinancingReceivableMortgagePrepaidLoanOutstanding", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-134", "name": "ctre:FinancingReceivableMortgagePrepaidLoanOutstanding", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentActivityDetails", "longName": "9955541 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Other Real Estate Related Investment Activity (Details)", "shortName": "OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Other Real Estate Related Investment Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NotesReceivableNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-154", "name": "us-gaap:NotesReceivableGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R56": { "role": "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofLoanReceivableActivityDetails", "longName": "9955542 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Loan Receivable Activity (Details)", "shortName": "OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Loan Receivable Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "ctre:FinancingReceivablePrincipalPaymentsReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfLoanReceivableActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ctre:FinancingReceivablePrincipalPaymentsReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfLoanReceivableActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofInterestandOtherIncomeDetails", "longName": "9955543 - Disclosure - OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Interest and Other Income (Details)", "shortName": "OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS - Schedule of Interest and Other Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestAndOtherIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ctre:OtherIncomeExcludingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:InterestAndOtherIncomeTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R58": { "role": "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails", "longName": "9955544 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Items Measured at Fair Value on a Recurring Basis (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Items Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-183", "name": "us-gaap:LoansReceivableFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-183", "name": "us-gaap:LoansReceivableFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails", "longName": "9955545 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Assets Measured at Fair Value on a Recurring Basis Using Level 3 Inputs (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Assets Measured at Fair Value on a Recurring Basis Using Level 3 Inputs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "ctre:UnrealizedGainLossOnOtherRealEstateRelatedInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-200", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R60": { "role": "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "longName": "9955546 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "ctre:UnrealizedGainLossOnOtherRealEstateRelatedInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-232", "name": "ctre:PreferredEquityInvestmentsMeasurementInput", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R61": { "role": "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails", "longName": "9955547 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Quantitative Information About Unobservable Inputs Related to Level 3 Fair Value Measurements (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Quantitative Information About Unobservable Inputs Related to Level 3 Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-213", "name": "ctre:LoansReceivableFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-213", "name": "ctre:LoansReceivableFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "longName": "9955548 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Face Value, Carrying Amount and Fair Value of Financial Instruments (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Face Value, Carrying Amount and Fair Value of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-220", "name": "us-gaap:EquityMethodInvestmentAggregateCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-220", "name": "us-gaap:EquityMethodInvestmentAggregateCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails", "longName": "9955549 - Disclosure - DEBT - Schedule of Debt Instruments (Details)", "shortName": "DEBT - Schedule of Debt Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails", "longName": "9955550 - Disclosure - DEBT - Senior Unsecured Notes Payable Narrative (Details)", "shortName": "DEBT - Senior Unsecured Notes Payable Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-238", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-238", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails", "longName": "9955551 - Disclosure - DEBT - Unsecured Revolving Credit Facility Narrative (Details)", "shortName": "DEBT - Unsecured Revolving Credit Facility Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LineOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-248", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R66": { "role": "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails", "longName": "9955552 - Disclosure - EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - Narrative (Details)", "shortName": "EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-256", "name": "ctre:SecuritiesOfferingAuthorizedAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-256", "name": "ctre:SecuritiesOfferingAuthorizedAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTScheduleofAtTheMarketOfferingProgramDetails", "longName": "9955553 - Disclosure - EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - Schedule of At-The-Market Offering Program (Details)", "shortName": "EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - Schedule of At-The-Market Offering Program (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-258", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R68": { "role": "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTScheduleofDividendsonCommonStockDetails", "longName": "9955554 - Disclosure - EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - Schedule of Dividends on Common Stock (Details)", "shortName": "EQUITY AND REDEEMABLE NONCONTROLLING INTEREST - Schedule of Dividends on Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DividendsPayableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R69": { "role": "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "longName": "9955555 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockAwardandPerformanceAwardActivityDetails", "longName": "9955556 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Award and Performance Award Activity (Details)", "shortName": "STOCK-BASED COMPENSATION - Schedule of Restricted Stock Award and Performance Award Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails", "longName": "9955557 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)", "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": null }, "R72": { "role": "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails", "longName": "9955558 - Disclosure - EARNINGS PER COMMON SHARE (Details)", "shortName": "EARNINGS PER COMMON SHARE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R73": { "role": "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails", "longName": "9955559 - Disclosure - SEGMENT REPORTING (Details)", "shortName": "SEGMENT REPORTING (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ctre:TransactionCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R74": { "role": "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails", "longName": "9955560 - Disclosure - VARIABLE INTEREST ENTITIES - Schedule of Variable Interest Entities Investments (Details)", "shortName": "VARIABLE INTEREST ENTITIES - Schedule of Variable Interest Entities Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-293", "name": "ctre:NumberOfFacilities", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-293", "name": "ctre:NumberOfFacilities", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "longName": "9955561 - Disclosure - VARIABLE INTEREST ENTITIES - Narrative (Details)", "shortName": "VARIABLE INTEREST ENTITIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-297", "name": "ctre:PreferredOwnershipPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-297", "name": "ctre:PreferredOwnershipPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesDetails", "longName": "9955562 - Disclosure - VARIABLE INTEREST ENTITIES - Schedule of Variable Interest Entities (Details)", "shortName": "VARIABLE INTEREST ENTITIES - Schedule of Variable Interest Entities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RealEstateInvestmentPropertyNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-293", "name": "us-gaap:RealEstateInvestmentPropertyNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R77": { "role": "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "longName": "9955563 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-299", "name": "ctre:AggregateRequiredFinancingOfCapitalExpendituresAsPercentageOfInitialInvestmentInProperty", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-299", "name": "ctre:AggregateRequiredFinancingOfCapitalExpendituresAsPercentageOfInitialInvestmentInProperty", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails", "longName": "9955564 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Commitments and Contingencies (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Schedule of Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommitmentsAndContingencies", "unitRef": "usd", "xsiNil": "true", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-308", "name": "ctre:ContingentEarnoutLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ctre:CommitmentsAndContingenciesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "unique": true } }, "R79": { "role": "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails", "longName": "9955565 - Disclosure - CONCENTRATION OF RISK (Details)", "shortName": "CONCENTRATION OF RISK (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-329", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-329", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails", "longName": "9955566 - Disclosure - SUBSEQUENT EVENTS (Details)", "shortName": "SUBSEQUENT EVENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-353", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-353", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ctre-20250331.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails", "http://www.caretrustreit.com/role/ORGANIZATIONDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable Type [Axis]", "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": [ "r94", "r99" ] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndOtherAccruedLiabilities", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, accrued liabilities and deferred rent liabilities", "label": "Accounts Payable and Other Accrued Liabilities", "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other." } } }, "auth_ref": [ "r686" ] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNet", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts and other receivables", "label": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r701", "r758", "r849", "r1060", "r1061" ] }, "us-gaap_AccumulatedDistributionsInExcessOfNetIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDistributionsInExcessOfNetIncome", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedLabel": "Cumulative distributions in excess of earnings", "label": "Accumulated Distributions in Excess of Net Income", "documentation": "The amount as of the balance sheet date by which cumulative distributions to shareholders (or partners) exceed retained earnings (or accumulated earnings)." } } }, "auth_ref": [ "r1091" ] }, "us-gaap_AccumulatedDistributionsInExcessOfNetIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDistributionsInExcessOfNetIncomeMember", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Distributions in Excess of Earnings", "label": "Accumulated Distributions in Excess of Net Income [Member]", "documentation": "Cumulative distributions to shareholders (or partners) in excess of retained earnings (or accumulated earnings)." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r894" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r95" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r668", "r979", "r980", "r981", "r982", "r1024", "r1097" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r907" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r907" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r907" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r907" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r52", "r53", "r439" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ctre_AggregateRequiredFinancingOfCapitalExpendituresAsPercentageOfInitialInvestmentInProperty": { "xbrltype": "percentItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "AggregateRequiredFinancingOfCapitalExpendituresAsPercentageOfInitialInvestmentInProperty", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate required financing of capital expenditures as percentage of initial investment in property (as percent)", "label": "Aggregate Required Financing Of Capital Expenditures As Percentage Of Initial Investment In Property", "documentation": "Aggregate Required Financing Of Capital Expenditures As Percentage Of Initial Investment In Property" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r940" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r866", "r876", "r886", "r918" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r869", "r879", "r889", "r921" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r941" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r907" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r914" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r870", "r880", "r890", "r914", "r922", "r926", "r934" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r932" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of stock-based compensation", "verboseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r469", "r474" ] }, "ctre_AmendedKalestaLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "AmendedKalestaLeaseMember", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended Kalesta Lease", "label": "Amended Kalesta Lease [Member]", "documentation": "Amended Kalesta Lease" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfBelowMarketLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfBelowMarketLease", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization of below market leases", "label": "Amortization of Below Market Lease", "documentation": "Amount of amortization of acquired leases acquired as part of a real property acquisition at below market lease rate with a finite life." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred financing costs", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r405", "r802", "r803", "r973", "r1037" ] }, "ctre_AnnualCashRent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "AnnualCashRent", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual cash rent", "label": "Annual Cash Rent", "documentation": "Annual Cash Rent" } } }, "auth_ref": [] }, "ctre_AnnualCashRentIncreaseUnderAmendedLease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "AnnualCashRentIncreaseUnderAmendedLease", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual cash rent increase under amended lease", "label": "Annual Cash Rent Increase Under Amended Lease", "documentation": "Annual Cash Rent Increase Under Amended Lease" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive unvested RSAs and TSR Units excluded from the computation (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r240" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Purchase Price", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r816", "r1020", "r1021", "r1022" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r136", "r153", "r177", "r201", "r244", "r253", "r272", "r276", "r323", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r488", "r492", "r530", "r629", "r706", "r786", "r787", "r829", "r857", "r1009", "r1010", "r1044" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsHeldForSaleNotPartOfDisposalGroup", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale, net", "label": "Asset, Held-for-Sale, Not Part of Disposal Group", "documentation": "Amount of assets held-for-sale that are not part of a disposal group." } } }, "auth_ref": [ "r117" ] }, "ctre_AssistedAndIndependentLivingPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "AssistedAndIndependentLivingPropertiesMember", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "ALF/ILF", "label": "Assisted and Independent Living Properties [Member]", "documentation": "Assisted and Independent Living Properties [Member]" } } }, "auth_ref": [] }, "ctre_AssistedLivingFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "AssistedLivingFacilitiesMember", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysDispositionsDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ALF", "label": "Assisted Living Facilities [Member]", "documentation": "Assisted Living Facilities" } } }, "auth_ref": [] }, "ctre_AssistedLivingFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "AssistedLivingFacilityMember", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assisted living", "label": "Assisted Living Facility [Member]", "documentation": "Assisted Living Facility [Member]" } } }, "auth_ref": [] }, "ctre_AtTheMarketOfferingProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "AtTheMarketOfferingProgramMember", "presentation": [ "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails", "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTScheduleofAtTheMarketOfferingProgramDetails", "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ATM Program", "label": "At-The-Market Offering Program [Member]", "documentation": "At-The-Market Offering Program [Member]" } } }, "auth_ref": [] }, "ctre_AuthorizedAnnualFund": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "AuthorizedAnnualFund", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized annual fund", "label": "Authorized Annual Fund", "documentation": "Authorized Annual Fund" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r929" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r930" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r925" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r925" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r925" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r925" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r925" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r925" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails", "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockAwardandPerformanceAwardActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r928" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r927" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r926" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r926" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BaseRateMember", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r113" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.caretrustreit.com/role/ORGANIZATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r350", "r351", "r352", "r353", "r354", "r484", "r810", "r811" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.caretrustreit.com/role/ORGANIZATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r54", "r55", "r350", "r351", "r352", "r353", "r354", "r484", "r810", "r811" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r484" ] }, "ctre_BusinessCombinationSharePriceExpected": { "xbrltype": "perShareItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "BusinessCombinationSharePriceExpected", "presentation": [ "http://www.caretrustreit.com/role/ORGANIZATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, share price, expected (in usd per share)", "label": "Business Combination, Share Price, Expected", "documentation": "Business Combination, Share Price, Expected" } } }, "auth_ref": [] }, "stpr_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "CA", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CA", "label": "CALIFORNIA" } } }, "auth_ref": [] }, "ctre_CTREMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "CTREMember", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CTRE", "label": "CTRE [Member]", "documentation": "CTRE" } } }, "auth_ref": [] }, "ctre_CampusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "CampusMember", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Campus", "label": "Campus [Member]", "documentation": "Campus" } } }, "auth_ref": [] }, "ctre_CapitalExpendituresMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "CapitalExpendituresMember", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital expenditures", "label": "Capital Expenditures [Member]", "documentation": "Capital Expenditures" } } }, "auth_ref": [] }, "ctre_CapitalImprovementsAtTripleNetLeasedFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "CapitalImprovementsAtTripleNetLeasedFacilitiesMember", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Certain Capital Improvements at Triple-Net Leased Facilities", "label": "Capital Improvements At Triple Net Leased Facilities [Member]", "documentation": "Capital Improvements At Triple Net Leased Facilities" } } }, "auth_ref": [] }, "ctre_CareREITPlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "CareREITPlcMember", "presentation": [ "http://www.caretrustreit.com/role/ORGANIZATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Care REIT plc", "label": "Care REIT plc [Member]", "documentation": "Care REIT plc" } } }, "auth_ref": [] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Amount", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r66", "r67" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 }, "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashCashEquivalentsandRestrictedCashDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r23", "r176", "r776" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r24", "r135" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash as of the beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash as of the end of period", "totalLabel": "Cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r23", "r110", "r198" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [ "http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents and Restricted Cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r110" ] }, "ctre_CashCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "CashCompensation", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash compensation", "label": "Cash Compensation", "documentation": "Cash Compensation" } } }, "auth_ref": [] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental schedule of noncash investing and financing activities:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "ctre_ChangeInFinancingReceivableAccruedInterestAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "ChangeInFinancingReceivableAccruedInterestAfterAllowanceForCreditLoss", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofRealEstateRelatedInvestmentActivityDetails": { "parentTag": "ctre_LoanReceivableNetChangeFairValue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofRealEstateRelatedInvestmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest, net", "label": "Change In Financing Receivable, Accrued Interest, After Allowance For Credit Loss", "documentation": "Change In Financing Receivable, Accrued Interest, After Allowance For Credit Loss" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r905" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r902" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r900" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r162", "r178", "r179", "r180", "r201", "r223", "r227", "r235", "r239", "r247", "r248", "r323", "r374", "r376", "r377", "r378", "r381", "r382", "r413", "r414", "r417", "r420", "r427", "r530", "r662", "r663", "r664", "r665", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r694", "r715", "r732", "r750", "r751", "r752", "r753", "r754", "r944", "r975", "r983" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails", "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTScheduleofAtTheMarketOfferingProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r178", "r179", "r180", "r247", "r413", "r414", "r415", "r417", "r420", "r425", "r427", "r662", "r663", "r664", "r665", "r804", "r944", "r975" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r906" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r906" ] }, "ctre_CommitmentCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "CommitmentCategoryAxis", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment Category [Axis]", "label": "Commitment Category [Axis]", "documentation": "Commitment Category" } } }, "auth_ref": [] }, "ctre_CommitmentCategoryDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "CommitmentCategoryDomain", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment Category [Domain]", "label": "Commitment Category [Domain]", "documentation": "Commitment Category" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails", "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 13)", "verboseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r90", "r140", "r630", "r693" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r120", "r366", "r367", "r760", "r1000", "r1005" ] }, "ctre_CommitmentsAndContingenciesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "CommitmentsAndContingenciesTableTextBlock", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Commitments and Contingencies", "label": "Commitments And Contingencies [Table Text Block]", "documentation": "Commitments And Contingencies" } } }, "auth_ref": [] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTERESTParenthetical", "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTScheduleofDividendsonCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common dividends (in usd per share)", "verboseLabel": "Dividends declared per share (in usd per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r128" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r846", "r847", "r848", "r850", "r851", "r852", "r853", "r979", "r980", "r982", "r1024", "r1092", "r1097" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in usd per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r93" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r93", "r694" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r93" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r93", "r694", "r712", "r1097", "r1098" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.01 par value; 500,000,000 shares authorized, 187,669,948 and 186,993,010 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r93", "r632", "r829" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r911" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r910" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r912" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r909" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r32", "r34", "r68", "r69", "r283", "r759" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r32", "r34", "r68", "r69", "r283", "r658", "r759" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r32", "r34", "r68", "r69", "r283", "r759", "r949" ] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISK" ], "lang": { "en-us": { "role": { "terseLabel": "CONCENTRATION OF RISK", "label": "Concentration Risk Disclosure [Text Block]", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": [ "r114" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r759" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of Total Revenue", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r32", "r34", "r68", "r69", "r283" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r31", "r32", "r34", "r35", "r68", "r134", "r759" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r32", "r34", "r68", "r69", "r283", "r759" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r204", "r488", "r489", "r492", "r493", "r552", "r765", "r1008", "r1011", "r1012" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]" } } }, "auth_ref": [ "r204", "r488", "r489", "r492", "r493", "r552", "r765", "r1008", "r1011", "r1012" ] }, "ctre_ContingentEarnoutLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "ContingentEarnoutLiability", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent earnout liability", "label": "Contingent Earnout Liability", "documentation": "Contingent Earnout Liability" } } }, "auth_ref": [] }, "ctre_ContractualCashYield": { "xbrltype": "percentItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "ContractualCashYield", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual cash yield", "label": "Contractual Cash Yield", "documentation": "Contractual Cash Yield" } } }, "auth_ref": [] }, "us-gaap_CostOfOtherPropertyOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfOtherPropertyOperatingExpense", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property operating expenses", "verboseLabel": "Property operating expenses", "label": "Cost of Other Property Operating Expense", "documentation": "Other operating costs incurred during the reporting period and may include amounts paid to maintain the property." } } }, "auth_ref": [ "r101" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r106" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r202", "r203", "r387", "r415", "r551", "r572", "r626", "r777", "r779" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails", "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r373", "r1006" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails", "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r373", "r1006", "r1007" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r115", "r283" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.caretrustreit.com/role/DEBT" ], "lang": { "en-us": { "role": { "terseLabel": "DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r121", "r199", "r359", "r360", "r361", "r362", "r363", "r372", "r373", "r383", "r389", "r390", "r391", "r392", "r393", "r394", "r399", "r406", "r407", "r409", "r539" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails", "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r13", "r83", "r84", "r137", "r139", "r204", "r384", "r385", "r386", "r387", "r388", "r390", "r395", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r799", "r800", "r801", "r802", "r803", "r828", "r976", "r1001", "r1002", "r1003", "r1036", "r1038" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate (as percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal Amount", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r13", "r139", "r410" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Senior unsecured notes payable, face value", "terseLabel": "Debt instrument, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r384", "r539", "r540", "r800", "r801", "r828" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate (as percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r86", "r385" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails", "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r204", "r384", "r385", "r386", "r387", "r388", "r390", "r395", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r408", "r799", "r800", "r801", "r802", "r803", "r828", "r976", "r1036", "r1038" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails", "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r13", "r204", "r384", "r385", "r386", "r387", "r388", "r390", "r395", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r799", "r800", "r801", "r802", "r803", "r828", "r976", "r1001", "r1002", "r1003", "r1036", "r1038" ] }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": [ "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Axis]", "label": "Debt Instrument, Redemption, Period [Axis]", "documentation": "Information by period of debt redemption feature under terms of debt agreement." } } }, "auth_ref": [ "r144" ] }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": [ "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Domain]", "label": "Debt Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": [ "r144" ] }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodThreeMember", "presentation": [ "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period after March 30 2028", "label": "Debt Instrument, Redemption, Period Three [Member]", "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r144" ] }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodTwoMember", "presentation": [ "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period prior to March 30 2028", "label": "Debt Instrument, Redemption, Period Two [Member]", "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r144" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption price of notes (as percent)", "label": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r144" ] }, "ctre_DebtInstrumentRedemptionPriceUponChangeOfControlAsPercentageOfPrincipalAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "DebtInstrumentRedemptionPriceUponChangeOfControlAsPercentageOfPrincipalAmount", "presentation": [ "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption price, percentage upon change of control (as percent)", "label": "Debt Instrument Redemption Price Upon Change Of Control As Percentage Of Principal Amount", "documentation": "Debt instrument redemption price upon change of control as percentage of principal amount." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails", "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r13", "r46", "r49", "r70", "r126", "r127", "r204", "r384", "r385", "r386", "r387", "r388", "r390", "r395", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r408", "r799", "r800", "r801", "r802", "r803", "r828", "r976", "r1036", "r1038" ] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred Loan Fees", "label": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1036", "r1038" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred financing costs, net", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1014", "r1035", "r1036", "r1038" ] }, "ctre_DeferredRentAsPercentageOfContractualCashYieldYearOne": { "xbrltype": "percentItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "DeferredRentAsPercentageOfContractualCashYieldYearOne", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred rent as percentage of contractual cash yield", "label": "Deferred Rent As Percentage Of Contractual Cash Yield, Year One", "documentation": "Deferred Rent As Percentage Of Contractual Cash Yield, Year One" } } }, "auth_ref": [] }, "ctre_DeferredRentAsPercentageOfContractualCashYieldYearTwo": { "xbrltype": "percentItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "DeferredRentAsPercentageOfContractualCashYieldYearTwo", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred rent as percentage of contractual cash yield, year two", "label": "Deferred Rent As Percentage Of Contractual Cash Yield, Year Two", "documentation": "Deferred Rent As Percentage Of Contractual Cash Yield, Year Two" } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r5", "r39" ] }, "ctre_DepreciationAndAmortizationIncludingBelowMarketGroundLeasesExcludingAmortizationOfDeferredFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "DepreciationAndAmortizationIncludingBelowMarketGroundLeasesExcludingAmortizationOfDeferredFinancingCosts", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization (including below-market ground leases)", "label": "Depreciation and Amortization (Including Below-Market Ground Leases, Excluding Amortization of Deferred Financing Costs)", "documentation": "Depreciation and Amortization (Including Below-Market Ground Leases, Excluding Amortization of Deferred Financing Costs)" } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Board of Directors", "label": "Director [Member]" } } }, "auth_ref": [ "r985", "r1093" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATION" ], "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r437", "r442", "r470", "r471", "r473", "r813" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysAssetsHeldforSaleActivityDetails", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysDispositionsDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r174" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysAssetsHeldforSaleActivityDetails", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysDispositionsDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposed of by Sale", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r6", "r12" ] }, "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Held for Sale", "label": "Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r1", "r6", "r12" ] }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysAssetsHeldforSaleActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Held-for-sale, Not Discontinued Operations", "label": "Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r1", "r12", "r174" ] }, "ctre_DistributionsToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "DistributionsToNoncontrollingInterests", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions to noncontrolling interests", "label": "Distributions to noncontrolling interests", "documentation": "Distributions to noncontrolling interests" } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStock", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "negatedLabel": "Common dividends", "label": "Dividends, Common Stock", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r3", "r128" ] }, "us-gaap_DividendsCommonStockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockAbstract", "presentation": [ "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTScheduleofDividendsonCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends on common stock", "label": "Dividends, Common Stock [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DividendsDeclaredTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsDeclaredTableTextBlock", "presentation": [ "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Dividends on Common Stock", "label": "Dividends Declared [Table Text Block]", "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends." } } }, "auth_ref": [] }, "us-gaap_DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTScheduleofDividendsonCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends payable as of record date", "label": "Dividends Payable, Current", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r84" ] }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Dividends payable", "label": "Dividends Payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding." } } }, "auth_ref": [ "r84", "r89", "r138", "r854", "r1057" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r861" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r893" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r904" ] }, "ctre_EarlyTerminationFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "EarlyTerminationFeePercentage", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Early termination fee", "label": "Early Termination Fee, Percentage", "documentation": "Early Termination Fee, Percentage" } } }, "auth_ref": [] }, "ctre_EarnOutObligationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "EarnOutObligationMember", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earn-out obligation", "label": "Earn-Out Obligation [Member]", "documentation": "Earn-Out Obligation" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in usd per share)", "verboseLabel": "Earnings per common share attributable to CareTrust REIT, Inc., basic (in usd per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r189", "r210", "r211", "r212", "r213", "r214", "r215", "r220", "r223", "r235", "r238", "r239", "r243", "r482", "r486", "r503", "r504", "r623", "r640", "r780" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in usd per share)", "verboseLabel": "Earnings per common share attributable to CareTrust REIT, Inc., diluted (in usd per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r189", "r210", "r211", "r212", "r213", "r214", "r215", "r223", "r235", "r238", "r239", "r243", "r482", "r486", "r503", "r504", "r623", "r640", "r780" ] }, "us-gaap_EarningsPerShareDilutedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedLineItems", "presentation": [ "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]", "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r223", "r227", "r235" ] }, "us-gaap_EarningsPerShareReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareReconciliationAbstract", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per common share attributable to CareTrust REIT, Inc:", "label": "Earnings Per Share Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS PER COMMON SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r219", "r240", "r241", "r242" ] }, "ctre_EduroAmendedTripleNetMasterLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "EduroAmendedTripleNetMasterLeaseMember", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eduro Amended Triple-Net Master Lease", "label": "Eduro Amended Triple-Net Master Lease [Member]", "documentation": "Eduro Amended Triple-Net Master Lease" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unamortized stock-based compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r472" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "ctre_EnsignAmendedTripleNetMasterLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "EnsignAmendedTripleNetMasterLeaseMember", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ensign Amended Triple-Net Master Lease", "label": "Ensign Amended Triple-Net Master Lease [Member]", "documentation": "Ensign Amended Triple-Net Master Lease" } } }, "auth_ref": [] }, "ctre_EnsignAndPennantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "EnsignAndPennantMember", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ensign and Pennant", "label": "Ensign And Pennant [Member]", "documentation": "Ensign And Pennant" } } }, "auth_ref": [] }, "ctre_EnsignMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "EnsignMember", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ensign", "label": "Ensign [Member]", "documentation": "Ensign [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r859" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r859" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r859" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r943" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r859" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r859" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r859" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r859" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r898" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r939" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r939" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r939" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r171", "r185", "r186", "r187", "r205", "r206", "r207", "r209", "r214", "r216", "r218", "r246", "r324", "r325", "r357", "r428", "r476", "r477", "r479", "r480", "r481", "r483", "r485", "r486", "r494", "r495", "r496", "r497", "r498", "r499", "r502", "r531", "r532", "r533", "r534", "r535", "r536", "r541", "r543", "r550", "r638", "r654", "r655", "r656", "r668", "r732" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r320", "r321", "r322", "r478", "r945", "r946", "r947", "r1016", "r1017", "r1018", "r1019" ] }, "us-gaap_EquityMethodInvestmentAggregateCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentAggregateCost", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred equity investments, face value", "label": "Equity Method Investment, Aggregate Cost", "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting." } } }, "auth_ref": [ "r81" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity ownership percentage (as percent)", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r320" ] }, "us-gaap_EquityMethodInvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred equity investments, fair value disclosure", "label": "Equity Method Investments, Fair Value Disclosure", "documentation": "Fair value portion of investments accounted under the equity method." } } }, "auth_ref": [ "r965", "r1026", "r1027", "r1031" ] }, "us-gaap_EquityMethodInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsMember", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofInterestandOtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred equity investment", "label": "Equity Method Investments [Member]", "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition." } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r908" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r866", "r876", "r886", "r918" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r863", "r873", "r883", "r915" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r397", "r529", "r800", "r801" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r914" ] }, "ctre_FacilitiesHeldForSaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "FacilitiesHeldForSaleMember", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facilities Held For Sale", "label": "Facilities Held For Sale [Member]", "documentation": "Facilities Held For Sale" } } }, "auth_ref": [] }, "ctre_FacilityCountByType": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "FacilityCountByType", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility Count and Type", "label": "Facility Count by Type", "documentation": "Facility Count by Type" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r506", "r507", "r520", "r819" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r506", "r507", "r520", "r819" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r508", "r509", "r510", "r821" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r508", "r509", "r510", "r821" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Quantitative Information About Unobservable Inputs Related to Level 3 Fair Value Measurements", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r508", "r509", "r821" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Items Measured at Fair Value on a Recurring Basis", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1026", "r1027" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Domain]", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r511", "r512", "r513", "r514", "r515", "r516", "r521", "r820" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument asset measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": [ "r511", "r512", "r513", "r514", "r515", "r516", "r521", "r820" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Axis]", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r511", "r512", "r513", "r514", "r515", "r516", "r521", "r820" ] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r66", "r67" ] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Face Value, Carrying Amount and Fair Value of Financial Instruments", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r66" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r397", "r430", "r431", "r432", "r433", "r434", "r435", "r505", "r507", "r508", "r509", "r510", "r519", "r520", "r522", "r559", "r560", "r561", "r800", "r801", "r807", "r808", "r809", "r819", "r821" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r397", "r800", "r801" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r506", "r507", "r508", "r510", "r819", "r1029", "r1032" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r397", "r800", "r801" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE MEASUREMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r515", "r517", "r518", "r519", "r522", "r523", "r524", "r525", "r526", "r621", "r819", "r822" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r397", "r430", "r435", "r507", "r520", "r559", "r807", "r808", "r809", "r819" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r397", "r430", "r435", "r507", "r508", "r520", "r560", "r800", "r801", "r807", "r808", "r809", "r819" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r397", "r430", "r431", "r432", "r433", "r434", "r435", "r507", "r508", "r509", "r510", "r520", "r561", "r800", "r801", "r807", "r808", "r809", "r819", "r821" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r511", "r512", "r513", "r514", "r515", "r516" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Assets Measured at Fair Value on a Recurring Basis Using Level 3 Inputs", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r511", "r516", "r521" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r506", "r507", "r508", "r510", "r819", "r1029", "r1032" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "ctre_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetAccruedInterestNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetAccruedInterestNet", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest, net", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Accrued Interest Net", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Accrued Interest Net" } } }, "auth_ref": [] }, "ctre_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetLoanOriginations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetLoanOriginations", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Originations", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Loan Originations", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Loan Originations" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at ending of period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r511", "r521", "r820" ] }, "ctre_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisRepaymentOfLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisRepaymentOfLoan", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Repayment Of Loan", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Repayment Of Loan" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r397", "r430", "r431", "r432", "r433", "r434", "r435", "r505", "r507", "r508", "r509", "r510", "r519", "r520", "r522", "r559", "r560", "r561", "r800", "r801", "r807", "r808", "r809", "r819", "r821" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r819", "r1026", "r1027", "r1028", "r1029", "r1030", "r1032" ] }, "ctre_FinanceReceivableExtensionOptionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "FinanceReceivableExtensionOptionTerm", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance receivable, extension option, term", "label": "Finance Receivable, Extension Option, Term", "documentation": "Finance Receivable, Extension Option, Term" } } }, "auth_ref": [] }, "ctre_FinanceReceivableNumberOfExtensionOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "FinanceReceivableNumberOfExtensionOptions", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance receivable, number of extension options", "label": "Finance Receivable, Number Of Extension Options", "documentation": "Finance Receivable, Number Of Extension Options" } } }, "auth_ref": [] }, "us-gaap_FinanceReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceReceivablesMember", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails", "http://www.caretrustreit.com/role/ORGANIZATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing receivable", "label": "Financing Receivable [Member]", "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r327", "r328", "r332", "r333", "r335", "r337", "r338", "r339", "r408", "r425", "r500", "r527", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r639", "r796", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r830", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r991", "r992", "r993", "r994", "r1025", "r1028", "r1029", "r1030", "r1031", "r1032" ] }, "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets:", "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities:", "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinancingReceivableAccruedInterestBeforeAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableAccruedInterestBeforeAllowanceForCreditLoss", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest, net", "label": "Financing Receivable, Accrued Interest, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of accrued interest on financing receivable." } } }, "auth_ref": [ "r334" ] }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableAllowanceForCreditLosses", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Expected credit loss", "label": "Financing Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement." } } }, "auth_ref": [ "r154", "r166", "r168", "r170", "r182", "r326", "r329", "r331", "r1053" ] }, "us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableAllowanceForCreditLossesLineItems", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofRealEstateRelatedInvestmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Allowance for Credit Loss [Line Items]", "label": "Financing Receivable, Allowance for Credit Loss [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r170", "r997" ] }, "ctre_FinancingReceivableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "FinancingReceivableFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Financing Receivable, Fair Value Disclosure", "documentation": "Financing Receivable, Fair Value Disclosure" } } }, "auth_ref": [] }, "ctre_FinancingReceivableMortgagePrepaidLoanAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "FinancingReceivableMortgagePrepaidLoanAmount", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing receivable, mortgage prepaid loan amount", "label": "Financing Receivable, Mortgage Prepaid Loan Amount", "documentation": "Financing Receivable, Mortgage Prepaid Loan Amount" } } }, "auth_ref": [] }, "ctre_FinancingReceivableMortgagePrepaidLoanOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "FinancingReceivableMortgagePrepaidLoanOutstanding", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing receivable, mortgage prepaid loan, outstanding", "label": "Financing Receivable, Mortgage Prepaid Loan, Outstanding", "documentation": "Financing Receivable, Mortgage Prepaid Loan, Outstanding" } } }, "auth_ref": [] }, "ctre_FinancingReceivablePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "FinancingReceivablePrincipalAmount", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofRealEstateRelatedInvestmentActivityDetails": { "parentTag": "ctre_LoanReceivableNetChangeFairValue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentActivityDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofRealEstateRelatedInvestmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal amount", "verboseLabel": "Origination of other real estate related investments", "label": "Financing Receivable, Principal Amount", "documentation": "Financing Receivable, Principal Amount" } } }, "auth_ref": [] }, "ctre_FinancingReceivablePrincipalPaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "FinancingReceivablePrincipalPaymentsReceived", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofLoanReceivableActivityDetails": { "parentTag": "ctre_LoanReceivableNetChange", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofLoanReceivableActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Principal payments", "label": "Financing Receivable, Principal Payments Received", "documentation": "Financing Receivable, Principal Payments Received" } } }, "auth_ref": [] }, "us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofInterestandOtherIncomeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentActivityDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofRealEstateRelatedInvestmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Financing Receivable [Axis]", "label": "Class of Financing Receivable [Axis]", "documentation": "Information by class of financing receivable determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk." } } }, "auth_ref": [ "r155", "r156", "r157", "r158", "r164", "r165", "r169", "r170", "r285", "r286", "r287", "r288", "r289", "r332", "r333", "r335", "r791", "r792", "r793", "r794", "r795", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r961", "r962", "r963", "r987" ] }, "us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofInterestandOtherIncomeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentActivityDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofRealEstateRelatedInvestmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Financing Receivable [Domain]", "label": "Class of Financing Receivable [Domain]", "documentation": "Financing receivables determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk." } } }, "auth_ref": [ "r158", "r164", "r165", "r169", "r170", "r285", "r286", "r287", "r288", "r289", "r791", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r961", "r962", "r963", "r987" ] }, "us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableRecordedInvestmentPastDueLineItems", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Past Due [Line Items]", "label": "Financing Receivable, Past Due [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r795", "r998" ] }, "ctre_FinancingReceivableVariableBasisInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "FinancingReceivableVariableBasisInterestRate", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate (percent)", "label": "Financing Receivable, Variable Basis Interest Rate", "documentation": "Financing Receivable, Variable Basis Interest Rate" } } }, "auth_ref": [] }, "ctre_FinancingReceivableWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "FinancingReceivableWeightedAverageInterestRate", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentActivityDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Contractual Interest Rate", "terseLabel": "Weighted average interest rate", "label": "Financing Receivable, Weighted Average Interest Rate", "documentation": "Financing Receivable, Weighted Average Interest Rate" } } }, "auth_ref": [] }, "us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivablesEqualToGreaterThan90DaysPastDueMember", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Greater than 90 Days Past Due", "label": "Financial Asset, Equal to or Greater than 90 Days Past Due [Member]", "documentation": "Financial asset equal to or greater than 90 days past due." } } }, "auth_ref": [ "r795" ] }, "us-gaap_FinancingReceivablesPeriodPastDueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivablesPeriodPastDueAxis", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Asset, Aging [Axis]", "label": "Financial Asset, Aging [Axis]", "documentation": "Information by period in which financial asset is past due or not past due." } } }, "auth_ref": [ "r157", "r332", "r795" ] }, "us-gaap_FinancingReceivablesPeriodPastDueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivablesPeriodPastDueDomain", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Asset, Aging [Domain]", "label": "Financial Asset, Aging [Domain]", "documentation": "Period in which financial asset is past due or not past due. For past due, element name and standard label in Financial Asset, [numeric lower end] to [numeric higher end] [date measure] Past Due [Member] or Financial Asset, Greater than [low end numeric value] [date measure] Past Due [Member] or Financial Asset, Less than [high end numeric value] [date measure] Past Due [Member] formats." } } }, "auth_ref": [ "r157", "r332", "r795" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofInvestmentinOwnedPropertiesDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofInvestmentinOwnedPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Identified intangible assets", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r340", "r355", "r590", "r798" ] }, "ctre_FirstOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "FirstOptionMember", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Option", "label": "First Option [Member]", "documentation": "First Option" } } }, "auth_ref": [] }, "us-gaap_FixturesAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FixturesAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofInvestmentinOwnedPropertiesDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofInvestmentinOwnedPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Integral equipment, furniture and fixtures", "label": "Fixtures and Equipment, Gross", "documentation": "Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r870", "r880", "r890", "r922" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r870", "r880", "r890", "r922" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r870", "r880", "r890", "r922" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r870", "r880", "r890", "r922" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r870", "r880", "r890", "r922" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r903" ] }, "us-gaap_GainsLossesOnSalesOfInvestmentRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnSalesOfInvestmentRealEstate", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS": { "parentTag": "us-gaap_NonoperatingGainsLosses", "weight": 1.0, "order": 1.0 }, "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysDispositionsDetails", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on sale of real estate, net", "negatedTerseLabel": "Gain on sale of real estate, net", "netLabel": "Net gain on sale", "label": "Gains (Losses) on Sales of Investment Real Estate", "documentation": "The net gain (loss) resulting from sales and other disposals of real estate owned for investment purposes." } } }, "auth_ref": [ "r159", "r160", "r161", "r968", "r969", "r973", "r1054", "r1096" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 }, "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "totalLabel": "Total general and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r103", "r717" ] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeographicConcentrationRiskMember", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographic Concentration Risk", "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r33", "r759" ] }, "us-gaap_ImpairmentLossesRelatedToRealEstatePartnerships": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentLossesRelatedToRealEstatePartnerships", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 }, "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Impairment of real estate investments", "terseLabel": "Impairment of real estate investments", "label": "Impairment Losses Related to Real Estate Partnerships", "documentation": "Impairment losses measured as the amount by which the carrying amount of the business or real estate partnerships exceeds the fair value of the business or partnership." } } }, "auth_ref": [ "r112", "r118" ] }, "us-gaap_ImpairmentOfRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfRealEstate", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of real estate investments", "label": "Impairment of Real Estate", "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value." } } }, "auth_ref": [ "r973", "r999" ] }, "ctre_ImpairmentOfRealEstateInvestmentsAssetsHeldForSaleAndAssetSalesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "ImpairmentOfRealEstateInvestmentsAssetsHeldForSaleAndAssetSalesTextBlock", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALES" ], "lang": { "en-us": { "role": { "terseLabel": "IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES", "label": "Impairment of Real Estate Investments, Assets Held for Sale And Asset Sales [Text Block]", "documentation": "Impairment of Real Estate Investments, Assets Held for Sale And Asset Sales" } } }, "auth_ref": [] }, "ctre_IncentiveCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "IncentiveCompensation", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incentive compensation", "label": "Incentive Compensation", "documentation": "Incentive Compensation" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysAssetsHeldforSaleActivityDetails", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysAssetsHeldforSaleActivityDetails", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r7", "r12", "r16", "r72", "r73", "r74", "r75", "r76", "r77", "r78", "r79", "r80", "r119" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, accrued liabilities and deferred rent liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts and other receivables", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "ctre_IncreaseDecreaseInAssetsHeldForSaleRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "IncreaseDecreaseInAssetsHeldForSaleRollForward", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysAssetsHeldforSaleActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase Decrease in Assets Held for Sale [Roll Forward]", "label": "Increase Decrease in Assets Held for Sale [Roll Forward]", "documentation": "Increase Decrease in Assets Held for Sale" } } }, "auth_ref": [] }, "ctre_IncreaseDecreaseInDividendsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "IncreaseDecreaseInDividendsPayable", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in dividends payable", "label": "Increase Decrease In Dividends Payable", "documentation": "Increase Decrease In Dividends Payable" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Change in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets, net", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive potential common shares (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r224", "r225", "r226", "r239", "r441" ] }, "ctre_IndependentLivingFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "IndependentLivingFacilityMember", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ILF", "label": "Independent Living Facility [Member]", "documentation": "Independent Living Facility" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r870", "r880", "r890", "r914", "r922", "r926", "r934" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r932" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r862", "r938" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r862", "r938" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r862", "r938" ] }, "us-gaap_InterestAndOtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestAndOtherIncome", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofInterestandOtherIncomeDetails", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income from other real estate related investments and other income", "verboseLabel": "Interest income from other real estate related investments and other income", "label": "Interest and Other Income", "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [] }, "us-gaap_InterestAndOtherIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestAndOtherIncomeTableTextBlock", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Interest and Other Income", "label": "Interest and Other Income [Table Text Block]", "documentation": "Tabular disclosure of interest income and income classified as other." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "verboseLabel": "Interest expense", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r244", "r253", "r257", "r263", "r276", "r538", "r786", "r787" ] }, "us-gaap_InterestIncomeFinancingReceivableBeforeAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeFinancingReceivableBeforeAllowanceForCreditLoss", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income from financing receivable", "verboseLabel": "Interest income from financing receivable", "label": "Interest Income, Financing Receivable, before Allowance for Credit Loss", "documentation": "Amount of interest income from financing receivable before allowance for credit loss." } } }, "auth_ref": [ "r162", "r163" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r193", "r196", "r197" ] }, "us-gaap_InvestmentBuildingAndBuildingImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentBuildingAndBuildingImprovements", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofInvestmentinOwnedPropertiesDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofInvestmentinOwnedPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings and improvements", "label": "Investment Building and Building Improvements", "documentation": "Aggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements." } } }, "auth_ref": [ "r1055", "r1056" ] }, "ctre_InvestmentFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "InvestmentFiveMember", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Five", "label": "Investment Five [Member]", "documentation": "Investment Five" } } }, "auth_ref": [] }, "ctre_InvestmentFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "InvestmentFourMember", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Four", "label": "Investment Four [Member]", "documentation": "Investment Four" } } }, "auth_ref": [] }, "us-gaap_InvestmentInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentInterestRate", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment interest rate (as percent)", "label": "Investment Interest Rate", "documentation": "Rate of interest on investment." } } }, "auth_ref": [ "r737", "r738", "r740", "r741", "r743", "r744", "r747", "r748", "r848", "r989", "r990" ] }, "ctre_InvestmentOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "InvestmentOneMember", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment One", "label": "Investment One [Member]", "documentation": "Investment One" } } }, "auth_ref": [] }, "ctre_InvestmentSevenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "InvestmentSevenMember", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Seven", "label": "Investment Seven [Member]", "documentation": "Investment Seven" } } }, "auth_ref": [] }, "ctre_InvestmentSixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "InvestmentSixMember", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Six", "label": "Investment Six [Member]", "documentation": "Investment Six" } } }, "auth_ref": [] }, "us-gaap_InvestmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTableTextBlock", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Real Estate Related Investments, at Fair Value", "label": "Investment [Table Text Block]", "documentation": "Tabular disclosure of investment." } } }, "auth_ref": [ "r951", "r952", "r988" ] }, "ctre_InvestmentThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "InvestmentThreeMember", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Three", "label": "Investment Three [Member]", "documentation": "Investment Three" } } }, "auth_ref": [] }, "ctre_InvestmentTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "InvestmentTwoMember", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Two", "label": "Investment Two [Member]", "documentation": "Investment Two" } } }, "auth_ref": [] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Investments", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Investment", "label": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": [ "r626", "r628", "r844", "r845" ] }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsAllOtherInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Investments, All Other Investments [Abstract]" } } }, "auth_ref": [] }, "ctre_InvestmentsInFinancingReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "InvestmentsInFinancingReceivableMember", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Financing Receivable", "label": "Investments in Financing Receivable [Member]", "documentation": "Investments in Financing Receivable" } } }, "auth_ref": [] }, "ctre_InvestmentsInMezzanineLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "InvestmentsInMezzanineLoansMember", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in Mezzanine Loans", "label": "Investments in Mezzanine Loans [Member]", "documentation": "Investments in Mezzanine Loans" } } }, "auth_ref": [] }, "ctre_InvestmentsInRealEstateSecuredLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "InvestmentsInRealEstateSecuredLoanMember", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in Real Estate Secured Loans", "label": "Investments in Real Estate Secured Loan [Member]", "documentation": "Investments in Real Estate Secured Loan" } } }, "auth_ref": [] }, "ctre_JVPartner97.5Member": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "JVPartner97.5Member", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "JV Partner 97.5%", "label": "JV Partner 97.5% [Member]", "documentation": "JV Partner 97.5%" } } }, "auth_ref": [] }, "ctre_JVPartnerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "JVPartnerMember", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Jv Partner", "label": "JV Partner [Member]", "documentation": "JV Partner" } } }, "auth_ref": [] }, "ctre_JaybirdLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "JaybirdLeaseMember", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Jaybird Lease", "label": "Jaybird Lease [Member]", "documentation": "Jaybird Lease" } } }, "auth_ref": [] }, "ctre_JaybirdSeniorLivingInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "JaybirdSeniorLivingInc.Member", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Jaybird Senior Living, Inc.", "label": "Jaybird Senior Living, Inc. [Member]", "documentation": "Jaybird Senior Living, Inc." } } }, "auth_ref": [] }, "ctre_JointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "JointVentureMember", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Joint Venture", "label": "Joint Venture [Member]", "documentation": "Joint Venture" } } }, "auth_ref": [] }, "us-gaap_Land": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Land", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofInvestmentinOwnedPropertiesDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofInvestmentinOwnedPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land", "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale." } } }, "auth_ref": [ "r966" ] }, "ctre_LeaseArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "LeaseArrangementsAxis", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Arrangements [Axis]", "label": "Lease Arrangements [Axis]", "documentation": "Lease Arrangements" } } }, "auth_ref": [] }, "ctre_LeaseArrangementsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "LeaseArrangementsDomain", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Arrangements [Domain]", "label": "Lease Arrangements [Domain]", "documentation": "Lease Arrangements" } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term [Axis]", "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r544", "r950" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term [Domain]", "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r544", "r950" ] }, "ctre_LeaseExtendedPeriodOfLease": { "xbrltype": "durationItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "LeaseExtendedPeriodOfLease", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease extended period", "label": "Lease Extended Period Of Lease", "documentation": "Lease Extended Period Of Lease" } } }, "auth_ref": [] }, "ctre_LeaseIncentiveAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "LeaseIncentiveAmortization", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRentalIncomeDetails": { "parentTag": "us-gaap_OperatingLeaseLeaseIncome", "weight": -1.0, "order": 1.0 }, "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of lease incentives", "negatedTerseLabel": "Amortization of lease incentives", "label": "Lease Incentive Amortization", "documentation": "Lease Incentive Amortization" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of contract", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1039" ] }, "ctre_LessorAnnualizedCashRevenueForContractsInPlace": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "LessorAnnualizedCashRevenueForContractsInPlace", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current cash rent", "label": "Lessor, Annualized Cash Revenue For Contracts In Place", "documentation": "Lessor, Annualized Cash Revenue For Contracts In Place" } } }, "auth_ref": [] }, "us-gaap_LessorLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorLeaseDescriptionLineItems", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessor, Lease, Description [Line Items]", "label": "Lessor, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r547" ] }, "us-gaap_LessorLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorLeaseDescriptionTable", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessor, Lease, Description [Table]", "label": "Lessor, Lease, Description [Table]", "documentation": "Disclosure of information about lessor's leases." } } }, "auth_ref": [ "r547" ] }, "ctre_LessorOperatingLeaseNumberOfRenewalOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "LessorOperatingLeaseNumberOfRenewalOptions", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of renewal options", "label": "Lessor, Operating Lease, Number Of Renewal Options", "documentation": "Lessor, Operating Lease, Number Of Renewal Options" } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future Contractual Minimum Rental Income", "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceived", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessor, Operating Lease, Payment to be Received", "documentation": "Amount of lease payments to be received by lessor for operating lease." } } }, "auth_ref": [ "r546" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2030", "label": "Lessor, Operating Lease, Payment to be Received, Year Five", "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r546" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r546" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Future Contractual Minimum Rental Income", "label": "Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]", "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease." } } }, "auth_ref": [ "r1040" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextRollingTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedNextRollingTwelveMonths", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessor, operating lease, payment to be received, next rolling 12 months", "label": "Lessor, Operating Lease, Payment to be Received, Next Rolling 12 Months", "documentation": "Amount of lease payments to be received by lessor in next rolling twelve months following latest statement of financial position date for operating lease. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r1040" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r546" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025 (nine months)", "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year", "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1040" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessor, Operating Lease, Payment to be Received, after Year Five", "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r546" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r546" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTotalFutureContractualMinimumRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r546" ] }, "ctre_LessorOperatingLeaseRenewalOptionsTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "LessorOperatingLeaseRenewalOptionsTerms", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessor, operating lease, renewal options terms", "label": "Lessor, Operating Lease, Renewal Options Terms", "documentation": "Lessor, Operating Lease, Renewal Options Terms" } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeaseRenewalTerm", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease renewal term (in years)", "label": "Lessor, Operating Lease, Renewal Term", "documentation": "Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1041" ] }, "ctre_LessorOperatingLeaseRentCalculatedAsAPercentageOfSubtenantsGrossRevenuePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "LessorOperatingLeaseRentCalculatedAsAPercentageOfSubtenantsGrossRevenuePeriod", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessor, operating lease, rent calculated as a percentage of subtenant's gross revenue, period", "label": "Lessor, Operating Lease, Rent Calculated As A Percentage Of Subtenant's Gross Revenue, Period", "documentation": "Lessor, Operating Lease, Rent Calculated As A Percentage Of Subtenant's Gross Revenue, Period" } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeaseTermOfContract", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial lease term (in years)", "label": "Lessor, Operating Lease, Term of Contract", "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1041" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r13", "r83", "r84", "r85", "r88", "r89", "r90", "r91", "r201", "r323", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r489", "r492", "r493", "r530", "r692", "r781", "r857", "r1009", "r1044", "r1045" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r98", "r142", "r634", "r829", "r977", "r995", "r1034" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Equity:", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unsecured revolving credit facility", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r13", "r139", "r1058" ] }, "ctre_LineOfCreditCommitmentFeeBasedOnInvestmentGradeRatingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "LineOfCreditCommitmentFeeBasedOnInvestmentGradeRatingPercentage", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility fee on revolving commitment fee based on investment grade ratings (as percent)", "label": "Line Of Credit, Commitment Fee Based On Investment Grade Rating, Percentage", "documentation": "Line Of Credit, Commitment Fee Based On Investment Grade Rating, Percentage" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility fee on revolving commitment fees (as percent)", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "ctre_LineOfCreditFacilityExtensionOptionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "LineOfCreditFacilityExtensionOptionTerm", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Extension option term (in months)", "label": "Line Of Credit Facility Extension Option Term", "documentation": "Line of credit facility extension option term." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Line Items]", "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r373", "r976", "r1006" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit facility borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r82", "r87" ] }, "ctre_LineOfCreditFacilityNumberOfExtensionOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "LineOfCreditFacilityNumberOfExtensionOptions", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of extension options", "label": "Line Of Credit Facility, Number Of Extension Options", "documentation": "Line Of Credit Facility, Number Of Extension Options" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Table]", "label": "Line of Credit Facility [Table]", "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement." } } }, "auth_ref": [ "r82", "r87", "r373", "r976", "r1006" ] }, "ctre_LineOfCreditSubfacilityCapacityAsPercentageOfAvailableRevolvingCommitments": { "xbrltype": "percentItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "LineOfCreditSubfacilityCapacityAsPercentageOfAvailableRevolvingCommitments", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subfacility capacity as percentage of available revolving commitments (as percent)", "label": "Line Of Credit, Subfacility, Capacity As Percentage Of Available Revolving Commitments", "documentation": "Line Of Credit, Subfacility, Capacity As Percentage Of Available Revolving Commitments" } } }, "auth_ref": [] }, "ctre_LoanReceivableAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "LoanReceivableAccruedInterest", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofLoanReceivableActivityDetails": { "parentTag": "ctre_LoanReceivableNetChange", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofLoanReceivableActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accrued interest, net", "label": "Loan Receivable, Accrued Interest", "documentation": "Loan Receivable, Accrued Interest" } } }, "auth_ref": [] }, "ctre_LoanReceivableNetChange": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "LoanReceivableNetChange", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofLoanReceivableActivityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofLoanReceivableActivityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in other loans receivable", "label": "Loan Receivable, Net Change", "documentation": "Loan Receivable, Net Change" } } }, "auth_ref": [] }, "ctre_LoanReceivableNetChangeFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "LoanReceivableNetChangeFairValue", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofRealEstateRelatedInvestmentActivityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofRealEstateRelatedInvestmentActivityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in other loans receivable", "label": "Loan Receivable, Net Change Fair Value", "documentation": "Loan Receivable, Net Change Fair Value" } } }, "auth_ref": [] }, "ctre_LoanReceivablePeriodOfUnpaidInterestPaymentsDueUponPrepayment": { "xbrltype": "durationItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "LoanReceivablePeriodOfUnpaidInterestPaymentsDueUponPrepayment", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period of unpaid interest payments due upon prepayment", "label": "Loan Receivable, Period Of Unpaid Interest Payments Due Upon Prepayment", "documentation": "Loan Receivable, Period Of Unpaid Interest Payments Due Upon Prepayment" } } }, "auth_ref": [] }, "us-gaap_LoansPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansPayableMember", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Loans Payable [Member]", "documentation": "Borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [] }, "ctre_LoansReceivableFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "LoansReceivableFairValue", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans receivable, book value", "label": "Loans Receivable, Fair Value", "documentation": "Loans Receivable, Fair Value" } } }, "auth_ref": [] }, "us-gaap_LoansReceivableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansReceivableFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Loan receivable", "label": "Loans Receivable, Fair Value Disclosure", "documentation": "Fair value portion of loan receivable, including, but not limited to, mortgage loans held for investment, finance receivables held for investment, policy loans on insurance contracts." } } }, "auth_ref": [ "r1033" ] }, "ctre_LoansReceivableMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "LoansReceivableMeasurementInput", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans receivable, measurement input", "label": "Loans Receivable, Measurement Input", "documentation": "Loans Receivable, Measurement Input" } } }, "auth_ref": [] }, "us-gaap_LoansReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansReceivableMember", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofInterestandOtherIncomeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentActivityDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofRealEstateRelatedInvestmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other loans receivable", "label": "Loans Receivable [Member]", "documentation": "Amount of money and property lent to borrower in exchange for promise to repay amount borrowed plus interest at date certain in future." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongLivedAssetsHeldForSaleByAssetTypeAxis", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Assets Held-for-Sale by Asset Type [Axis]", "label": "Long-Lived Asset, Held-for-Sale, Type [Axis]", "documentation": "Information by long-lived asset held for sale." } } }, "auth_ref": [ "r7" ] }, "us-gaap_LongLivedAssetsHeldForSaleNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongLivedAssetsHeldForSaleNameDomain", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Assets Held-for-Sale, Name [Domain]", "label": "Long-Lived Assets Held-for-Sale, Name [Domain]", "documentation": "A name of the assets to be disposed." } } }, "auth_ref": [ "r7" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Carrying Amount", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r13", "r139", "r396", "r411", "r800", "r801", "r828", "r1058" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails", "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r13", "r1001", "r1002", "r1003" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails", "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r13", "r40", "r1001", "r1002", "r1003" ] }, "stpr_MD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "MD", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MARYLAND", "label": "MARYLAND" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r283", "r806", "r839", "r843", "r1015", "r1062", "r1063", "r1064", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090" ] }, "us-gaap_MarketApproachValuationTechniqueMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketApproachValuationTechniqueMember", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation, Market Approach", "label": "Valuation, Market Approach [Member]", "documentation": "Valuation approach using price and other relevant information generated by market transaction involving identical or comparable asset, liability, or group of assets and liabilities." } } }, "auth_ref": [ "r1028", "r1029", "r1030" ] }, "ctre_MasterLeaseTerminationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "MasterLeaseTerminationMember", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Master Lease Termination", "label": "Master Lease Termination [Member]", "documentation": "Master Lease Termination" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails", "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r368", "r369", "r370", "r371", "r436", "r475", "r510", "r588", "r652", "r653", "r657", "r683", "r684", "r737", "r740", "r744", "r745", "r747", "r773", "r774", "r791", "r804", "r812", "r821", "r822", "r826", "r827", "r840", "r1013", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r906" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r906" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount Rate", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r1028", "r1029", "r1030" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r508", "r509", "r510", "r821" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r508", "r509", "r510", "r821" ] }, "ctre_MezzanineLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "MezzanineLoanMember", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mezzanine Loan", "label": "Mezzanine Loan [Member]", "documentation": "Mezzanine Loan" } } }, "auth_ref": [] }, "ctre_MezzanineLoanReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "MezzanineLoanReceivableMember", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails", "http://www.caretrustreit.com/role/ORGANIZATIONDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofInterestandOtherIncomeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Mezzanine loans receivable", "terseLabel": "Mezzanine Loan Receivable [Member]", "label": "Mezzanine Loan Receivable [Member]", "documentation": "Mezzanine Loan Receivable" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails", "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r368", "r369", "r370", "r371", "r436", "r475", "r510", "r588", "r652", "r653", "r657", "r683", "r684", "r737", "r740", "r744", "r745", "r747", "r773", "r774", "r791", "r804", "r812", "r821", "r822", "r826", "r840", "r1013", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r97", "r141", "r201", "r323", "r374", "r376", "r377", "r378", "r381", "r382", "r530", "r633", "r695" ] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions to noncontrolling interests", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": [ "r128" ] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestLineItems", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Line Items]", "label": "Noncontrolling Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage held by noncontrolling interest (as percent)", "label": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestTable", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Table]", "label": "Noncontrolling Interest [Table]", "documentation": "Disclosure of information about noncontrolling interest, including, but not limited to, name of subsidiary, ownership percentage held by parent, ownership percentage held by noncontrolling owner, amount of noncontrolling interest and its location in statement of financial position, explanation of increase (decrease) in noncontrolling interest, noncontrolling interest share of net income (loss) of subsidiary and its location in statement of income, amount of noncontrolling interest represented by preferred stock, description and dividend requirement of preferred stock, and nature of noncontrolling interest." } } }, "auth_ref": [ "r57", "r58", "r97", "r100" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r925" ] }, "ctre_MortgageLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "MortgageLoanMember", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage Loan", "label": "Mortgage Loan [Member]", "documentation": "Mortgage Loan" } } }, "auth_ref": [] }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate, Type of Property [Axis]", "label": "Real Estate, Type of Property [Axis]" } } }, "auth_ref": [ "r757", "r761", "r762", "r763", "r764", "r767", "r768", "r769", "r770", "r771" ] }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate [Domain]", "label": "Real Estate [Domain]" } } }, "auth_ref": [ "r761", "r762", "r763", "r764", "r767", "r768", "r769", "r770", "r771" ] }, "us-gaap_MortgageReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MortgageReceivablesMember", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage loans", "label": "Mortgage Receivable [Member]", "documentation": "Amounts due the Company for loans secured by the collateral of specified real estate property and which loan the borrower (debtor) is obligated to repay in accordance with a predetermined set of payments." } } }, "auth_ref": [] }, "ctre_MortgageSecuredAndMezzanineLoansReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "MortgageSecuredAndMezzanineLoansReceivableMember", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage Secured and Mezzanine Loans Receivable", "label": "Mortgage Secured And Mezzanine Loans Receivable [Member]", "documentation": "Mortgage Secured And Mezzanine Loans Receivable" } } }, "auth_ref": [] }, "ctre_MortgageSecuredLoanReceivableJanuary12027MaturityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "MortgageSecuredLoanReceivableJanuary12027MaturityMember", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage secured loan receivable", "label": "Mortgage Secured Loan Receivable January 1, 2027 Maturity [Member]", "documentation": "Mortgage Secured Loan Receivable January 1, 2027 Maturity" } } }, "auth_ref": [] }, "ctre_MortgageSecuredLoanReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "MortgageSecuredLoanReceivableMember", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails", "http://www.caretrustreit.com/role/ORGANIZATIONDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofInterestandOtherIncomeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage secured loans receivable", "verboseLabel": "Mortgage secured loans receivable", "label": "Mortgage Secured Loan Receivable [Member]", "documentation": "Mortgage Secured Loan Receivable" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r933" ] }, "ctre_MultiServiceCampusPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "MultiServiceCampusPropertiesMember", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Multi-service campuses", "verboseLabel": "Campus", "label": "Multi-Service Campus Properties [Member]", "documentation": "Multi-Service Campus Properties [Member]" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r283", "r806", "r839", "r843", "r1015", "r1062", "r1063", "r1064", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r907" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r195" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r195" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r110", "r111", "r112" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 }, "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to CareTrust REIT, Inc.", "verboseLabel": "Net income attributable to CareTrust REIT, Inc.", "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r102", "r112", "r143", "r175", "r183", "r184", "r187", "r201", "r208", "r210", "r211", "r212", "r213", "r214", "r217", "r218", "r232", "r323", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r482", "r486", "r504", "r530", "r637", "r714", "r730", "r731", "r855", "r1009" ] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAbstract", "presentation": [ "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income attributable to noncontrolling interests", "verboseLabel": "Net (loss) income attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r65", "r132", "r183", "r184", "r214", "r217", "r218", "r636", "r967" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Numerator for basic earnings available to common stockholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r190", "r210", "r211", "r212", "r213", "r220", "r221", "r234", "r239", "r486" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Numerator for diluted earnings available to common stockholders", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r190", "r222", "r228", "r229", "r230", "r231", "r234", "r239" ] }, "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)", "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest", "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity." } } }, "auth_ref": [ "r15", "r132", "r133" ] }, "ctre_NewCascadeLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NewCascadeLeaseMember", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Cascade Lease", "label": "New Cascade Lease [Member]", "documentation": "New Cascade Lease" } } }, "auth_ref": [] }, "ctre_NewEmbassyLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NewEmbassyLeaseAgreementMember", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Embassy Lease Agreement", "label": "New Embassy Lease Agreement [Member]", "documentation": "New Embassy Lease Agreement" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r906" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r870", "r880", "r890", "r914", "r922" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r897" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r896" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r914" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r933" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r933" ] }, "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of real estate settled with note receivable", "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received", "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction." } } }, "auth_ref": [ "r25", "r26", "r27" ] }, "us-gaap_NoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestAbstract", "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Contributions from noncontrolling interests", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders." } } }, "auth_ref": [ "r8", "r50", "r131" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r56", "r428", "r979", "r980", "r981", "r982", "r1097" ] }, "ctre_NoncontrollingInterestOwnersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NoncontrollingInterestOwnersMember", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests", "label": "Noncontrolling Interest Owners [Member]", "documentation": "Noncontrolling Interest Owners" } } }, "auth_ref": [] }, "us-gaap_NonoperatingGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingGainsLosses", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (loss)", "label": "Nonoperating Gains (Losses)", "documentation": "The aggregate amount of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth)." } } }, "auth_ref": [ "r104", "r105" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (loss):", "verboseLabel": "Other income (loss):", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NotesPayableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior unsecured notes payable, fair value disclosure", "label": "Notes Payable, Fair Value Disclosure", "documentation": "Fair value portion of notes payable." } } }, "auth_ref": [ "r13", "r83", "r84", "r1027", "r1031" ] }, "us-gaap_NotesReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesReceivableGross", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage loan receivable", "label": "Financing Receivable, before Allowance for Credit Loss", "documentation": "Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": [ "r155", "r157", "r166", "r167", "r181", "r284", "r332", "r336", "r794", "r795", "r960", "r996" ] }, "us-gaap_NotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesReceivableNet", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentActivityDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Financing receivable, at fair value (including accrued interest of $905000 as of March 31, 2025 and $281000 as of December 31, 2024)", "terseLabel": "Net change in other real estate related investments", "netLabel": "Net change in other real estate related investments", "label": "Financing Receivable, after Allowance for Credit Loss", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": [ "r336", "r701", "r986", "r1060" ] }, "ctre_NumberOfBedsOrUnitsInPropertiesAcquired": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfBedsOrUnitsInPropertiesAcquired", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Beds/Units", "label": "Number Of Beds Or Units In Properties Acquired", "documentation": "Number Of Beds Or Units In Properties Acquired" } } }, "auth_ref": [] }, "ctre_NumberOfFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfFacilities", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of facilities", "terseLabel": "Number of Facilities", "label": "Number Of Facilities", "documentation": "Number Of Facilities" } } }, "auth_ref": [] }, "ctre_NumberOfFacilitiesAcquired": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfFacilitiesAcquired", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of facilities acquired", "label": "Number Of Facilities Acquired", "documentation": "Number Of Facilities Acquired" } } }, "auth_ref": [] }, "ctre_NumberOfFacilitiesCurrentlyHeldForSale": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfFacilitiesCurrentlyHeldForSale", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of facilities currently held for sale", "label": "Number Of Facilities Currently Held For Sale", "documentation": "Number Of Facilities Currently Held For Sale" } } }, "auth_ref": [] }, "ctre_NumberOfFacilitiesDisposed": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfFacilitiesDisposed", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of facilities", "label": "Number Of Facilities Disposed", "documentation": "Number Of Facilities Disposed" } } }, "auth_ref": [] }, "ctre_NumberOfFacilitiesInProcessOfTransferringOperations": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfFacilitiesInProcessOfTransferringOperations", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of facilities in process of transferring operations", "label": "Number Of Facilities In Process Of Transferring Operations", "documentation": "Number Of Facilities In Process Of Transferring Operations" } } }, "auth_ref": [] }, "ctre_NumberOfLeasesAmended": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfLeasesAmended", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of leases amended", "label": "Number Of Leases Amended", "documentation": "Number Of Leases Amended" } } }, "auth_ref": [] }, "ctre_NumberOfLoans": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfLoans", "presentation": [ "http://www.caretrustreit.com/role/ORGANIZATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of loans", "label": "Number Of Loans", "documentation": "Number Of Loans" } } }, "auth_ref": [] }, "ctre_NumberOfMonthlyInstallmentPayments": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfMonthlyInstallmentPayments", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of monthly installment payments", "label": "Number Of Monthly Installment Payments", "documentation": "Number Of Monthly Installment Payments" } } }, "auth_ref": [] }, "ctre_NumberOfOperationalBedsAndUnitsInFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfOperationalBedsAndUnitsInFacilities", "presentation": [ "http://www.caretrustreit.com/role/ORGANIZATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operational beds and units in facilities", "label": "Number Of Operational Beds And Units In Facilities", "documentation": "Number Of Operational Beds And Units In Facilities" } } }, "auth_ref": [] }, "ctre_NumberOfPreferredEquityInvestment": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfPreferredEquityInvestment", "presentation": [ "http://www.caretrustreit.com/role/ORGANIZATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of preferred equity investments", "label": "Number Of Preferred Equity Investment", "documentation": "Number Of Preferred Equity Investment" } } }, "auth_ref": [] }, "ctre_NumberOfPropertiesAcquired": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfPropertiesAcquired", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Properties", "label": "Number Of Properties Acquired", "documentation": "Number Of Properties Acquired" } } }, "auth_ref": [] }, "ctre_NumberOfPropertiesWithRightToOperate": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfPropertiesWithRightToOperate", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of properties with right to operate", "label": "Number Of Properties With Right To Operate", "documentation": "Number Of Properties With Right To Operate" } } }, "auth_ref": [] }, "ctre_NumberOfPropertiesWithTenantPurchaseOption": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfPropertiesWithTenantPurchaseOption", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Properties", "label": "Number Of Properties With Tenant Purchase Option", "documentation": "Number Of Properties With Tenant Purchase Option" } } }, "auth_ref": [] }, "ctre_NumberOfPropertySecuredByAPledge": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfPropertySecuredByAPledge", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of property secured by pledge", "label": "Number Of Property Secured By A Pledge", "documentation": "Number Of Property Secured By A Pledge" } } }, "auth_ref": [] }, "ctre_NumberOfPurchaseOptionTypes": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfPurchaseOptionTypes", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of purchase option types", "label": "Number of Purchase Option Types", "documentation": "Number of Purchase Option Types" } } }, "auth_ref": [] }, "ctre_NumberOfPurchaseOptionWindow": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfPurchaseOptionWindow", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of purchase option window", "label": "Number Of Purchase Option Window", "documentation": "Number Of Purchase Option Window" } } }, "auth_ref": [] }, "us-gaap_NumberOfRealEstateProperties": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfRealEstateProperties", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysAssetsHeldforSaleActivityDetails", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysDispositionsDetails", "http://www.caretrustreit.com/role/ORGANIZATIONDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of properties", "terseLabel": "Number of properties", "periodStartLabel": "Number of facilities at beginning", "periodEndLabel": "Number of facilities at ending", "label": "Number of Real Estate Properties", "documentation": "The number of real estate properties owned as of the balance sheet date." } } }, "auth_ref": [] }, "ctre_NumberOfRealEstatePropertiesHeldForSale": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfRealEstatePropertiesHeldForSale", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysAssetsHeldforSaleActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of facilities, additions to assets held for sale", "label": "Number Of Real Estate Properties, Held-for-Sale", "documentation": "Number Of Real Estate Properties, Held-for-Sale" } } }, "auth_ref": [] }, "ctre_NumberOfRealEstatePropertiesImpairmentOfRealEstateHeldForSale": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfRealEstatePropertiesImpairmentOfRealEstateHeldForSale", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysAssetsHeldforSaleActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of facilities, impairment of real estate held for sale", "label": "Number Of Real Estate Properties, Impairment Of Real Estate Held For Sale", "documentation": "Number Of Real Estate Properties, Impairment Of Real Estate Held For Sale" } } }, "auth_ref": [] }, "ctre_NumberOfRealEstatePropertiesSold": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfRealEstatePropertiesSold", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysAssetsHeldforSaleActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of facilities, assets sold", "label": "Number Of Real Estate Properties Sold", "documentation": "Number Of Real Estate Properties Sold" } } }, "auth_ref": [] }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfStatesInWhichEntityOperates", "presentation": [ "http://www.caretrustreit.com/role/ORGANIZATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of states with properties", "label": "Number of States in which Entity Operates", "documentation": "The number of states the entity operates in as of the balance sheet date." } } }, "auth_ref": [] }, "ctre_NumberOfUnitsAndBedsInFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "NumberOfUnitsAndBedsInFacilities", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Beds/Units", "label": "Number Of Units And Beds In Facilities", "documentation": "Number Of Units And Beds In Facilities" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses:", "verboseLabel": "Expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLeaseIncome", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 }, "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRentalIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRentalIncomeDetails", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rental income", "totalLabel": "Total", "verboseLabel": "Rental income", "label": "Operating Lease, Lease Income", "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": [ "r245", "r545", "r548" ] }, "ctre_OperatingLeaseLeaseIncomeAmortizationOfBelowMarketLeaseIntangible": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "OperatingLeaseLeaseIncomeAmortizationOfBelowMarketLeaseIntangible", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRentalIncomeDetails": { "parentTag": "us-gaap_OperatingLeaseLeaseIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of below-market lease intangibles", "label": "Operating Lease, Lease Income, Amortization Of Below-Market Lease Intangible", "documentation": "Operating Lease, Lease Income, Amortization Of Below-Market Lease Intangible" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLeaseIncomeLeasePayments", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRentalIncomeDetails": { "parentTag": "us-gaap_OperatingLeaseLeaseIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual rent due", "label": "Operating Lease, Lease Income, Lease Payments", "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": [ "r245", "r549" ] }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Rental Income", "label": "Operating Lease, Lease Income [Table Text Block]", "documentation": "Tabular disclosure of components of income from operating lease." } } }, "auth_ref": [ "r245", "r548" ] }, "ctre_OperatingLeaseLessorCashYieldPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "OperatingLeaseLessorCashYieldPercentage", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial contractual cash yield", "label": "Operating Lease Lessor Cash Yield Percentage", "documentation": "Operating Lease Lessor Cash Yield Percentage" } } }, "auth_ref": [] }, "ctre_OperatingLeaseLessorCashYieldTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "OperatingLeaseLessorCashYieldTerm", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease lessor cash yield term", "label": "Operating Lease Lessor Cash Yield Term", "documentation": "Operating Lease Lessor Cash Yield Term" } } }, "auth_ref": [] }, "ctre_OperatingLeasesAnticipatedInitialAnnualLeaseRevenues": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "OperatingLeasesAnticipatedInitialAnnualLeaseRevenues", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial Annual Cash Rent", "label": "Operating Leases, Anticipated Initial Annual Lease Revenues", "documentation": "Operating Leases, Anticipated Initial Annual Lease Revenues" } } }, "auth_ref": [] }, "ctre_OperatingLeasesTenantOperatingExpenseReimbursement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "OperatingLeasesTenantOperatingExpenseReimbursement", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRentalIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tenant operating expense reimbursement", "label": "Operating Leases, Tenant Operating Expense Reimbursement", "documentation": "Operating Leases, Tenant Operating Expense Reimbursement" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.caretrustreit.com/role/ORGANIZATION" ], "lang": { "en-us": { "role": { "terseLabel": "ORGANIZATION", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r71", "r130", "r659", "r660" ] }, "us-gaap_OtherCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitment", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Funding commitment", "label": "Other Commitment", "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsAxis", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Axis]", "label": "Other Commitments [Axis]", "documentation": "Information by type of other commitment." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsDomain", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Domain]", "label": "Other Commitments [Domain]", "documentation": "Other future obligation." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsLineItems", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Line Items]", "label": "Other Commitments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsTable", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Table]", "label": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": [] }, "ctre_OtherFinancingReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "OtherFinancingReceivablesMember", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofInterestandOtherIncomeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing receivable", "label": "Other Financing Receivables [Member]", "documentation": "Other Financing Receivables" } } }, "auth_ref": [] }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other expenses", "label": "Other General and Administrative Expense", "documentation": "Amount of general and administrative expense classified as other." } } }, "auth_ref": [ "r103", "r1095" ] }, "ctre_OtherIncomeExcludingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "OtherIncomeExcludingInterest", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofInterestandOtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Income, Excluding Interest", "label": "Other Income, Excluding Interest", "documentation": "Other Income, Excluding Interest" } } }, "auth_ref": [] }, "us-gaap_OtherInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherInvestmentsMember", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Investments", "label": "Other Investments [Member]", "documentation": "Primary financial statement caption encompassing other investments." } } }, "auth_ref": [] }, "ctre_OtherLoansReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "OtherLoansReceivableMember", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other loans receivable", "label": "Other Loans Receivable [Member]", "documentation": "Other Loans Receivable" } } }, "auth_ref": [] }, "ctre_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "OtherMember", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofInterestandOtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other [Member]", "documentation": "Other" } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Noncash interest income", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r112" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r906" ] }, "ctre_OtherRealEstateRelatedAndOtherInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "OtherRealEstateRelatedAndOtherInvestmentsTextBlock", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS", "label": "Other Real Estate Related And Other Investments [Text Block]", "documentation": "Other Real Estate Related And Other Investments" } } }, "auth_ref": [] }, "ctre_OtherRealEstateRelatedInvestmentsFairValueAdjustmentsUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "OtherRealEstateRelatedInvestmentsFairValueAdjustmentsUnrealizedGain", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other real estate related investments, fair value adjustments, unrealized gain", "label": "Other Real Estate Related Investments, Fair Value Adjustments, Unrealized Gain", "documentation": "Other Real Estate Related Investments, Fair Value Adjustments, Unrealized Gain" } } }, "auth_ref": [] }, "ctre_OtherRealEstateRelatedInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "OtherRealEstateRelatedInvestmentsMember", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofRealEstateRelatedInvestmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Real Estate Related Investments", "label": "Other Real Estate Related Investments [Member]", "documentation": "Other Real Estate Related Investments" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r868", "r878", "r888", "r920" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r871", "r881", "r891", "r923" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r871", "r881", "r891", "r923" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParentMember", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Total Stockholders\u2019 Equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r895" ] }, "ctre_PayablesForPurchaseOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PayablesForPurchaseOfPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payables for purchase of property plant and equipment", "label": "Payables for Purchase of Property Plant and Equipment", "documentation": "Payables for Purchase of Property Plant and Equipment" } } }, "auth_ref": [] }, "us-gaap_PaymentsForDepositsOnRealEstateAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForDepositsOnRealEstateAcquisitions", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Escrow deposits for potential acquisitions of real estate", "label": "Payments for Deposits on Real Estate Acquisitions", "documentation": "Cash outflow related to amounts given in advance to show or confirm an intention to complete an acquisition of land, buildings, other structures, or any item classified as real estate." } } }, "auth_ref": [ "r971" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends paid on common stock", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r109" ] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of deferred financing costs", "label": "Payments of Financing Costs", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": [ "r22" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTScheduleofAtTheMarketOfferingProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commissions paid on stock issuance", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r22" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net-settle adjustment on restricted stock", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r192" ] }, "us-gaap_PaymentsToAcquireCommercialRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireCommercialRealEstate", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisitions of real estate, net of deposits applied", "label": "Payments to Acquire Commercial Real Estate", "documentation": "The cash outflow from the acquisition of property as primarily intended to generate income for its owner." } } }, "auth_ref": [ "r108" ] }, "ctre_PaymentsToAcquireEquipmentFurnitureAndFixturesAndDevelopRealEstateAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PaymentsToAcquireEquipmentFurnitureAndFixturesAndDevelopRealEstateAssets", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of equipment, furniture and fixtures and improvements to real estate", "label": "Payments To Acquire Equipment, Furniture And Fixtures And Develop Real Estate Assets", "documentation": "Payments To Acquire Equipment, Furniture And Fixtures And Develop Real Estate Assets" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireInterestInJointVenture": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInterestInJointVenture", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contributed to JV", "label": "Payments to Acquire Interest in Joint Venture", "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group." } } }, "auth_ref": [ "r19" ] }, "us-gaap_PaymentsToAcquireLoansReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireLoansReceivable", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Investment in real estate related investments", "label": "Payments to Acquire Loans Receivable", "documentation": "The cash outflow for the purchase of loan receivable arising from the financing of goods and services." } } }, "auth_ref": [ "r18" ] }, "us-gaap_PaymentsToMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToMinorityShareholders", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions to noncontrolling interests", "label": "Payments to Noncontrolling Interests", "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest." } } }, "auth_ref": [ "r22" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r905" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r905" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r897" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r914" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r907" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r896" ] }, "ctre_PercentageCap": { "xbrltype": "percentItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PercentageCap", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage cap", "label": "Percentage Cap", "documentation": "Percentage Cap" } } }, "auth_ref": [] }, "ctre_PerformanceSharesTSRUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PerformanceSharesTSRUnitsMember", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Shares T S R Units", "label": "Performance Shares T S R Units [Member]", "documentation": "Performance Shares T S R Units" } } }, "auth_ref": [] }, "ctre_PerformanceStockAwardsAndTotalShareholderReturnUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PerformanceStockAwardsAndTotalShareholderReturnUnitsMember", "presentation": [ "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PSAs and TSR Units", "label": "Performance Stock Awards And Total Shareholder Return Units [Member]", "documentation": "Performance Stock Awards And Total Shareholder Return Units" } } }, "auth_ref": [] }, "ctre_PeriodOfOptionWindow": { "xbrltype": "durationItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PeriodOfOptionWindow", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period of option window", "label": "Period Of Option Window", "documentation": "Period Of Option Window" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r898" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r942" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r897" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r528" ] }, "ctre_PortionOfCommitmentSubjectToRentIncreaseAtTimeOfFunding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PortionOfCommitmentSubjectToRentIncreaseAtTimeOfFunding", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion of funding commitment subject to rent increase at time of funding", "label": "Portion Of Commitment Subject To Rent Increase At Time Of Funding", "documentation": "Portion Of Commitment Subject To Rent Increase At Time Of Funding" } } }, "auth_ref": [] }, "ctre_PreferredEquityInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PreferredEquityInvestmentMember", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred equity investments", "label": "Preferred Equity Investment [Member]", "documentation": "Preferred Equity Investment" } } }, "auth_ref": [] }, "ctre_PreferredEquityInvestmentsMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PreferredEquityInvestmentsMeasurementInput", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement input", "label": "Preferred Equity Investments, Measurement Input", "documentation": "Preferred Equity Investments, Measurement Input" } } }, "auth_ref": [] }, "ctre_PreferredEquityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PreferredEquityMember", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred equity", "label": "Preferred Equity [Member]", "documentation": "Preferred Equity" } } }, "auth_ref": [] }, "ctre_PreferredOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PreferredOwnershipPercentage", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred ownership (as percent)", "label": "Preferred Ownership Percentage", "documentation": "Preferred Ownership Percentage" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in usd per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r92", "r413" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r92", "r694" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r92", "r413" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r92", "r694", "r712", "r1097", "r1098" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued and outstanding as of March 31, 2025 and December 31, 2024", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r92", "r631", "r829" ] }, "us-gaap_PrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other assets, net", "verboseLabel": "Prepaid and other assets", "label": "Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets." } } }, "auth_ref": [] }, "ctre_PrepaymentsOfOtherRealEstateRelatedInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PrepaymentsOfOtherRealEstateRelatedInvestments", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofRealEstateRelatedInvestmentActivityDetails": { "parentTag": "ctre_LoanReceivableNetChangeFairValue", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofRealEstateRelatedInvestmentActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepayments of other real estate related investments", "label": "Prepayments Of Other Real Estate Related Investments", "documentation": "Prepayments Of Other Real Estate Related Investments" } } }, "auth_ref": [] }, "ctre_PricePerUnitValueMeasurementInput": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PricePerUnitValueMeasurementInput", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prices per unit input", "label": "Price Per Unit, Value, Measurement Input", "documentation": "Price Per Unit, Value, Measurement Input" } } }, "auth_ref": [] }, "ctre_PrincipalAmountAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PrincipalAmountAfterAllowanceForCreditLoss", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal Balance", "label": "Principal Amount after Allowance for Credit Loss", "documentation": "Principal Amount after Allowance for Credit Loss" } } }, "auth_ref": [] }, "ctre_PriorityManagementGroupLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PriorityManagementGroupLLCMember", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PACS", "label": "Priority Management Group LLC [Member]", "documentation": "Priority Management Group LLC" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromCollectionOfLoansReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromCollectionOfLoansReceivable", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Principal payments received on real estate related investments and other loans receivable", "label": "Proceeds from Collection of Loans Receivable", "documentation": "The cash inflow associated with the collection, including prepayments, of loans receivable issued for financing of goods and services." } } }, "auth_ref": [ "r17" ] }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from issuance", "label": "Proceeds from Debt, Net of Issuance Costs", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination." } } }, "auth_ref": [ "r191" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTScheduleofAtTheMarketOfferingProgramDetails" ], "lang": { "en-us": { "role": { "netLabel": "Proceeds from the issuance of common stock, net", "terseLabel": "Gross proceeds", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfUnsecuredDebt", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Gross proceeds from issuance", "label": "Proceeds from Issuance of Unsecured Debt", "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance or sale of equity", "label": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r2", "r662" ] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings under unsecured revolving credit facility", "label": "Proceeds from Long-Term Lines of Credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ProceedsFromMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMinorityShareholders", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Contributions from noncontrolling interests", "label": "Proceeds from Noncontrolling Interests", "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ProceedsFromSaleOfFinanceReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfFinanceReceivables", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of finance receivables", "label": "Proceeds from Sale of Finance Receivables", "documentation": "The cash inflow associated with the sale of receivables arising from the financing of goods and services." } } }, "auth_ref": [ "r970" ] }, "us-gaap_ProceedsFromSaleOfRealEstateHeldforinvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfRealEstateHeldforinvestment", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from sales of real estate", "netLabel": "Net sales proceeds", "label": "Proceeds from Sale, Real Estate, Held-for-Investment", "documentation": "Cash received from the sale of real estate that is held for investment, that is, it is part of an investing activity during the period." } } }, "auth_ref": [ "r107" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfessionalFees", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Professional services", "label": "Professional Fees", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r786", "r855", "r1094", "r1095" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 }, "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "terseLabel": "Net income (loss)", "verboseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r175", "r183", "r184", "r194", "r201", "r208", "r214", "r217", "r218", "r323", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r482", "r486", "r487", "r490", "r491", "r504", "r530", "r624", "r635", "r667", "r714", "r730", "r731", "r817", "r818", "r856", "r967", "r1009" ] }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationJanuary2030NextOption2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PropertiesWithPurchaseOptionLeaseExpirationJanuary2030NextOption2026Member", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Expiration January 2030, Next Option 2026", "label": "Properties With Purchase Option, Lease Expiration January 2030, Next Option 2026 [Member]", "documentation": "Properties With Purchase Option, Lease Expiration January 2030, Next Option 2026" } } }, "auth_ref": [] }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationMarch2029NextOption2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PropertiesWithPurchaseOptionLeaseExpirationMarch2029NextOption2022Member", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Expiration March 2029, Next option 2022", "label": "Properties With Purchase Option, Lease Expiration March 2029, Next Option 2022 [Member]", "documentation": "Properties With Purchase Option, Lease Expiration March 2029, Next Option 2022" } } }, "auth_ref": [] }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2026Member", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Expiration May 2034, Next option 2026", "label": "Properties With Purchase Option, Lease Expiration May 2034, Next Option 2026 [Member]", "documentation": "Properties With Purchase Option, Lease Expiration May 2034, Next Option 2026" } } }, "auth_ref": [] }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2027Member", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Expiration May 2034, Next option 2027", "label": "Properties With Purchase Option, Lease Expiration May 2034, Next Option 2027 [Member]", "documentation": "Properties With Purchase Option, Lease Expiration May 2034, Next Option 2027" } } }, "auth_ref": [] }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationNovember2034NextOption2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PropertiesWithPurchaseOptionLeaseExpirationNovember2034NextOption2027Member", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Expiration November 2034, Next Option 2027", "label": "Properties With Purchase Option, Lease Expiration November 2034, Next Option 2027 [Member]", "documentation": "Properties With Purchase Option, Lease Expiration November 2034, Next Option 2027" } } }, "auth_ref": [] }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationNovember2039NextOption2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PropertiesWithPurchaseOptionLeaseExpirationNovember2039NextOption2027Member", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Expiration November 2039, Next Option 2027", "label": "Properties With Purchase Option, Lease Expiration November 2039, Next Option 2027 [Member]", "documentation": "Properties With Purchase Option, Lease Expiration November 2039, Next Option 2027" } } }, "auth_ref": [] }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationOctober2032NextOption2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PropertiesWithPurchaseOptionLeaseExpirationOctober2032NextOption2027Member", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Expiration October 2032, Next option 2027", "label": "Properties With Purchase Option, Lease Expiration October 2032, Next Option 2027 [Member]", "documentation": "Properties With Purchase Option, Lease Expiration October 2032, Next Option 2027" } } }, "auth_ref": [] }, "us-gaap_ProvisionForLoanLossesExpensed": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForLoanLossesExpensed", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for loan losses, net", "label": "Financing Receivable, Credit Loss, Expense (Reversal)", "documentation": "Amount of credit loss expense (reversal of expense) for financing receivable." } } }, "auth_ref": [ "r330", "r622" ] }, "ctre_PurchaseOptionNumberOfProperties": { "xbrltype": "integerItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PurchaseOptionNumberOfProperties", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase option, number of properties", "label": "Purchase Option, Number Of Properties", "documentation": "Purchase Option, Number Of Properties" } } }, "auth_ref": [] }, "ctre_PurchaseOptionWindowOpenPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "PurchaseOptionWindowOpenPeriod", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase option, window open period", "label": "Purchase Option, Window Open Period", "documentation": "Purchase Option, Window Open Period" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r895" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r895" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails", "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r368", "r369", "r370", "r371", "r429", "r436", "r465", "r466", "r467", "r475", "r510", "r562", "r571", "r588", "r652", "r653", "r657", "r683", "r684", "r737", "r740", "r744", "r745", "r747", "r773", "r774", "r791", "r804", "r812", "r821", "r822", "r826", "r827", "r840", "r848", "r1004", "r1013", "r1029", "r1047", "r1048", "r1049", "r1050", "r1051" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails", "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r368", "r369", "r370", "r371", "r429", "r436", "r465", "r466", "r467", "r475", "r510", "r562", "r571", "r588", "r652", "r653", "r657", "r683", "r684", "r737", "r740", "r744", "r745", "r747", "r773", "r774", "r791", "r804", "r812", "r821", "r822", "r826", "r827", "r840", "r848", "r1004", "r1013", "r1029", "r1047", "r1048", "r1049", "r1050", "r1051" ] }, "us-gaap_RealEstateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateAbstract", "lang": { "en-us": { "role": { "terseLabel": "Real Estate [Abstract]", "label": "Real Estate [Abstract]" } } }, "auth_ref": [] }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysDispositionsDetails", "http://www.caretrustreit.com/role/ORGANIZATIONDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Axis]", "label": "Name of Property [Axis]" } } }, "auth_ref": [ "r761", "r766", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106" ] }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysDispositionsDetails", "http://www.caretrustreit.com/role/ORGANIZATIONDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Domain]", "label": "Name of Property [Domain]" } } }, "auth_ref": [ "r761", "r766", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106" ] }, "us-gaap_RealEstateDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateDisclosureTextBlock", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNET" ], "lang": { "en-us": { "role": { "terseLabel": "REAL ESTATE INVESTMENTS, NET", "label": "Real Estate Disclosure [Text Block]", "documentation": "The entire disclosure for certain real estate investment financial statements, real estate investment trust operating support agreements, real estate owned, retail land sales, time share transactions, as well as other real estate related disclosures." } } }, "auth_ref": [ "r145", "r146", "r147", "r148", "r149", "r772" ] }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofInvestmentinOwnedPropertiesDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofInvestmentinOwnedPropertiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated depreciation and amortization", "label": "Real Estate Investment Property, Accumulated Depreciation", "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes." } } }, "auth_ref": [ "r625" ] }, "ctre_RealEstateInvestmentPropertyAssetsHeldForSaleAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "RealEstateInvestmentPropertyAssetsHeldForSaleAdditions", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysAssetsHeldforSaleActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net carrying value, additions to assets held for sale", "label": "Real Estate Investment Property, Assets Held For Sale, Additions", "documentation": "Real Estate Investment Property, Assets Held For Sale, Additions" } } }, "auth_ref": [] }, "ctre_RealEstateInvestmentPropertyAssetsHeldForSaleDispositions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "RealEstateInvestmentPropertyAssetsHeldForSaleDispositions", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysAssetsHeldforSaleActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net carrying value, assets sold", "label": "Real Estate Investment Property, Assets Held For Sale, Dispositions", "documentation": "Real Estate Investment Property, Assets Held For Sale, Dispositions" } } }, "auth_ref": [] }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateInvestmentPropertyAtCost", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofInvestmentinOwnedPropertiesDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysAssetsHeldforSaleActivityDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofInvestmentinOwnedPropertiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Real estate investments", "periodStartLabel": "Net carrying value at beginning", "periodEndLabel": "Net carrying value at ending", "label": "Real Estate Investment Property, at Cost", "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments." } } }, "auth_ref": [ "r626", "r627" ] }, "ctre_RealEstateInvestmentPropertyImpairmentOfRealEstateHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "RealEstateInvestmentPropertyImpairmentOfRealEstateHeldForSale", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysAssetsHeldforSaleActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net carrying value, impairment of real estate held for sale", "label": "Real Estate Investment Property, Impairment Of Real Estate Held For Sale", "documentation": "Real Estate Investment Property, Impairment Of Real Estate Held For Sale" } } }, "auth_ref": [] }, "us-gaap_RealEstateInvestmentPropertyNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateInvestmentPropertyNet", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofInvestmentinOwnedPropertiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofInvestmentinOwnedPropertiesDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real estate investments, net", "totalLabel": "Real estate investments, net", "label": "Real Estate Investment Property, Net", "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments." } } }, "auth_ref": [ "r1055", "r1056" ] }, "ctre_RealEstateInvestmentPropertyNetCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "RealEstateInvestmentPropertyNetCarryingValue", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESScheduleofCompanysDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net carrying value", "label": "Real Estate Investment Property, Net Carrying Value", "documentation": "Real Estate Investment Property, Net Carrying Value" } } }, "auth_ref": [] }, "ctre_RealEstateInvestmentsAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "RealEstateInvestmentsAccruedInterest", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Other real estate related investments, accrued interest", "label": "Real Estate Investments, Accrued Interest", "documentation": "Real Estate Investments, Accrued Interest" } } }, "auth_ref": [] }, "us-gaap_RealEstateInvestmentsJointVentures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateInvestmentsJointVentures", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.caretrustreit.com/role/ORGANIZATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other real estate related investments (including accrued interest of $6,005 as of March 31, 2025 and $4,725 as of December 31, 2024)", "verboseLabel": "Aggregate carrying value", "label": "Real Estate Investments, Joint Ventures", "documentation": "The book value of investments in real estate joint ventures including direct and indirect investments." } } }, "auth_ref": [ "r1055", "r1056" ] }, "us-gaap_RealEstateLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateLineItems", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate [Line Items]", "label": "Real Estate [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r773" ] }, "us-gaap_RealEstatePropertiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstatePropertiesLineItems", "presentation": [ "http://www.caretrustreit.com/role/ORGANIZATIONDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofInterestandOtherIncomeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentActivityDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Properties [Line Items]", "label": "Real Estate Properties [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RealEstateTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateTable", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate [Table]", "label": "Real Estate [Table]", "documentation": "Disclosure of information about real estate investment companies including, but not limited to, real estate investment trusts, real estate owned, retail land sales, and time share transactions." } } }, "auth_ref": [ "r773" ] }, "us-gaap_RealEstateTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateTaxExpense", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property taxes", "verboseLabel": "Property taxes", "label": "Real Estate Tax Expense", "documentation": "A tax based on the assessed value of real estate by the local government. The tax is usually based on the value of property (including the land)." } } }, "auth_ref": [ "r815" ] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivableTypeDomain", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofItemsMeasuredatFairValueonaRecurringBasisDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails", "http://www.caretrustreit.com/role/ORGANIZATIONDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable [Domain]", "label": "Receivable [Domain]", "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": [ "r94", "r99" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r863", "r873", "r883", "r915" ] }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable noncontrolling interest", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } }, "auth_ref": [ "r42", "r43", "r123", "r124" ] }, "ctre_RemainingCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "RemainingCommitmentMember", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Commitment", "label": "Remaining Commitment [Member]", "documentation": "Remaining Commitment" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of Debt", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r972" ] }, "ctre_ReportableSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "ReportableSegmentMember", "presentation": [ "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reportable Segment", "label": "Reportable Segment [Member]", "documentation": "Reportable Segment" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r202", "r203", "r387", "r415", "r551", "r572", "r626", "r778", "r779" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r864", "r874", "r884", "r916" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r865", "r875", "r885", "r917" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r872", "r882", "r892", "r924" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 }, "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "verboseLabel": "Restricted cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r964", "r974", "r1052", "r1059" ] }, "ctre_RestrictedStockAndPerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "RestrictedStockAndPerformanceSharesMember", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSAs and PSAs", "label": "Restricted Stock And Performance Shares [Member]", "documentation": "Restricted Stock And Performance Shares [Member]" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockAwardandPerformanceAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSAs", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r29" ] }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of stock-based compensation awards, net of shares withheld for employee taxes (in shares)", "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of stock-based compensation awards, net of shares withheld for employee taxes", "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth_ref": [] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r150", "r151", "r188", "r201", "r244", "r254", "r255", "r270", "r276", "r279", "r281", "r283", "r323", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r530", "r624", "r786", "r1009" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues:", "verboseLabel": "Revenues:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails", "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unsecured revolving credit facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Risks and Uncertainties [Abstract]", "label": "Risks and Uncertainties [Abstract]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r933" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r933" ] }, "us-gaap_SaleLeasebackTransactionLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleLeasebackTransactionLeaseTerm", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale leaseback transaction, lease term", "label": "Sale Leaseback Transaction, Lease Term", "documentation": "Lease term for sale and leaseback transaction, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1042" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails", "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTScheduleofAtTheMarketOfferingProgramDetails", "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, number of shares issued in transaction", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price (in usd per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rental Revenue", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r283", "r948" ] }, "ctre_ScheduleOfAssetSalesAndHeldForSaleReclassificationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "ScheduleOfAssetSalesAndHeldForSaleReclassificationsTableTextBlock", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Asset Sales and Held for Sale Reclassifications", "label": "Schedule Of Asset Sales And Held For Sale Reclassifications [Table Text Block]", "documentation": "Schedule Of Asset Sales And Held For Sale Reclassifications" } } }, "auth_ref": [] }, "ctre_ScheduleOfAssetsAcquisitionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "ScheduleOfAssetsAcquisitionsTableTextBlock", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recent Real Estate Acquisitions", "label": "Schedule Of Assets Acquisitions [Table Text Block]", "documentation": "Schedule Of Assets Acquisitions" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r54", "r55", "r484" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.caretrustreit.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash, Cash Equivalents and Restricted Cash", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.caretrustreit.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r13", "r46", "r49", "r70", "r126", "r127", "r800", "r802", "r978", "r1036" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Weighted-Average Common Shares Outstanding Used in Calculation of Basic EPS to Diluted EPS", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r984" ] }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable", "presentation": [ "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]", "label": "Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]", "documentation": "Disclosure of information about diluted earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": [ "r28", "r30", "r223", "r227", "r235" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r51" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r320", "r321", "r322", "r478", "r945", "r946", "r947", "r1016", "r1017", "r1018", "r1019" ] }, "us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFinancingReceivableAllowanceForCreditLossesTable", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofRealEstateRelatedInvestmentActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Allowance for Credit Loss [Table]", "label": "Financing Receivable, Allowance for Credit Loss [Table]", "documentation": "Disclosure of information about allowance for credit loss on financing receivable." } } }, "auth_ref": [ "r170", "r997" ] }, "us-gaap_ScheduleOfFinancingReceivablesPastDueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFinancingReceivablesPastDueTable", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Past Due [Table]", "label": "Financing Receivable, Past Due [Table]", "documentation": "Disclosure of information about aging analysis for financing receivable." } } }, "auth_ref": [ "r795", "r998" ] }, "ctre_ScheduleOfLoanReceivableActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "ScheduleOfLoanReceivableActivityTableTextBlock", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Loan Receivable Activity", "label": "Schedule of Loan Receivable Activity [Table Text Block]", "documentation": "Schedule of Loan Receivable Activity" } } }, "auth_ref": [] }, "ctre_ScheduleOfOtherRealEstateInvestmentActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "ScheduleOfOtherRealEstateInvestmentActivityTableTextBlock", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Real Estate Related Investment Activity", "label": "Schedule of Other Real Estate Investment Activity [Table Text Block]", "documentation": "Schedule of Other Real Estate Investment Activity" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRealEstatePropertiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRealEstatePropertiesTable", "presentation": [ "http://www.caretrustreit.com/role/ORGANIZATIONDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofInterestandOtherIncomeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentActivityDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Real Estate Properties [Table]", "label": "Real Estate Property, Ownership [Table]", "documentation": "Disclosure of information about real estate property by ownership of property." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRealEstatePropertiesTableTextBlock", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investment in Owned Properties", "label": "Schedule of Real Estate Properties [Table Text Block]", "documentation": "Tabular disclosure of real estate properties and units in those properties that are included in the discussion of the nature of an entity's operations." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r36", "r37", "r38" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.caretrustreit.com/role/SEGMENTREPORTINGTables" ], "lang": { "en-us": { "role": { "terseLabel": "CODM Evaluation of Performance Based on Net Income", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r36", "r37", "r38" ] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Award and Performance Award Activity", "label": "Share-Based Payment Arrangement, Activity [Table Text Block]", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": [ "r10", "r11", "r129" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockAwardandPerformanceAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r438", "r440", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails", "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTScheduleofAtTheMarketOfferingProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r44", "r45", "r46", "r47", "r48", "r49", "r122", "r126", "r127", "r128", "r178", "r179", "r180", "r247", "r413", "r414", "r415", "r417", "r420", "r425", "r427", "r662", "r663", "r664", "r665", "r804", "r944", "r975" ] }, "us-gaap_ScheduleOfStockByClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTextBlock", "presentation": [ "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of At-The-Market Offering Program", "label": "Schedule of Stock by Class [Table Text Block]", "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding." } } }, "auth_ref": [ "r14", "r41", "r44", "r45", "r46", "r47", "r48", "r49", "r92", "r93", "r126", "r127", "r128" ] }, "ctre_ScheduleOfTenantPurchaseOptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "ScheduleOfTenantPurchaseOptionsTableTextBlock", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Tenant Purchase Options", "label": "Schedule of Tenant Purchase Options [Table Text Block]", "documentation": "Schedule of Tenant Purchase Options" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Variable Interest Entities", "label": "Schedule of Variable Interest Entities [Table Text Block]", "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide." } } }, "auth_ref": [ "r59", "r60", "r61", "r62", "r63" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedules of Concentration of Risk", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r31", "r32", "r34", "r35", "r68", "r134" ] }, "ctre_SecondOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "SecondOptionMember", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second Option", "label": "Second Option [Member]", "documentation": "Second Option" } } }, "auth_ref": [] }, "ctre_SecuredAndMezzanineLoansReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "SecuredAndMezzanineLoansReceivableMember", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured and Mezzanine Loans Receivable", "label": "Secured And Mezzanine Loans Receivable [Member]", "documentation": "Secured And Mezzanine Loans Receivable" } } }, "auth_ref": [] }, "ctre_SecuredOvernightFinancingRateSOFRFloorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "SecuredOvernightFinancingRateSOFRFloorMember", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR) Floor", "label": "Secured Overnight Financing Rate (SOFR) Floor [Member]", "documentation": "Secured Overnight Financing Rate (SOFR) Floor" } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": [ "r1023" ] }, "ctre_SecuritiesOfferingAuthorizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "SecuritiesOfferingAuthorizedAmount", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized aggregate offering price of common stock", "label": "Securities Offering, Authorized Amount", "documentation": "Securities Offering, Authorized Amount" } } }, "auth_ref": [] }, "ctre_SecuritiesOfferingRemainingAuthorizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "SecuritiesOfferingRemainingAuthorizedAmount", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining offering amount available", "label": "Securities Offering, Remaining Authorized Amount", "documentation": "Securities Offering, Remaining Authorized Amount" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r858" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r860" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r150", "r151", "r152", "r153", "r244", "r250", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r264", "r265", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r276", "r277", "r278", "r283", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r356", "r364", "r365", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r783", "r786", "r787", "r797", "r842", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails", "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r281", "r282", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r680", "r681", "r682", "r739", "r742", "r746", "r749", "r757", "r761", "r762", "r763", "r764", "r767", "r768", "r769", "r770", "r771", "r775", "r805", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r841", "r848", "r1015", "r1062", "r1063", "r1064", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.caretrustreit.com/role/SEGMENTREPORTING" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT REPORTING", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r153", "r244", "r249", "r250", "r251", "r252", "r253", "r266", "r268", "r269", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r283", "r782", "r784", "r785", "r786", "r788", "r789", "r790" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": [ "http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails", "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Notes payable", "terseLabel": "Notes Payable", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "ctre_SeniorUnsecuredNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "SeniorUnsecuredNotesMember", "presentation": [ "http://www.caretrustreit.com/role/DEBTScheduleofDebtInstrumentsDetails", "http://www.caretrustreit.com/role/DEBTSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior unsecured notes payable", "verboseLabel": "2028 Senior Notes", "label": "Senior Unsecured Notes [Member]", "documentation": "Senior Unsecured Notes [Member]" } } }, "auth_ref": [] }, "ctre_SeniorUnsecuredTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "SeniorUnsecuredTermLoanMember", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior unsecured term loan", "label": "Senior Unsecured Term Loan [Member]", "documentation": "Senior Unsecured Term Loan [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r813" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockAwardandPerformanceAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r457" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockAwardandPerformanceAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r457" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockAwardandPerformanceAwardActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested, beginning balance (in shares)", "periodEndLabel": "Unvested, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r454", "r455" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockAwardandPerformanceAwardActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested, beginning balance (in usd per share)", "periodEndLabel": "Unvested, ending balance (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r454", "r455" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockAwardandPerformanceAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Share Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockAwardandPerformanceAwardActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r458" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockAwardandPerformanceAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r458" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockAwardandPerformanceAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r438", "r440", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockAwardandPerformanceAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized for awards (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r814" ] }, "ctre_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingBasedOnTotalShareholderReturnMetricPercentageOfOriginalAwardsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingBasedOnTotalShareholderReturnMetricPercentageOfOriginalAwardsGranted", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment award, percentage of original awards granted", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Based On Total Shareholder Return Metric, Percentage Of Original Awards Granted", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Based On Total Shareholder Return Metric, Percentage Of Original Awards Granted" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails", "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockAwardandPerformanceAwardActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining vesting period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r462" ] }, "ctre_SharesIssuedDuringPeriodAveragePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "SharesIssuedDuringPeriodAveragePricePerShare", "presentation": [ "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTScheduleofAtTheMarketOfferingProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average sales price per share (in usd per share)", "label": "Shares Issued During Period, Average Price Per Share", "documentation": "Shares Issued During Period, Average Price Per Share" } } }, "auth_ref": [] }, "ctre_SkilledNursingAndCampusFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "SkilledNursingAndCampusFacilitiesMember", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "SNF / Campus", "label": "Skilled Nursing And Campus Facilities [Member]", "documentation": "Skilled Nursing And Campus Facilities" } } }, "auth_ref": [] }, "ctre_SkilledNursingFacilityCaliforniaJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "SkilledNursingFacilityCaliforniaJointVentureMember", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Skilled Nursing Facility, California, Joint Venture", "label": "Skilled Nursing Facility, California, Joint Venture [Member]", "documentation": "Skilled Nursing Facility, California, Joint Venture" } } }, "auth_ref": [] }, "ctre_SkilledNursingFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "SkilledNursingFacilityMember", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails", "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofOtherRealEstateRelatedInvestmentsAtFairValueDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofTenantPurchaseOptionsDetails", "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "SNF", "terseLabel": "SNF", "label": "Skilled Nursing Facility [Member]", "documentation": "Skilled Nursing Facility [Member]" } } }, "auth_ref": [] }, "ctre_SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember", "presentation": [ "http://www.caretrustreit.com/role/ORGANIZATIONDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities", "terseLabel": "Skilled Nursing, Multi-Service Campuses, Assisted living and Independent Living Facilities", "label": "Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities [Member]", "documentation": "Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities" } } }, "auth_ref": [] }, "ctre_SkilledNursingPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "SkilledNursingPropertiesMember", "presentation": [ "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETLeaseAmendmentsandTerminationsNarrativeDetails", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Skilled nursing", "label": "Skilled Nursing Properties [Member]", "documentation": "Skilled Nursing Properties [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r150", "r151", "r152", "r153", "r173", "r244", "r250", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r264", "r265", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r276", "r277", "r278", "r283", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r356", "r358", "r364", "r365", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r783", "r786", "r787", "r797", "r842", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r162", "r178", "r179", "r180", "r201", "r223", "r227", "r235", "r239", "r247", "r248", "r323", "r374", "r376", "r377", "r378", "r381", "r382", "r413", "r414", "r417", "r420", "r427", "r530", "r662", "r663", "r664", "r665", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r694", "r715", "r732", "r750", "r751", "r752", "r753", "r754", "r944", "r975", "r983" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r93", "r96", "r97", "r171", "r185", "r186", "r187", "r205", "r206", "r207", "r209", "r214", "r216", "r218", "r246", "r324", "r325", "r357", "r428", "r476", "r477", "r479", "r480", "r481", "r483", "r485", "r486", "r494", "r495", "r496", "r497", "r498", "r499", "r502", "r531", "r532", "r533", "r534", "r535", "r536", "r541", "r543", "r550", "r638", "r654", "r655", "r656", "r668", "r732" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails", "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r281", "r282", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r680", "r681", "r682", "r739", "r742", "r746", "r749", "r757", "r761", "r762", "r763", "r764", "r767", "r768", "r769", "r770", "r771", "r775", "r805", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r841", "r848", "r1015", "r1062", "r1063", "r1064", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r205", "r206", "r207", "r246", "r543", "r589", "r661", "r679", "r685", "r687", "r688", "r689", "r690", "r691", "r694", "r696", "r697", "r698", "r699", "r700", "r702", "r703", "r704", "r705", "r707", "r708", "r709", "r710", "r711", "r713", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r732", "r849" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r205", "r206", "r207", "r246", "r284", "r543", "r589", "r661", "r679", "r685", "r687", "r688", "r689", "r690", "r691", "r694", "r696", "r697", "r698", "r699", "r700", "r702", "r703", "r704", "r705", "r707", "r708", "r709", "r710", "r711", "r713", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r732", "r849" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r867", "r877", "r887", "r919" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST", "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTScheduleofAtTheMarketOfferingProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock, net (in shares)", "verboseLabel": "Number of shares (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r9", "r92", "r93", "r128", "r662", "r732", "r751" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock, net", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r9", "r92", "r93", "r128", "r668", "r732", "r751", "r856" ] }, "ctre_StockIssuedTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "StockIssuedTerm", "presentation": [ "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term", "label": "Stock Issued, Term", "documentation": "Stock Issued, Term" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r93", "r96", "r97", "r116", "r695", "r712", "r733", "r734", "r829", "r857", "r977", "r995", "r1034", "r1097" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r56", "r57", "r64", "r171", "r172", "r186", "r205", "r206", "r207", "r209", "r214", "r216", "r324", "r325", "r357", "r428", "r476", "r477", "r479", "r480", "r481", "r483", "r485", "r486", "r494", "r495", "r496", "r497", "r498", "r499", "r502", "r531", "r532", "r536", "r542", "r550", "r655", "r656", "r666", "r695", "r712", "r733", "r734", "r755", "r856", "r977", "r995", "r1034", "r1097" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "EQUITY AND REDEEMABLE NONCONTROLLING INTEREST", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r125", "r200", "r412", "r414", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r426", "r428", "r501", "r735", "r736", "r756" ] }, "us-gaap_StraightLineRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StraightLineRent", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRentalIncomeDetails": { "parentTag": "us-gaap_OperatingLeaseLeaseIncome", "weight": 1.0, "order": 4.0 }, "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.caretrustreit.com/role/REALESTATEINVESTMENTSNETScheduleofRentalIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Straight-line rental income", "terseLabel": "Straight-line rent", "label": "Straight Line Rent", "documentation": "Difference between actual rental income due and rental income recognized on a straight-line basis." } } }, "auth_ref": [ "r4" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r537", "r554" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r537", "r554" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r537", "r554" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r537", "r554" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r537", "r554" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.caretrustreit.com/role/SUBSEQUENTEVENTS" ], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r553", "r555" ] }, "ctre_SubservicingFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "SubservicingFeePercentage", "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subservicing fee percentage", "label": "Subservicing Fee Percentage", "documentation": "Subservicing Fee Percentage" } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails", "http://www.caretrustreit.com/role/EQUITYANDREDEEMABLENONCONTROLLINGINTERESTScheduleofAtTheMarketOfferingProgramDetails", "http://www.caretrustreit.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosures of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ctre_SwinglineLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "SwinglineLoanMember", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Swingline Loan", "label": "Swingline Loan [Member]", "documentation": "Swingline Loan [Member]" } } }, "auth_ref": [] }, "stpr_TN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "TN", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TN", "label": "TENNESSEE" } } }, "auth_ref": [] }, "stpr_TX": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "TX", "presentation": [ "http://www.caretrustreit.com/role/CONCENTRATIONOFRISKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TX", "label": "TEXAS" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r913" ] }, "ctre_TaxesAndInsuranceExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "TaxesAndInsuranceExpenses", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes and insurance", "label": "Taxes And Insurance Expenses", "documentation": "Taxes And Insurance Expenses" } } }, "auth_ref": [] }, "ctre_TemporaryEquityContributionsFromNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "TemporaryEquityContributionsFromNoncontrollingInterests", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Contributions from noncontrolling interests", "label": "Temporary Equity, Contributions From Noncontrolling Interests", "documentation": "Temporary Equity, Contributions From Noncontrolling Interests" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityNetIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityNetIncome", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)", "label": "Temporary Equity, Net Income", "documentation": "The portion of net income or loss attributable to temporary equity interest." } } }, "auth_ref": [] }, "ctre_TenantESGProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "TenantESGProgramMember", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tenant ESG Program", "label": "Tenant ESG Program [Member]", "documentation": "Tenant ESG Program" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r985", "r1043" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.caretrustreit.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r905" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r912" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r932" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r934" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ctre_TransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "TransactionCosts", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs", "label": "Transaction Costs", "documentation": "Transaction Costs" } } }, "auth_ref": [] }, "ctre_TransferOfPreacquisitionCostsToAcquiredAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "TransferOfPreacquisitionCostsToAcquiredAssets", "crdr": "debit", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer of pre-acquisition costs to acquired assets", "label": "Transfer Of Preacquisition Costs To Acquired Assets", "documentation": "Transfer Of Preacquisition Costs To Acquired Assets" } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r408", "r425", "r500", "r527", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r639", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r830", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r991", "r992", "r993", "r994", "r1025", "r1028", "r1029", "r1030", "r1031", "r1032" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r935" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r936" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r936" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r934" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r934" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r937" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r935" ] }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "crdr": "debit", "calculation": { "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Net income allocated to participating securities", "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic", "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method." } } }, "auth_ref": [ "r233", "r236", "r237" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r931" ] }, "ctre_UnrealizedGainLossOnDecreaseInProjectedForwardInterestRates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "UnrealizedGainLossOnDecreaseInProjectedForwardInterestRates", "crdr": "credit", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on increases in projected forward interest rates", "label": "Unrealized Gain (Loss) On Decrease In Projected Forward Interest Rates", "documentation": "Unrealized Gain (Loss) On Decrease In Projected Forward Interest Rates" } } }, "auth_ref": [] }, "ctre_UnrealizedGainLossOnOtherRealEstateRelatedInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "UnrealizedGainLossOnOtherRealEstateRelatedInvestments", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS": { "parentTag": "us-gaap_NonoperatingGainsLosses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails", "http://www.caretrustreit.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on other real estate related investments, net", "verboseLabel": "Unrealized gain, net", "negatedTerseLabel": "Unrealized (gain) loss on other real estate related investments, net", "netLabel": "Unrealized gain (loss) on other real estate related investments, net", "label": "Unrealized Gain (Loss) On Other Real Estate Related Investments", "documentation": "Unrealized Gain (Loss) On Other Real Estate Related Investments" } } }, "auth_ref": [] }, "ctre_UnrealizedGainLossOnOtherRealEstateRelatedInvestmentsOperatingCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "UnrealizedGainLossOnOtherRealEstateRelatedInvestmentsOperatingCashFlows", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized (gain) loss on other real estate related investments, net", "label": "Unrealized Gain (Loss) On Other Real Estate Related Investments, Operating Cash Flows", "documentation": "Unrealized Gain (Loss) On Other Real Estate Related Investments, Operating Cash Flows" } } }, "auth_ref": [] }, "ctre_UnrealizedLossOnOtherRealEstateRelatedInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caretrustreit.com/20250331", "localname": "UnrealizedLossOnOtherRealEstateRelatedInvestments", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofRealEstateRelatedInvestmentActivityDetails": { "parentTag": "ctre_LoanReceivableNetChangeFairValue", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSScheduleofRealEstateRelatedInvestmentActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized gain (loss) on other real estate related investments, net", "label": "Unrealized Loss on Other Real Estate Related Investments", "documentation": "Unrealized Loss on Other Real Estate Related Investments" } } }, "auth_ref": [] }, "us-gaap_UnsecuredLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnsecuredLongTermDebt", "crdr": "credit", "calculation": { "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Senior unsecured notes payable, net", "label": "Unsecured Long-Term Debt, Noncurrent", "documentation": "Carrying value as of the balance sheet date of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r13" ] }, "stpr_VA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "VA", "presentation": [ "http://www.caretrustreit.com/role/COMMITMENTSANDCONTINGENCIESScheduleofCommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "VIRGINIA", "label": "VIRGINIA" } } }, "auth_ref": [] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueAxis", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Axis]", "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r508", "r509", "r821", "r1030" ] }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discounted cash flow", "label": "Valuation Technique, Discounted Cash Flow [Member]", "documentation": "Valuation technique calculating present value of future cash flows." } } }, "auth_ref": [ "r821", "r1028", "r1029", "r1030" ] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDomain", "presentation": [ "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.caretrustreit.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationAboutUnobservableInputsRelatedtoLevel3FairValueMeasurementsDetails", "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Domain]", "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r508", "r509", "r821", "r1030" ] }, "us-gaap_VariableInterestEntityDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityDisclosureTextBlock", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIES" ], "lang": { "en-us": { "role": { "terseLabel": "VARIABLE INTEREST ENTITIES", "label": "Variable Interest Entity Disclosure [Text Block]", "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss." } } }, "auth_ref": [ "r130" ] }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "presentation": [ "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesDetails", "http://www.caretrustreit.com/role/VARIABLEINTERESTENTITIESScheduleofVariableInterestEntitiesInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity, Primary Beneficiary", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity." } } }, "auth_ref": [ "r59", "r488", "r489", "r492", "r493" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [ "http://www.caretrustreit.com/role/DEBTUnsecuredRevolvingCreditFacilityNarrativeDetails", "http://www.caretrustreit.com/role/OTHERREALESTATERELATEDANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r901" ] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "WeightedAverageMember", "presentation": [ "http://www.caretrustreit.com/role/IMPAIRMENTOFREALESTATEINVESTMENTSASSETSHELDFORSALEANDASSETSALESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average", "label": "Weighted Average [Member]" } } }, "auth_ref": [ "r510", "r571", "r773", "r774", "r821", "r1046", "r1048", "r1051" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average diluted common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r222", "r239" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average number of common shares:", "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caretrustreit.com/role/CONDENSEDCONSOLIDATEDINCOMESTATEMENTS", "http://www.caretrustreit.com/role/EARNINGSPERCOMMONSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average basic common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r220", "r239" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r899" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(3)", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(12)(c)", "Section": "S99", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(16)(c)", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-6" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-9" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482309/360-10-15-4" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(14)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(15)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "970", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/970/tableOfContent" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "972", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/972/tableOfContent" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "974", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/974/tableOfContent" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "976", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/976/tableOfContent" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "978", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/978/tableOfContent" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-29" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481774/310-40-40-7A" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "360", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477875/944-360-45-3" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "SubTopic": "360", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477875/944-360-45-4" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "360", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478586/944-360-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1404", "Paragraph": "a", "Publisher": "SEC" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1404", "Paragraph": "b", "Publisher": "SEC" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(1)", "Publisher": "SEC" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(2)", "Publisher": "SEC" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(3)", "Publisher": "SEC" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(4)", "Publisher": "SEC" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "c", "Publisher": "SEC" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "65", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-65" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "66", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-66" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-6A" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-42" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-42" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-42" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "44", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-44" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479016/842-30-45-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-12" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(10)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "974", "SubTopic": "720", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477728/974-720-50-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-11" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "79", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-79" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "80", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-80" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-3" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478790/946-405-45-2" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r944": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r945": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r946": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r947": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/321/tableOfContent" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "325", "Publisher": "FASB", "URI": "https://asc.fasb.org/325/tableOfContent" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1404", "Paragraph": "a", "Publisher": "SEC" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(1)", "Publisher": "SEC" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(2)", "Publisher": "SEC" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(3)", "Publisher": "SEC" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-12" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-2" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(14)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" } } } ZIP 98 0001628280-25-021524-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-25-021524-xbrl.zip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ctre-20250331_htm.xml IDEA: XBRL DOCUMENT 0001590717 2025-01-01 2025-03-31 0001590717 2025-04-30 0001590717 2025-03-31 0001590717 2024-12-31 0001590717 2024-01-01 2024-03-31 0001590717 us-gaap:CommonStockMember 2024-12-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2024-12-31 0001590717 us-gaap:ParentMember 2024-12-31 0001590717 us-gaap:NoncontrollingInterestMember 2024-12-31 0001590717 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001590717 us-gaap:ParentMember 2025-01-01 2025-03-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2025-01-01 2025-03-31 0001590717 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0001590717 us-gaap:CommonStockMember 2025-03-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2025-03-31 0001590717 us-gaap:ParentMember 2025-03-31 0001590717 us-gaap:NoncontrollingInterestMember 2025-03-31 0001590717 us-gaap:CommonStockMember 2023-12-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2023-12-31 0001590717 us-gaap:ParentMember 2023-12-31 0001590717 us-gaap:NoncontrollingInterestMember 2023-12-31 0001590717 2023-12-31 0001590717 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001590717 us-gaap:ParentMember 2024-01-01 2024-03-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2024-01-01 2024-03-31 0001590717 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001590717 us-gaap:CommonStockMember 2024-03-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2024-03-31 0001590717 us-gaap:ParentMember 2024-03-31 0001590717 us-gaap:NoncontrollingInterestMember 2024-03-31 0001590717 2024-03-31 0001590717 ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember 2025-03-31 0001590717 ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember 2025-01-01 2025-03-31 0001590717 ctre:MortgageSecuredLoanReceivableMember 2025-01-01 2025-03-31 0001590717 ctre:MezzanineLoanReceivableMember 2025-01-01 2025-03-31 0001590717 us-gaap:FinanceReceivablesMember 2025-01-01 2025-03-31 0001590717 us-gaap:FinanceReceivablesMember 2025-03-31 0001590717 ctre:CareREITPlcMember 2025-03-11 0001590717 ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2025-03-31 0001590717 ctre:SkilledNursingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationMarch2029NextOption2022Member 2025-03-31 0001590717 ctre:SkilledNursingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationJanuary2030NextOption2026Member 2025-03-31 0001590717 ctre:SkilledNursingAndCampusFacilitiesMember ctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2032NextOption2027Member 2025-03-31 0001590717 ctre:SkilledNursingAndCampusFacilitiesMember ctre:PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2026Member 2025-03-31 0001590717 ctre:SkilledNursingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2034NextOption2027Member 2025-03-31 0001590717 ctre:SkilledNursingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2039NextOption2027Member 2025-03-31 0001590717 ctre:SkilledNursingAndCampusFacilitiesMember ctre:PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2026Member 2025-01-01 2025-03-31 0001590717 srt:MinimumMember ctre:SkilledNursingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2039NextOption2027Member 2025-01-01 2025-03-31 0001590717 srt:MaximumMember ctre:SkilledNursingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2039NextOption2027Member 2025-01-01 2025-03-31 0001590717 ctre:SkilledNursingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2039NextOption2027Member 2025-01-01 2025-03-31 0001590717 ctre:SkilledNursingFacilityMember 2025-03-31 0001590717 ctre:SkilledNursingAndCampusFacilitiesMember ctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2032NextOption2027Member 2025-01-01 2025-03-31 0001590717 srt:MinimumMember ctre:SkilledNursingAndCampusFacilitiesMember 2025-03-31 0001590717 srt:MaximumMember ctre:SkilledNursingAndCampusFacilitiesMember 2025-03-31 0001590717 ctre:SkilledNursingAndCampusFacilitiesMember ctre:FirstOptionMember ctre:PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2027Member 2025-03-31 0001590717 ctre:SkilledNursingAndCampusFacilitiesMember ctre:FirstOptionMember ctre:PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2027Member 2025-01-01 2025-03-31 0001590717 ctre:SkilledNursingAndCampusFacilitiesMember ctre:SecondOptionMember ctre:PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2027Member 2025-03-31 0001590717 ctre:SkilledNursingAndCampusFacilitiesMember ctre:SecondOptionMember ctre:PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2027Member 2025-01-01 2025-03-31 0001590717 srt:MinimumMember ctre:PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2027Member 2025-03-31 0001590717 srt:MaximumMember ctre:PropertiesWithPurchaseOptionLeaseExpirationMay2034NextOption2027Member 2025-03-31 0001590717 ctre:SkilledNursingPropertiesMember 2025-01-01 2025-03-31 0001590717 ctre:AssistedLivingFacilityMember 2025-01-01 2025-03-31 0001590717 ctre:SkilledNursingPropertiesMember ctre:JointVentureMember 2025-01-01 2025-03-31 0001590717 ctre:AmendedKalestaLeaseMember 2025-03-31 0001590717 ctre:AmendedKalestaLeaseMember 2025-02-28 0001590717 ctre:JaybirdSeniorLivingInc.Member ctre:AssistedLivingFacilityMember 2024-08-01 2024-08-01 0001590717 ctre:JaybirdLeaseMember 2025-03-31 0001590717 ctre:JaybirdLeaseMember 2025-01-01 0001590717 ctre:JaybirdLeaseMember 2025-01-01 2025-03-31 0001590717 ctre:JaybirdLeaseMember 2024-08-01 2024-08-01 0001590717 ctre:MasterLeaseTerminationMember 2025-01-01 0001590717 ctre:SkilledNursingPropertiesMember 2024-03-01 2024-03-01 0001590717 ctre:EnsignAmendedTripleNetMasterLeaseMember 2024-03-01 0001590717 ctre:EnsignMember ctre:SkilledNursingFacilityMember 2024-03-01 0001590717 ctre:EduroAmendedTripleNetMasterLeaseMember 2024-03-01 0001590717 ctre:SkilledNursingFacilityMember ctre:NewEmbassyLeaseAgreementMember 2024-01-01 0001590717 ctre:MultiServiceCampusPropertiesMember ctre:NewEmbassyLeaseAgreementMember 2024-01-01 0001590717 ctre:NewEmbassyLeaseAgreementMember 2024-01-01 0001590717 ctre:FacilitiesHeldForSaleMember 2025-03-31 0001590717 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:MarketApproachValuationTechniqueMember 2024-03-31 0001590717 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:MarketApproachValuationTechniqueMember 2024-03-31 0001590717 srt:WeightedAverageMember us-gaap:FairValueInputsLevel3Member us-gaap:MarketApproachValuationTechniqueMember 2024-03-31 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2025-01-01 2025-03-31 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2024-01-01 2024-03-31 0001590717 ctre:AssistedLivingFacilitiesMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2025-01-01 2025-03-31 0001590717 ctre:AssistedLivingFacilitiesMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2024-01-31 0001590717 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2024-12-31 0001590717 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2025-01-01 2025-03-31 0001590717 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2025-03-31 0001590717 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2023-12-31 0001590717 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2024-01-01 2024-03-31 0001590717 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2024-03-31 0001590717 ctre:SkilledNursingFacilityMember us-gaap:LoansReceivableMember ctre:MortgageSecuredLoanReceivableMember 2025-03-31 0001590717 ctre:CampusMember us-gaap:LoansReceivableMember ctre:MortgageSecuredLoanReceivableMember 2025-03-31 0001590717 ctre:AssistedLivingFacilitiesMember us-gaap:LoansReceivableMember ctre:MortgageSecuredLoanReceivableMember 2025-03-31 0001590717 ctre:IndependentLivingFacilityMember us-gaap:LoansReceivableMember ctre:MortgageSecuredLoanReceivableMember 2025-03-31 0001590717 us-gaap:LoansReceivableMember ctre:MortgageSecuredLoanReceivableMember 2025-03-31 0001590717 us-gaap:LoansReceivableMember ctre:MortgageSecuredLoanReceivableMember 2024-12-31 0001590717 ctre:SkilledNursingFacilityMember us-gaap:LoansReceivableMember ctre:MezzanineLoanReceivableMember 2025-03-31 0001590717 ctre:CampusMember us-gaap:LoansReceivableMember ctre:MezzanineLoanReceivableMember 2025-03-31 0001590717 ctre:AssistedLivingFacilitiesMember us-gaap:LoansReceivableMember ctre:MezzanineLoanReceivableMember 2025-03-31 0001590717 ctre:IndependentLivingFacilityMember us-gaap:LoansReceivableMember ctre:MezzanineLoanReceivableMember 2025-03-31 0001590717 us-gaap:LoansReceivableMember ctre:MezzanineLoanReceivableMember 2025-03-31 0001590717 us-gaap:LoansReceivableMember ctre:MezzanineLoanReceivableMember 2024-12-31 0001590717 us-gaap:LoansReceivableMember 2025-03-31 0001590717 us-gaap:LoansReceivableMember 2024-12-31 0001590717 us-gaap:OtherInvestmentsMember ctre:PreferredEquityMember 2025-03-31 0001590717 us-gaap:OtherInvestmentsMember ctre:PreferredEquityMember 2024-12-31 0001590717 us-gaap:OtherInvestmentsMember 2025-03-31 0001590717 us-gaap:OtherInvestmentsMember 2024-12-31 0001590717 ctre:SkilledNursingFacilityMember us-gaap:OtherInvestmentsMember ctre:OtherFinancingReceivablesMember 2025-03-31 0001590717 ctre:CampusMember us-gaap:OtherInvestmentsMember ctre:OtherFinancingReceivablesMember 2025-03-31 0001590717 ctre:AssistedLivingFacilitiesMember us-gaap:OtherInvestmentsMember ctre:OtherFinancingReceivablesMember 2025-03-31 0001590717 ctre:IndependentLivingFacilityMember us-gaap:OtherInvestmentsMember ctre:OtherFinancingReceivablesMember 2025-03-31 0001590717 us-gaap:OtherInvestmentsMember ctre:OtherFinancingReceivablesMember 2025-03-31 0001590717 us-gaap:OtherInvestmentsMember ctre:OtherFinancingReceivablesMember 2024-12-31 0001590717 ctre:MortgageSecuredLoanReceivableMember 2025-03-31 0001590717 ctre:MezzanineLoanReceivableMember 2025-03-31 0001590717 ctre:MortgageSecuredAndMezzanineLoansReceivableMember 2025-01-01 2025-03-31 0001590717 us-gaap:LoansReceivableMember ctre:OtherFinancingReceivablesMember 2025-03-31 0001590717 us-gaap:LoansReceivableMember ctre:OtherFinancingReceivablesMember 2024-12-31 0001590717 us-gaap:OtherInvestmentsMember ctre:OtherFinancingReceivablesMember 2025-01-01 2025-03-31 0001590717 ctre:OtherRealEstateRelatedInvestmentsMember 2025-03-31 0001590717 ctre:OtherRealEstateRelatedInvestmentsMember 2024-03-31 0001590717 ctre:SkilledNursingFacilityMember ctre:MezzanineLoanMember 2025-01-10 0001590717 ctre:SkilledNursingFacilityMember stpr:MD ctre:MezzanineLoanMember 2025-01-10 0001590717 ctre:MultiServiceCampusPropertiesMember ctre:MezzanineLoanReceivableMember 2024-12-20 0001590717 ctre:SkilledNursingFacilityMember 2025-02-01 2025-02-28 0001590717 2025-02-01 2025-02-28 0001590717 ctre:MortgageSecuredLoanReceivableJanuary12027MaturityMember 2024-01-01 0001590717 ctre:AssistedLivingFacilitiesMember ctre:MortgageSecuredLoanReceivableJanuary12027MaturityMember 2024-01-01 0001590717 ctre:SkilledNursingFacilityMember ctre:MezzanineLoanMember 2024-01-25 0001590717 ctre:MezzanineLoanMember 2024-01-25 0001590717 ctre:MezzanineLoanMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-25 0001590717 ctre:MezzanineLoanMember ctre:SecuredOvernightFinancingRateSOFRFloorMember 2024-01-25 0001590717 srt:MinimumMember ctre:SkilledNursingFacilityMember ctre:MezzanineLoanMember 2024-01-25 0001590717 srt:MaximumMember ctre:SkilledNursingFacilityMember ctre:MezzanineLoanMember 2024-01-25 0001590717 ctre:SkilledNursingFacilityMember ctre:MezzanineLoanMember 2024-02-01 0001590717 ctre:MezzanineLoanMember 2024-02-01 0001590717 ctre:SkilledNursingFacilityMember ctre:MezzanineLoanMember 2024-02-02 0001590717 ctre:MezzanineLoanMember 2024-02-02 0001590717 ctre:MezzanineLoanMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-02-02 0001590717 ctre:MezzanineLoanMember ctre:SecuredOvernightFinancingRateSOFRFloorMember 2024-02-02 0001590717 srt:MinimumMember ctre:SkilledNursingFacilityMember ctre:MezzanineLoanMember 2024-02-02 0001590717 srt:MaximumMember ctre:SkilledNursingFacilityMember ctre:MezzanineLoanMember 2024-02-02 0001590717 us-gaap:OtherInvestmentsMember ctre:OtherFinancingReceivablesMember 2024-12-05 0001590717 ctre:NewCascadeLeaseMember 2024-12-05 2024-12-05 0001590717 ctre:NewCascadeLeaseMember 2024-12-01 2024-12-01 0001590717 us-gaap:LoansReceivableMember 2025-03-31 0001590717 us-gaap:LoansReceivableMember 2024-12-31 0001590717 us-gaap:LoansReceivableMember 2024-01-01 2024-03-31 0001590717 us-gaap:LoansReceivableMember 2025-01-01 2025-03-31 0001590717 ctre:MortgageSecuredLoanReceivableMember 2025-01-01 2025-03-31 0001590717 ctre:MortgageSecuredLoanReceivableMember 2024-01-01 2024-03-31 0001590717 ctre:MezzanineLoanReceivableMember 2025-01-01 2025-03-31 0001590717 ctre:MezzanineLoanReceivableMember 2024-01-01 2024-03-31 0001590717 us-gaap:EquityMethodInvestmentsMember 2025-01-01 2025-03-31 0001590717 us-gaap:EquityMethodInvestmentsMember 2024-01-01 2024-03-31 0001590717 ctre:OtherFinancingReceivablesMember 2025-01-01 2025-03-31 0001590717 ctre:OtherFinancingReceivablesMember 2024-01-01 2024-03-31 0001590717 ctre:OtherMember 2025-01-01 2025-03-31 0001590717 ctre:OtherMember 2024-01-01 2024-03-31 0001590717 ctre:MortgageSecuredLoanReceivableMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001590717 ctre:MortgageSecuredLoanReceivableMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001590717 ctre:MortgageSecuredLoanReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001590717 ctre:MortgageSecuredLoanReceivableMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001590717 ctre:MezzanineLoanReceivableMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001590717 ctre:MezzanineLoanReceivableMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001590717 ctre:MezzanineLoanReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001590717 ctre:MezzanineLoanReceivableMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001590717 us-gaap:FinanceReceivablesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001590717 us-gaap:FinanceReceivablesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001590717 us-gaap:FinanceReceivablesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001590717 us-gaap:FinanceReceivablesMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001590717 ctre:MortgageSecuredAndMezzanineLoansReceivableMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001590717 ctre:MortgageSecuredAndMezzanineLoansReceivableMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001590717 ctre:MortgageSecuredAndMezzanineLoansReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001590717 ctre:MortgageSecuredAndMezzanineLoansReceivableMember 2025-03-31 0001590717 ctre:MortgageSecuredLoanReceivableMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001590717 ctre:MortgageSecuredLoanReceivableMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001590717 ctre:MortgageSecuredLoanReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001590717 ctre:MortgageSecuredLoanReceivableMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001590717 ctre:MezzanineLoanReceivableMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001590717 ctre:MezzanineLoanReceivableMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001590717 ctre:MezzanineLoanReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001590717 ctre:MezzanineLoanReceivableMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001590717 us-gaap:FinanceReceivablesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001590717 us-gaap:FinanceReceivablesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001590717 us-gaap:FinanceReceivablesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001590717 us-gaap:FinanceReceivablesMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001590717 ctre:MortgageSecuredAndMezzanineLoansReceivableMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001590717 ctre:MortgageSecuredAndMezzanineLoansReceivableMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001590717 ctre:MortgageSecuredAndMezzanineLoansReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001590717 ctre:MortgageSecuredAndMezzanineLoansReceivableMember 2024-12-31 0001590717 ctre:InvestmentsInRealEstateSecuredLoanMember 2024-12-31 0001590717 ctre:InvestmentsInMezzanineLoansMember 2024-12-31 0001590717 ctre:InvestmentsInFinancingReceivableMember 2024-12-31 0001590717 ctre:InvestmentsInRealEstateSecuredLoanMember 2025-01-01 2025-03-31 0001590717 ctre:InvestmentsInMezzanineLoansMember 2025-01-01 2025-03-31 0001590717 ctre:InvestmentsInFinancingReceivableMember 2025-01-01 2025-03-31 0001590717 ctre:InvestmentsInRealEstateSecuredLoanMember 2025-03-31 0001590717 ctre:InvestmentsInMezzanineLoansMember 2025-03-31 0001590717 ctre:InvestmentsInFinancingReceivableMember 2025-03-31 0001590717 ctre:SecuredAndMezzanineLoansReceivableMember 2025-01-01 2025-03-31 0001590717 ctre:SecuredAndMezzanineLoansReceivableMember 2024-01-01 2024-03-31 0001590717 us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember 2025-03-31 0001590717 us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember 2024-12-31 0001590717 ctre:MortgageSecuredLoanReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-03-31 0001590717 srt:MinimumMember ctre:MortgageSecuredLoanReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-03-31 0001590717 srt:MaximumMember ctre:MortgageSecuredLoanReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-03-31 0001590717 ctre:MezzanineLoanReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-03-31 0001590717 srt:MinimumMember ctre:MezzanineLoanReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-03-31 0001590717 srt:MaximumMember ctre:MezzanineLoanReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-03-31 0001590717 us-gaap:FinanceReceivablesMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2025-03-31 0001590717 us-gaap:FairValueInputsLevel3Member ctre:PreferredEquityInvestmentMember 2025-03-31 0001590717 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember ctre:PreferredEquityInvestmentMember 2025-03-31 0001590717 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember ctre:PreferredEquityInvestmentMember 2025-03-31 0001590717 us-gaap:FairValueInputsLevel3Member ctre:PreferredEquityInvestmentMember 2024-12-31 0001590717 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember ctre:PreferredEquityInvestmentMember 2024-12-31 0001590717 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember ctre:PreferredEquityInvestmentMember 2024-12-31 0001590717 ctre:SeniorUnsecuredNotesMember us-gaap:FairValueInputsLevel2Member 2025-03-31 0001590717 ctre:SeniorUnsecuredNotesMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-31 0001590717 ctre:SeniorUnsecuredNotesMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-31 0001590717 ctre:SeniorUnsecuredNotesMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0001590717 ctre:SeniorUnsecuredNotesMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-12-31 0001590717 ctre:SeniorUnsecuredNotesMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-12-31 0001590717 srt:MinimumMember us-gaap:FairValueInputsLevel3Member 2025-03-31 0001590717 srt:MaximumMember us-gaap:FairValueInputsLevel3Member 2025-03-31 0001590717 ctre:SeniorUnsecuredNotesMember us-gaap:SeniorNotesMember 2025-03-31 0001590717 ctre:SeniorUnsecuredNotesMember us-gaap:SeniorNotesMember 2024-12-31 0001590717 us-gaap:RevolvingCreditFacilityMember 2025-03-31 0001590717 us-gaap:RevolvingCreditFacilityMember 2024-12-31 0001590717 ctre:SeniorUnsecuredNotesMember us-gaap:SeniorNotesMember 2021-06-17 0001590717 ctre:SeniorUnsecuredNotesMember us-gaap:SeniorNotesMember 2021-06-17 2021-06-17 0001590717 ctre:SeniorUnsecuredNotesMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:SeniorNotesMember 2021-06-17 2021-06-17 0001590717 ctre:SeniorUnsecuredNotesMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember us-gaap:SeniorNotesMember 2021-06-17 2021-06-17 0001590717 us-gaap:RevolvingCreditFacilityMember 2024-12-18 0001590717 us-gaap:LetterOfCreditMember 2022-12-16 0001590717 ctre:SwinglineLoanMember 2022-12-16 0001590717 us-gaap:RevolvingCreditFacilityMember 2019-02-08 0001590717 us-gaap:LetterOfCreditMember 2019-02-08 0001590717 ctre:SwinglineLoanMember 2019-02-08 0001590717 ctre:SeniorUnsecuredTermLoanMember us-gaap:LoansPayableMember 2019-02-08 0001590717 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2019-02-08 2019-02-08 0001590717 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrMember 2019-02-08 2019-02-08 0001590717 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember 2019-02-08 2019-02-08 0001590717 us-gaap:RevolvingCreditFacilityMember 2019-02-08 2019-02-08 0001590717 ctre:AtTheMarketOfferingProgramMember 2025-01-21 0001590717 ctre:AtTheMarketOfferingProgramMember 2024-12-31 0001590717 ctre:AtTheMarketOfferingProgramMember 2025-01-01 2025-03-31 0001590717 ctre:AtTheMarketOfferingProgramMember 2024-01-01 2024-03-31 0001590717 ctre:AtTheMarketOfferingProgramMember 2025-03-31 0001590717 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001590717 us-gaap:RestrictedStockMember 2025-01-01 2025-03-31 0001590717 srt:DirectorMember us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001590717 ctre:PerformanceSharesTSRUnitsMember 2025-01-01 2025-03-31 0001590717 srt:MinimumMember ctre:PerformanceSharesTSRUnitsMember 2025-01-01 2025-03-31 0001590717 srt:MaximumMember ctre:PerformanceSharesTSRUnitsMember 2025-01-01 2025-03-31 0001590717 ctre:RestrictedStockAndPerformanceSharesMember 2025-01-01 2025-03-31 0001590717 ctre:PerformanceStockAwardsAndTotalShareholderReturnUnitsMember 2025-01-01 2025-03-31 0001590717 ctre:PerformanceStockAwardsAndTotalShareholderReturnUnitsMember 2024-01-01 2024-03-31 0001590717 ctre:ReportableSegmentMember 2025-01-01 2025-03-31 0001590717 ctre:ReportableSegmentMember 2024-01-01 2024-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:SkilledNursingFacilityMember ctre:InvestmentOneMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:CTREMember ctre:SkilledNursingFacilityMember ctre:InvestmentOneMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:NoncontrollingInterestOwnersMember ctre:SkilledNursingFacilityMember ctre:InvestmentOneMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:SkilledNursingFacilityMember ctre:InvestmentTwoMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:CTREMember ctre:SkilledNursingFacilityMember ctre:InvestmentTwoMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:NoncontrollingInterestOwnersMember ctre:SkilledNursingFacilityMember ctre:InvestmentTwoMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:AssistedLivingFacilitiesMember ctre:InvestmentThreeMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:CTREMember ctre:AssistedLivingFacilitiesMember ctre:InvestmentThreeMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:NoncontrollingInterestOwnersMember ctre:AssistedLivingFacilitiesMember ctre:InvestmentThreeMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:MultiServiceCampusPropertiesMember ctre:InvestmentFourMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:CTREMember ctre:MultiServiceCampusPropertiesMember ctre:InvestmentFourMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:NoncontrollingInterestOwnersMember ctre:MultiServiceCampusPropertiesMember ctre:InvestmentFourMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:SkilledNursingFacilityMember ctre:InvestmentFiveMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:CTREMember ctre:SkilledNursingFacilityMember ctre:InvestmentFiveMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:NoncontrollingInterestOwnersMember ctre:SkilledNursingFacilityMember ctre:InvestmentFiveMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:SkilledNursingFacilityMember ctre:InvestmentSixMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:CTREMember ctre:SkilledNursingFacilityMember ctre:InvestmentSixMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:NoncontrollingInterestOwnersMember ctre:SkilledNursingFacilityMember ctre:InvestmentSixMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:InvestmentSevenMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:CTREMember ctre:InvestmentSevenMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:NoncontrollingInterestOwnersMember ctre:InvestmentSevenMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:CTREMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember ctre:NoncontrollingInterestOwnersMember 2025-03-31 0001590717 ctre:JVPartner97.5Member 2025-03-31 0001590717 ctre:JVPartnerMember 2025-03-31 0001590717 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-12-31 0001590717 ctre:EnsignAndPennantMember 2025-03-31 0001590717 ctre:TenantESGProgramMember 2025-03-31 0001590717 ctre:CapitalExpendituresMember ctre:RemainingCommitmentMember 2025-03-31 0001590717 us-gaap:MortgageReceivablesMember ctre:RemainingCommitmentMember 2025-03-31 0001590717 ctre:OtherLoansReceivableMember ctre:RemainingCommitmentMember 2025-03-31 0001590717 ctre:EarnOutObligationMember ctre:RemainingCommitmentMember 2025-03-31 0001590717 ctre:RemainingCommitmentMember 2025-03-31 0001590717 ctre:CapitalImprovementsAtTripleNetLeasedFacilitiesMember 2025-03-31 0001590717 ctre:SkilledNursingFacilityMember us-gaap:MortgageReceivablesMember 2025-01-01 2025-03-31 0001590717 ctre:SkilledNursingFacilityMember stpr:VA 2025-01-01 2025-03-31 0001590717 ctre:SkilledNursingFacilityMember stpr:VA 2025-03-31 0001590717 ctre:EnsignMember ctre:SkilledNursingFacilityMember 2025-03-31 0001590717 ctre:EnsignMember ctre:MultiServiceCampusPropertiesMember 2025-03-31 0001590717 ctre:EnsignMember ctre:AssistedAndIndependentLivingPropertiesMember 2025-03-31 0001590717 ctre:EnsignMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0001590717 ctre:PriorityManagementGroupLLCMember ctre:SkilledNursingFacilityMember 2025-03-31 0001590717 ctre:PriorityManagementGroupLLCMember ctre:MultiServiceCampusPropertiesMember 2025-03-31 0001590717 ctre:PriorityManagementGroupLLCMember ctre:AssistedAndIndependentLivingPropertiesMember 2025-03-31 0001590717 ctre:PriorityManagementGroupLLCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0001590717 ctre:EnsignMember ctre:SkilledNursingFacilityMember 2024-03-31 0001590717 ctre:EnsignMember ctre:MultiServiceCampusPropertiesMember 2024-03-31 0001590717 ctre:EnsignMember ctre:AssistedAndIndependentLivingPropertiesMember 2024-03-31 0001590717 ctre:EnsignMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001590717 ctre:PriorityManagementGroupLLCMember ctre:SkilledNursingFacilityMember 2024-03-31 0001590717 ctre:PriorityManagementGroupLLCMember ctre:MultiServiceCampusPropertiesMember 2024-03-31 0001590717 ctre:PriorityManagementGroupLLCMember ctre:AssistedAndIndependentLivingPropertiesMember 2024-03-31 0001590717 ctre:PriorityManagementGroupLLCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001590717 ctre:SkilledNursingFacilityMember stpr:CA 2025-03-31 0001590717 ctre:MultiServiceCampusPropertiesMember stpr:CA 2025-03-31 0001590717 ctre:AssistedAndIndependentLivingPropertiesMember stpr:CA 2025-03-31 0001590717 stpr:CA us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2025-01-01 2025-03-31 0001590717 ctre:SkilledNursingFacilityMember stpr:TX 2025-03-31 0001590717 ctre:MultiServiceCampusPropertiesMember stpr:TX 2025-03-31 0001590717 ctre:AssistedAndIndependentLivingPropertiesMember stpr:TX 2025-03-31 0001590717 stpr:TX us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2025-01-01 2025-03-31 0001590717 ctre:SkilledNursingFacilityMember stpr:TN 2025-03-31 0001590717 ctre:MultiServiceCampusPropertiesMember stpr:TN 2025-03-31 0001590717 ctre:AssistedAndIndependentLivingPropertiesMember stpr:TN 2025-03-31 0001590717 stpr:TN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2025-01-01 2025-03-31 0001590717 ctre:SkilledNursingFacilityMember stpr:CA 2024-03-31 0001590717 ctre:MultiServiceCampusPropertiesMember stpr:CA 2024-03-31 0001590717 ctre:AssistedAndIndependentLivingPropertiesMember stpr:CA 2024-03-31 0001590717 stpr:CA us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-03-31 0001590717 ctre:SkilledNursingFacilityMember stpr:TX 2024-03-31 0001590717 ctre:MultiServiceCampusPropertiesMember stpr:TX 2024-03-31 0001590717 ctre:AssistedAndIndependentLivingPropertiesMember stpr:TX 2024-03-31 0001590717 stpr:TX us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-03-31 0001590717 ctre:SkilledNursingFacilityMember ctre:SkilledNursingFacilityCaliforniaJointVentureMember us-gaap:SubsequentEventMember 2025-04-01 0001590717 ctre:SkilledNursingFacilityCaliforniaJointVentureMember us-gaap:SubsequentEventMember 2025-04-01 2025-04-01 0001590717 ctre:SkilledNursingFacilityMember ctre:SkilledNursingFacilityCaliforniaJointVentureMember us-gaap:SubsequentEventMember 2025-04-01 2025-04-01 0001590717 ctre:SkilledNursingFacilityMember ctre:SkilledNursingFacilityCaliforniaJointVentureMember us-gaap:SubsequentEventMember 2025-04-01 0001590717 ctre:SkilledNursingFacilityMember ctre:JVPartnerMember us-gaap:SubsequentEventMember 2025-04-01 2025-04-01 0001590717 ctre:SkilledNursingFacilityMember us-gaap:SubsequentEventMember 2025-04-01 0001590717 ctre:MortgageLoanMember us-gaap:SubsequentEventMember 2025-04-01 2025-04-30 0001590717 us-gaap:SubsequentEventMember ctre:AtTheMarketOfferingProgramMember 2025-04-01 2025-04-30 0001590717 us-gaap:SubsequentEventMember ctre:AtTheMarketOfferingProgramMember 2025-04-30 shares iso4217:USD iso4217:USD shares ctre:facility ctre:bed ctre:state ctre:investment ctre:loan iso4217:GBP shares ctre:property ctre:numberOfFacility ctre:option ctre:option_to_renew ctre:lease ctre:renewal_option pure ctre:paymentInstallment ctre:extension_option ctre:unit_bed 0001590717 --12-31 2025 Q1 false 10-Q true 2025-03-31 false 001-36181 CareTrust REIT, Inc. MD 46-3999490 905 Calle Amanecer Suite 300 San Clemente CA 92673 949 542-3130 Common Stock, par value $0.01 per share CTRE NYSE Yes Yes Large Accelerated Filer false false false 191688997 2252279000 2226740000 905000 281000 96628000 96004000 6005000 4725000 799799000 795203000 16736000 57261000 26510000 213822000 606000000 0 1954000 1174000 73890000 35608000 10652000 11204000 3884448000 3437016000 397149000 396927000 425000000 0 51069000 56318000 63053000 54388000 936271000 507633000 17396000 18243000 0.01 0.01 100000000 100000000 0 0 0 0 0 0 0.01 0.01 500000000 500000000 187669948 187669948 186993010 186993010 1877000 1870000 3455256000 3439117000 529821000 532570000 2927312000 2908417000 3469000 2723000 2930781000 2911140000 3884448000 3437016000 71646000 53502000 2807000 0 22168000 9568000 96621000 63070000 17841000 13448000 6669000 8228000 2065000 1801000 0 2744000 888000 0 105000 660000 9023000 6838000 36591000 33719000 3876000 11000 1287000 -612000 5163000 -601000 65193000 28750000 -609000 4000 65802000 28746000 0.35 0.22 0.35 0.22 187152000 132836000 187416000 133202000 186993010 1870000 3439117000 -532570000 2908417000 2723000 2911140000 18243000 553023 6000 15556000 15562000 15562000 123915 1000 -3326000 -3325000 -3325000 3909000 3909000 3909000 0.335 63053000 63053000 63053000 2000 2000 900000 642000 642000 768000 65802000 65802000 106000 65908000 -715000 187669948 1877000 3455256000 -529821000 2927312000 3469000 2930781000 17396000 129992796 1300000 1883147000 -467628000 1416819000 1898000 1418717000 0 11600000 116000 269671000 269787000 269787000 119369 1000 -2484000 -2483000 -2483000 2120000 2120000 2120000 0.29 41192000 41192000 41192000 47000 47000 444000 444000 28746000 28746000 4000 28750000 141712165 1417000 2152454000 -480074000 1673797000 2299000 1676096000 0 65193000 28750000 17865000 13462000 914000 614000 1287000 -612000 3909000 2120000 -7000 -7000 49000 0 926000 575000 1904000 425000 3876000 11000 0 2744000 788000 15000 3451000 322000 -4323000 1859000 71382000 48820000 40162000 66619000 2276000 398000 6389000 52165000 4582000 0 36066000 4105000 44401000 46000 -35910000 -123241000 15562000 269787000 425000000 0 141000 24000 3325000 2483000 54388000 36531000 1410000 444000 902000 47000 383216000 231146000 418688000 156725000 213822000 294448000 632510000 451173000 450000 3771000 8665000 4661000 0 5000 0 1000000 ORGANIZATION<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of Business—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CareTrust REIT, Inc.’s (“CareTrust REIT” or the “Company”) primary business consists of acquiring, financing, developing and owning real property to be leased to third-party tenants in the healthcare sector. As of March 31, 2025, the Company owned, directly or through joint ventures, and leased to independent operators 255 skilled nursing facilities (“SNFs”), multi-service campuses, assisted living facilities (“ALFs”) and independent living facilities (“ILFs”) consisting of 27,672 operational beds and units located in 32 states with the highest concentration of properties by rental income located in California, Texas and Tennessee. As of March 31, 2025, the Company also had other real estate related investments consisting of three preferred equity investments, 15 real estate secured loans receivable, and five mezzanine loans receivable with a carrying value of $799.8 million and one financing receivable with a carrying value of $96.6 million. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Planned Acquisition—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2025, the Company announced (the “Rule 2.7 Announcement”) pursuant to Rule 2.7 of the United Kingdom City Code on Takeovers and Mergers (the “Code”) a firm intention to make a cash offer (the “Offer”) to acquire (the “Acquisition”), through its wholly-owned direct subsidiary, CR United Bidco Limited (“Bidco”), the entire issued and to be issued ordinary share capital (other than Scheme Restricted Shares (as defined in the Rule 2.7 Announcement)) of Care REIT plc (“Target”) for 108 pence in cash per ordinary share of Target. Target is a UK-based real estate investment trust listed on the Main Market of the London Stock Exchange focused on investing in care homes throughout the United Kingdom. The Acquisition is intended to be effected by means of a scheme of arrangement (the “Scheme”) under Part 26 of the United Kingdom Companies Act 2006, meaning it is subject to court approval and the satisfaction or waiver of other ordinary conditions to closing, following approval by Target’s shareholders.</span></div> 255 27672 32 3 15 5 799800000 1 96600000 108 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:12pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. The accompanying consolidated financial statements of the Company include the accounts of CareTrust REIT, its wholly-owned subsidiaries, and variable interest entities (“VIEs”) over which the Company exercises control. All intercompany transactions and account balances within the Company have been eliminated, and net earnings are reduced by the portion of net earnings attributable to noncontrolling interests. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company presents cash and cash equivalents separately from restricted cash within the Company’s condensed consolidated balance sheets. The Company includes restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the condensed consolidated statements of cash flows. The Company provides a reconciliation between the balance sheets and statements of cash flows, as required when the balance includes more than one line item for cash, cash equivalents and restricted cash. The Company also provides a disclosure of the nature of the restrictions related to material restricted cash balances. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Company had $606.0 million in restricted cash related to the cash deposited with the trustee for the planned acquisition of Care REIT plc.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash consisted of the following as of March 31, 2025 and December 31, 2024 (dollars in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,510 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,822 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632,510 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,822 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span>—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. The accompanying consolidated financial statements of the Company include the accounts of CareTrust REIT, its wholly-owned subsidiaries, and variable interest entities (“VIEs”) over which the Company exercises control. All intercompany transactions and account balances within the Company have been eliminated, and net earnings are reduced by the portion of net earnings attributable to noncontrolling interests. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash</span>—The Company presents cash and cash equivalents separately from restricted cash within the Company’s condensed consolidated balance sheets. The Company includes restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the condensed consolidated statements of cash flows. The Company provides a reconciliation between the balance sheets and statements of cash flows, as required when the balance includes more than one line item for cash, cash equivalents and restricted cash. The Company also provides a disclosure of the nature of the restrictions related to material restricted cash balances. 606000000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash consisted of the following as of March 31, 2025 and December 31, 2024 (dollars in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,510 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,822 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632,510 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,822 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 26510000 213822000 606000000 0 632510000 213822000 REAL ESTATE INVESTMENTS, NET<div style="margin-bottom:9pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s investment in owned properties, and properties held in consolidated joint ventures, held for use as of March 31, 2025 and December 31, 2024 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377,669 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,044 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253,424 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220,287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integral equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identified intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,748,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,705,522 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(496,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(478,782)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252,279 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,226,740 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, all of the Company’s owned facilities held for investment were leased to various operators under triple-net leases. All of the triple-net leases contain annual escalators based on the percentage change in the Consumer Price Index (“CPI”) (but not less than zero), some of which are subject to a cap, or fixed rent escalators. As of March 31, 2025, six facilities were held for sale. See Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Real Estate Investments, Assets Held for Sale and Asset Sales,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements and assets held for sale, was as follows (dollars in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 (nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,437 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,536 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,367,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,971,283 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenant Purchase Options</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.414%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Type</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Properties</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Expiration</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Period Open Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Type</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Cash Rent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/01/2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A / B</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/01/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF / Campus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2032</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/05/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF / Campus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2034</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06/01/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(11)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/01/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2039</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/01/2027</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,160 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) The Company has not received notice of exercise for the option periods that are currently open.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Option type includes:</span></div><div style="padding-left:63pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A - Fixed base price.</span></div><div style="padding-left:63pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B - Fixed capitalization rate on lease revenue.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Based on annualized cash revenue for contracts in place as of March 31, 2025.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Option window is open until the expiration of the lease term.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5) Option window is open for six months from the option period open date.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6) Option window is open for nine months from the option period open date.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7) Lease agreement provides for the purchase of one to two facilities in each window over four option windows, for a total of six facilities. Each option window opens at the beginning of each of lease years four, five, six, and seven beginning December 1, 2027 and is open for one year. </span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8) Option reflects two option types.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)     Lease provides for abatement in the first three months. Annual rent beginning in month four is $1.2 million.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10) Option provides for purchase of any two of the three facilities. The current cash rent shown is an average of the range of $3.2 million to $3.5 million. </span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(11)     Option provides for purchase of any one of five facilities in the first option window and another one of five facilities in the second option window beginning June 1, 2027. The current cash rent shown is an average of the range of $2.4 million to $3.1 million. Provided the operator exercises its option to extend the term of the master lease, beginning on June 1, 2035 and ending nine months thereafter, the operator will have an option for all facilities then remaining in the master lease. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rental Income</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes components of the Company’s rental income (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rental Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual rent due</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,776 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,934 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of below-market lease intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,646 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,502 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received. Tenant operating expense reimbursements for the three months ended March 31, 2025 and 2024 were $2.3 million and $1.5 million, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Real Estate Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s acquisitions for the three months ended March 31, 2025 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.350%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Property</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Initial Annual Cash Rent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Properties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Beds/Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled nursing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,448 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assisted living</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,637 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,085 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,896 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Purchase price includes capitalized acquisition costs.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Initial annual cash rent represents initial cash rent for the first twelve months.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) The number of beds/units includes operating beds at the acquisition date. </span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Includes one SNF held through a joint venture. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, for additional information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Amendments and Terminations</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended Kalesta Lease. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 28, 2025, the Company acquired one ALF. In connection with the acquisition, the Company amended its existing triple-net master lease with affiliates of Kalesta Healthcare, LLC (“Kalesta”) to include the one ALF and extended the initial lease term. The Kalesta master lease, as amended, had a remaining term at the date of amendment of approximately 15 years. Annual cash rent under the amended Kalesta master lease increased by approximately $1.9 million. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ridgeline Lease Termination and NC Jaybird Lease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Effective December 31, 2024, the Company terminated its master lease with affiliates of Ridgeline Properties, LLC (“Ridgeline”). The Company entered into a new master lease (the “NC Jaybird Lease”) with affiliates of Jaybird Senior Living, Inc. (“Jaybird”) with respect to two ALFs in North Carolina previously leased to Ridgeline. The NC Jaybird Lease commenced on January 1, 2025 with an initial term of approximately 12 years, featuring two five-year renewal options and CPI-based rent escalators. Under the NC Jaybird Lease, Jaybird will receive three months of abated rent, followed by 15 months of rent calculated as a percentage of the tenants’ gross revenue. Subsequently, the next twelve months will have a fixed annual cash rent amount of $0.8 million increasing annually based on CPI. Annual cash rent under the terminated master lease for the two ALFs in North Carolina was $0.8 million. Four facilities which were under the Ridgeline master lease are currently held for sale and two facilities are in the process of transferring operations. </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended Eduro Lease and Amended Ensign Lease. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2024, operations of two SNFs in Colorado operated by affiliates of Eduro Healthcare, LLC (“Eduro”) were transferred to subsidiaries of The Ensign Group, Inc. (“Ensign”). In connection with the transfer, the Company partially terminated the Eduro master lease and amended one existing triple-net master lease with Ensign to include the two SNFs and extended the initial lease term by 15 years. The applicable Ensign master lease, as amended, had a remaining term at the date of amendment of approximately 20 years with two five-year renewal options and CPI-based rent escalators. Annual cash rent under the applicable Ensign master lease, as amended, increased by approximately $2.1 million and annual cash rent under the Eduro master lease, as amended, decreased by the same amount.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Embassy Lease and Hillstone Lease Termination.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On December 31, 2023, the Company terminated its master lease with affiliates of Hillstone Healthcare, Inc. (“Hillstone”). Effective January 1, 2024, in connection with the December 31, 2023 lease termination, one SNF was removed from the Hillstone master lease, was classified as held for sale as of March 31, 2024 and was sold during the three months ended June 30, 2024. See Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Real Estate Investments, Assets Held for Sale and Asset Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information. In connection with the lease termination, the Company entered into a new triple-net master lease with a subsidiary of Embassy Healthcare Holdings, Inc. (“Embassy”) with respect to one multi-service campus. The Embassy lease has an initial term of approximately 10 years with two five-year renewal options and CPI-based rent escalators. Initial annual cash rent under the lease is approximately $0.6 million and the master lease provides Embassy with a partial rent abatement until required authorizations with respect to the ALF portion of the facility are obtained and occupancy levels reach a certain percentage.</span></div> <div style="margin-bottom:9pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s investment in owned properties, and properties held in consolidated joint ventures, held for use as of March 31, 2025 and December 31, 2024 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377,669 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,044 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253,424 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220,287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integral equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identified intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,748,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,705,522 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(496,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(478,782)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252,279 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,226,740 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 377669000 367044000 2253424000 2220287000 113402000 113803000 4083000 4388000 2748578000 2705522000 496299000 478782000 2252279000 2226740000 6 <div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements and assets held for sale, was as follows (dollars in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 (nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,437 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,536 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,367,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,971,283 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 210437000 283552000 281850000 280536000 276512000 271031000 1367365000 2971283000 <div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.414%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Type</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Properties</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Expiration</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Period Open Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Type</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Cash Rent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/01/2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A / B</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/01/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF / Campus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2032</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/05/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF / Campus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2034</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06/01/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(11)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/01/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2039</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/01/2027</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,160 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) The Company has not received notice of exercise for the option periods that are currently open.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Option type includes:</span></div><div style="padding-left:63pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A - Fixed base price.</span></div><div style="padding-left:63pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B - Fixed capitalization rate on lease revenue.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Based on annualized cash revenue for contracts in place as of March 31, 2025.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Option window is open until the expiration of the lease term.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5) Option window is open for six months from the option period open date.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6) Option window is open for nine months from the option period open date.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7) Lease agreement provides for the purchase of one to two facilities in each window over four option windows, for a total of six facilities. Each option window opens at the beginning of each of lease years four, five, six, and seven beginning December 1, 2027 and is open for one year. </span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8) Option reflects two option types.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)     Lease provides for abatement in the first three months. Annual rent beginning in month four is $1.2 million.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10) Option provides for purchase of any two of the three facilities. The current cash rent shown is an average of the range of $3.2 million to $3.5 million. </span></div>(11)     Option provides for purchase of any one of five facilities in the first option window and another one of five facilities in the second option window beginning June 1, 2027. The current cash rent shown is an average of the range of $2.4 million to $3.1 million. Provided the operator exercises its option to extend the term of the master lease, beginning on June 1, 2035 and ending nine months thereafter, the operator will have an option for all facilities then remaining in the master lease. 1 858000 1 1200000 2 3367000 2 2714000 1 1100000 6 10160000 P6M P9M 1 2 4 6 P1Y 2 1200000 2 3 3200000 3500000 1 5 1 5 2400000 3100000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes components of the Company’s rental income (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rental Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual rent due</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,776 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,934 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of below-market lease intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,646 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,502 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received. Tenant operating expense reimbursements for the three months ended March 31, 2025 and 2024 were $2.3 million and $1.5 million, respectively. 70776000 52934000 -7000 -7000 49000 0 926000 575000 71646000 53502000 2300000 1500000 <div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s acquisitions for the three months ended March 31, 2025 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.350%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Property</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Initial Annual Cash Rent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Properties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Beds/Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled nursing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,448 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assisted living</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,637 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,085 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,896 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Purchase price includes capitalized acquisition costs.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Initial annual cash rent represents initial cash rent for the first twelve months.</span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) The number of beds/units includes operating beds at the acquisition date. </span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Includes one SNF held through a joint venture. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, for additional information.</span></div> 20448000 2000000 1 124 20637000 1896000 1 160 41085000 3896000 2 284 1 P15Y 1900000 2 P12Y 2 P5Y P15M 800000 2 800000 4 2 2 1 2 P15Y P20Y 2 P5Y 2100000 1 1 P10Y 2 P5Y 600000 IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE AND ASSET SALES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Impairment of Real Estate Investments Held for Sale</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not recognize any impairment during the three months ended March 31, 2025. During the three months ended March 31, 2024, the Company recognized aggregate impairment charges of $2.7 million related to properties held for sale, which is reported in impairment of real estate investments in the condensed consolidated income statements. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, there were six facilities classified as held for sale, all of which have been recorded at the lesser of their carrying value or fair value less estimated costs to sell.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the assets held for sale were based on estimated sales prices, which are considered to be Level 3 (as defined below) measurements within the fair value hierarchy. Estimated sales prices were determined using a market approach (comparable sales model), which relies on certain assumptions by management, including: (i) comparable market transactions, (ii) estimated prices per unit, and (iii) binding agreements for sales and non-binding offers to purchase from unrelated third-parties. There are inherent uncertainties in making these assumptions. For the Company’s impairment calculations during the three months ended March 31, 2024, the Company’s fair value estimates primarily relied on a market approach and utilized prices per unit ranging from $12,000 to $36,000, with a weighted average price per unit of $16,000. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Sales and Held for Sale Reclassifications</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s dispositions for the three months ended March 31, 2025 and 2024 (dollars in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales proceeds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,876 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) One non-operational previously impaired facility sold during the three months ended March 31, 2025 was not classified as held for sale as of December 31, 2024. </span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Net sales proceeds for the three months ended March 31, 2024 includes $1.0 million of seller financing in connection with the sale of one ALF in January 2024. </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s assets held for sale activity for the periods presented (dollars in thousands):</span></div><div style="margin-bottom:18pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Facilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,736 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of real estate held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,744)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,483 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0 2700000 6 12000 36000 16000 <div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s dispositions for the three months ended March 31, 2025 and 2024 (dollars in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales proceeds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,876 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) One non-operational previously impaired facility sold during the three months ended March 31, 2025 was not classified as held for sale as of December 31, 2024. </span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Net sales proceeds for the three months ended March 31, 2024 includes $1.0 million of seller financing in connection with the sale of one ALF in January 2024. </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s assets held for sale activity for the periods presented (dollars in thousands):</span></div><div style="margin-bottom:18pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Facilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,736 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of real estate held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,744)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,483 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 5 2 44401000 1046000 40525000 1035000 3876000 11000 1000000 1 57261000 10 40525000 4 16736000 6 15011000 14 1251000 1 1035000 2 2744000 0 12483000 13 OTHER REAL ESTATE RELATED AND OTHER INVESTMENTS<div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December 31, 2024, the Company’s other real estate related investments, inclusive of accrued interest, consisted of the following (dollars in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Facility Count and Type</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of March 31, 2025</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loans Receivable, at Fair Value:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ALF</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ILF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Balance as of March 31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Contractual Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2), (3)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage secured loans receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,040 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658,427 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/31/2025 - 9/30/2039</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loans receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/25/2027 - 12/31/2034</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742,716 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,004 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of March 31, 2025</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Balance as of March 31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Book Value as of March 31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Book Value as of </span><span style="background-color:#cceeff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Contractual Interest Rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity Date</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,782 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,199 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,199 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,782 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Facility Count and Type</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of March 31, 2025</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing Receivable, at Fair Value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ALF</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ILF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Balance as of March 31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Effective Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity Date</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing Receivable</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,723 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,628 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,004 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/30/2039</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,723 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,628 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,004 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Fair value of mortgage secured loans receivable includes $4.6 million and $3.4 million of accrued interest as of March 31, 2025 and December 31, 2024, respectively. Fair value of mezzanine loans receivable includes $1.0 million and $0.9 million of accrued interest as of March 31, 2025 and December 31, 2024, respectively.</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Rates are net of subservicing fee, if applicable.</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Three mortgage secured loans receivable and two mezzanine loans receivable use term secured overnight financing rate (“SOFR”), which are subject to a floor for certain of the loans. Term SOFR used as of March 31, 2025 was 4.32%. </span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">If the Company also has extended mezzanine financing to an affiliate of the borrower under a mortgage loan receivable, the applicable facility counts are included in both respective totals.</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Fair value of financing receivable includes $0.9 million and $0.3 million of accrued interest as of March 31, 2025 and December 31, 2024, respectively.</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">The Company leased these facilities back to the seller under a 15-year contract, with two five-year renewal options. The agreement provides for an initial contractual cash yield of 11.0% for the first three years, with annual CPI-based escalators beginning in year four, subject to a 3% cap. The agreement provides for deferred payments equal to 2.0% of the contractual cash yield in the first year and 0.5% of the contractual cash yield in the second year. The agreement also provides for purchase options. At the time the seller-lessee exercises its purchase options, option proceeds will be used to repay any outstanding deferred payments as well as additional payments such that the Company receives a contractual cash yield of 12.5% on its gross investment in the applicable properties through the option exercise date. If any deferred amounts remain unpaid, beginning in year eight, the deferred amounts are to be repaid in 24 equal monthly payments. The Company has not received notice of exercise for the purchase option period currently open. </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s other real estate related investments activity for the three months ended March 31, 2025 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (dollars in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Origination of other real estate related investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on other real estate related investments, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayments of other real estate related investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,360)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in other real estate related investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,596 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,978 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Other Real Estate Related Investment Transactions</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 10, 2025, the Company advanced the second installment of a mezzanine loan for one SNF secured by a pledge of membership interests in an up-tier holding company of the borrower group for $6.4 million. The loan bears interest at a rate of 13%, with annual CPI-based escalators. The mezzanine loan is set to mature on December 31, 2034. The mezzanine loan may not be prepaid in whole or in part prior to maturity. The Company elected the fair value option for the mezzanine loan.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2025, the Company received a partial prepayment on one mortgage loan in the amount of $4.4 million in connection with the borrower’s election to release one skilled nursing facility from the loan. The remaining outstanding balance of $2.9 million was subsequently paid off, see Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Other Real Estate Related Investment Transactions</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2024, the Company closed on the sale of one ALF. In connection with the sale, the Company provided affiliates of the purchaser of the property with a $1.0 million mortgage loan which bears interest at a rate of 9.0%. The mortgage loan is secured by the ALF and is set to mature on January 1, 2027. The mortgage loan may be prepaid in whole before the maturity date. The Company elected the fair value option for the mortgage loan.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2024, the Company extended a $9.8 million mezzanine loan for a portfolio of ten SNFs located in Missouri secured by a pledge of membership interests in an up-tier holding company of the borrower group. The Company participated in the loan alongside a co-lender pursuant to a participation agreement entered into between the Company and the co-lender. Pursuant to such agreement, the Company provided $9.8 million in mezzanine loan proceeds and the co-lender provided the remaining $10.2 million of loan proceeds. As a participant in the loan, and subject to limited exceptions, the Company is entitled to receive its proportionate share of loan payments made by the borrower with each co-lender’s proportionate share being given equal weight. The loan bears interest at term SOFR plus 8.75%, with a term SOFR floor of 6%, payable monthly and net of a 0.75% subservicing fee. Commencing on February 1, 2026, monthly principal payments shall be due. The mezzanine loan is set to mature on July 25, 2027, with two six-month extension options and may (subject to certain restrictions) be prepaid in whole before the maturity date for an exit fee ranging from 1% to 2% of the loan plus unpaid interest payments equal to 24 months (less the amount of monthly interest payments made by the borrower through the date of prepayment). The Company elected the fair value option for the mezzanine loan.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, the Company extended a $7.4 million mezzanine loan for one SNF located in California secured by a pledge of membership interests in an up-tier holding company of the borrower group. The loan bears interest at 11.5%, payable monthly. The mezzanine loan is set to mature on January 31, 2029, and may not (subject to certain limited exceptions) be prepaid prior to the date that is 18 months following the loan closing. The Company elected the fair value option for the mezzanine loan.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2024, the Company extended a $35.0 million mezzanine loan for a portfolio of 15 SNFs located in Virginia secured by a pledge of membership interests in an up-tier holding company of the borrower group. The Company participated in the loan alongside a co-lender pursuant to a participation agreement entered into between the Company and the co-lender. Pursuant to such agreement, the Company provided $35.0 million in mezzanine loan proceeds and the co-lender provided the remaining $50.0 million of loan proceeds. As a participant in the loan, and subject to limited exceptions, the Company is entitled to receive its proportionate share of loan payments made by the borrower with each co-lender’s proportionate share being given equal weight. The loan bears interest at term SOFR plus 8.75%, with a term SOFR floor of 6%, payable monthly and net of a 0.75% subservicing fee. Commencing on February 2, 2026, monthly principal payments shall be due. The mezzanine loan is set to mature on August 1, 2027, with two six-month extension options and may (subject to certain restrictions) be prepaid in whole before the maturity date for an exit fee ranging from 1% to 2% of the loan plus unpaid interest payments equal to 18 months (less the amount of monthly interest payments made by the borrower through the date of prepayment). The Company elected the fair value option for the mezzanine loan.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Receivable</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 5, 2024, the Company invested $95.7 million, exclusive of transaction costs, to acquire a portfolio of 46 properties in Illinois in a sale and leaseback transaction with affiliates of Cascade Capital Partners, LLC (“Cascade”). In connection with the transaction, the Company entered into a new triple-net master lease with Cascade and provided Cascade with options to repurchase the properties, structured over multiple tranches, with various option window start dates, beginning December 1, 2024, and open through the remainder of the 15-year term. As such, the Company determined that the sale and leaseback transaction met the accounting criteria to be presented as a financing receivable on its consolidated balance sheets and recorded interest income from financing receivable on its consolidated statements of operations. Interest income is based on an imputed interest rate over the term of the applicable financing arrangement and as a result the interest recognized in any particular period will not equal the cash payments from the agreement in that period. Cash received from the financing receivable was $2.2 million during the three months ended March 31, 2025. The Company elected the fair value option for the financing receivable.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Loans Receivables</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025 and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December 31, 2024, the Company’s other loans receivable, included in prepaid expenses and other assets, net on the Company’s condensed consolidated balance sheets, consisted of the following (dollars in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of March 31, 2025</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Balance as of March 31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Book Value as of March 31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Book Value as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Contractual Interest Rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loans receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,820 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,010 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2025 - 12/31/2027</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected credit loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,994)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,994)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,757 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,826 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,016 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s other loans receivable activity for the three months ended March 31, 2025 and 2024 (dollars in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:63.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.836%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.838%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in other loans receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected credit losses and recoveries are recorded in provision for loan losses, net in the condensed consolidated income statements. During both the three months ended March 31, 2025 and 2024, the Company had no additional expected credit loss and did not consider any loan receivable investments to be impaired.</span></div><div style="margin-bottom:6pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marizes the interest and other income recognized from the Company’s loans receivable and other investments during the three months ended March 31, 2025 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024 (dollars in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage secured loans receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,388 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loans receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred equity investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loans receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,975 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,568 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Other income is comprised of interest income on money market funds and escrow deposits.</span></div> <div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December 31, 2024, the Company’s other real estate related investments, inclusive of accrued interest, consisted of the following (dollars in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Facility Count and Type</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of March 31, 2025</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loans Receivable, at Fair Value:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ALF</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ILF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Balance as of March 31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Contractual Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2), (3)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage secured loans receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,040 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658,427 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/31/2025 - 9/30/2039</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loans receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/25/2027 - 12/31/2034</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742,716 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,004 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of March 31, 2025</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Balance as of March 31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Book Value as of March 31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Book Value as of </span><span style="background-color:#cceeff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Contractual Interest Rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity Date</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,782 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,199 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,199 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,782 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Facility Count and Type</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of March 31, 2025</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing Receivable, at Fair Value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ALF</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ILF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Balance as of March 31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Effective Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity Date</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing Receivable</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,723 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,628 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,004 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/30/2039</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,723 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,628 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,004 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Fair value of mortgage secured loans receivable includes $4.6 million and $3.4 million of accrued interest as of March 31, 2025 and December 31, 2024, respectively. Fair value of mezzanine loans receivable includes $1.0 million and $0.9 million of accrued interest as of March 31, 2025 and December 31, 2024, respectively.</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Rates are net of subservicing fee, if applicable.</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Three mortgage secured loans receivable and two mezzanine loans receivable use term secured overnight financing rate (“SOFR”), which are subject to a floor for certain of the loans. Term SOFR used as of March 31, 2025 was 4.32%. </span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">If the Company also has extended mezzanine financing to an affiliate of the borrower under a mortgage loan receivable, the applicable facility counts are included in both respective totals.</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Fair value of financing receivable includes $0.9 million and $0.3 million of accrued interest as of March 31, 2025 and December 31, 2024, respectively.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span>The Company leased these facilities back to the seller under a 15-year contract, with two five-year renewal options. The agreement provides for an initial contractual cash yield of 11.0% for the first three years, with annual CPI-based escalators beginning in year four, subject to a 3% cap. The agreement provides for deferred payments equal to 2.0% of the contractual cash yield in the first year and 0.5% of the contractual cash yield in the second year. The agreement also provides for purchase options. At the time the seller-lessee exercises its purchase options, option proceeds will be used to repay any outstanding deferred payments as well as additional payments such that the Company receives a contractual cash yield of 12.5% on its gross investment in the applicable properties through the option exercise date. If any deferred amounts remain unpaid, beginning in year eight, the deferred amounts are to be repaid in 24 equal monthly payments. The Company has not received notice of exercise for the purchase option period currently open. 61 4 19 2 654040000 658427000 660392000 0.088 41 4 2 0 88676000 87173000 80612000 0.128 742716000 745600000 741004000 53782000 54199000 54199000 0.111 53782000 54199000 54199000 39 0 5 2 95723000 96628000 96004000 0.120 95723000 96628000 96004000 4600000 3400000 1000000 900000 3 2 0.0432 900000 300000 P15Y 2 P5Y 0.110 P3Y 0.03 0.020 0.005 0.125 24 <div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s other real estate related investments activity for the three months ended March 31, 2025 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (dollars in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Origination of other real estate related investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on other real estate related investments, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayments of other real estate related investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,360)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in other real estate related investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,596 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,978 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025 and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December 31, 2024, the Company’s other loans receivable, included in prepaid expenses and other assets, net on the Company’s condensed consolidated balance sheets, consisted of the following (dollars in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of March 31, 2025</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Balance as of March 31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Book Value as of March 31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Book Value as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Contractual Interest Rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loans receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,820 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,010 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2025 - 12/31/2027</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected credit loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,994)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,994)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,757 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,826 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,016 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div> 6389000 53165000 1280000 425000 -1287000 612000 4360000 0 4596000 52978000 1 6400000 0.13 4400000 2900000 1 1000000 0.090 9800000 10 9800000 10200000 0.0875 0.06 0.0075 2 P6M 0.01 0.02 P24M 7400000 1 0.115 P18M 35000000 15 35000000 50000000 0.0875 0.06 0.0075 2 P6M 0.01 0.02 P18M 95700000 46 P15Y 2200000 21757000 21820000 22010000 0.090 6994000 6994000 21757000 14826000 15016000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s other loans receivable activity for the three months ended March 31, 2025 and 2024 (dollars in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:63.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.836%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.838%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in other loans receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 222000 0 -32000 0 -190000 0 0 0 <div style="margin-bottom:6pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marizes the interest and other income recognized from the Company’s loans receivable and other investments during the three months ended March 31, 2025 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024 (dollars in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage secured loans receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,388 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loans receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred equity investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loans receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,975 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,568 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Other income is comprised of interest income on money market funds and escrow deposits.</span></div> 14388000 3772000 2821000 1895000 1497000 68000 334000 331000 2807000 0 3128000 3502000 24975000 9568000 FAIR VALUE MEASUREMENTS<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company’s assets measured at fair value on a recurring basis as of March 31, 2025 and December 31, 2024, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2025</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage secured loans receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loans receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842,228 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842,228 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage secured loans receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loans receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,612 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,612 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,004 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,004 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837,008 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837,008 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the Company’s assets measured at fair value on a recurring basis using Level 3 inputs (dollars in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investments in Real Estate Secured Loans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investments in Mezzanine Loans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investment in Financing Receivable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,612 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,004 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Originations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2025</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658,427 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,173 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,628 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real estate secured and mezzanine loans receivable:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of the secured and mezzanine loans receivables were estimated using an internal valuation model that considered the expected future cash flows of the investment, the underlying collateral value, market interest rates and other credit enhancements. As such, the Company classifies each instrument as Level 3 due to the significant unobservable inputs used in determining market interest rates for investments with similar terms. During the three months ended March 31, 2025, the Company recorded a net unrealized gain of $1.3 million on its secured and mezzanine loans receivable, to bring the interest rates in line with market rates. During the three months ended March 31, 2024, the Company recorded an unrealized loss of $0.8 million on the Company’s secured and mezzanine loans receivable due to rising interest rates, partially offset by unrealized gains of $0.2 million due to increases in expected cash flows on floating rate loans. Future changes in market interest rates or collateral value could materially impact the estimated discounted cash flows that are used to determine the fair value of the secured and mezzanine loans receivable. As of March 31, 2025 and December 31, 2024, the Company did not have any loans that were 90 days or more past due.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the quantitative information about unobservable inputs related to the Level 3 fair value measurements comprising the investments in secured and mezzanine loans receivables as of March 31, 2025:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Book Value as of March 31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage secured loans receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658,427 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8% - 14%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loans receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12% - 14%</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing receivable: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value was determined using a widely accepted valuation technique, discounted cash flow analysis, on the expected cash flows. The discount rate used to value the future cash inflows of the financing receivable at March 31, 2025 was 12%.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025, there were no classification changes in assets and liabilities with Level 3 inputs in the fair value hierarchy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items Disclosed at Fair Value</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Considerable judgment is necessary to estimate the fair value disclosure of financial instruments. The estimates of fair value presented herein are not necessarily indicative of the amounts that could be realized upon disposition of the financial instruments. A summary of the face value, carrying amount and fair value of the Company’s preferred equity investments and the Notes (as defined in Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below) as of March 31, 2025 and December 31, 2024 is as follows (dollars in thousands): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Face<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Face<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,782 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,782 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior unsecured notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,880 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396,927 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents, restricted cash, accounts and other receivables, accounts payable, and accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values for these instruments approximate their fair values due to the short-term nature of these instruments.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred equity investments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the preferred equity investments was estimated using an internal valuation model that considered the expected future cash flows of the investment, the underlying collateral value, market interest rates and other credit enhancements. The Company utilized discount rates of 11% to 15% in its fair value calculation. As such, the Company classifies these instruments as Level 3.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior unsecured notes payable:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of the Notes was determined using third-party quotes derived from orderly trades.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unsecured revolving credit facility:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value approximates the carrying value as the interest rates are variable and approximate prevailing market interest rates and spreads for similar debt arrangements.</span></div> <div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.</span></div> <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company’s assets measured at fair value on a recurring basis as of March 31, 2025 and December 31, 2024, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2025</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage secured loans receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loans receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842,228 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842,228 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage secured loans receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loans receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,612 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,612 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,004 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,004 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837,008 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837,008 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 658427000 658427000 0 0 87173000 87173000 0 0 96628000 96628000 0 0 842228000 842228000 0 0 660392000 660392000 0 0 80612000 80612000 0 0 96004000 96004000 0 0 837008000 837008000 <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the Company’s assets measured at fair value on a recurring basis using Level 3 inputs (dollars in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investments in Real Estate Secured Loans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investments in Mezzanine Loans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investment in Financing Receivable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,612 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,004 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Originations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2025</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658,427 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,173 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,628 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 660392000 80612000 96004000 0 6389000 0 1173000 107000 624000 1222000 65000 0 4360000 0 0 658427000 87173000 96628000 1300000 -800000 200000 0 0 <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the quantitative information about unobservable inputs related to the Level 3 fair value measurements comprising the investments in secured and mezzanine loans receivables as of March 31, 2025:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Book Value as of March 31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage secured loans receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658,427 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8% - 14%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loans receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12% - 14%</span></div></td></tr></table></div> 658427000 0.08 0.14 87173000 0.12 0.14 0.12 A summary of the face value, carrying amount and fair value of the Company’s preferred equity investments and the Notes (as defined in Note 7, <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below) as of March 31, 2025 and December 31, 2024 is as follows (dollars in thousands): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Face<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Face<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,782 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,782 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior unsecured notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,880 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396,927 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 53782000 54199000 54199000 53782000 54199000 54199000 400000000 397149000 374880000 400000000 396927000 381812000 0.11 0.15 DEBT<div style="margin-top:6pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of the Company’s indebtedness as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December 31, 2024 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:29.985%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Loan Fees</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Loan Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,851)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397,149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,073)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396,927 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unsecured revolving credit facility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,851)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822,149 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,073)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396,927 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Deferred financing fees are included in deferred financing costs, net on the balance sheet, and not reflected as a reduction to the unsecured revolving credit facility. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes Payable</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2028 Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On June 17, 2021, the Company’s wholly owned subsidiary, CTR Partnership, L.P. (the “Operating Partnership”), and its wholly owned subsidiary, CareTrust Capital Corp. (together with the Operating Partnership, the “Issuers”), completed a private offering of $400.0 million aggregate principal amount of 3.875% Senior Notes due 2028 (the “Notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A and to non-U.S. persons </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended. The Notes were issued at par, resulting in gross proceeds of $400.0 million and net proceeds of approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$393.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> after deducting underwriting fees and other offering expenses. The Notes mature on June 30, 2028. The Notes accrue interest at a rate of 3.875% per annum payable semiannually in arrears on June 30 and December 30 of each year, commencing on December 30, 2021.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Issuers may redeem some or all of the Notes at any time prior to March 30, 2028 at a price equal to 100% of the principal amount of the Notes redeemed plus accrued and unpaid interest on the Notes, if any, to, but not including, the redemption date, plus a “make-whole” premium. At any time on or after March 30, 2028, the Issuers may redeem some or all of the Notes at a redemption price equal to 100% of the principal amount of the Notes redeemed plus accrued interest on the Notes, if any, to, but not including, the redemption date. If certain changes of control of the Company occur, the Issuers will be required to make an offer to holders of the Notes to repurchase their Notes at a price of 101% of their principal amount plus accrued and unpaid interest, if any, to, but not including, the repurchase date.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations under the Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by the Company and all of CareTrust’s existing and future subsidiaries (other than the Issuers) that guarantee obligations under the Amended Credit Facility (as defined below); provided, however, that such guarantees are subject to automatic release under certain customary circumstances.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture governing the Notes contains customary covenants such as limiting the ability of the Company and its restricted subsidiaries to: incur or guarantee additional indebtedness; incur or guarantee secured indebtedness; pay dividends or distributions on, or redeem or repurchase, capital stock; make certain investments or other restricted payments; sell assets; enter into transactions with affiliates; merge or consolidate or sell all or substantially all of their assets; and create restrictions on the ability of the Issuers and their restricted subsidiaries to pay dividends or other amounts to the Issuers. The indenture governing the Notes also requires the Company and its restricted subsidiaries to maintain a specified ratio of unencumbered assets to unsecured indebtedness. These covenants are subject to a number of important and significant limitations, qualifications and exceptions. The indenture governing the Notes also contains customary events of default.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Company was in compliance with all applicable financial covenants under the indenture governing the Notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unsecured Revolving Credit Facility</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2024, the Operating Partnership, as the borrower, the Company, as guarantor, CareTrust GP, LLC, and certain of the Operating Partnership’s wholly owned subsidiaries, entered into a third amended and restated credit and guaranty agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender (as amended from time to time, the “Third Amended Credit Agreement”). The Third Amended Credit Agreement, which amends and restates the Second Amended Credit Agreement (as defined below) provides for an upsized unsecured revolving credit facility (the “Third Amended Revolving Facility”) with revolving commitments in an aggregate principal amount of $1.2 billion, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments. Future borrowings under the Third Amended Revolving Facility will be used for working capital purposes, for capital expenditures, to fund acquisitions and for general corporate purposes.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2022, the Operating Partnership, as the borrower, the Company, as guarantor, CareTrust GP, LLC, and certain of the Operating Partnership’s wholly owned subsidiaries, entered into a second amended and restated credit and guaranty agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender (as amended from time to time, the “Second Amended Credit Agreement”). The Second Amended Credit Agreement, which amends and restates the Company’s amended and restated credit and guaranty agreement, dated as of February 8, 2019 (as amended, the “Prior Credit Agreement”) provided for: (i) an unsecured revolving credit facility (the “Revolving Facility”) with revolving commitments in an aggregate principal amount of $600.0 million, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments and (ii) the continuation of the unsecured term loan credit facility which was previously extended under the Prior Credit Agreement (the “Term Loan” and together with the Revolving Facility, the “Second Amended Credit Facility”) in an aggregate principal amount of $200.0 million. </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2023, the Operating Partnership, the Company, CareTrust GP, LLC, certain of the Operating Partnership’s wholly owned subsidiaries and KeyBank National Association entered into the First Amendment to the Second Amended Credit Agreement (the “First Amendment”). The First Amendment restates the definition of Consolidated Total Asset Value to include net proceeds from at-the-market forward commitments executed but not yet closed as of the relevant date as if such proceeds had actually been received. </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rates applicable to loans under the Third Amended Revolving Facility are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.05% to 0.55% per annum or Adjusted Term SOFR or Adjusted Daily Simple SOFR (each as defined in the Third Amended Credit Agreement) plus a margin ranging from 1.05% to 1.55% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). In addition, the Operating Partnership will pay a facility fee on the revolving commitments under the Third Amended Revolving Facility ranging from 0.15% to 0.35% per annum, based on the debt to asset value ratio of the Company and its consolidated subsidiaries (unless the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt and the Operating Partnership elects to decrease the applicable margin as described above, in which case the Operating Partnership will pay a facility fee on the revolving commitments ranging from 0.125% to 0.30% per annum based on the credit ratings of the Company’s senior long-term unsecured debt). </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Operating Partnership had borrowings outstanding of $425.0 million under the Third Amended Revolving Facility. </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Third Amended Revolving Facility has a maturity date of February 9, 2029, and includes, at the sole discretion of the Operating Partnership, two six-month extension options. </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Third Amended Credit Facility is guaranteed, jointly and severally, by the Company and its wholly owned subsidiaries that are party to the Third Amended Credit Agreement (other than the Operating Partnership). The Third Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend organizational documents and pay certain dividends and other restricted payments. The Third Amended Credit Agreement requires the Company to comply with financial maintenance covenants to be tested quarterly, consisting of a maximum debt to asset value ratio, a minimum fixed charge coverage ratio, a minimum tangible net worth, a maximum secured debt to asset value ratio, a maximum unsecured debt to unencumbered properties asset value ratio and a minimum unsecured interest coverage ratio. The Third Amended Credit Agreement also contains certain customary events of default, including the failure to make timely payments under the Third Amended Credit Facility or other material indebtedness, the failure to satisfy certain covenants (including the financial maintenance covenants), the occurrence of change of control and specified events of bankruptcy and insolvency.</span></div><div style="margin-bottom:18pt;margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Company was in compliance with all applicable financial covenants under the Third Amended Credit Agreement.</span></div> <div style="margin-top:6pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of the Company’s indebtedness as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December 31, 2024 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:29.985%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Loan Fees</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Loan Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,851)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397,149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,073)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396,927 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unsecured revolving credit facility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,851)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822,149 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,073)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396,927 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1) Deferred financing fees are included in deferred financing costs, net on the balance sheet, and not reflected as a reduction to the unsecured revolving credit facility. 400000000 2851000 397149000 400000000 3073000 396927000 425000000 0 425000000 0 0 0 825000000 2851000 822149000 400000000 3073000 396927000 400000000 0.03875 400000000 393800000 0.03875 1 1 1.01 1200000000 0.10 0.10 600000000.0 0.10 0.10 200000000.0 0.0005 0.0055 0.0105 0.0155 0.0015 0.0035 0.00125 0.0030 425000000.0 2 P6M EQUITY AND REDEEMABLE NONCONTROLLING INTEREST<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-The-Market Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—On January 21, 2025, the Company entered into a new equity distribution agreement to issue and sell, from time to time, up to $750.0 million in aggregate offering price of its common stock through an “at-the-market” equity offering program (the “New ATM Program”) and terminated its previous $750.0 million “at-the-market” equity offering program (together, with all previous at-the-market equity offering programs, the “Previous ATM Programs” and together with the New ATM Program, the “ATM Program”). In addition to the issuance and sale of shares of its common stock, the ATM Program also provides for the ability to enter into one or more forward sales agreements (each, an “ATM forward contract”) with sales agents for the sale of the Company’s shares of common stock under the ATM Program.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Company enters into an ATM forward contract to sell shares of common stock pursuant to the ATM Program, the Company would expect to fully physically settle forward equity sales by delivery of shares of common stock to the forward purchaser and receive cash proceeds upon one or more settlement dates, which are typically a one-year term, at the Company’s discretion, prior to the final settlement date, at which time the Company would expect to receive aggregate net cash proceeds at settlement equal to the number of shares sold on a forward basis multiplied by the relevant forward price per share. The weighted average forward sale price that the Company would expect to receive upon physical settlement would be subject to adjustment for (i) a floating interest rate factor equal to a specified daily rate less a spread, (ii) the forward purchaser’s stock borrowing costs and (iii) scheduled dividends through the settlement. </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the ATM Program activity (or activity under any predecessor at-the-market equity offering programs) for the three months ended March 31, 2025 and 2024 (in thousands, except per share amounts):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.276%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average sales price per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross proceeds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,964 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,233 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Total gross proceeds is before $0.2 million and $3.4 million of commissions paid to the sales agents during the three months ended March 31, 2025 and 2024, respectively, under the ATM Program.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Company had $734.0 million available for future issuances under the New ATM Program. </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends on Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The following table summarizes the cash dividends per share of common stock declared by the Company’s board of directors for the first three months of 2025 (dollars in thousands, except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.335 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payment date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 15, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable as of record date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,053 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends record date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Redeemable Noncontrolling Interest</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements with noncontrolling interest holders are assessed for appropriate balance sheet classification based on the redemption and other rights held by the noncontrolling interest holder. One of the Company’s noncontrolling interest holders has the ability to put its equity interest to the Company during specified option exercise periods, subject to certain conditions. The put option is payable in cash and subject to changes in redemption value. Accordingly, the Company records the redeemable noncontrolling interest outside of permanent equity. The redeemable noncontrolling interest is adjusted for additional contributions and distributions and the proportionate share of the net earnings or losses. When the redemption of the noncontrolling interest becomes probable, the Company will record the redeemable noncontrolling interest at the greater of its carrying amount or redemption value at the end of each reporting period by making an election either to accrete changes in the redemption value of the redeemable noncontrolling interest over the period from the date it is probable of exercise to the earliest redemption date or to recognize the entire adjustment on the date redemption becomes probable. In addition to the rights of the redeemable noncontrolling interest holder, the Company has the ability to call the interest of the noncontrolling interest holder during specified option exercise periods.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the redeemable noncontrolling interest did not meet the conditions for redemption.</span></div> 750000000.0 750000000 P1Y <div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the ATM Program activity (or activity under any predecessor at-the-market equity offering programs) for the three months ended March 31, 2025 and 2024 (in thousands, except per share amounts):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.276%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average sales price per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross proceeds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,964 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,233 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Total gross proceeds is before $0.2 million and $3.4 million of commissions paid to the sales agents during the three months ended March 31, 2025 and 2024, respectively, under the ATM Program.</span></div> 553000 11600000 28.87 23.55 15964000 273233000 200000 3400000 734000000.0 The following table summarizes the cash dividends per share of common stock declared by the Company’s board of directors for the first three months of 2025 (dollars in thousands, except per share amounts):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.335 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payment date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 15, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable as of record date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,053 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends record date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 0.335 63053000 STOCK-BASED COMPENSATION<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based awards are subject to the terms of the CareTrust REIT, Inc. and CTR Partnership, L.P. Incentive Award Plan (the “Plan”). The Plan provides for the granting of stock-based compensation, including stock options, restricted stock, performance awards, restricted stock units, relative total stockholder return based stock awards and other incentive awards to officers, employees and directors in connection with their employment with or services provided to the Company. Under the Plan, 5,000,000 shares have been authorized for awards.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Plan, restricted stock awards (“RSAs”) typically vest in equal annual installments over a three year period. The board of directors granted certain RSAs in 2025 (“2025 RSAs”) which vest in one installment over one year. RSAs granted to non-employee members of the board of directors (“Board Awards”) vest in full on the earlier to occur of the Company’s next Annual Meeting of Stockholders or one year. Relative total shareholder return units (“TSR Units”) granted since 2021 are subject to both time and market based conditions and cliff vest after a three-year period. The amount of such market awards that will ultimately vest is dependent on the Company’s total shareholder return (“TSR”) performance relative to a custom TSR peer group consisting of other publicly traded healthcare REITs and will range from 0% to 200% of the TSR Units initially granted. The RSAs and Board Awards are valued on the date of grant based on the closing price of the Company’s common stock, while the TSR Units are valued on the date of grant using a Monte Carlo valuation model. The vesting of certain awards may accelerate, as defined in the grant agreement, upon retirement, a change in control or other events.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the status of the restricted stock award activity for the three months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Share Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,951)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544,968 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.42 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the weighted-average remaining vesting period of such award</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s was 2.0 years.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized for the periods presented (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,909 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>As of March 31, 2025, there was $15.8 million of unamortized stock-based compensation expense related to the unvested RSAs and TSR Units. 5000000 P3Y P1Y P1Y P3Y 0 2 <div style="margin-top:6pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the status of the restricted stock award activity for the three months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Share Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,951)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544,968 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.42 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 552999 23.86 137920 27.17 145951 21.16 544968 25.42 P2Y <div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized for the periods presented (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,909 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 3909000 2120000 15800000 EARNINGS PER COMMON SHARE<div style="margin-top:12pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted earnings per common share attributable to CareTrust REIT, Inc. (“EPS”) for the Company’s common stock for the three months ended March 31, 2025 and 2024, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (dollars and shares in thousands, except per share amounts):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.107%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to CareTrust REIT, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,746 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income allocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for basic and diluted earnings available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,619 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,650 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,836 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common shares - TSR Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,416 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,202 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share attributable to CareTrust REIT, Inc., basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share attributable to CareTrust REIT, Inc., diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antidilutive unvested RSAs excluded from the computation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span>For the three months ended March 31, 2025 and 2024, RSAs are antidilutive. <div style="margin-top:12pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted earnings per common share attributable to CareTrust REIT, Inc. (“EPS”) for the Company’s common stock for the three months ended March 31, 2025 and 2024, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (dollars and shares in thousands, except per share amounts):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.107%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to CareTrust REIT, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,746 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income allocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for basic and diluted earnings available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,619 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,650 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,836 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common shares - TSR Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,416 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,202 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share attributable to CareTrust REIT, Inc., basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share attributable to CareTrust REIT, Inc., diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antidilutive unvested RSAs excluded from the computation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span>For the three months ended March 31, 2025 and 2024, RSAs are antidilutive. 65802000 28746000 183000 96000 65619000 65619000 28650000 28650000 187152000 132836000 264000 366000 187416000 133202000 0.35 0.22 0.35 0.22 545000 330000 SEGMENT REPORTING<div style="margin-top:12pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company represents a single reportable segment, based on how its chief operating decision maker (“CODM”) evaluates the businesses and allocates resources. The CODM assesses performance for the Company and decides how to allocate resources based on consolidated net income that is also reported on the condensed consolidated income statements. The CODM does not review segment assets at a different asset level or category than the amounts disclosed in the condensed consolidated balance sheets. The CODM uses net income to evaluate the performance of the Company in deciding whether to reinvest profits into the Company. </span></div><div style="margin-top:12pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM evaluates performance based on net income, as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.107%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 19pt 0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income from financing receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income from other real estate related investments and other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,568 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 37pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of real estate investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,090 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,909 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes and insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total general and administrative</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,023 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,838 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,591 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 37pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,719 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (loss):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of real estate, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on other real estate related investments, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,163 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(601)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,193 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,750 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to CareTrust REIT, Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,802 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,746 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Other expenses include certain overhead expenses.</span></div> <div style="margin-top:12pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM evaluates performance based on net income, as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.107%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 19pt 0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income from financing receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income from other real estate related investments and other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,568 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 37pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of real estate investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,090 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,909 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes and insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total general and administrative</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,023 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,838 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,591 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 37pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,719 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (loss):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of real estate, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on other real estate related investments, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,163 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(601)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,193 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,750 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to CareTrust REIT, Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,802 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,746 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Other expenses include certain overhead expenses.</span></div> 71646000 53502000 2807000 0 22168000 9568000 96621000 63070000 17841000 13448000 6669000 8228000 2065000 1801000 0 2744000 888000 0 105000 660000 2090000 1765000 1225000 1500000 3909000 2120000 876000 738000 218000 205000 705000 510000 9023000 6838000 36591000 33719000 3876000 11000 1287000 -612000 5163000 -601000 65193000 28750000 -609000 4000 65802000 28746000 VARIABLE INTEREST ENTITIES<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company has entered into ventures with unrelated third parties to own real estate and has concluded that such ventures are VIEs. As the Company exercises power over and receives economic benefits from the VIEs, the Company is considered the primary beneficiary and consolidates the VIEs. </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contributions to joint ventures that are consolidated variable interest entities through March 31, 2025 (dollars in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:14.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Investment</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investment Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Facility Type</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Facilities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CTRE</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,036 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-service campuses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 / 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TN, AL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 / 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599,057 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,179 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,236 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) The noncontrolling interest is classified as a redeemable noncontrolling interest on the consolidated balance sheets. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) The Company entered into a joint venture to acquire real estate. The gross investment amounts represent a deposit. See Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Company’s joint ventures (“JVs”), the Company typically contributes at least 90% of the JV’s total investment amount and receives 100% of the preferred equity interest in the JV and a 50% common equity interest in the JV. The Company’s JV partner contributes the remaining total investment amount in exchange for a 50% common equity interest in the JV. </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets and total liabilities include VIE assets and liabilities as follows (dollars in thousands):</span></div><div style="margin-bottom:12pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581,959 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,959 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts and other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629,831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580,782 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and deferred rent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,847 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,332 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contributions to joint ventures that are consolidated variable interest entities through March 31, 2025 (dollars in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:14.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Investment</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investment Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Facility Type</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Facilities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CTRE</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,036 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-service campuses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 / 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TN, AL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 / 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599,057 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,179 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,236 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) The noncontrolling interest is classified as a redeemable noncontrolling interest on the consolidated balance sheets. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) The Company entered into a joint venture to acquire real estate. The gross investment amounts represent a deposit. See Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets and total liabilities include VIE assets and liabilities as follows (dollars in thousands):</span></div><div style="margin-bottom:12pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581,959 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,959 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts and other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629,831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580,782 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and deferred rent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,847 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,332 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1 25459000 653000 26112000 2 34269000 879000 35148000 1 10760000 276000 11036000 2 28076000 720000 28796000 1 24503000 628000 25131000 28 442327000 19156000 461483000 0 33663000 867000 34530000 35 599057000 23179000 622236000 0.90 1 0.50 0.50 581959000 565959000 6762000 6506000 32000 0 41078000 8317000 629831000 580782000 7847000 10332000 7847000 10332000 COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are and may become from time to time a party to various claims and lawsuits arising in the ordinary course of business, which are not individually or in the aggregate anticipated to have a material adverse effect on the Company’s results of operations, financial condition or cash flows. Claims and lawsuits may include matters involving general or professional liability asserted against the Company’s tenants, which are the responsibility of the Company’s tenants and for which the Company is entitled to be indemnified by its tenants under the insurance and indemnification provisions in the applicable leases.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into various commitments, typically consisting of funding of capital expenditures and short-term working capital loans to existing tenants while they await licensure and certification or are conducting turnaround work in one or more of the Company’s properties.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures for each property leased under the Company’s triple-net leases are generally the responsibility of the tenant, except for the facilities leased under certain master lease agreements, with certain subsidiaries of Ensign and Pennant, under which the tenant will have an option to require the Company to finance certain capital expenditures up to an aggregate of 20% of the Company’s initial investment in such property, subject to a corresponding rent increase at the time of funding. For the Company’s other triple-net master leases, the tenants also have the option to request capital expenditure funding that would generally be subject to a corresponding rent increase at the time of funding, which are subject to tenant compliance with the conditions to the Company’s approval and funding of their requests. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also provided select tenants with strategic capital for facility upkeep and modernization. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Tenant Code of Conduct and Corporate Responsibility policy (the “Tenant ESG Program”) provides eligible triple-net tenants of the Company with monetary inducements to make sustainable improvements to the Company’s properties. Incentive options include a wide variety of opportunities for tenants to upgrade everything from energy and environmental systems to water-saving landscaping and more. The Company’s board of directors has authorized annual allocations of up to $500,000 to fund the Tenant ESG Program.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company’s existing, known commitments and contingencies as of March 31, 2025 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.502%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining Commitment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,163 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loans receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earn-out obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,395 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">As of March 31, 2025, the Company had committed to fund expansions, construction, capital improvements and ESG incentives at certain triple-net leased facilities totaling $7.2 million, of which $6.3 million is subject to rent increase at the time of funding. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes an earn-out advance of $9.0 million related to one mortgage loan, upon satisfaction of certain conditions. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents non-real estate secured loan commitments.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes an earn-out obligation of up to $10.0 million under a purchase and sale agreement for one SNF in Virginia, which was acquired during 2024. The earn-out is available, contingent on the operator achieving certain thresholds per the agreement, beginning in October 2025 through October 2026.</span></div> 0.20 500000 <div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company’s existing, known commitments and contingencies as of March 31, 2025 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.502%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining Commitment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,163 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loans receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earn-out obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,395 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">As of March 31, 2025, the Company had committed to fund expansions, construction, capital improvements and ESG incentives at certain triple-net leased facilities totaling $7.2 million, of which $6.3 million is subject to rent increase at the time of funding. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes an earn-out advance of $9.0 million related to one mortgage loan, upon satisfaction of certain conditions. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents non-real estate secured loan commitments.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes an earn-out obligation of up to $10.0 million under a purchase and sale agreement for one SNF in Virginia, which was acquired during 2024. The earn-out is available, contingent on the operator achieving certain thresholds per the agreement, beginning in October 2025 through October 2026.</span></div> 7163000 9066000 12166000 10000000 38395000 7200000 6300000 9000000 10000000 1 CONCENTRATION OF RISK<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrations of credit risk arise when one or more tenants, operators, or obligors related to the Company’s investments are engaged in similar business activities or activities in the same geographic region, or have similar economic features that would cause their ability to meet contractual obligations, including those to the Company, to be similarly affected by changes in economic conditions.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Major operator concentration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operators from which it derived 10% or more of its revenue for the three months ended March 31, 2025 and 2024. The following table sets forth information regarding the Company’s major operators as of March 31, 2025 and 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.919%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Facilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Beds/Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Total Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operator/Borrower</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALF/ILF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALF/ILF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ensign</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PACS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ensign</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority Management Group</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) The Company’s rental income and interest income on other real estate related investments, exclusive of operating expense reimbursements.</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Ensign and the PACS Group, Inc. (“PACS”) are subject to the registration and reporting requirements of the SEC and are required to file with the SEC annual reports containing audited financial information and quarterly reports containing unaudited financial information. Ensign and PACS’s financial statements, as filed with the SEC, can be found at http://www.sec.gov. The Company has not verified this information through an independent investigation or otherwise. </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Major geographic concentration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – The following table provides information regarding the Company’s concentrations with respect to certain states, from which the Company derived 10% or more of its revenue for the three months ended March 31, 2025 and 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.212%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Facilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Beds/Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Total Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALF/ILF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALF/ILF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,004 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Based on the Company’s rental income and interest income on other real estate related investments, exclusive of operating expense reimbursements.</span></div> <div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Major operator concentration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operators from which it derived 10% or more of its revenue for the three months ended March 31, 2025 and 2024. The following table sets forth information regarding the Company’s major operators as of March 31, 2025 and 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.919%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Facilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Beds/Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Total Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operator/Borrower</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALF/ILF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALF/ILF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ensign</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PACS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ensign</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority Management Group</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) The Company’s rental income and interest income on other real estate related investments, exclusive of operating expense reimbursements.</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Ensign and the PACS Group, Inc. (“PACS”) are subject to the registration and reporting requirements of the SEC and are required to file with the SEC annual reports containing audited financial information and quarterly reports containing unaudited financial information. Ensign and PACS’s financial statements, as filed with the SEC, can be found at http://www.sec.gov. The Company has not verified this information through an independent investigation or otherwise. </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Major geographic concentration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – The following table provides information regarding the Company’s concentrations with respect to certain states, from which the Company derived 10% or more of its revenue for the three months ended March 31, 2025 and 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.212%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Facilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Beds/Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Total Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALF/ILF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALF/ILF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,004 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Based on the Company’s rental income and interest income on other real estate related investments, exclusive of operating expense reimbursements.</span></div> 89 7 7 9288 843 661 0.21 23 3 0 2809 322 0 0.11 85 8 7 9024 997 661 0.30 13 2 0 1742 402 0 0.13 42 12 11 4979 2004 1032 0.23 38 3 2 4772 476 212 0.12 29 0 0 3098 0 0 0.12 42 9 9 5000 1527 723 0.31 41 4 2 5193 630 212 0.20 SUBSEQUENT EVENTS<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates subsequent events in accordance with ASC 855, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company evaluates subsequent events up until the date the condensed consolidated financial statements are issued.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Acquisitions</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2025, the Company purchased one multi-service campus in California for $34.7 million, inclusive of transaction costs, through a JV. The Company contributed $33.8 million to the JV. In exchange, the Company holds 100% of the preferred equity interests in the JV and 50% of the common equity interest in the JV. The JV partner contributed the remaining $0.9 million of the total investment in exchange for 50% of the common equity interest in the JV. In connection with the acquisition of the facility, subsidiaries of the JV entered into a new master lease with affiliates of Ensign. The master lease has an initial term of approximately 15 years, with two five-year renewal options. Annual cash rent under the lease is $3.5 million, with annual CPI-based escalators. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mortgage Loan Prepayment</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2025, one mortgage loan with a principal balance of $2.9 million was fully prepaid, including all unpaid accrued interest. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-The-Market Offering of Common Stock</span></div>In April 2025, the Company sold 3.4 million shares under the ATM Program for gross proceeds of $99.5 million at an average sales price per share of $28.90. 1 34700000 33800000 1 0.50 900000 0.50 P15Y 2 P5Y 3500000 2900000 3400000 99500000 28.90 false false false false